Unnamed: 0 stringlengths 3 8 | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher stringclasses 1 value | Author stringclasses 1 value | Article stringlengths 1 343k | Lsa_summary stringlengths 3 53.9k | Luhn_summary stringlengths 1 53.9k | Textrank_summary stringlengths 1 53.9k | Lexrank_summary stringlengths 1 53.9k |
|---|---|---|---|---|---|---|---|---|---|---|---|
33000.0 | 2019-04-17 00:00:00 UTC | Abbott Q1 19 Earnings Conference Call At 9:00 AM ET | ABT | https://www.nasdaq.com/articles/abbott-q1-19-earnings-conference-call-9%3A00-am-et-2019-04-17 | nan | nan | (RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:00 AM ET on April 17, 2019, to discuss Q1 19 earnings results.
To access the live webcast, log on to www.abbottinvestor.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:00 AM ET on April 17, 2019, to discuss Q1 19 earnings results. To access the live webcast, log on to www.abbottinvestor.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:00 AM ET on April 17, 2019, to discuss Q1 19 earnings results. To access the live webcast, log on to www.abbottinvestor.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:00 AM ET on April 17, 2019, to discuss Q1 19 earnings results. To access the live webcast, log on to www.abbottinvestor.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott Laboratories (ABT) will host a conference call at 9:00 AM ET on April 17, 2019, to discuss Q1 19 earnings results. To access the live webcast, log on to www.abbottinvestor.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
33001.0 | 2019-04-17 00:00:00 UTC | Abbott Lab's first-quarter sales beat expectations | ABT | https://www.nasdaq.com/articles/abbott-labs-first-quarter-sales-beat-expectations-2019-04-17 | nan | nan | April 17 (Reuters) - Abbott Laboratories Inc reported first-quarter sales ahead of Wall Street expectations on Wednesday, on double digit growth of its Freestyle Libre glucose monitoring device and as more of its heart valves were used in surgical procedures.
"The decisions we made three, five, seven years ago - and the ones we're making today - are driving positive long-term outlooks for all of our businesses," said Chief Executive Officer Miles White.
The company, whose products range from medical devices to infant nutritional formula, posted net earnings of $672 million, or 38 cents per share, in the first quarter ended March 31, from $418 million, or 23 cents per share.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | April 17 (Reuters) - Abbott Laboratories Inc reported first-quarter sales ahead of Wall Street expectations on Wednesday, on double digit growth of its Freestyle Libre glucose monitoring device and as more of its heart valves were used in surgical procedures. "The decisions we made three, five, seven years ago - and the ones we're making today - are driving positive long-term outlooks for all of our businesses," said Chief Executive Officer Miles White. The company, whose products range from medical devices to infant nutritional formula, posted net earnings of $672 million, or 38 cents per share, in the first quarter ended March 31, from $418 million, or 23 cents per share. | April 17 (Reuters) - Abbott Laboratories Inc reported first-quarter sales ahead of Wall Street expectations on Wednesday, on double digit growth of its Freestyle Libre glucose monitoring device and as more of its heart valves were used in surgical procedures. The company, whose products range from medical devices to infant nutritional formula, posted net earnings of $672 million, or 38 cents per share, in the first quarter ended March 31, from $418 million, or 23 cents per share. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | "The decisions we made three, five, seven years ago - and the ones we're making today - are driving positive long-term outlooks for all of our businesses," said Chief Executive Officer Miles White. The company, whose products range from medical devices to infant nutritional formula, posted net earnings of $672 million, or 38 cents per share, in the first quarter ended March 31, from $418 million, or 23 cents per share. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | April 17 (Reuters) - Abbott Laboratories Inc reported first-quarter sales ahead of Wall Street expectations on Wednesday, on double digit growth of its Freestyle Libre glucose monitoring device and as more of its heart valves were used in surgical procedures. "The decisions we made three, five, seven years ago - and the ones we're making today - are driving positive long-term outlooks for all of our businesses," said Chief Executive Officer Miles White. The company, whose products range from medical devices to infant nutritional formula, posted net earnings of $672 million, or 38 cents per share, in the first quarter ended March 31, from $418 million, or 23 cents per share. |
33002.0 | 2019-04-17 00:00:00 UTC | Abbott Labs beats first-quarter expectations on higher diabetes devices sales | ABT | https://www.nasdaq.com/articles/abbott-labs-beats-first-quarter-expectations-higher-diabetes-devices-sales-2019-04-17 | nan | nan | By Manas Mishra
April 17 () - Abbott Laboratories Inc reported higher-than-expected quarterly profit and sales on surging demand for its glucose monitoring device, but an unchanged forecast along with regulatory uncertainty kept investors on the edge.
Healthcare stocks have been under pressure due to concerns over new regulations, more so after U.S. Senator Bernie Sanders unveiled the latest version of his "Medicare-for-All" plan that would eliminate private insurance and shift all Americans to a public healthcare plan.
"The management is conservative at the start of the year... It was a beat-and-not-a-raise quarter on a weak day in the market," Rick Wise, analyst with Stifel said.
"Make no mistake, this was an excellent quarter."
The company, whose products range from medical devices to infant nutritional formula, defended its move to not raise forecasts, saying it was too early in the year.
"I rarely, if ever, raise in the first quarter. I kind of feel like if I raised in the first quarter, why didn't I put it in the original plan 3 months ago or 6 months ago," Chief Executive Officer Miles White said on a conference call.
Abbott expects full-year adjusted earnings per share from continuing operations of $3.15 to $3.25, and sales growth, excluding currency impact, of 6.5 to 7.5 percent.
The device helps people track blood sugar levels without having to prick their fingers.
While total medical device sales rose 5.5 percent to $2.90 billion and came in-line with expectations, sales in its generic drugs unit fell 4.9 percent to $992 million and missed expectations of $1 billion.
The unit sells generic drugs in emerging markets such as India, China and Brazil, and sales have been hit by a strong dollar.
Excluding items, Abbott earned 63 cents per share, ahead of the average analyst estimate of 61 cents per share, according to IBES data from Refinitiv.
"The debate will be... why guidance was not tweaked up despite the beat," Evercore ISI analyst Vijay Kumar wrote in a note.
Abbott's shares were down about 4 percent at $73.44 in afternoon trading.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | By Manas Mishra April 17 () - Abbott Laboratories Inc reported higher-than-expected quarterly profit and sales on surging demand for its glucose monitoring device, but an unchanged forecast along with regulatory uncertainty kept investors on the edge. The company, whose products range from medical devices to infant nutritional formula, defended its move to not raise forecasts, saying it was too early in the year. Abbott expects full-year adjusted earnings per share from continuing operations of $3.15 to $3.25, and sales growth, excluding currency impact, of 6.5 to 7.5 percent. | I kind of feel like if I raised in the first quarter, why didn't I put it in the original plan 3 months ago or 6 months ago," Chief Executive Officer Miles White said on a conference call. While total medical device sales rose 5.5 percent to $2.90 billion and came in-line with expectations, sales in its generic drugs unit fell 4.9 percent to $992 million and missed expectations of $1 billion. Excluding items, Abbott earned 63 cents per share, ahead of the average analyst estimate of 61 cents per share, according to IBES data from Refinitiv. | By Manas Mishra April 17 () - Abbott Laboratories Inc reported higher-than-expected quarterly profit and sales on surging demand for its glucose monitoring device, but an unchanged forecast along with regulatory uncertainty kept investors on the edge. I kind of feel like if I raised in the first quarter, why didn't I put it in the original plan 3 months ago or 6 months ago," Chief Executive Officer Miles White said on a conference call. While total medical device sales rose 5.5 percent to $2.90 billion and came in-line with expectations, sales in its generic drugs unit fell 4.9 percent to $992 million and missed expectations of $1 billion. | The company, whose products range from medical devices to infant nutritional formula, defended its move to not raise forecasts, saying it was too early in the year. "I rarely, if ever, raise in the first quarter. While total medical device sales rose 5.5 percent to $2.90 billion and came in-line with expectations, sales in its generic drugs unit fell 4.9 percent to $992 million and missed expectations of $1 billion. |
33003.0 | 2019-04-16 00:00:00 UTC | Close Update: Nasdaq Closes Above 8,000 as Stocks Post Modest Advance in Tuesday Trading | ABT | https://www.nasdaq.com/articles/close-update-nasdaq-closes-above-8000-stocks-post-modest-advance-tuesday-trading-2019-04-0 | nan | nan | Stocks posted slight gains Tuesday as the Nasdaq Composite Index closed above 8,000 for the first time since October.
Financial companies in the S&P 500 rose 1.4% as a group and were the best performing sector in the index. The Dow Jones Industrial Average and the Nasdaq Composite Index both added 0.3%. The S&P 500 rose fractionally as losses in real estate, healthcare and utilities held back a bigger advance for the S&P 500.
Meanwhile, late in the session Qualcomm ( QCOM ) jumped after it and Apple ( AAPL ) agreed to settle all litigation between the companies around the world. The deal includes a payment to Qualcomm from the iPhone maker. Qualcomm surged 23% and was the biggest gaining stock in the S&P 500. Apple was little changed.
Economic news Tuesday was light. The National Association of Home Builders Housing Market Index was 63 for April, in line with expectations, according to Econoday. Industrial production fell 0.1% in March, compared with the consensus expecting a gain of 0.3%, according to Econoday.
Looking ahead to Wednesday's earnings, Abbott Laboratories ( ABT ), PepsiCo ( PEP ) and US Bancorp ( USB ) are among a host of companies set to report.
US MARKETS
Dow Jones Industrial Average was up 67.89 points (+0.26%) to 26,452.66
S&P 500 was up 1.48 points (+0.05%) to 2,907.06
Nasdaq Composite Index was up 24.21 points (+0.30%) to 8,000.23
GLOBAL SENTIMENT
FTSE 100 was up 33.05 points (+0.44%) to 7,469.92
Hang Seng Index was up 319.15 points (+1.07%) to 30,129.87
Shanghai China Composite Index was up 75.81 points (+2.39%) to 3,253.60
UPSIDE MOVERS
(+) WDC (+4.69%) Deutsche Bank upgrades rating on shares
(+) BLK (+3.25) Posts better-than-expected Q1 results
(+) SGMS (+8.04%) Announces digital sports betting deal with Wynn
DOWNSIDE MOVERS
(-) PKG (-3.52%) BofA-Merrill Lynch cuts rating on stock
(-) BRS (-41.93%) Exercises option to delay interest payment
(-) JBHT (-4.95%) Misses Q1 EPS Wall Street consensus
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Looking ahead to Wednesday's earnings, Abbott Laboratories ( ABT ), PepsiCo ( PEP ) and US Bancorp ( USB ) are among a host of companies set to report. Meanwhile, late in the session Qualcomm ( QCOM ) jumped after it and Apple ( AAPL ) agreed to settle all litigation between the companies around the world. (+) WDC (+4.69%) Deutsche Bank upgrades rating on shares (+) BLK (+3.25) Posts better-than-expected Q1 results (+) SGMS (+8.04%) Announces digital sports betting deal with Wynn | Looking ahead to Wednesday's earnings, Abbott Laboratories ( ABT ), PepsiCo ( PEP ) and US Bancorp ( USB ) are among a host of companies set to report. Stocks posted slight gains Tuesday as the Nasdaq Composite Index closed above 8,000 for the first time since October. The Dow Jones Industrial Average and the Nasdaq Composite Index both added 0.3%. | Looking ahead to Wednesday's earnings, Abbott Laboratories ( ABT ), PepsiCo ( PEP ) and US Bancorp ( USB ) are among a host of companies set to report. Dow Jones Industrial Average was up 67.89 points (+0.26%) to 26,452.66 S&P 500 was up 1.48 points (+0.05%) to 2,907.06 Nasdaq Composite Index was up 24.21 points (+0.30%) to 8,000.23 FTSE 100 was up 33.05 points (+0.44%) to 7,469.92 Hang Seng Index was up 319.15 points (+1.07%) to 30,129.87 Shanghai China Composite Index was up 75.81 points (+2.39%) to 3,253.60 | Looking ahead to Wednesday's earnings, Abbott Laboratories ( ABT ), PepsiCo ( PEP ) and US Bancorp ( USB ) are among a host of companies set to report. Stocks posted slight gains Tuesday as the Nasdaq Composite Index closed above 8,000 for the first time since October. The Dow Jones Industrial Average and the Nasdaq Composite Index both added 0.3%. |
33004.0 | 2019-04-16 00:00:00 UTC | Pre-Market Earnings Report for April 17, 2019 : PEP, ABT, ASML, USB, MS, BK, ERIC, TXT, KSU, SBNY, PNR, POL | ABT | https://www.nasdaq.com/articles/pre-market-earnings-report-april-17-2019-pep-abt-asml-usb-ms-bk-eric-txt-ksu-sbny-pnr-pol | nan | nan | The following companies are expected to repor t earnings prior to market open on 04/17/2019. Visit our Earnings Calendar for a full list of expected earnings releases.
Pepsico, Inc. ( PEP ) is reporting for the quarter ending March 31, 2019. The beverages company's consensus earnings per share forecast from the 8 analysts that follow the stock is $0.92. This value represents a 4.17% decrease compared to the same quarter last year. In the past year PEP has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2019 Price to Earnings ratio for PEP is 22.48 vs. an industry ratio of 20.90, implying that they will have a higher earnings growth than their competitors in the same industry.
Abbott Laboratories ( ABT ) is reporting for the quarter ending March 31, 2019. The medical products company's consensus earnings per share forecast from the 9 analysts that follow the stock is $0.61. This value represents a 3.39% increase compared to the same quarter last year. In the past year ABT has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2019 Price to Earnings ratio for ABT is 24.22 vs. an industry ratio of 9.00, implying that they will have a higher earnings growth than their competitors in the same industry.
ASML Holding N.V. ( ASML ) is reporting for the quarter ending March 31, 2019. The capital goods company's consensus earnings per share forecast from the 1 analyst that follows the stock is $0.54. This value represents a 65.16% decrease compared to the same quarter last year. ASML missed the consensus earnings per share in the 3rd calendar quarter of 2018 by -2.11%. Zacks Investment Research reports that the 2019 Price to Earnings ratio for ASML is 28.92 vs. an industry ratio of 18.30, implying that they will have a higher earnings growth than their competitors in the same industry.
U.S. Bancorp ( USB ) is reporting for the quarter ending March 31, 2019. The bank company's consensus earnings per share forecast from the 11 analysts that follow the stock is $1.00. This value represents a 5.26% increase compared to the same quarter last year. In the past year USB has beat the expectations every quarter. The highest one was in the 4th calendar quarter where they beat the consensus by 0.94%. Zacks Investment Research reports that the 2019 Price to Earnings ratio for USB is 11.58 vs. an industry ratio of 10.90, implying that they will have a higher earnings growth than their competitors in the same industry.
Morgan Stanley ( MS ) is reporting for the quarter ending March 31, 2019. The investment bankers company's consensus earnings per share forecast from the 4 analysts that follow the stock is $1.17. This value represents a 19.31% decrease compared to the same quarter last year. MS missed the consensus earnings per share in the 4th calendar quarter of 2018 by -18.89%. Zacks Investment Research reports that the 2019 Price to Earnings ratio for MS is 9.78 vs. an industry ratio of 11.20.
Bank Of New York Mellon Corporation ( BK ) is reporting for the quarter ending March 31, 2019. The bank company's consensus earnings per share forecast from the 7 analysts that follow the stock is $0.96. This value represents a 12.73% decrease compared to the same quarter last year. In the past year BK has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2019 Price to Earnings ratio for BK is 12.38 vs. an industry ratio of 10.90, implying that they will have a higher earnings growth than their competitors in the same industry.
Ericsson ( ERIC ) is reporting for the quarter ending March 31, 2019. The wireless equipment company's consensus earnings per share forecast from the 3 analysts that follow the stock is $0.04. This value represents a 300.00% increase compared to the same quarter last year. Zacks Investment Research reports that the 2019 Price to Earnings ratio for ERIC is 30.19 vs. an industry ratio of -231.00, implying that they will have a higher earnings growth than their competitors in the same industry.
Textron Inc. ( TXT ) is reporting for the quarter ending March 31, 2019. The aerospace and defense company's consensus earnings per share forecast from the 5 analysts that follow the stock is $0.70. This value represents a 2.78% decrease compared to the same quarter last year. TXT missed the consensus earnings per share in the 3rd calendar quarter of 2018 by -19.74%. Zacks Investment Research reports that the 2019 Price to Earnings ratio for TXT is 14.01 vs. an industry ratio of 23.90.
Kansas City Southern ( KSU ) is reporting for the quarter ending March 31, 2019. The transportation (rail) company's consensus earnings per share forecast from the 6 analysts that follow the stock is $1.45. This value represents a 11.54% increase compared to the same quarter last year. Zacks Investment Research reports that the 2019 Price to Earnings ratio for KSU is 17.40 vs. an industry ratio of 17.40.
Signature Bank ( SBNY ) is reporting for the quarter ending March 31, 2019. The bank (northeast) company's consensus earnings per share forecast from the 17 analysts that follow the stock is $2.76. This value represents a 2.60% increase compared to the same quarter last year. In the past year SBNY has beat the expectations every quarter. The highest one was in the 4th calendar quarter where they beat the consensus by 5.38%. Zacks Investment Research reports that the 2019 Price to Earnings ratio for SBNY is 11.75 vs. an industry ratio of 11.70, implying that they will have a higher earnings growth than their competitors in the same industry.
Pentair plc. ( PNR ) is reporting for the quarter ending March 31, 2019. The machinery (thermal proc) company's consensus earnings per share forecast from the 8 analysts that follow the stock is $0.43. This value represents a 51.14% decrease compared to the same quarter last year. In the past year PNR has beat the expectations every quarter. The highest one was in the 4th calendar quarter where they beat the consensus by 1.69%. Zacks Investment Research reports that the 2019 Price to Earnings ratio for PNR is 17.12 vs. an industry ratio of 19.00.
PolyOne Corporation ( POL ) is reporting for the quarter ending March 31, 2019. The plastics company's consensus earnings per share forecast from the 8 analysts that follow the stock is $0.65. This value represents a 4.41% decrease compared to the same quarter last year. POL missed the consensus earnings per share in the 2nd calendar quarter of 2018 by -1.39%. Zacks Investment Research reports that the 2019 Price to Earnings ratio for POL is 11.90 vs. an industry ratio of 10.20, implying that they will have a higher earnings growth than their competitors in the same industry.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) is reporting for the quarter ending March 31, 2019. In the past year ABT has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2019 Price to Earnings ratio for ABT is 24.22 vs. an industry ratio of 9.00, implying that they will have a higher earnings growth than their competitors in the same industry. | Zacks Investment Research reports that the 2019 Price to Earnings ratio for ABT is 24.22 vs. an industry ratio of 9.00, implying that they will have a higher earnings growth than their competitors in the same industry. Abbott Laboratories ( ABT ) is reporting for the quarter ending March 31, 2019. In the past year ABT has met analyst expectations once and beat the expectations the other three quarters. | Abbott Laboratories ( ABT ) is reporting for the quarter ending March 31, 2019. In the past year ABT has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2019 Price to Earnings ratio for ABT is 24.22 vs. an industry ratio of 9.00, implying that they will have a higher earnings growth than their competitors in the same industry. | Abbott Laboratories ( ABT ) is reporting for the quarter ending March 31, 2019. In the past year ABT has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2019 Price to Earnings ratio for ABT is 24.22 vs. an industry ratio of 9.00, implying that they will have a higher earnings growth than their competitors in the same industry. |
33005.0 | 2019-04-16 00:00:00 UTC | Is AbbVie Stock An Undiscovered Cannabis Play Waiting For Some Attention? | ABT | https://www.nasdaq.com/articles/abbvie-stock-undiscovered-cannabis-play-waiting-some-attention-2019-04-16 | nan | nan | The market opportunity for cannabis is enormous. According to Grand View Research, the spending is expected to hit a staggering $146.4 billion in the U.S. by the end of 2025.
Nowadays there are more publicly traded companies to play this , including names like Canopy Growth (NYSE:), Aurora Cannabis (NYSE:), Cronos Group (NASDAQ:), and Tilray (NASDAQ:). Beyond these stocks’ extreme volatility, they also fetch sky-high valuations, with price-to-sales multiples often well over 50x.
So, is there way to get exposure to the cannabis opportunity — but not take on too much risk? Interestingly enough, there is one such stock to consider: AbbVie (NYSE:). It’s a company that rarely pops up on many people’s radar screen when it comes to cannabis. After all, it’s one of the world’s largest traditional pharma operators, with roots going back to 1888. Keep in mind that ABBV stock was spun-off from Abbott Laboratories (NYSE:) in 2013.
So what does ABBV stock have to do with cannabis? Well, consider that the company has a drug on the market, called Marinol. It is based on a compound known as dronabinol, a synthetic form of THC, which is a natural part of the marijuana plant (that is, cannabis sativa). This is what activates the “high.”
Now Marinol has proven to be effective in dealing with the symptoms of a host of terrible diseases. For example, it helps deal with the nausea from chemotherapy and the weight problems resulting from those who suffer from AIDS.
Granted, Marinol is not a blockbuster drug. But then again, it does show the promise of cannabis as a treatment. More importantly, as for AbbVie stock, the drug is an indication of the company’s ability to push innovation with alternative treatments. In other words, it would not be a surprise that it will go on to leverage this experience to look at more treatments.
What’s more, the use of cannabis for medical purposes is certainly a major opportunity. There are already , whether on a federal or state level.
Bottom Line on AbbVie Stock
Granted, it would not be a good idea to invest in AbbVie stock just because it has a cannabis drug. To be sure, as seen with the latest earnings report, the company does have some problems as it issued disappointing guidance. Since early this year, ABBV stock has sunk from $91 to $81.
The nagging issue is the company’s most important drug, Humira (this is for the treatment of arthritis, plaque psoriasis, Crohn’s disease, and ulcerative colitis). For the most part, the growth is slowing. And yes, there are worries about when the U.S. patent protection comes off in 2023.
Despite all this, I still think there is a bullish case for AbbVie stock. One, the company has a decent roster of drug candidates that could move the needle — and help make up for a shortfall in Humira. For example, it has (risankizumab and upadacitinib) that should hit the markets this year. Interestingly enough, when it comes to the pipeline, AbbVie has lots of potential with the cancer market. To this end, its drug Imbruvica is likely to spin-off various treatments for the category.
And who knows, perhaps there could be potential from cannabis as well? I think so.
In the meantime, AbbVie stock sports a dirt-cheap valuation, with the forward price-to-earnings multiple at only 8.6x. Oh, and the dividend is at 5.15%, making it one of the highest among the major pharma companies.
Tom Taulli is the author of , All About Commodities and . Follow him on Twitter at @ttaulli. As of this writing, he did not hold a position in any of the aforementioned securities.
The post appeared first on InvestorPlace.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | It is based on a compound known as dronabinol, a synthetic form of THC, which is a natural part of the marijuana plant (that is, cannabis sativa). More importantly, as for AbbVie stock, the drug is an indication of the company’s ability to push innovation with alternative treatments. The nagging issue is the company’s most important drug, Humira (this is for the treatment of arthritis, plaque psoriasis, Crohn’s disease, and ulcerative colitis). | Nowadays there are more publicly traded companies to play this , including names like Canopy Growth (NYSE:), Aurora Cannabis (NYSE:), Cronos Group (NASDAQ:), and Tilray (NASDAQ:). Bottom Line on AbbVie Stock Granted, it would not be a good idea to invest in AbbVie stock just because it has a cannabis drug. Since early this year, ABBV stock has sunk from $91 to $81. | Nowadays there are more publicly traded companies to play this , including names like Canopy Growth (NYSE:), Aurora Cannabis (NYSE:), Cronos Group (NASDAQ:), and Tilray (NASDAQ:). More importantly, as for AbbVie stock, the drug is an indication of the company’s ability to push innovation with alternative treatments. Bottom Line on AbbVie Stock Granted, it would not be a good idea to invest in AbbVie stock just because it has a cannabis drug. | Interestingly enough, there is one such stock to consider: AbbVie (NYSE:). So what does ABBV stock have to do with cannabis? Well, consider that the company has a drug on the market, called Marinol. |
33006.0 | 2019-04-15 00:00:00 UTC | Interesting ABT Put Options For May 31st | ABT | https://www.nasdaq.com/articles/interesting-abt-put-options-may-31st-2019-04-15 | nan | nan | Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the May 31st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new May 31st contracts and identified the following put contract of particular interest.
The put contract at the $70.00 strike price has a current bid of 24 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $70.00, but will also collect the premium, putting the cost basis of the shares at $69.76 (before broker commissions). To an investor already interested in purchasing shares of ABT, that could represent an attractive alternative to paying $77.88/share today.
Because the $70.00 strike represents an approximate 10% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 93%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 0.34% return on the cash commitment, or 2.72% annualized — at Stock Options Channel we call this the YieldBoost.
Below is a chart showing the trailing twelve month trading history for Abbott Laboratories, and highlighting in green where the $70.00 strike is located relative to that history:
The implied volatility in the put contract example above is 31%.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 251 trading day closing values as well as today's price of $77.88) to be 21%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Puts of Stocks Analysts Like »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the May 31st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new May 31st contracts and identified the following put contract of particular interest. To an investor already interested in purchasing shares of ABT, that could represent an attractive alternative to paying $77.88/share today. | To an investor already interested in purchasing shares of ABT, that could represent an attractive alternative to paying $77.88/share today. Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the May 31st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new May 31st contracts and identified the following put contract of particular interest. | At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new May 31st contracts and identified the following put contract of particular interest. Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the May 31st expiration. To an investor already interested in purchasing shares of ABT, that could represent an attractive alternative to paying $77.88/share today. | At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new May 31st contracts and identified the following put contract of particular interest. Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the May 31st expiration. To an investor already interested in purchasing shares of ABT, that could represent an attractive alternative to paying $77.88/share today. |
33007.0 | 2019-04-15 00:00:00 UTC | The Future Keeps Looking Better and Better for BAX Stock | ABT | https://www.nasdaq.com/articles/future-keeps-looking-better-and-better-bax-stock-2019-04-15 | nan | nan | Good news continues to benefit Baxter International (NYSE:) stock. The Deerfield, Illinois-based medical equipment company received Food and Drug Administration (FDA) approval for its latest version of Floseal. Floseal already led the industry among blood-clotting solutions, so how it affects BAX stock remains unclear.
Source: Shutterstock
However, with a demographic trend that continues to favor all things healthcare, it serves as yet another reason to buy Baxter International stock.
Baxter Improves Floseal
Baxter just received approval from the FDA for its next generation of its Floseal Hemostatic Matrix. The company designed Floseal to stop bleeding during surgeries when more conventional procedures fail. The company reduced both the components and the steps to prepare by 20% in this .
Floseal has become a success for Baxter. Despite its higher price, it , the competing product produced by Johnson & Johnson’s (NYSE:) Ethicon.
The Bulls and BAX stock
Interestingly, despite the compelling benefits Floseal appears to offer, it may not affect BAX significantly. The Advanced Surgery division which produces Floseal remains one of the company’s smaller divisions. The Renal Care, Medication Delivery, Pharmaceuticals, and Clinical Nutrition divisions all generate more revenue for the company.
Moreover, the slow, steady increases in BAX began 3.5 years ago. It traded at just under $33 per share in the fall of 2015. Today, it has risen to over $79 per share. This places it just shy of its all-time high of $82.25 per share where it peaked last month.
BAX also continues a pace of steady profit growth, which should rise to double-digit levels next year. Moreover, it trades at a forward price-to-earnings (PE) ratio of 21.3. This places its multiple close to long-term averages. It also makes it a cheaper stock than another peer, Abbott Laboratories (NYSE:)
Medicare Is Key for BAX
In most cases, I would call a stock with such metrics a hold. However, demographics provide a catalyst that will help BAX for now even if it failed to improve its products. The baby boom generation continues to age into Medicare at a rapid pace. A similar trend has appeared in other countries. This population’s need for more medical care almost guarantees an increase in profits for BAX over the next few years.
The peak of the baby boom occurred in 1957. Hence, age-ins to Medicare will peak 65 years after that year, meaning 2022. For this reason, I would expect at least three more years of a rising BAX.
This trend has already helped take the financials higher. Both revenue and dividends for BAX have risen every year since 2016. The 0.95% yield on the dividend probably will not motivate investors to buy. However, the annual increases for the payout likely reflect the bullish sentiment.
The Bottom Line on BAX Stock
Although a better Floseal should bring improved revenues to Baxter, demographics will continue to serve as the driving force behind BAX. As the leading product for blood clotting, the enhanced version of Floseal should help ensure that Baxter maintains its lead over Ethicon’s Surgiflo.
Still, the millions of baby boomers entering Medicare will more than likely remain the number one reason to buy BAX stock. With a greater need for care and the backing behind Medicare to pay, Baxter will benefit from this growing book of business for years to come.
The market will always welcome product improvements. Despite this benefit, the growth in BAX will remain tied primarily to Medicare age-ins for the foreseeable future.
As of this writing, Will Healy did not hold a position in any of the aforementioned stocks. You can at @HealyWriting.
More From InvestorPlace
The post appeared first on InvestorPlace.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The Deerfield, Illinois-based medical equipment company received Food and Drug Administration (FDA) approval for its latest version of Floseal. Source: Shutterstock However, with a demographic trend that continues to favor all things healthcare, it serves as yet another reason to buy Baxter International stock. Still, the millions of baby boomers entering Medicare will more than likely remain the number one reason to buy BAX stock. | Good news continues to benefit Baxter International (NYSE:) stock. Baxter Improves Floseal Baxter just received approval from the FDA for its next generation of its Floseal Hemostatic Matrix. The Bottom Line on BAX Stock Although a better Floseal should bring improved revenues to Baxter, demographics will continue to serve as the driving force behind BAX. | Baxter Improves Floseal Baxter just received approval from the FDA for its next generation of its Floseal Hemostatic Matrix. The Bulls and BAX stock Interestingly, despite the compelling benefits Floseal appears to offer, it may not affect BAX significantly. The Bottom Line on BAX Stock Although a better Floseal should bring improved revenues to Baxter, demographics will continue to serve as the driving force behind BAX. | Both revenue and dividends for BAX have risen every year since 2016. The Bottom Line on BAX Stock Although a better Floseal should bring improved revenues to Baxter, demographics will continue to serve as the driving force behind BAX. Still, the millions of baby boomers entering Medicare will more than likely remain the number one reason to buy BAX stock. |
33008.0 | 2019-04-13 00:00:00 UTC | 3 Top Diabetes Stocks to Watch in April | ABT | https://www.nasdaq.com/articles/3-top-diabetes-stocks-watch-april-2019-04-13-0 | nan | nan | The diabetes market is massive and gets bigger every year. The numbers are so big that investors have lots of publicly traded companies to choose from that address diabetes treatment.
So which diabetes stocks do our team of Motley Fool contributors have their eyes on right now? They've called out Dexcom (NASDAQ: DXCM) , Tandem Diabetes Care (NASDAQ: TNDM) , and Medtronic (NYSE: MDT) .
The CGM Leader
Todd Campbell (Dexcom): The expected launch of Abbott Labs ' (NYSE: ABT) next-generation Freestyle Libre 2.0 continuous glucose monitor (CGM) has increased worries that Dexcom's status as the best-in-breed CGM player could be in jeopardy.
Diabetics often rely on frequent finger sticks to determine insulin dosing, but that approach only provides point-in-time insight, so patients spend a lot of their day outside their desired range. That's a problem, because it can lead to dangerous glucose highs and lows that contribute to disease progression.
To better control their disease, patients are embracing CGMs for real-time insight. Dexcom and Abbott are the biggest CGM manufacturers, and sales at both companies have been surging because of new products. Dexcom's revenue has been rising because of its G6 launch in the U.S., while Abbott's sales have benefited from the launch of the Freestyle Libre 2.0 in Europe.
There's no timeline for a Freestyle Libre 2.0 approval in the U.S., but it's expected this year. When the Libre 2.0 launches, Abbott should be able to better compete against Dexcom, because the Libre 2.0 is the first Abbott system to include glucose high-and-low alarms, and its sensors last 14 days, versus 10 days for the G6. The Libre 2.0 is also expected to launch in the U.S. at a price that could undercut the G6, making it even more attractive to users.
The Libre 2.0 threat shouldn't be ignored, but investors might not want to bet against Dexcom. Millions of patients can benefit from CGMs, so there's room for multiple offerings. In addition, the G6 is incorporated into Tandem Diabetes' insulin delivery system, which pairs it with a pump to deliver insulin automatically. A similar system incorporating the G6 is expected to be available from Insulet (NASDAQ: PODD) in 2020. The G6 is also being incorporated into smart insulin devices at Eli Lilly and Novo Nordisk , the two biggest insulin drugmakers.
Furthermore, Dexcom's collaborating with Alphabet spinoff Verily on the G7, a cheaper solution that could help insulate it against Abbott beginning late next year.
There's no telling how market share will shake out, but Dexcom reports its most recent quarterly results on May 1, so investors will want to tune in to see what it says about the competitive landscape, market share, and its progress on the G7.
The comeback kid
Brian Feroldi (Tandem Diabetes Care): I worked in the diabetes industry for more than a decade, so I've been following Tandem Diabetes Care since its product first hit the market. I've been highly skeptical of the company for years, since I didn't think its product offering was different enough to set it apart in a crowded market. I even thought the company was going to have to close up shop last year, since it was running out of money and its stock price had fallen drastically.
Thus far, Tandem has proved me wrong on both accounts. The company has done an incredible job at stealing market share from the likes of Medtronic and Insulet. What's more, the stock price has seen a remarkable recovery ever since the company performed an incredibly dilutive common stock offering in early 2018 -- Tandem sold 34.5 million shares of stock for just $2 each, which diluted existing shareholders by several hundred percent at the time.
Tandem is in a much better financial position today than it was just a year ago, and it looks poised to continued rapid growth. Management is calling for revenue growth of at least 39% in 2019, which is a clear sign that it expects the company to continue grabbing market share. That fact alone puts this company high on my watch list.
To be clear, "watch" is the keyword I want to emphasize. Tandem does look poised for continued growth, but I can't help thinking Wall Street's enthusiasm for this company has gotten way ahead of the fundamentals. Shares are currently trading for more than 20 times trailing sales , a figure that's pricing in a lot of continued prosperity. While I'm no longer fearful about this company's ability to survive, I do question whether it can live up to the extreme optimism baked into its share price. After all, the company is still squaring off against formidable competition, its longtime CEO is stepping down, and it's still expected to post big losses both this year and next. When combined with an astronomical valuation, I can't help thinking caution is warranted.
I've been dead wrong about Tandem before, and it's possible the company could go on to be a great investment from here. However, my view is that the risk/reward ratio is very unfavorable at today's prices, so I'm happy to watch this story from the safety of the sidelines.
The closest thing to an artificial pancreas
Chuck Saletta(Medtronic): Type 1 diabetics are typically totally dependent on externally supplied insulin for their survival. Without it, their bodies can't metabolize sugar properly, and they would eventually die from the disease if left untreated.
The challenge with treating diabetes with externally administered insulin, however, is that patients need to be careful how much they take and when they take it. Dosing insulin incorrectly can itself cause health problems, so vigilance is the constant refrain of Type 1 diabetics who want to live long and otherwise healthy lives.
Yet while there still isn't a clear cure for Type 1 diabetes , there is a treatment that can help sufferers of the disease better manage their condition. It's called an insulin pump, and it can monitor diabetics' blood sugar levels and automatically provide appropriate dosages as needed. The typical insulin pump user has better A1C scores -- an important measure for how in control a diabetic's condition is -- and lower risks of complications than those that don't use the technology.
When it comes to insulin pumps, Medtronic stands out as a clear winner in the space. Its pumps have been called "probably the closest systems to artificial pancreases available on the market today." That leadership position gives investors reason to believe the business has staying power. The fact that its shares have drifted down over the past six months makes it worth looking at today.
Thanks to that downward direction in its stock price, Medtronic can now be purchased for around 16 times the company's anticipated forward earnings. With those earnings expected to grow at around 7.8% annualized over the next five or so years, today's investors are getting an opportunity to consider buying a strong company at a reasonable valuation.
10 stocks we like better than Medtronic
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Medtronic wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 1, 2019
Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Brian Feroldi owns shares of Alphabet (A shares) and Alphabet (C shares). Chuck Saletta has no position in any of the stocks mentioned. Todd Campbell owns shares of Alphabet (C shares) and DexCom. The Motley Fool owns shares of and recommends Alphabet (A shares) and Alphabet (C shares). The Motley Fool recommends Insulet and Novo Nordisk. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The CGM Leader Todd Campbell (Dexcom): The expected launch of Abbott Labs ' (NYSE: ABT) next-generation Freestyle Libre 2.0 continuous glucose monitor (CGM) has increased worries that Dexcom's status as the best-in-breed CGM player could be in jeopardy. Diabetics often rely on frequent finger sticks to determine insulin dosing, but that approach only provides point-in-time insight, so patients spend a lot of their day outside their desired range. The closest thing to an artificial pancreas Chuck Saletta(Medtronic): Type 1 diabetics are typically totally dependent on externally supplied insulin for their survival. | The CGM Leader Todd Campbell (Dexcom): The expected launch of Abbott Labs ' (NYSE: ABT) next-generation Freestyle Libre 2.0 continuous glucose monitor (CGM) has increased worries that Dexcom's status as the best-in-breed CGM player could be in jeopardy. They've called out Dexcom (NASDAQ: DXCM) , Tandem Diabetes Care (NASDAQ: TNDM) , and Medtronic (NYSE: MDT) . The Motley Fool owns shares of and recommends Alphabet (A shares) and Alphabet (C shares). | The CGM Leader Todd Campbell (Dexcom): The expected launch of Abbott Labs ' (NYSE: ABT) next-generation Freestyle Libre 2.0 continuous glucose monitor (CGM) has increased worries that Dexcom's status as the best-in-breed CGM player could be in jeopardy. The comeback kid Brian Feroldi (Tandem Diabetes Care): I worked in the diabetes industry for more than a decade, so I've been following Tandem Diabetes Care since its product first hit the market. What's more, the stock price has seen a remarkable recovery ever since the company performed an incredibly dilutive common stock offering in early 2018 -- Tandem sold 34.5 million shares of stock for just $2 each, which diluted existing shareholders by several hundred percent at the time. | The CGM Leader Todd Campbell (Dexcom): The expected launch of Abbott Labs ' (NYSE: ABT) next-generation Freestyle Libre 2.0 continuous glucose monitor (CGM) has increased worries that Dexcom's status as the best-in-breed CGM player could be in jeopardy. In addition, the G6 is incorporated into Tandem Diabetes' insulin delivery system, which pairs it with a pump to deliver insulin automatically. Management is calling for revenue growth of at least 39% in 2019, which is a clear sign that it expects the company to continue grabbing market share. |
33009.0 | 2019-04-11 00:00:00 UTC | Abbott Laboratories (ABT) Ex-Dividend Date Scheduled for April 12, 2019 | ABT | https://www.nasdaq.com/articles/abbott-laboratories-abt-ex-dividend-date-scheduled-april-12-2019-2019-04-11 | nan | nan | Abbott Laboratories ( ABT ) will begin trading ex-dividend on April 12, 2019. A cash dividend payment of $0.32 per share is scheduled to be paid on May 15, 2019. Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. This represents an 14.29% increase over prior dividend payment. At the current stock price of $78.97, the dividend yield is 1.62%.
The previous trading day's last sale of ABT was $78.97, representing a -2.19% decrease from the 52 week high of $80.74 and a 39.01% increase over the 52 week low of $56.81.
ABT is a part of the Health Care sector, which includes companies such as Johnson & Johnson ( JNJ ) and Pfizer, Inc. ( PFE ). ABT's current earnings per share, an indicator of a company's profitability, is $1.33. Zacks Investment Research reports ABT's forecasted earnings growth in 2019 as 11.21%, compared to an industry average of 6.5%.
For more information on the declaration, record and payment dates, visit the ABT Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to ABT through an Exchange Traded Fund [ETF]?
The following ETF(s) have ABT as a top-10 holding:
First Trust Nasdaq Pharmaceuticals ETF ( FTXH )
Invesco Dynamic Pharmaceuticals ETF ( PJP )
AdvisorShares Vice ETF ( ACT )
SPDR Select Sector Fund - Health Care ( XLV )
iShares U.S. Medical Devices ETF ( IHI ).
The top-performing ETF of this group is IHI with an increase of 11.73% over the last 100 days. FTXH has the highest percent weighting of ABT at 8.2%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. Zacks Investment Research reports ABT's forecasted earnings growth in 2019 as 11.21%, compared to an industry average of 6.5%. For more information on the declaration, record and payment dates, visit the ABT Dividend History page. | The following ETF(s) have ABT as a top-10 holding: First Trust Nasdaq Pharmaceuticals ETF ( FTXH ) Invesco Dynamic Pharmaceuticals ETF ( PJP ) AdvisorShares Vice ETF ( ACT ) SPDR Select Sector Fund - Health Care ( XLV ) iShares U.S. Medical Devices ETF ( IHI ). The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Abbott Laboratories ( ABT ) will begin trading ex-dividend on April 12, 2019. | Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. For more information on the declaration, record and payment dates, visit the ABT Dividend History page. The following ETF(s) have ABT as a top-10 holding: First Trust Nasdaq Pharmaceuticals ETF ( FTXH ) Invesco Dynamic Pharmaceuticals ETF ( PJP ) AdvisorShares Vice ETF ( ACT ) SPDR Select Sector Fund - Health Care ( XLV ) iShares U.S. Medical Devices ETF ( IHI ). | ABT's current earnings per share, an indicator of a company's profitability, is $1.33. The following ETF(s) have ABT as a top-10 holding: First Trust Nasdaq Pharmaceuticals ETF ( FTXH ) Invesco Dynamic Pharmaceuticals ETF ( PJP ) AdvisorShares Vice ETF ( ACT ) SPDR Select Sector Fund - Health Care ( XLV ) iShares U.S. Medical Devices ETF ( IHI ). Abbott Laboratories ( ABT ) will begin trading ex-dividend on April 12, 2019. |
33010.0 | 2019-04-10 00:00:00 UTC | ProShares UltraPro S&P500 Experiences Big Outflow | ABT | https://www.nasdaq.com/articles/proshares-ultrapro-sp500-experiences-big-outflow-2019-04-10 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the ProShares UltraPro S&P500 (Symbol: UPRO) where we have detected an approximate $54.2 million dollar outflow -- that's a 3.8% decrease week over week (from 27,600,000 to 26,550,000). Among the largest underlying components of UPRO, in trading today Walt Disney Co. (Symbol: DIS) is up about 0.1%, Abbott Laboratories (Symbol: ABT) is up about 0.6%, and Amgen Inc (Symbol: AMGN) is relatively unchanged. For a complete list of holdings, visit the UPRO Holdings page » The chart below shows the one year price performance of UPRO, versus its 200 day moving average:
Looking at the chart above, UPRO's low point in its 52 week range is $28.65 per share, with $58.95 as the 52 week high point — that compares with a last trade of $51.72. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of UPRO, in trading today Walt Disney Co. (Symbol: DIS) is up about 0.1%, Abbott Laboratories (Symbol: ABT) is up about 0.6%, and Amgen Inc (Symbol: AMGN) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the ProShares UltraPro S&P500 (Symbol: UPRO) where we have detected an approximate $54.2 million dollar outflow -- that's a 3.8% decrease week over week (from 27,600,000 to 26,550,000). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of UPRO, in trading today Walt Disney Co. (Symbol: DIS) is up about 0.1%, Abbott Laboratories (Symbol: ABT) is up about 0.6%, and Amgen Inc (Symbol: AMGN) is relatively unchanged. For a complete list of holdings, visit the UPRO Holdings page » The chart below shows the one year price performance of UPRO, versus its 200 day moving average: Looking at the chart above, UPRO's low point in its 52 week range is $28.65 per share, with $58.95 as the 52 week high point — that compares with a last trade of $51.72. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of UPRO, in trading today Walt Disney Co. (Symbol: DIS) is up about 0.1%, Abbott Laboratories (Symbol: ABT) is up about 0.6%, and Amgen Inc (Symbol: AMGN) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the ProShares UltraPro S&P500 (Symbol: UPRO) where we have detected an approximate $54.2 million dollar outflow -- that's a 3.8% decrease week over week (from 27,600,000 to 26,550,000). For a complete list of holdings, visit the UPRO Holdings page » The chart below shows the one year price performance of UPRO, versus its 200 day moving average: Looking at the chart above, UPRO's low point in its 52 week range is $28.65 per share, with $58.95 as the 52 week high point — that compares with a last trade of $51.72. | Among the largest underlying components of UPRO, in trading today Walt Disney Co. (Symbol: DIS) is up about 0.1%, Abbott Laboratories (Symbol: ABT) is up about 0.6%, and Amgen Inc (Symbol: AMGN) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the ProShares UltraPro S&P500 (Symbol: UPRO) where we have detected an approximate $54.2 million dollar outflow -- that's a 3.8% decrease week over week (from 27,600,000 to 26,550,000). For a complete list of holdings, visit the UPRO Holdings page » The chart below shows the one year price performance of UPRO, versus its 200 day moving average: Looking at the chart above, UPRO's low point in its 52 week range is $28.65 per share, with $58.95 as the 52 week high point — that compares with a last trade of $51.72. |
33011.0 | 2019-04-10 00:00:00 UTC | Ex-Dividend Reminder: Becton, Dickinson, AbbVie and Abbott Laboratories | ABT | https://www.nasdaq.com/articles/ex-dividend-reminder-becton-dickinson-abbvie-and-abbott-laboratories-2019-04-10 | nan | nan | Looking at the universe of stocks we cover at Dividend Channel, on 4/12/19, Becton, Dickinson & Co (Symbol: BDXA), AbbVie Inc (Symbol: ABBV), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. Becton, Dickinson & Co will pay its quarterly dividend of $0.7656 on 5/1/19, AbbVie Inc will pay its quarterly dividend of $1.07 on 5/15/19, and Abbott Laboratories will pay its quarterly dividend of $0.32 on 5/15/19. As a percentage of BDXA's recent stock price of $62.09, this dividend works out to approximately 1.23%, so look for shares of Becton, Dickinson & Co to trade 1.23% lower — all else being equal — when BDXA shares open for trading on 4/12/19. Similarly, investors should look for ABBV to open 1.29% lower in price and for ABT to open 0.41% lower, all else being equal.
Below are dividend history charts for BDXA, ABBV, and ABT, showing historical dividends prior to the most recent ones declared.
Becton, Dickinson & Co (Symbol: BDXA):
AbbVie Inc (Symbol: ABBV):
Abbott Laboratories (Symbol: ABT):
In general, dividends are not always predictable, following the ups and downs of company profits over time. Therefore, a good first due diligence step in forming an expectation of annual yield going forward, is looking at the history above, for a sense of stability over time. This can help in judging whether the most recent dividends from these companies are likely to continue. If they do continue, the current estimated yields on annualized basis would be 4.93% for Becton, Dickinson & Co, 5.15% for AbbVie Inc, and 1.63% for Abbott Laboratories.
In Wednesday trading, Becton, Dickinson & Co shares are currently down about 0.4%, AbbVie Inc shares are up about 0.5%, and Abbott Laboratories shares are up about 0.1% on the day.
Click here to learn which 25 S.A.F.E. dividend stocks should be on your radar screen »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Looking at the universe of stocks we cover at Dividend Channel, on 4/12/19, Becton, Dickinson & Co (Symbol: BDXA), AbbVie Inc (Symbol: ABBV), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. Similarly, investors should look for ABBV to open 1.29% lower in price and for ABT to open 0.41% lower, all else being equal. Below are dividend history charts for BDXA, ABBV, and ABT, showing historical dividends prior to the most recent ones declared. | Looking at the universe of stocks we cover at Dividend Channel, on 4/12/19, Becton, Dickinson & Co (Symbol: BDXA), AbbVie Inc (Symbol: ABBV), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. Becton, Dickinson & Co (Symbol: BDXA): AbbVie Inc (Symbol: ABBV): Abbott Laboratories (Symbol: ABT): In general, dividends are not always predictable, following the ups and downs of company profits over time. Similarly, investors should look for ABBV to open 1.29% lower in price and for ABT to open 0.41% lower, all else being equal. | Looking at the universe of stocks we cover at Dividend Channel, on 4/12/19, Becton, Dickinson & Co (Symbol: BDXA), AbbVie Inc (Symbol: ABBV), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. Becton, Dickinson & Co (Symbol: BDXA): AbbVie Inc (Symbol: ABBV): Abbott Laboratories (Symbol: ABT): In general, dividends are not always predictable, following the ups and downs of company profits over time. Similarly, investors should look for ABBV to open 1.29% lower in price and for ABT to open 0.41% lower, all else being equal. | Looking at the universe of stocks we cover at Dividend Channel, on 4/12/19, Becton, Dickinson & Co (Symbol: BDXA), AbbVie Inc (Symbol: ABBV), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. Similarly, investors should look for ABBV to open 1.29% lower in price and for ABT to open 0.41% lower, all else being equal. Below are dividend history charts for BDXA, ABBV, and ABT, showing historical dividends prior to the most recent ones declared. |
33012.0 | 2019-04-09 00:00:00 UTC | Abbott (ABT) Gains As Market Dips: What You Should Know | ABT | https://www.nasdaq.com/articles/abbott-abt-gains-as-market-dips%3A-what-you-should-know-2019-04-09-0 | nan | nan | Abbott (ABT) closed the most recent trading day at $78.67, moving +0.19% from the previous trading session. The stock outpaced the S&P 500's daily loss of 0.61%. At the same time, the Dow lost 0.72%, and the tech-heavy Nasdaq lost 0.56%.
Prior to today's trading, shares of the maker of infant formula, medical devices and drugs had gained 0.91% over the past month. This has lagged the Medical sector's gain of 2.13% and the S&P 500's gain of 5.68% in that time.
Wall Street will be looking for positivity from ABT as it approaches its nex t earnings report date. This is expected to be April 17, 2019. In tha t report , analysts expect ABT to post earnings of $0.61 per share. This would mark year-over-year growth of 3.39%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $7.48 billion, up 1.17% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $3.20 per share and revenue of $31.80 billion. These totals would mark changes of +11.11% and +4.01%, respectively, from last year.
Any recent changes to analyst estimates for ABT should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. ABT currently has a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that ABT has a Forward P/E ratio of 24.52 right now. Its industry sports an average Forward P/E of 24.73, so we one might conclude that ABT is trading at a discount comparatively.
Meanwhile, ABT's PEG ratio is currently 2.09. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. Medical - Products stocks are, on average, holding a PEG ratio of 2.34 based on yesterday's closing prices.
The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 158, which puts it in the bottom 39% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott (ABT) closed the most recent trading day at $78.67, moving +0.19% from the previous trading session. Wall Street will be looking for positivity from ABT as it approaches its nex t earnings report date. In tha t report , analysts expect ABT to post earnings of $0.61 per share. | Abbott (ABT) closed the most recent trading day at $78.67, moving +0.19% from the previous trading session. Wall Street will be looking for positivity from ABT as it approaches its nex t earnings report date. In tha t report , analysts expect ABT to post earnings of $0.61 per share. | Abbott (ABT) closed the most recent trading day at $78.67, moving +0.19% from the previous trading session. Wall Street will be looking for positivity from ABT as it approaches its nex t earnings report date. In tha t report , analysts expect ABT to post earnings of $0.61 per share. | Any recent changes to analyst estimates for ABT should also be noted by investors. Abbott (ABT) closed the most recent trading day at $78.67, moving +0.19% from the previous trading session. Wall Street will be looking for positivity from ABT as it approaches its nex t earnings report date. |
33013.0 | 2019-04-07 00:00:00 UTC | Better Buy: AbbVie vs. Johnson & Johnson | ABT | https://www.nasdaq.com/articles/better-buy-abbvie-vs-johnson-johnson-2019-04-07 | nan | nan | AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) are both monster healthcare companies that have been stellar holdings for long-term shareholders. Both of these healthcare giants post consistent growth, crank out profits, and have a history of sharing the wealth with their investors.
But which is the better choice for new money today?
Image source: Getty Images.
Growth
You can't talk about AbbVie's growth prospects without focusing on a single drug: Humira. This blockbuster compound accounts for more than 60% of total revenue, and has been the company's primary driver for years.
The big concern facing Humira right now is that biosimilar competition is starting to enter the picture. That pressure is currently just limited to Europe, but it should spill over into the U.S. within just a few years.
AbbVie is aware of the headwinds, and has been aggressively developing new drugs to help fill in the eventual void. Current winners include the hematology drugs Imbruvica and Venclexta, as well as the hepatitis C drug Mavyret. These drugs are still in growth mode, and are expecting to pull in billions in annual revenue in the years ahead. The company's pipeline is also expected to go a long way toward overcoming the decline.
All told, Wall Street currently believes that AbbVie's bottom-line will grow in excess of 9% annually over the next five years. That's a pretty solid growth rate for such a mature business.
While Johnson & Johnson is a far more diversified business than AbbVie, it is having troubles with biosimilars too. Sales of the company's top-selling cancer drug, Remicade, are falling by double digits from the pressure of copycat competition.
J&J's management team has also focused its attention on new drug launches to help pick up the slack. The company's current winners include Stelara, Tremfy, Darzalex, and Zytiga, among others.
Unlike AbbVie, J&J isn't just a drug maker. The company also pulls in billions in annual sales from its consumer healthcare division and its medical device business. When combined, these two units pull in more than half of total sales, and are also helping to cushion the Remicade weakness.
Market watchers currently think that J&J will remain in growth mode over the next half-decade. The current estimate calls for more than 6% growth in profits over the next five years.
It is great to see that both of these businesses are still growing, but AbbVie's higher expected growth rate gives it the gold medal in this category.
Winner: AbbVie
Value
AbbVie is currently trading for 22.5 times its trailing earnings, which isn't all that enticing of a price. However, the number looks much better when you value this company based on its future earnings. AbbVie is currently trading for less than nine times next year's earnings estimates.
It's a similar situation with Johnson & Johnson. The stock is currently valued at more than 24 times trailing earnings, but that number drops all the way to below 15 when you use next year's estimated earnings.
There's an argument to be made that both of these stocks are cheap right now, but there's no doubt that AbbVie's stock is more of a bargain at the moment.
Winner: AbbVie
Income
AbbVie and Johnson & Johnson are both dividend dynamos.
AbbVie has paid out a solid dividend ever since it was spun-off of its former parent company Abbott Laboratories (NYSE: ABT) back in 2013. AbbVie's yield currently tops 5.1%, which is a monster number. What's more, the dividend only consumes about 55% of trailing earnings, so there's ample room left for future dividend hikes.
Johnson & Johnson also offers a market-topping yield of 2.6% right now, which is also quite attractive. The dividend only consumes about 44% of net income, so this one looks very safe too.
With a dividend yield that is nearly twice as high as its counterpart, AbbVie is the clear winner here.
Winner: AbbVie
The better buy
There is a legitimate argument to be made that Johnson & Johnson's stock is the better choice right now since AbbVie's future is so heavily reliant on the success of Humira. That's a fair criticism that shouldn't be taken lightly.
However, for this matchup there's no doubt who the clear winner is. AbbVie is growing faster, pays out a better dividend, and is trading at a cheaper valuation than Johnson & Johnson. That one-two-three punch is simply too tough to beat.
10 stocks we like better than Johnson & Johnson
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Johnson & Johnson wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 1, 2019
Brian Feroldi has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie has paid out a solid dividend ever since it was spun-off of its former parent company Abbott Laboratories (NYSE: ABT) back in 2013. Both of these healthcare giants post consistent growth, crank out profits, and have a history of sharing the wealth with their investors. Sales of the company's top-selling cancer drug, Remicade, are falling by double digits from the pressure of copycat competition. | AbbVie has paid out a solid dividend ever since it was spun-off of its former parent company Abbott Laboratories (NYSE: ABT) back in 2013. AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) are both monster healthcare companies that have been stellar holdings for long-term shareholders. Winner: AbbVie Value AbbVie is currently trading for 22.5 times its trailing earnings, which isn't all that enticing of a price. | AbbVie has paid out a solid dividend ever since it was spun-off of its former parent company Abbott Laboratories (NYSE: ABT) back in 2013. AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) are both monster healthcare companies that have been stellar holdings for long-term shareholders. Winner: AbbVie Income AbbVie and Johnson & Johnson are both dividend dynamos. | AbbVie has paid out a solid dividend ever since it was spun-off of its former parent company Abbott Laboratories (NYSE: ABT) back in 2013. These drugs are still in growth mode, and are expecting to pull in billions in annual revenue in the years ahead. The current estimate calls for more than 6% growth in profits over the next five years. |
33014.0 | 2019-04-07 00:00:00 UTC | Better Buy: AbbVie vs. Johnson & Johnson | ABT | https://www.nasdaq.com/articles/better-buy-abbvie-vs-johnson-johnson-2019-04-07-0 | nan | nan | AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) are both monster healthcare companies that have been stellar holdings for long-term shareholders. Both of these healthcare giants post consistent growth, crank out profits, and have a history of sharing the wealth with their investors.
But which is the better choice for new money today?
Growth
You can't talk about AbbVie's growth prospects without focusing on a single drug: Humira. This blockbuster compound accounts for more than 60% of total revenue, and has been the company's primary driver for years.
The big concern facing Humira right now is that biosimilar competition is starting to enter the picture. That pressure is currently just limited to Europe, but it should spill over into the U.S. within just a few years .
AbbVie is aware of the headwinds, and has been aggressively developing new drugs to help fill in the eventual void. Current winners include the hematology drugs Imbruvica and Venclexta, as well as the hepatitis C drug Mavyret. These drugs are still in growth mode, and are expecting to pull in billions in annual revenue in the years ahead. The company's pipeline is also expected to go a long way toward overcoming the decline.
All told, Wall Street currently believes that AbbVie's bottom-line will grow in excess of 9% annually over the next five years. That's a pretty solid growth rate for such a mature business.
While Johnson & Johnson is a far more diversified business than AbbVie, it is having troubles with biosimilars too. Sales of the company's top-selling cancer drug, Remicade, are falling by double digits from the pressure of copycat competition .
J&J's management team has also focused its attention on new drug launches to help pick up the slack. The company's current winners include Stelara, Tremfy, Darzalex, and Zytiga, among others.
Unlike AbbVie, J&J isn't just a drug maker. The company also pulls in billions in annual sales from its consumer healthcare division and its medical device business. When combined, these two units pull in more than half of total sales, and are also helping to cushion the Remicade weakness.
Market watchers currently think that J&J will remain in growth mode over the next half-decade. The current estimate calls for more than 6% growth in profits over the next five years.
It is great to see that both of these businesses are still growing, but AbbVie's higher expected growth rate gives it the gold medal in this category.
Winner: AbbVie
Value
AbbVie is currently trading for 22.5 times its trailing earnings, which isn't all that enticing of a price. However, the number looks much better when you value this company based on its future earnings. AbbVie is currently trading for less than nine times next year's earnings estimates.
It's a similar situation with Johnson & Johnson. The stock is currently valued at more than 24 times trailing earnings, but that number drops all the way to below 15 when you use next year's estimated earnings.
There's an argument to be made that both of these stocks are cheap right now, but there's no doubt that AbbVie's stock is more of a bargain at the moment.
Winner: AbbVie
Income
AbbVie and Johnson & Johnson are both dividend dynamos.
AbbVie has paid out a solid dividend ever since it was spun-off of its former parent company Abbott Laboratories (NYSE: ABT) back in 2013. AbbVie's yield currently tops 5.1%, which is a monster number. What's more, the dividend only consumes about 55% of trailing earnings, so there's ample room left for future dividend hikes.
Johnson & Johnson also offers a market-topping yield of 2.6% right now, which is also quite attractive. The dividend only consumes about 44% of net income, so this one looks very safe too.
With a dividend yield that is nearly twice as high as its counterpart, AbbVie is the clear winner here.
Winner: AbbVie
The better buy
There is a legitimate argument to be made that Johnson & Johnson's stock is the better choice right now since AbbVie's future is so heavily reliant on the success of Humira. That's a fair criticism that shouldn't be taken lightly.
However, for this matchup there's no doubt who the clear winner is. AbbVie is growing faster, pays out a better dividend, and is trading at a cheaper valuation than Johnson & Johnson. That one-two-three punch is simply too tough to beat.
10 stocks we like better than Johnson & Johnson
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Johnson & Johnson wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 1, 2019
Brian Feroldi has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie has paid out a solid dividend ever since it was spun-off of its former parent company Abbott Laboratories (NYSE: ABT) back in 2013. Both of these healthcare giants post consistent growth, crank out profits, and have a history of sharing the wealth with their investors. Sales of the company's top-selling cancer drug, Remicade, are falling by double digits from the pressure of copycat competition . | AbbVie has paid out a solid dividend ever since it was spun-off of its former parent company Abbott Laboratories (NYSE: ABT) back in 2013. AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) are both monster healthcare companies that have been stellar holdings for long-term shareholders. Winner: AbbVie Value AbbVie is currently trading for 22.5 times its trailing earnings, which isn't all that enticing of a price. | AbbVie has paid out a solid dividend ever since it was spun-off of its former parent company Abbott Laboratories (NYSE: ABT) back in 2013. AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) are both monster healthcare companies that have been stellar holdings for long-term shareholders. Winner: AbbVie Income AbbVie and Johnson & Johnson are both dividend dynamos. | AbbVie has paid out a solid dividend ever since it was spun-off of its former parent company Abbott Laboratories (NYSE: ABT) back in 2013. These drugs are still in growth mode, and are expecting to pull in billions in annual revenue in the years ahead. The current estimate calls for more than 6% growth in profits over the next five years. |
33015.0 | 2019-04-04 00:00:00 UTC | Here's Why DexCom Shares Slumped 14.5% in March | ABT | https://www.nasdaq.com/articles/heres-why-dexcom-shares-slumped-145-march-2019-04-04-0 | nan | nan | What happened
After a report was released by short-sellers last month highlighting threats facing the company, shares in DexCom (NASDAQ: DXCM) stumbled 14.5% in March, according to S&P Global Market Intelligence .
So what
DexCom's continuous glucose monitors (CGMs) help diabetics track their blood glucose levels better, reducing dangerous blood sugar highs and lows and potentially slowing disease progression.
In 2018, DexCom sales soared 44% year over year to $1.032 billion following the launch of its latest system, the G6. In 2019, sales could be harder to come by, though, according to short-seller Spruce Point Capital Management. In a report released last month, Spruce Point said the launch of Abbott Labs ' (NYSE: ABT) next-generation Freestyle Libre CGM and a maturing market among type 1 patients could cause DexCom to lose significant value.
Currently, DexCom competes against Medtronic 's Guardian brand of CGMs and the first-generation Freestyle Libre, a CGM that, unlike DexCom's G6, still requires patients to prick their fingers during the first 11 hours of wear to confirm readings -- and doesn't include blood glucose high and low alarms.
Abbott's already next-generation finger-stick-less Freestyle Libre has launched overseas, and while there's no timeline for a potential launch in the U.S., an eventual release could challenge DexCom because G6 sensors are approved for only 10 days of wear, while Freestyle Libre's sensors can be worn for 14 days. The longer wear can reduce patient's costs, making it attractive to patients with limited insurance coverage for the G6.
Now what
In 2019, DexCom doesn't expect to deliver growth similar to 2018, but it's still targeting revenue to increase by 15% to 20% to $1.175 billion- $1.225 billion. DexCom's also said its plan is to grow sales at a compounded annual rate of 15% through 2023.
Although more type 1 diabetics are using CGMs than ever before, the opportunity to penetrate the market for type 2 patients and others in need of monitoring, such as patients with gestational diabetes, is significant. Only 12.5% of the roughly 200 million people with diabetes worldwide achieve their desired blood glucose target.
The G6 is the only CGM to have secured an FDA approval for interoperability, so it stands to benefit from next-generation blood glucose control systems, including automated insulin devices from Tandem Diabetes and Insulet , and smart pen solutions at Eli Lilly and Novo Nordisk , the two largest manufacturers of insulin products. Tandem launched its first automated system last year; Insulet's system is expected next year; and Eli Lilly and Novo Nordisk's solutions are on deck.
Furthermore, DexCom could benefit from the anticipated launch of its G7 in 2020. Developed with help from Verily, a healthcare technology company spun off from Alphabet , the G7 is expected include a low-cost, disposable sensor that may allow DexCom to penetrate the type 2 market more effectively.
The threat posed by Abbott Labs shouldn't be ignored, but the size of this market and the potential advances in the next 12 to 24 months could make buying shares on this sell-off wise.
10 stocks we like better than DexCom
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 1, 2019
Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Todd Campbell owns shares of Alphabet (C shares) and DexCom. His clients may have positions in the companies mentioned.
The Motley Fool owns shares of and recommends Alphabet (A shares) and Alphabet (C shares). The Motley Fool recommends Insulet and Novo Nordisk. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In a report released last month, Spruce Point said the launch of Abbott Labs ' (NYSE: ABT) next-generation Freestyle Libre CGM and a maturing market among type 1 patients could cause DexCom to lose significant value. What happened After a report was released by short-sellers last month highlighting threats facing the company, shares in DexCom (NASDAQ: DXCM) stumbled 14.5% in March, according to S&P Global Market Intelligence . Developed with help from Verily, a healthcare technology company spun off from Alphabet , the G7 is expected include a low-cost, disposable sensor that may allow DexCom to penetrate the type 2 market more effectively. | In a report released last month, Spruce Point said the launch of Abbott Labs ' (NYSE: ABT) next-generation Freestyle Libre CGM and a maturing market among type 1 patients could cause DexCom to lose significant value. The G6 is the only CGM to have secured an FDA approval for interoperability, so it stands to benefit from next-generation blood glucose control systems, including automated insulin devices from Tandem Diabetes and Insulet , and smart pen solutions at Eli Lilly and Novo Nordisk , the two largest manufacturers of insulin products. Tandem launched its first automated system last year; Insulet's system is expected next year; and Eli Lilly and Novo Nordisk's solutions are on deck. | In a report released last month, Spruce Point said the launch of Abbott Labs ' (NYSE: ABT) next-generation Freestyle Libre CGM and a maturing market among type 1 patients could cause DexCom to lose significant value. Currently, DexCom competes against Medtronic 's Guardian brand of CGMs and the first-generation Freestyle Libre, a CGM that, unlike DexCom's G6, still requires patients to prick their fingers during the first 11 hours of wear to confirm readings -- and doesn't include blood glucose high and low alarms. Abbott's already next-generation finger-stick-less Freestyle Libre has launched overseas, and while there's no timeline for a potential launch in the U.S., an eventual release could challenge DexCom because G6 sensors are approved for only 10 days of wear, while Freestyle Libre's sensors can be worn for 14 days. | In a report released last month, Spruce Point said the launch of Abbott Labs ' (NYSE: ABT) next-generation Freestyle Libre CGM and a maturing market among type 1 patients could cause DexCom to lose significant value. Although more type 1 diabetics are using CGMs than ever before, the opportunity to penetrate the market for type 2 patients and others in need of monitoring, such as patients with gestational diabetes, is significant. The Motley Fool owns shares of and recommends Alphabet (A shares) and Alphabet (C shares). |
33016.0 | 2019-04-03 00:00:00 UTC | Abbott (ABT) Stock Sinks As Market Gains: What You Should Know | ABT | https://www.nasdaq.com/articles/abbott-abt-stock-sinks-as-market-gains%3A-what-you-should-know-2019-04-03-0 | nan | nan | Abbott (ABT) closed the most recent trading day at $79.50, moving -0.15% from the previous trading session. This change lagged the S&P 500's daily gain of 0.22%. At the same time, the Dow added 0.15%, and the tech-heavy Nasdaq gained 0.6%.
Coming into today, shares of the maker of infant formula, medical devices and drugs had gained 1.79% in the past month. In that same time, the Medical sector lost 0.07%, while the S&P 500 gained 2.39%.
ABT will be looking to display strength as it nears its nex t earnings release, which is expected to be April 17, 2019. In tha t report , analysts expect ABT to post earnings of $0.61 per share. This would mark year-over-year growth of 3.39%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $7.48 billion, up 1.17% from the year-ago period.
ABT's full-year Zacks Consensus Estimates are calling for earnings of $3.20 per share and revenue of $31.80 billion. These results would represent year-over-year changes of +11.11% and +4.01%, respectively.
Any recent changes to analyst estimates for ABT should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. ABT currently has a Zacks Rank of #3 (Hold).
Digging into valuation, ABT currently has a Forward P/E ratio of 24.86. For comparison, its industry has an average Forward P/E of 25.04, which means ABT is trading at a discount to the group.
Meanwhile, ABT's PEG ratio is currently 2.12. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. Medical - Products stocks are, on average, holding a PEG ratio of 2.31 based on yesterday's closing prices.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 102, putting it in the top 40% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow ABT in the coming trading sessions, be sure to utilize Zacks.com.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott (ABT) closed the most recent trading day at $79.50, moving -0.15% from the previous trading session. ABT will be looking to display strength as it nears its nex t earnings release, which is expected to be April 17, 2019. In tha t report , analysts expect ABT to post earnings of $0.61 per share. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott (ABT) closed the most recent trading day at $79.50, moving -0.15% from the previous trading session. ABT will be looking to display strength as it nears its nex t earnings release, which is expected to be April 17, 2019. | ABT's full-year Zacks Consensus Estimates are calling for earnings of $3.20 per share and revenue of $31.80 billion. ABT currently has a Zacks Rank of #3 (Hold). Abbott (ABT) closed the most recent trading day at $79.50, moving -0.15% from the previous trading session. | In tha t report , analysts expect ABT to post earnings of $0.61 per share. ABT currently has a Zacks Rank of #3 (Hold). Abbott (ABT) closed the most recent trading day at $79.50, moving -0.15% from the previous trading session. |
33017.0 | 2019-04-02 00:00:00 UTC | IHI, ABT, MDT, TMO: ETF Inflow Alert | ABT | https://www.nasdaq.com/articles/ihi-abt-mdt-tmo-etf-inflow-alert-2019-04-02 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $138.7 million dollar inflow -- that's a 3.9% increase week over week in outstanding units (from 15,200,000 to 15,800,000). Among the largest underlying components of IHI, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.3%, Medtronic PLC (Symbol: MDT) is down about 0.2%, and Thermo Fisher Scientific Inc (Symbol: TMO) is lower by about 0.5%. For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average:
Looking at the chart above, IHI's low point in its 52 week range is $179.371 per share, with $233.99 as the 52 week high point — that compares with a last trade of $230.35. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IHI, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.3%, Medtronic PLC (Symbol: MDT) is down about 0.2%, and Thermo Fisher Scientific Inc (Symbol: TMO) is lower by about 0.5%. For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $179.371 per share, with $233.99 as the 52 week high point — that compares with a last trade of $230.35. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IHI, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.3%, Medtronic PLC (Symbol: MDT) is down about 0.2%, and Thermo Fisher Scientific Inc (Symbol: TMO) is lower by about 0.5%. For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $179.371 per share, with $233.99 as the 52 week high point — that compares with a last trade of $230.35. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ». | Among the largest underlying components of IHI, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.3%, Medtronic PLC (Symbol: MDT) is down about 0.2%, and Thermo Fisher Scientific Inc (Symbol: TMO) is lower by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $138.7 million dollar inflow -- that's a 3.9% increase week over week in outstanding units (from 15,200,000 to 15,800,000). For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $179.371 per share, with $233.99 as the 52 week high point — that compares with a last trade of $230.35. | Among the largest underlying components of IHI, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.3%, Medtronic PLC (Symbol: MDT) is down about 0.2%, and Thermo Fisher Scientific Inc (Symbol: TMO) is lower by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $138.7 million dollar inflow -- that's a 3.9% increase week over week in outstanding units (from 15,200,000 to 15,800,000). For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $179.371 per share, with $233.99 as the 52 week high point — that compares with a last trade of $230.35. |
33018.0 | 2019-04-02 00:00:00 UTC | IHI, ABT, MDT, TMO: ETF Inflow Alert | ABT | https://www.nasdaq.com/articles/ihi-abt-mdt-tmo-etf-inflow-alert-2019-04-02-0 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $138.7 million dollar inflow -- that's a 3.9% increase week over week in outstanding units (from 15,200,000 to 15,800,000). Among the largest underlying components of IHI, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.3%, Medtronic PLC (Symbol: MDT) is down about 0.2%, and Thermo Fisher Scientific Inc (Symbol: TMO) is lower by about 0.5%. For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average:
Looking at the chart above, IHI's low point in its 52 week range is $179.371 per share, with $233.99 as the 52 week high point - that compares with a last trade of $230.35. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IHI, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.3%, Medtronic PLC (Symbol: MDT) is down about 0.2%, and Thermo Fisher Scientific Inc (Symbol: TMO) is lower by about 0.5%. For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $179.371 per share, with $233.99 as the 52 week high point - that compares with a last trade of $230.35. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IHI, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.3%, Medtronic PLC (Symbol: MDT) is down about 0.2%, and Thermo Fisher Scientific Inc (Symbol: TMO) is lower by about 0.5%. For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $179.371 per share, with $233.99 as the 52 week high point - that compares with a last trade of $230.35. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IHI, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.3%, Medtronic PLC (Symbol: MDT) is down about 0.2%, and Thermo Fisher Scientific Inc (Symbol: TMO) is lower by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $138.7 million dollar inflow -- that's a 3.9% increase week over week in outstanding units (from 15,200,000 to 15,800,000). For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $179.371 per share, with $233.99 as the 52 week high point - that compares with a last trade of $230.35. | Among the largest underlying components of IHI, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.3%, Medtronic PLC (Symbol: MDT) is down about 0.2%, and Thermo Fisher Scientific Inc (Symbol: TMO) is lower by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $138.7 million dollar inflow -- that's a 3.9% increase week over week in outstanding units (from 15,200,000 to 15,800,000). For a complete list of holdings, visit the IHI Holdings page » The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $179.371 per share, with $233.99 as the 52 week high point - that compares with a last trade of $230.35. |
33019.0 | 2019-03-28 00:00:00 UTC | How Much Can Intuitive Surgical's Share Price Grow If da Vinci Systems Garner 25% Share In Global Surgical Robots Market? | ABT | https://www.nasdaq.com/articles/how-much-can-intuitive-surgicals-share-price-grow-if-da-vinci-systems-garner-25-share | nan | nan | Intuitive Surgical (NASDAQ:ISRG) could see an upside of over 30% to its stock price, if da Vinci systems garners 25% share in the global surgical robots market. The da Vinci surgical systems have seen strong growth in the recent years with sales exceeding $1.1 billion in 2018, reflecting a growth of over 21% over the prior year. According to Trefis analysis, this can be attributed to an overall increase in demand for the robotic surgical procedures, given its advantages to both surgeons and patients. Below we discuss the upside potential for Intuitive Surgical based on its da Vinci systems sales growth. We have created an interactive dashboard analysis ~ What’s The Upside For Intuitive Surgical If da Vinci Systems Garners 25% Share of The Global Surgical Robots Market By 2025? You can adjust various drivers to see the impact on the adjusted earnings, and price estimate, based on da Vinci sales. Also, here’s more Healthcare Data.
da Vinci Systems’ Current Market Share ~ 17%
The da Vinci systems current market share of 17% is derived from its reported sales of $1.1 billion, and an estimated global surgical robots market size of a little over $6.8 billion in 2018. The da Vinci systems are computer assisted surgical systems that help surgeons perform minimally invasive surgeries by controlling the device from a console. The system has multiple arms that are used to hold operating tools to perform the surgery, along with an endoscopic camera, which enables the surgeons to look inside the body with a 3-D view.
Global Surgical Robots Market Size Is Estimated To Grow In Low Teens
The global surgical robots market is estimated to grow at a CAGR of 13.8% to $17 billion by 2025. This growth will likely be led by higher demand for minimally invasive procedures. It is estimated that over one million surgeries were performed using da Vinci systems in 2018, and over six million since its launch.
If da Vinci systems manages to garner 25% market share by 2025 as compared to 17% currently, it will result in incremental sales of over $1.4 billion. This is possible given that the da Vinci system has several advantages over regular surgical procedures. The surgical systems not only provides surgeons with a similar range of motion as the human wrist in the surgical field, it also removes the instability of the human hand. Additionally, these minimally invasive surgeries have the benefits of reduced surgical complications, faster recovery processes, and lower hospitalization costs. Also, these surgical systems have been widely adopted for select procedures, but there are still many for which they have not been adopted. Until a few years back, the most common procedures were prostatectomies and hysterectomies, which accounted for more than 50% of total procedures using da Vinci systems. However other procedures are being adopted at a growing rate and we expect this to continue in the future. A wider range of possible procedures will likely result in greater demand for the company’s systems. Given these factors, da Vinci systems will likely see continued strong growth in the coming years, and garner higher share in the global surgical robots market.
How Does da Vinci Systems’ Market Share Gains Impact Intuitive Surgical’s Earnings & Price Estimate?
If da Vinci systems manages to garner 25% share in the global surgical robots market, it will result in $3.95 incremental earnings on an adjusted basis. We use 34.5% adjusted net income margin, similar to that for overall Intuitive Surgical in calculating the EPS impact. We use a price to earnings multiple of 47x to arrive at a $186 impact on Intuitive Surgical’s share price, or a 33% increase to its current market price of $562.
What’s behind Trefis? See How It’s Powering New Collaboration and What-Ifs
For CFOs and Finance Teams | Product, R&D, and Marketing Teams
More Trefis Research
Like our charts? Explore example interactive dashboards and create your own.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The system has multiple arms that are used to hold operating tools to perform the surgery, along with an endoscopic camera, which enables the surgeons to look inside the body with a 3-D view. Given these factors, da Vinci systems will likely see continued strong growth in the coming years, and garner higher share in the global surgical robots market. If da Vinci systems manages to garner 25% share in the global surgical robots market, it will result in $3.95 incremental earnings on an adjusted basis. | We have created an interactive dashboard analysis ~ What’s The Upside For Intuitive Surgical If da Vinci Systems Garners 25% Share of The Global Surgical Robots Market By 2025? da Vinci Systems’ Current Market Share ~ 17% The da Vinci systems current market share of 17% is derived from its reported sales of $1.1 billion, and an estimated global surgical robots market size of a little over $6.8 billion in 2018. How Does da Vinci Systems’ Market Share Gains Impact Intuitive Surgical’s Earnings & Price Estimate? | Intuitive Surgical (NASDAQ:ISRG) could see an upside of over 30% to its stock price, if da Vinci systems garners 25% share in the global surgical robots market. We have created an interactive dashboard analysis ~ What’s The Upside For Intuitive Surgical If da Vinci Systems Garners 25% Share of The Global Surgical Robots Market By 2025? da Vinci Systems’ Current Market Share ~ 17% The da Vinci systems current market share of 17% is derived from its reported sales of $1.1 billion, and an estimated global surgical robots market size of a little over $6.8 billion in 2018. | We have created an interactive dashboard analysis ~ What’s The Upside For Intuitive Surgical If da Vinci Systems Garners 25% Share of The Global Surgical Robots Market By 2025? Given these factors, da Vinci systems will likely see continued strong growth in the coming years, and garner higher share in the global surgical robots market. How Does da Vinci Systems’ Market Share Gains Impact Intuitive Surgical’s Earnings & Price Estimate? |
33020.0 | 2019-03-28 00:00:00 UTC | How Much Can Intuitive Surgical's Share Price Grow If da Vinci Systems Garner 25% Share In Global Surgical Robots Market? | ABT | https://www.nasdaq.com/articles/how-much-can-intuitive-surgicals-share-price-grow-if-da-vinci-systems-garner-25-share-0 | nan | nan | Intuitive Surgical ( ISRG ) could see an upside of over 30% to its stock price, if da Vinci systems garners 25% share in the global surgical robots market. The da Vinci surgical systems have seen strong growth in the recent years with sales exceeding $1.1 billion in 2018, reflecting a growth of over 21% over the prior year. According to Trefis analysis, this can be attributed to an overall increase in demand for the robotic surgical procedures, given its advantages to both surgeons and patients. Below we discuss the upside potential for Intuitive Surgical based on its da Vinci systems sales growth. We have created an interactive dashboard analysis ~ What's The Upside For Intuitive Surgical If da Vinci Systems Garners 25% Share of The Global Surgical Robots Market By 2025? You can adjust various drivers to see the impact on the adjusted earnings, and price estimate, based on da Vinci sales. Also, here's more Healthcare Data .
da Vinci Systems' Current Market Share ~ 17%
The da Vinci systems current market share of 17% is derived from its reported sales of $1.1 billion, and an estimated global surgical robots market size of a little over $6.8 billion in 2018. The da Vinci systems are computer assisted surgical systems that help surgeons perform minimally invasive surgeries by controlling the device from a console. The system has multiple arms that are used to hold operating tools to perform the surgery, along with an endoscopic camera, which enables the surgeons to look inside the body with a 3-D view.
Global Surgical Robots Market Size Is Estimated To Grow In Low Teens
The global surgical robots market is estimated to grow at a CAGR of 13.8% to $17 billion by 2025. This growth will likely be led by higher demand for minimally invasive procedures. It is estimated that over one million surgeries were performed using da Vinci systems in 2018, and over six million since its launch.
If da Vinci systems manages to garner 25% market share by 2025 as compared to 17% currently, it will result in incremental sales of over $1.4 billion. This is possible given that the da Vinci system has several advantages over regular surgical procedures. The surgical systems not only provides surgeons with a similar range of motion as the human wrist in the surgical field, it also removes the instability of the human hand. Additionally, these minimally invasive surgeries have the benefits of reduced surgical complications, faster recovery processes, and lower hospitalization costs. Also, these surgical systems have been widely adopted for select procedures, but there are still many for which they have not been adopted. Until a few years back, the most common procedures were prostatectomies and hysterectomies, which accounted for more than 50% of total procedures using da Vinci systems. However other procedures are being adopted at a growing rate and we expect this to continue in the future. A wider range of possible procedures will likely result in greater demand for the company's systems. Given these factors, da Vinci systems will likely see continued strong growth in the coming years, and garner higher share in the global surgical robots market.
How Does da Vinci Systems' Market Share Gains Impact Intuitive Surgical's Earnings & Price Estimate?
If da Vinci systems manages to garner 25% share in the global surgical robots market, it will result in $3.95 incremental earnings on an adjusted basis. We use 34.5% adjusted net income margin, similar to that for overall Intuitive Surgical in calculating the EPS impact. We use a price to earnings multiple of 47x to arrive at a $186 impact on Intuitive Surgical's share price, or a 33% increase to its current market price of $562.
What's behind Trefis? See How It's Powering New Collaboration and What-Ifs
For CFOs and Finance Teams | Product, R&D, and Marketing Teams
More Trefis Research
Like our charts? Explore example interactive dashboards and create your own.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The system has multiple arms that are used to hold operating tools to perform the surgery, along with an endoscopic camera, which enables the surgeons to look inside the body with a 3-D view. Given these factors, da Vinci systems will likely see continued strong growth in the coming years, and garner higher share in the global surgical robots market. If da Vinci systems manages to garner 25% share in the global surgical robots market, it will result in $3.95 incremental earnings on an adjusted basis. | We have created an interactive dashboard analysis ~ What's The Upside For Intuitive Surgical If da Vinci Systems Garners 25% Share of The Global Surgical Robots Market By 2025? da Vinci Systems' Current Market Share ~ 17% The da Vinci systems current market share of 17% is derived from its reported sales of $1.1 billion, and an estimated global surgical robots market size of a little over $6.8 billion in 2018. How Does da Vinci Systems' Market Share Gains Impact Intuitive Surgical's Earnings & Price Estimate? | Intuitive Surgical ( ISRG ) could see an upside of over 30% to its stock price, if da Vinci systems garners 25% share in the global surgical robots market. We have created an interactive dashboard analysis ~ What's The Upside For Intuitive Surgical If da Vinci Systems Garners 25% Share of The Global Surgical Robots Market By 2025? da Vinci Systems' Current Market Share ~ 17% The da Vinci systems current market share of 17% is derived from its reported sales of $1.1 billion, and an estimated global surgical robots market size of a little over $6.8 billion in 2018. | We have created an interactive dashboard analysis ~ What's The Upside For Intuitive Surgical If da Vinci Systems Garners 25% Share of The Global Surgical Robots Market By 2025? Given these factors, da Vinci systems will likely see continued strong growth in the coming years, and garner higher share in the global surgical robots market. How Does da Vinci Systems' Market Share Gains Impact Intuitive Surgical's Earnings & Price Estimate? |
33021.0 | 2019-03-26 00:00:00 UTC | What Are Abbott Laboratories' Key Sources of Revenue? | ABT | https://www.nasdaq.com/articles/what-are-abbott-laboratories-key-sources-revenue-2019-03-26 | nan | nan | Abbott Labs (NYSE:ABT) generates its revenues from Medical Devices, Nutritionals, Diagnostics, and Generic Pharmaceuticals business. Medical Devices is the largest segment, and accounts for more than one-third of the company’s total revenues and profits. The company’s acquisitions of St. Jude Medical, and Alere, has strengthened its Medical Devices and Diagnostics business in the recent years. We forecast mid-single-digit revenue growth for Abbott in 2019, led by steady growth across its businesses. We have created an interactive dashboard ~ What Are Abbott’s Key Sources of Revenue. You can adjust segment-wise sales to see the impact on the company’s overall revenues. Also, here’s more Healthcare Data.
Expect Revenues To Grow In Mid-Single-Digits
Abbott’s Medical Devices business includes minimally invasive medical devices for heart diseases, stroke, carotid artery disease, and other vascular conditions. In addition, it also contains St. Jude Medical’s business, which Abbott acquired in 2017. The segment revenues grew from $5.3 billion in 2016 to $11.4 billion in 2018, primarily reflecting the impact of the St. Jude acquisition. We forecast the revenues to grow in high single-digits in 2019, and in mid-single-digits thereafter, primarily led by electrophysiology, and neuromodulation business. Electrophysiology refers to a test performed to assess the heart’s activity and is used to diagnose arrhythmia. Abbott’s electrophysiology product line primarily includes catheters, which are used to run this test. The company is seeing strong demand for heart mapping and ablation portfolio, while neuromodulation is seeing growth in its product line for the treatment of chronic pain and movement disorders. Apart from electrophysiology, structural heart continues to benefit from higher MitraClip sales. In fact, MitraClip was recently approved by the U.S. FDA for the treatment of heart failure in patients with clinically significant secondary mitral regurgitation.
Abbott’s Diagnostics business includes systems and tests such as immunoassay, assays used for screening for drugs of abuse, cancer, therapeutic drug monitoring, fertility, physiological diseases, and infectious diseases. An assay is a quantitative or qualitative test of a drug to determine its components. The segment revenues have grown from $4.8 billion in 2016 to $7.5 billion in 2018, primarily reflecting the impact of the Alere acquisition. We expect the division’s revenue to grow in mid-single-digits in the coming years. This can primarily be attributed to the Alere acquisition, which will further strengthen Abbott’s share in the diagnostics business. With this acquisition Abbott has added the tests for heart attacks, influenza, and drug abuse to its suite of diagnostic products.
The company’s Nutritionals business, which primarily includes dietary supplements, functional foods, and clinical & medical foods, hasn’t seen much growth over the past few years, and the revenues have hovered around $7 billion. We don’t expect any significant growth in this segment, given the nutritional industry is highly fragmented, and large pharmaceutical companies and packaged food and beverage companies compete for the same consumer base. Further, there is also a challenge from local label brands.
Looking at Abbott’s generic pharmaceutical business, the segment includes branded generic drugs such as Creon, Biaxin, Klacid, Influvac, Brufen, Synthroid, and Dicetel among others. The segment revenues have grown from $3.9 billion in 2016 to $4.4 billion in 2018. We forecast mid-single-digits growth in revenues in the coming years, primarily led by its expansion in emerging markets. The company has been focused on the emerging markets, especially Brazil, Russia, China, and India, and it is seeing strong growth in these regions. However, the pharmaceutical industry is characterized by intense competition globally, as many companies compete for the same consumer base. This will likely cap the overall sales growth for the segment.
What’s behind Trefis? See How it’s Powering New Collaboration and What-Ifs
For CFOs and Finance Teams | Product, R&D, and Marketing Teams
All Trefis Data
Like our charts? Explore example interactive dashboards and create your own.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Labs (NYSE:ABT) generates its revenues from Medical Devices, Nutritionals, Diagnostics, and Generic Pharmaceuticals business. The company is seeing strong demand for heart mapping and ablation portfolio, while neuromodulation is seeing growth in its product line for the treatment of chronic pain and movement disorders. In fact, MitraClip was recently approved by the U.S. FDA for the treatment of heart failure in patients with clinically significant secondary mitral regurgitation. | Abbott Labs (NYSE:ABT) generates its revenues from Medical Devices, Nutritionals, Diagnostics, and Generic Pharmaceuticals business. The company’s acquisitions of St. Jude Medical, and Alere, has strengthened its Medical Devices and Diagnostics business in the recent years. Expect Revenues To Grow In Mid-Single-Digits Abbott’s Medical Devices business includes minimally invasive medical devices for heart diseases, stroke, carotid artery disease, and other vascular conditions. | Abbott Labs (NYSE:ABT) generates its revenues from Medical Devices, Nutritionals, Diagnostics, and Generic Pharmaceuticals business. We forecast mid-single-digit revenue growth for Abbott in 2019, led by steady growth across its businesses. Expect Revenues To Grow In Mid-Single-Digits Abbott’s Medical Devices business includes minimally invasive medical devices for heart diseases, stroke, carotid artery disease, and other vascular conditions. | Abbott Labs (NYSE:ABT) generates its revenues from Medical Devices, Nutritionals, Diagnostics, and Generic Pharmaceuticals business. The company’s acquisitions of St. Jude Medical, and Alere, has strengthened its Medical Devices and Diagnostics business in the recent years. Expect Revenues To Grow In Mid-Single-Digits Abbott’s Medical Devices business includes minimally invasive medical devices for heart diseases, stroke, carotid artery disease, and other vascular conditions. |
33022.0 | 2019-03-25 00:00:00 UTC | Abbott's New CE Mark to Boost Core Laboratory Diagnostics Arm | ABT | https://www.nasdaq.com/articles/abbotts-new-ce-mark-to-boost-core-laboratory-diagnostics-arm-2019-03-25 | nan | nan | Expanding offerings within the Core Laboratory Diagnostics business, AbbottABT recently announced the receipt of CE Mark for the Alinity m diagnostics system and assays. This new offering from Abbott will provide increased flexibility and time efficiency while catering to the rising demand for infectious disease testing.
Commercially available in countries identifying CE Mark, Alinity m provides initial assays, including virologic testing for human immunodeficiency virus type 1 (HIV-1), hepatitis B virus and hepatitis C virus. It also offers sexual health-related testing for Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis and Mycoplasma genitalium or CT/NG/TV/MG panel along with high-risk human papillomavirus testing.
However, Alinity m is in development in the United States and therefore, commercially unavailable.
Market Potential
Per a MarketsandMarkets report, the global infectious disease diagnostics market is likely to reach a worth of $19.35 billion in 2022, at a CAGR of 5.6% between 2017 and 2022. Rising incidences of infectious diseases, growing research funds on the same and change of focus to decentralized point-of-care testing are expected to drive demand in the future as well.
Moreover, the World Health Organization reports that more than a billion people are suffering from infectious diseases globally. Hence, we believe that the recent development will help Abbott rake in increased top-line contributions from the Core Laboratory Diagnostics business.
Alinity - a Strong Growth Driver
Abbott's Core Laboratory Diagnostics offers a suite of products in the areas of immunoassay, clinical chemistry, hematology and transfusion, including the Alinity family of instruments, ARCHITECT, ABBOTT PRISM and Cell-Dyn. The business also provides assays used for screening and/or diagnosis for cancer, cardiac, metabolics, drugs of abuse, fertility, general chemistries, infectious diseases such as hepatitis and HIV, and therapeutic drug monitoring.
Sales within the segment rose 9.4% on an organic basis in the fourth quarter of 2018. The Core Laboratory Diagnostics arm delivered above-market growth in the United States and globally. Continued strong adoption of Alinity has been largely driving the top line. Furthermore, Alinity is achieving accelerated growth and strong competitive win rates in Europe. The global rollout of Alinity positions this business for a consistent above-market growth for years to come.
Price Performance
Over the past year, Abbott's shares have outperformed the industry it belongs to. The stock has rallied 27.6% compared with the industry's growth of 7.5%.
Zacks Rank & Other Key Picks
Abbott currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the broader medical space are Integer Holdings Corporation ITGR , Veeva Systems Inc. VEEV and Hologic, Inc. HOLX .
Integer Holdings projects earnings growth rate of 31.2% for the first quarter. It currently carries a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Veeva Systems' long-term earnings growth rate is projected at 14.8%. The stock currently carries a Zacks Rank of 2.
Hologic's long-term earnings growth rate is projected at 8.9%. The stock presently has a Zacks Rank #2.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 - 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Veeva Systems Inc. (VEEV): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Integer Holdings Corporation (ITGR): Free Stock Analysis Report
Hologic, Inc. (HOLX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Expanding offerings within the Core Laboratory Diagnostics business, AbbottABT recently announced the receipt of CE Mark for the Alinity m diagnostics system and assays. Click to get this free report Veeva Systems Inc. (VEEV): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Integer Holdings Corporation (ITGR): Free Stock Analysis Report Hologic, Inc. (HOLX): Free Stock Analysis Report To read this article on Zacks.com click here. This new offering from Abbott will provide increased flexibility and time efficiency while catering to the rising demand for infectious disease testing. | Click to get this free report Veeva Systems Inc. (VEEV): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Integer Holdings Corporation (ITGR): Free Stock Analysis Report Hologic, Inc. (HOLX): Free Stock Analysis Report To read this article on Zacks.com click here. Expanding offerings within the Core Laboratory Diagnostics business, AbbottABT recently announced the receipt of CE Mark for the Alinity m diagnostics system and assays. Commercially available in countries identifying CE Mark, Alinity m provides initial assays, including virologic testing for human immunodeficiency virus type 1 (HIV-1), hepatitis B virus and hepatitis C virus. | Expanding offerings within the Core Laboratory Diagnostics business, AbbottABT recently announced the receipt of CE Mark for the Alinity m diagnostics system and assays. Click to get this free report Veeva Systems Inc. (VEEV): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Integer Holdings Corporation (ITGR): Free Stock Analysis Report Hologic, Inc. (HOLX): Free Stock Analysis Report To read this article on Zacks.com click here. Alinity - a Strong Growth Driver Abbott's Core Laboratory Diagnostics offers a suite of products in the areas of immunoassay, clinical chemistry, hematology and transfusion, including the Alinity family of instruments, ARCHITECT, ABBOTT PRISM and Cell-Dyn. | Expanding offerings within the Core Laboratory Diagnostics business, AbbottABT recently announced the receipt of CE Mark for the Alinity m diagnostics system and assays. Click to get this free report Veeva Systems Inc. (VEEV): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Integer Holdings Corporation (ITGR): Free Stock Analysis Report Hologic, Inc. (HOLX): Free Stock Analysis Report To read this article on Zacks.com click here. This new offering from Abbott will provide increased flexibility and time efficiency while catering to the rising demand for infectious disease testing. |
33023.0 | 2019-03-25 00:00:00 UTC | Quest Diagnostics Grows on New Pacts Amid Reimbursement Issue | ABT | https://www.nasdaq.com/articles/quest-diagnostics-grows-on-new-pacts-amid-reimbursement-issue-2019-03-25 | nan | nan | On Mar 22, we issued an updated research report on Quest Diagnostics, Inc.DGX . As a part of its two-point strategy, Quest Diagnostics has been focusing on areas with high potential. However, the reimbursement scenario remains a major cause of concern for thisZacks Rank #3 (Hold) company.
Quest Diagnostics is currently focusing on diagnostic information services and disciplined capital deployment. Meanwhile, the company's acquisitions and collaborations with hospitals and integrated delivery networks act as major growth drivers.
We are upbeat about the company's partnership with UnitedHealthcare, a business of UnitedHealth Group, to operate as a preferred national laboratory for the latter's members since Jan 1, 2019.
This agreement will provide in-network access to Quest Diagnostics' complete portfolio of laboratory services to more than 48 million eligible members. Under the expanded tie-up, the companies are going to collaborate on a variety of value-based programs.
Quest Diagnostics Incorporated Price
Quest Diagnostics Incorporated Price | Quest Diagnostics Incorporated Quote
Of late, major developments included the company's progress in prescription drug monitoring, QuantiFERON and non-invasive prenatal screening. In advanced diagnostics, it witnessed a strong uptick. This apart, the buyout of Med Fusion has helped accelerate growth for the company's tumor panels.
On the flip side, the company exited the fourth quarter on a sluggish note. A decline in Diagnostic information services revenues was disappointing. Moreover, we are concerned about factors like unfavorable changes in prescription drug monitoring, vitamin D and hepatitis C testing marketplace that can dent growth. A rise in patient concession along with certain reserve adjustments affected the top line, inducing lower revenue per requisition.
This apart, Quest Diagnostics is apprehensive about dealing with a massive reimbursement pressurein 2019 which may get partially offset by steady execution of the Invigorate program. The company expects about a 10% reduction in Medicare reimbursement rates this year. The impact of these cutbacks will be more significant on smaller independent hospital outreach laboratories, which the company believes can eliminate majority of profit and bring about market consolidation.
Shares of Quest Diagnostics have outperformed its industry in the past six months. The stock has declined 17% compared with the 25.6% fall of the industry.
Stocks to Consider
A few better-ranked stocks in the broader medical space are Abbott Laboratories ABT , Penumbra, Inc., PEN and Masimo, Inc. MASI . Notably, each of these stocks currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Abbott's long-term earnings growth rate is projected at 11.73%
Penumbra's long-term earnings growth rate is estimated at 20.93%.
Masimo's long-term earnings are projected to grow 15.60%.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 - 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Masimo Corporation (MASI): Free Stock Analysis Report
Penumbra, Inc. (PEN): Free Stock Analysis Report
Quest Diagnostics Incorporated (DGX): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks to Consider A few better-ranked stocks in the broader medical space are Abbott Laboratories ABT , Penumbra, Inc., PEN and Masimo, Inc. MASI . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report Penumbra, Inc. (PEN): Free Stock Analysis Report Quest Diagnostics Incorporated (DGX): Free Stock Analysis Report To read this article on Zacks.com click here. This agreement will provide in-network access to Quest Diagnostics' complete portfolio of laboratory services to more than 48 million eligible members. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report Penumbra, Inc. (PEN): Free Stock Analysis Report Quest Diagnostics Incorporated (DGX): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks to Consider A few better-ranked stocks in the broader medical space are Abbott Laboratories ABT , Penumbra, Inc., PEN and Masimo, Inc. MASI . Quest Diagnostics Incorporated Price Quest Diagnostics Incorporated Price | Quest Diagnostics Incorporated Quote Of late, major developments included the company's progress in prescription drug monitoring, QuantiFERON and non-invasive prenatal screening. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report Penumbra, Inc. (PEN): Free Stock Analysis Report Quest Diagnostics Incorporated (DGX): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks to Consider A few better-ranked stocks in the broader medical space are Abbott Laboratories ABT , Penumbra, Inc., PEN and Masimo, Inc. MASI . Quest Diagnostics is currently focusing on diagnostic information services and disciplined capital deployment. | Stocks to Consider A few better-ranked stocks in the broader medical space are Abbott Laboratories ABT , Penumbra, Inc., PEN and Masimo, Inc. MASI . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report Penumbra, Inc. (PEN): Free Stock Analysis Report Quest Diagnostics Incorporated (DGX): Free Stock Analysis Report To read this article on Zacks.com click here. Quest Diagnostics is currently focusing on diagnostic information services and disciplined capital deployment. |
33024.0 | 2019-03-25 00:00:00 UTC | 6 Excellent Dividend Growth Stocks to Buy Now | ABT | https://www.nasdaq.com/articles/6-excellent-dividend-growth-stocks-buy-now-2019-03-25 | nan | nan | The return of volatility with the escalation of global growth concerns and the risk of recession in the United States has raised the appeal for dividend growth stocks. This is because dividend-paying securities are the major sources of consistent income when returns from the equity market are at risk.
While there are several dividend stocks that could provide capital appreciation, zeroing in on the stocks that not only pay dividends but also consistently increase the payout ratio could be some excellent choices.
Dividend Growth: A Winning Strategy
Stocks that have a strong history of dividend growth belong to mature companies, which are less susceptible to large swings in the market, and thus act as a hedge against economic or political uncertainty as well as stock market volatility. At the same time, these offer downside protection with their consistent increase in payouts.
Additionally, these stocks have superior fundamentals that make dividend growth a quality and promising investment for the long term. These include a sustainable business model, a long track of profitability, rising cash flows, good liquidity, a strong balance sheet and some value characteristics. Further, a history of strong dividend growth indicates that dividend increase is likely in the future.
Moreover, a history of dividend growth year over year leads to a healthy portfolio with a greater scope of capital appreciation as opposed to simple dividend paying stocks or those with high yields. Although these stocks do not necessarily have the highest yields, they have outperformed for a longer period than the broader stock market or any other dividend-paying stock.
As a result, picking dividend growth stocks appear as winning strategies when some other parameters are also included.
5-Year Historical Dividend Growth greater than zero : This selects stocks with a solid dividend growth history.
5-Year Historical Sales Growth greater than zero : This represents stocks with a strong record of growing revenue.
5-Year Historical EPS Growth greater than zero : This represents stocks with a solid earnings growth history.
Next 3-5 Year EPS Growth Rate greater than zero : This represents the rate at which a company's earnings are expected to grow. Improving earnings should help companies sustain dividend payments.
Price/Cash Flow less than M-Industry : A ratio less than M-industry indicates that the stock is undervalued in that industry and that an investor needs to pay less for better cash flow generated by the company.
52-Week Price Change greater than S&P 500 (Market Weight) : This ensures that the stock appreciated more than the S&P 500 over the past one year.
Top Zacks Rank : Stocks having a Zacks Rank #1 (Strong Buy) and 2 (Buy) generally outperform their peers in all types of market environment.
Growth Score of B or better: Our research shows that stocks with a Growth Score of A or B when combined with a Zacks Rank #1 or 2 offer the best upside potential.
Here are six of the 13 stocks that fit the bill:
Oregon-based Columbia Sportswear Company COLM is a global leader in design, sourcing, marketing and distribution of active outdoor apparel and footwear with operations in North America, Europe and Asia. It has seen a positive earnings estimate revision of four cents for this year over the past month and delivered average positive surprise of 83.45% in the last four quarters. The stock sports a Zacks Rank #1 and a Growth Score of A. You can see the complete list of today's Zacks #1 Rank stocks here .
California-based Robert Half International Inc. RHI is the world's first and the largest specialized staffing firm. It has pulled off avera ge earnings surprise of 5.78% in the last four quarters and expects its earnings to grow 13.02% for the current year. The stock has a Zacks Rank 1 and a Growth Score of A.
Lowa-based Caseys General Stores Inc. CASY operates convenience stores under the Casey's and Casey's General Store names. The company saw a solid earnings estimate revision of 14 cents over the past 30 days for the fiscal year (ending April 2019) and has an expected earnings growth rate of 35.96%. It has a Zacks Rank #2 and a Growth Score of A.
Illinois-based Abbott Laboratories ABT discovers, develops, manufactures and sells health care products worldwide. It has an estimated earnings growth rate of 11.11% for the ongoing year and delivered average beat of 1.47% in the last four quarters. The stock has a Zacks Rank of2 and a Growth Score of B.
Massachusetts-based LPL Financial Holdings Inc. LPLA is engaged in providing an integrated platform of brokerage and investment advisory services to independent financial advisors and financial advisors at financial institutions in the United States. The stock has delivered average positive surprise of 17.06% in the trailing four quarters and has an expected earnings growth rate of 21.20%. The stock is a Zacks #1 Ranked player and has a Growth Score of A.
Connecticut-based SS&C Technologies Holdings Inc. SSNC delivers investment and financial management software and related services, focused exclusively on the financial services industry. It has an estimated earnings growth rate of 30.48% for 2019 and came up with average beat of 5.98% for the previous four quarters. SS&C Technologies is a #1 Ranked player and has a Growth Score of A.
You can get the rest of the stocks on this list by signing up now for your 2-week free trial to the Research Wizard and start using this screen in your own trading. Further, you can also create your own strategies and test them first before taking the investment plunge.
The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out.
Click here to sign up for a free trial to the Research Wizard today .
Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.
Disclosure: Performance information for Zacks' portfolios and strategies are available at:https://www.zacks.com/performance.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
LPL Financial Holdings Inc. (LPLA): Free Stock Analysis Report
SS&C Technologies Holdings, Inc. (SSNC): Free Stock Analysis Report
Caseys General Stores, Inc. (CASY): Free Stock Analysis Report
Columbia Sportswear Company (COLM): Free Stock Analysis Report
Robert Half International Inc. (RHI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | It has a Zacks Rank #2 and a Growth Score of A. Illinois-based Abbott Laboratories ABT discovers, develops, manufactures and sells health care products worldwide. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report LPL Financial Holdings Inc. (LPLA): Free Stock Analysis Report SS&C Technologies Holdings, Inc. (SSNC): Free Stock Analysis Report Caseys General Stores, Inc. (CASY): Free Stock Analysis Report Columbia Sportswear Company (COLM): Free Stock Analysis Report Robert Half International Inc. (RHI): Free Stock Analysis Report To read this article on Zacks.com click here. These include a sustainable business model, a long track of profitability, rising cash flows, good liquidity, a strong balance sheet and some value characteristics. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report LPL Financial Holdings Inc. (LPLA): Free Stock Analysis Report SS&C Technologies Holdings, Inc. (SSNC): Free Stock Analysis Report Caseys General Stores, Inc. (CASY): Free Stock Analysis Report Columbia Sportswear Company (COLM): Free Stock Analysis Report Robert Half International Inc. (RHI): Free Stock Analysis Report To read this article on Zacks.com click here. It has a Zacks Rank #2 and a Growth Score of A. Illinois-based Abbott Laboratories ABT discovers, develops, manufactures and sells health care products worldwide. Top Zacks Rank : Stocks having a Zacks Rank #1 (Strong Buy) and 2 (Buy) generally outperform their peers in all types of market environment. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report LPL Financial Holdings Inc. (LPLA): Free Stock Analysis Report SS&C Technologies Holdings, Inc. (SSNC): Free Stock Analysis Report Caseys General Stores, Inc. (CASY): Free Stock Analysis Report Columbia Sportswear Company (COLM): Free Stock Analysis Report Robert Half International Inc. (RHI): Free Stock Analysis Report To read this article on Zacks.com click here. It has a Zacks Rank #2 and a Growth Score of A. Illinois-based Abbott Laboratories ABT discovers, develops, manufactures and sells health care products worldwide. Dividend Growth: A Winning Strategy Stocks that have a strong history of dividend growth belong to mature companies, which are less susceptible to large swings in the market, and thus act as a hedge against economic or political uncertainty as well as stock market volatility. | It has a Zacks Rank #2 and a Growth Score of A. Illinois-based Abbott Laboratories ABT discovers, develops, manufactures and sells health care products worldwide. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report LPL Financial Holdings Inc. (LPLA): Free Stock Analysis Report SS&C Technologies Holdings, Inc. (SSNC): Free Stock Analysis Report Caseys General Stores, Inc. (CASY): Free Stock Analysis Report Columbia Sportswear Company (COLM): Free Stock Analysis Report Robert Half International Inc. (RHI): Free Stock Analysis Report To read this article on Zacks.com click here. Further, a history of strong dividend growth indicates that dividend increase is likely in the future. |
33025.0 | 2019-03-25 00:00:00 UTC | Abbott (ABT) Gains As Market Dips: What You Should Know | ABT | https://www.nasdaq.com/articles/abbott-abt-gains-as-market-dips%3A-what-you-should-know-2019-03-25 | nan | nan | Abbott (ABT) closed the most recent trading day at $78.23, moving +0.33% from the previous trading session. This move outpaced the S&P 500's daily loss of 0.08%. Meanwhile, the Dow gained 0.06%, and the Nasdaq, a tech-heavy index, lost 0.07%.
Prior to today's trading, shares of the maker of infant formula, medical devices and drugs had gained 3.77% over the past month. This has outpaced the Medical sector's loss of 0.22% and the S&P 500's gain of 0.52% in that time.
Wall Street will be looking for positivity from ABT as it approaches its nex t earnings report date. This is expected to be April 17, 2019. The company is expected to report EPS of $0.61, up 3.39% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $7.48 billion, up 1.17% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $3.20 per share and revenue of $31.80 billion, which would represent changes of +11.11% and +4.01%, respectively, from the prior year.
Any recent changes to analyst estimates for ABT should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. ABT is currently a Zacks Rank #2 (Buy).
Looking at its valuation, ABT is holding a Forward P/E ratio of 24.34. This represents a discount compared to its industry's average Forward P/E of 24.88.
It is also worth noting that ABT currently has a PEG ratio of 2.08. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. Medical - Products stocks are, on average, holding a PEG ratio of 2.22 based on yesterday's closing prices.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 75, putting it in the top 30% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow ABT in the coming trading sessions, be sure to utilize Zacks.com.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott (ABT) closed the most recent trading day at $78.23, moving +0.33% from the previous trading session. Wall Street will be looking for positivity from ABT as it approaches its nex t earnings report date. Any recent changes to analyst estimates for ABT should also be noted by investors. | Abbott (ABT) closed the most recent trading day at $78.23, moving +0.33% from the previous trading session. Wall Street will be looking for positivity from ABT as it approaches its nex t earnings report date. Any recent changes to analyst estimates for ABT should also be noted by investors. | Abbott (ABT) closed the most recent trading day at $78.23, moving +0.33% from the previous trading session. Wall Street will be looking for positivity from ABT as it approaches its nex t earnings report date. Any recent changes to analyst estimates for ABT should also be noted by investors. | Abbott (ABT) closed the most recent trading day at $78.23, moving +0.33% from the previous trading session. Wall Street will be looking for positivity from ABT as it approaches its nex t earnings report date. Any recent changes to analyst estimates for ABT should also be noted by investors. |
33026.0 | 2019-03-25 00:00:00 UTC | Thermo Fisher to Buy Brammer Bio, Tightens Gene Therapy Grip | ABT | https://www.nasdaq.com/articles/thermo-fisher-to-buy-brammer-bio-tightens-gene-therapy-grip-2019-03-25 | nan | nan | Thermo Fisher Scientific Inc.TMO recently made a major investment in the emerging space of gene therapy to strengthen its portfolio. The company has entered into a definitive agreement to acquire Brammer Bio, a prominent name in gene and cell therapy domain for a deal value of $1.7 billion in cash.
The transaction is expected to close by the end of the second quarter of 2019, subject to the fulfilment of certain closing conditions.
Brammer Bio is a viral vector contract development and manufacturing organization (CDMO). The company with its services enables the biopharma customers to develop gene therapies and gene-modified cell therapies, thereby aiding them to deliver advanced medicines to patients.
Brammer Bio holds an impressive track record of revenue growth. The company is making concerted efforts to generate $250 million of revenues in 2019 and expects to consistently exceed the projected market growth rate of 25% over the mid-term.
Is the Deal Strategic Fit?
The gene therapy is an attractive area for drug development and it is gaining popularity quite fast given that it can better address the root cause of a severe disease. Per Allied Market Research, for certain disorders wherein genetic mutations may induce a deficient or a non-functional protein production, there gene therapy can fix the underlying defect and provide a path to produce the functional protein.
According to an Allied Market Research report, the gene therapy market holds immense potential worldwide. Globally, the market is projected to reach $4,402 million by 2023 from $584 million in 2016, thus witnessing an encouraging CAGR of 33.3%.
Thermo Fisher Scientific Inc. Price
Thermo Fisher Scientific Inc. Price | Thermo Fisher Scientific Inc. Quote
This clearly indicates that the latest move by Thermo Fisher is strategically aligned and well timed.
The Consolidation at a Glance
On completion of the deal, Brammer Bio will emerge as part of Thermo Fisher's pharma services business within its Laboratory Products and Services wing. According to the company, Brammer Bio's viral vector capabilities combined with the former's GMP production expertise and proprietary bioprocessing plus cell culture technologies, will create a unique position for the combined entity in this incredibly rapidly-growing market.
Thermo Fisher expects this inclusion to be accretive to its adjusted EPS by 10 cents in the first full-year of the integration.
Zacks Rank and Key Picks
Thermo Fisher currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are Abbott Laboratories ABT , Penumbra, Inc., PEN and Masimo, Inc. MASI , each stock currently carrying a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Abbott's long-term earnings growth rate is projected to be 11.73%
Penumbra's long-term earnings growth rate is expected at 20.93%.
Masimo's long-term earnings are forecast to grow at 15.60% rate.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 - 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Thermo Fisher Scientific Inc. (TMO): Free Stock Analysis Report
Masimo Corporation (MASI): Free Stock Analysis Report
Penumbra, Inc. (PEN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the broader medical space are Abbott Laboratories ABT , Penumbra, Inc., PEN and Masimo, Inc. MASI , each stock currently carrying a Zacks Rank #2 (Buy). Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc. (TMO): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report Penumbra, Inc. (PEN): Free Stock Analysis Report To read this article on Zacks.com click here. Thermo Fisher Scientific Inc.TMO recently made a major investment in the emerging space of gene therapy to strengthen its portfolio. | Some better-ranked stocks in the broader medical space are Abbott Laboratories ABT , Penumbra, Inc., PEN and Masimo, Inc. MASI , each stock currently carrying a Zacks Rank #2 (Buy). Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc. (TMO): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report Penumbra, Inc. (PEN): Free Stock Analysis Report To read this article on Zacks.com click here. Thermo Fisher Scientific Inc. Price Thermo Fisher Scientific Inc. Price | Thermo Fisher Scientific Inc. Quote This clearly indicates that the latest move by Thermo Fisher is strategically aligned and well timed. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc. (TMO): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report Penumbra, Inc. (PEN): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader medical space are Abbott Laboratories ABT , Penumbra, Inc., PEN and Masimo, Inc. MASI , each stock currently carrying a Zacks Rank #2 (Buy). Thermo Fisher Scientific Inc. Price Thermo Fisher Scientific Inc. Price | Thermo Fisher Scientific Inc. Quote This clearly indicates that the latest move by Thermo Fisher is strategically aligned and well timed. | Some better-ranked stocks in the broader medical space are Abbott Laboratories ABT , Penumbra, Inc., PEN and Masimo, Inc. MASI , each stock currently carrying a Zacks Rank #2 (Buy). Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Thermo Fisher Scientific Inc. (TMO): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report Penumbra, Inc. (PEN): Free Stock Analysis Report To read this article on Zacks.com click here. Thermo Fisher Scientific Inc. Price Thermo Fisher Scientific Inc. Price | Thermo Fisher Scientific Inc. Quote This clearly indicates that the latest move by Thermo Fisher is strategically aligned and well timed. |
33027.0 | 2019-03-22 00:00:00 UTC | Baxter (BAX) Soars to 52-Week High, Time to Cash Out? | ABT | https://www.nasdaq.com/articles/baxter-bax-soars-to-52-week-high-time-to-cash-out-2019-03-22 | nan | nan | Have you been paying attention to shares of Baxter International (BAX)? Shares have been on the move with the stock up 6% over the past month. The stock hit a new 52-week high of $78.46 in the previous session. Baxter International has gained 19.2% since the start of the year compared to the 10.4% move for the Zacks Medical sector and the 14.3% return for the Zacks Medical - Products industry.
What's Driving the Outperformance?
The stock has a great record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the last four quarters. In its las t earnings report on January 31, 2019, Baxter reported EPS of $0.78 versus consensus estimate of $0.73 while it beat the consensus revenue estimate by 1.45%.
For the current fiscal year, Baxter is expected to post earnings of $3.27 per share on $11.22 billion in revenues. This represents a 7.21% change in EPS on a 0.83% change in revenues. For the next fiscal year, the company is expected to earn $3.7 per share on $11.76 billion in revenues. This represents a year-over-year change of 13.09% and 4.8%, respectively.
Valuation Metrics
Baxter may be at a 52-week high right now, but what might the future hold for the stock? A key aspect of this question is taking a look at valuation metrics in order to determine if the company is due for a pullback from this level.
On this front, we can look at the Zacks Style Scores, as these give investors a variety of ways to comb through stocks (beyond looking at the Zacks Rank of a security). These styles are represented by grades running from A to F in the categories of Value, Growth, and Momentum, while there is a combined VGM Score as well. The idea behind the style scores is to help investors pick the most appropriate Zacks Rank stocks based on their individual investment style.
Baxter has a Value Score of C. The stock's Growth and Momentum Scores are B and C, respectively, giving the company a VGM Score of B.
In terms of its value breakdown, the stock currently trades at 24X current fiscal year EPS estimates. On a trailing cash flow basis, the stock currently trades at 17X versus its peer group's average of 18.2X. Additionally, the stock has a PEG ratio of 1.97. This isn't enough to put the company in the top echelon of all stocks we cover from a value perspective.
Zacks Rank
We also need to look at the Zacks Rank for the stock, as this supersedes any trend on the style score front. Fortunately, Baxter currently has a Zacks Rank of #2 (Buy) thanks to favorable earnings estimate revisions from covering analysts.
Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if Baxter passes the test. Thus, it seems as though Baxter shares could have potential in the weeks and months to come.
How Does Baxter Stack Up to the Competition?
Shares of Baxter have been rising, and the company still appears to be a decent choice, but what about the rest of the industry? Some of its industry peers are also impressive, including Abbott Laboratories (ABT), Stryker (SYK), and ICU Medical (ICUI), all of which currently have a Zacks Rank of at least #2 and a VGM Score of at least B, making them well-rounded choices.
The Zacks Industry Rank is in the top 35% of all the industries we have in our universe, so it looks like there are some nice tailwinds for Baxter, even beyond its own solid fundamental situation.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Baxter International Inc. (BAX): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
ICU Medical, Inc. (ICUI): Free Stock Analysis Report
Stryker Corporation (SYK): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some of its industry peers are also impressive, including Abbott Laboratories (ABT), Stryker (SYK), and ICU Medical (ICUI), all of which currently have a Zacks Rank of at least #2 and a VGM Score of at least B, making them well-rounded choices. Click to get this free report Baxter International Inc. (BAX): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report ICU Medical, Inc. (ICUI): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report To read this article on Zacks.com click here. A key aspect of this question is taking a look at valuation metrics in order to determine if the company is due for a pullback from this level. | Some of its industry peers are also impressive, including Abbott Laboratories (ABT), Stryker (SYK), and ICU Medical (ICUI), all of which currently have a Zacks Rank of at least #2 and a VGM Score of at least B, making them well-rounded choices. Click to get this free report Baxter International Inc. (BAX): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report ICU Medical, Inc. (ICUI): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report To read this article on Zacks.com click here. In terms of its value breakdown, the stock currently trades at 24X current fiscal year EPS estimates. | Click to get this free report Baxter International Inc. (BAX): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report ICU Medical, Inc. (ICUI): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report To read this article on Zacks.com click here. Some of its industry peers are also impressive, including Abbott Laboratories (ABT), Stryker (SYK), and ICU Medical (ICUI), all of which currently have a Zacks Rank of at least #2 and a VGM Score of at least B, making them well-rounded choices. Zacks Rank We also need to look at the Zacks Rank for the stock, as this supersedes any trend on the style score front. | Some of its industry peers are also impressive, including Abbott Laboratories (ABT), Stryker (SYK), and ICU Medical (ICUI), all of which currently have a Zacks Rank of at least #2 and a VGM Score of at least B, making them well-rounded choices. Click to get this free report Baxter International Inc. (BAX): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report ICU Medical, Inc. (ICUI): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report To read this article on Zacks.com click here. In its las t earnings report on January 31, 2019, Baxter reported EPS of $0.78 versus consensus estimate of $0.73 while it beat the consensus revenue estimate by 1.45%. |
33028.0 | 2019-03-22 00:00:00 UTC | Varian (VAR) Scales New 52-Week High on Solid Prospects | ABT | https://www.nasdaq.com/articles/varian-var-scales-new-52-week-high-on-solid-prospects-2019-03-22 | nan | nan | Shares of VarianMedical Systems, Inc.VAR scaled a new 52-week high of $138.35 on Mar 21, closing nominally lower at $137.78. The company has gained 22.4% over the past six months against the industry's 3.4% decline. The stock also fared better than the S&P 500's decline of 1.3%.
The company has a market cap of $12.50 billion.
Further, Varian's estimate revision trend for the current year is favorable. In the past 60 days, two estimates moved up while none shifted down. Consequently, estimates were up 0.21% from $4.69 a share.
The company also has a trailing four-quarter average positive earnings surprise of 2.24%. It also has an impressive long-term growth rate of 8%.
Varian currently holds a Zacks Rank #2 (Buy).
Growth Drivers
Increasing net sales from Oncology Systems and Proton Solutions have been a major growth driver for Varian.
Market seems upbeat about the strong and consistent revenue growth at Oncology Systems over the last two quarters. The segment's performance was aided by a year-over-year increase in global net installed base. Gross orders of oncology system units surged particularly in the Americas, EMEA and APAC regions. The radiation therapy market has been contributing to this segment's growth as well.
In the last two quarters, the Proton Solutions segment of Varian witnessed robust growth on several clinical handovers within the United Kingdom. The FlashForward Consortium and ProBeam 360, both launched near 2018-end, have been building momentum within this segment. Continued investment in sales, marketing and R&D within this segment is expected to keep strengthening the company.
Of late, a rising number of orders for the Halcyon radio therapy platform, launched and approved in the fourth quarter of fiscal 2018, have been crucial for the company. The platform was granted exclusion from U.S. tariffs, which is another major positive.
A few months back, Varian announced the acquisition of Noona, a developer of cloud-based technology designed to highlight cancer patient outcomes. Around that time, the Paul Scherrer Institute initiated the use of Varian software solution for advanced proton therapy treatments. Varian also announced that it was selected by Medical Specialist Holdings (MSH) to extend its treatment facilities to seven of its centers in South Africa.
In August 2018, Varian announced the acquisition of humediQ, with the agenda of strengthening its oncology portfolio. It also launched the Bravos brachytherapy afterloader system in order to enhance clinical experience.
We believe all these factors have lifted the stock to a 52-week high.
Other Key Picks
Some other top-ranked stocks in the broader medical space are Abbott Laboratories ABT , Penumbra, Inc., PEN and Masimo, Inc. MASI . Notably, each of these stocks currently carries a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here.
Abbott's long-term earnings growth rate is projected at 11.73%
Penumbra's long-term earnings growth rate is estimated at 20.93%.
Masimo's long-term earnings are projected to grow 15.60%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They're also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98% , +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report
Penumbra, Inc. (PEN): Free Stock Analysis Report
Masimo Corporation (MASI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Other Key Picks Some other top-ranked stocks in the broader medical space are Abbott Laboratories ABT , Penumbra, Inc., PEN and Masimo, Inc. MASI . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Penumbra, Inc. (PEN): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report To read this article on Zacks.com click here. Of late, a rising number of orders for the Halcyon radio therapy platform, launched and approved in the fourth quarter of fiscal 2018, have been crucial for the company. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Penumbra, Inc. (PEN): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report To read this article on Zacks.com click here. Other Key Picks Some other top-ranked stocks in the broader medical space are Abbott Laboratories ABT , Penumbra, Inc., PEN and Masimo, Inc. MASI . Growth Drivers Increasing net sales from Oncology Systems and Proton Solutions have been a major growth driver for Varian. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Penumbra, Inc. (PEN): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report To read this article on Zacks.com click here. Other Key Picks Some other top-ranked stocks in the broader medical space are Abbott Laboratories ABT , Penumbra, Inc., PEN and Masimo, Inc. MASI . Growth Drivers Increasing net sales from Oncology Systems and Proton Solutions have been a major growth driver for Varian. | Other Key Picks Some other top-ranked stocks in the broader medical space are Abbott Laboratories ABT , Penumbra, Inc., PEN and Masimo, Inc. MASI . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Penumbra, Inc. (PEN): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report To read this article on Zacks.com click here. Growth Drivers Increasing net sales from Oncology Systems and Proton Solutions have been a major growth driver for Varian. |
33029.0 | 2019-03-21 00:00:00 UTC | Notable ETF Outflow Detected - IWD, INTC, T, ABT | ABT | https://www.nasdaq.com/articles/notable-etf-outflow-detected-iwd-intc-t-abt-2019-03-21 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 Value ETF (Symbol: IWD) where we have detected an approximate $43.1 million dollar outflow -- that's a 0.1% decrease week over week (from 307,000,000 to 306,650,000). Among the largest underlying components of IWD, in trading today Intel Corp (Symbol: INTC) is up about 1.1%, AT&T Inc (Symbol: T) is up about 1.1%, and Abbott Laboratories (Symbol: ABT) is up by about 0.3%. For a complete list of holdings, visit the IWD Holdings page » The chart below shows the one year price performance of IWD, versus its 200 day moving average:
Looking at the chart above, IWD's low point in its 52 week range is $104.0697 per share, with $129.82 as the 52 week high point - that compares with a last trade of $123.47. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IWD, in trading today Intel Corp (Symbol: INTC) is up about 1.1%, AT&T Inc (Symbol: T) is up about 1.1%, and Abbott Laboratories (Symbol: ABT) is up by about 0.3%. For a complete list of holdings, visit the IWD Holdings page » The chart below shows the one year price performance of IWD, versus its 200 day moving average: Looking at the chart above, IWD's low point in its 52 week range is $104.0697 per share, with $129.82 as the 52 week high point - that compares with a last trade of $123.47. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IWD, in trading today Intel Corp (Symbol: INTC) is up about 1.1%, AT&T Inc (Symbol: T) is up about 1.1%, and Abbott Laboratories (Symbol: ABT) is up by about 0.3%. For a complete list of holdings, visit the IWD Holdings page » The chart below shows the one year price performance of IWD, versus its 200 day moving average: Looking at the chart above, IWD's low point in its 52 week range is $104.0697 per share, with $129.82 as the 52 week high point - that compares with a last trade of $123.47. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of IWD, in trading today Intel Corp (Symbol: INTC) is up about 1.1%, AT&T Inc (Symbol: T) is up about 1.1%, and Abbott Laboratories (Symbol: ABT) is up by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 1000 Value ETF (Symbol: IWD) where we have detected an approximate $43.1 million dollar outflow -- that's a 0.1% decrease week over week (from 307,000,000 to 306,650,000). For a complete list of holdings, visit the IWD Holdings page » The chart below shows the one year price performance of IWD, versus its 200 day moving average: Looking at the chart above, IWD's low point in its 52 week range is $104.0697 per share, with $129.82 as the 52 week high point - that compares with a last trade of $123.47. | Among the largest underlying components of IWD, in trading today Intel Corp (Symbol: INTC) is up about 1.1%, AT&T Inc (Symbol: T) is up about 1.1%, and Abbott Laboratories (Symbol: ABT) is up by about 0.3%. For a complete list of holdings, visit the IWD Holdings page » The chart below shows the one year price performance of IWD, versus its 200 day moving average: Looking at the chart above, IWD's low point in its 52 week range is $104.0697 per share, with $129.82 as the 52 week high point - that compares with a last trade of $123.47. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). |
33030.0 | 2019-03-21 00:00:00 UTC | Abbott's (ABT) HeartMate 3 Pump Study Shows Favorable Results | ABT | https://www.nasdaq.com/articles/abbotts-abt-heartmate-3-pump-study-shows-favorable-results-2019-03-21 | nan | nan | Abbott LaboratoriesABT recently announced late-breaking results from the MOMENTUM 3 randomized control clinical trial. Data highlighted the favorable outcome of the HeartMate 3 left ventricular assist device (LVAD) in patients with advanced heart failure.
MOMENTUM 3 data was reviewed across the complete 1028 patient cohort which showed that the device could efficiently extend life-term, improve the quality of life and reduce the incidence of adverse events in such patients.
More on the Study Results
Presented at the American College of Cardiology, the data testified that Abbott's HeartMate 3 is much superior compared to HeartMate II. The upgraded pump also helped 98.6% patients avoid thrombosis as compared to 86.1%, who used HeartMate II.
Apart from confirming improved survival rates, data showed that complications of stroke, bleeding and the need for surgically removing erroneous pumps can be reduced with the use of the HeartMate 3 pump.
The study also confirms that favorable patient outcome is dependent on the specific design of the pump and not the implant technique.
Market Prospects
Per Allied market research, the global ventricular assist devices market is projected toreach a worth of $1.78 billion by 2023, at a CAGR of 11.8% during the 2017-2023 period.
Abbott is gradually widening the offerings within its Cardiovascular and Neuromodulation arm. However, imminent threat from bigwigs like Medtronic plc MDT , Boston Scientific Corporation BSX and Stryker Corporation SYK is concerning. Meanwhile, the company aims to withstand competitive pressure banking on benefits from technological advantages of certain products.
Other Researches By Abbott
Abbottrecently announced favorable results from two distinctly-conducted analyses of the two-year long COAPT clinical trial, to demonstrate the additional benefits of the company's mitral valve repair device, MitraClip.
In February 2019, Abbott announced real-world research findings that highlighted the global impact of its FreeStyle Libre flash glucose monitoring system on health outcomes for people affected with diabetes.
In January 2019, Abbott presented study-based data which proved the benefits of BURSTDR spinal cord stimulation for treating chronic pain.
In September 2018, real-world research proved that Abbott's Portico transcatheter aortic valve was equipped to treat severe aortic stenosis.
In November 2018, Abbott started conducting studies to assess the efficacy of ablation in treating complex cardiac arrythmia patients.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, wouldn't you like to know about our 10 finest buy-and-holds for the year? From more than 4,000 companies covered by the Zacks Rank, these 10 were picked by a process that consistently beats the market. Even during 2018 while the market dropped -5.2%, our Top 10s were up well into double-digits. And during bullish 2012 - 2017, they soared far above the market's +126.3%, reaching +181.9%. This year, the portfolio features a player that thrives on volatility, an AI comer, and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs.
See Stocks Today >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Boston Scientific Corporation (BSX): Free Stock Analysis Report
Stryker Corporation (SYK): Free Stock Analysis Report
Medtronic PLC (MDT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott LaboratoriesABT recently announced late-breaking results from the MOMENTUM 3 randomized control clinical trial. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. Other Researches By Abbott Abbottrecently announced favorable results from two distinctly-conducted analyses of the two-year long COAPT clinical trial, to demonstrate the additional benefits of the company's mitral valve repair device, MitraClip. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT recently announced late-breaking results from the MOMENTUM 3 randomized control clinical trial. However, imminent threat from bigwigs like Medtronic plc MDT , Boston Scientific Corporation BSX and Stryker Corporation SYK is concerning. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT recently announced late-breaking results from the MOMENTUM 3 randomized control clinical trial. Market Prospects Per Allied market research, the global ventricular assist devices market is projected toreach a worth of $1.78 billion by 2023, at a CAGR of 11.8% during the 2017-2023 period. | Abbott LaboratoriesABT recently announced late-breaking results from the MOMENTUM 3 randomized control clinical trial. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Stryker Corporation (SYK): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. Data highlighted the favorable outcome of the HeartMate 3 left ventricular assist device (LVAD) in patients with advanced heart failure. |
33031.0 | 2019-03-21 00:00:00 UTC | Edwards Lifesciences Presents Positive Partner 3 Trial Data | ABT | https://www.nasdaq.com/articles/edwards-lifesciences-presents-positive-partner-3-trial-data-2019-03-21 | nan | nan | Edwards Lifesciences CorporationEW recently announced favorable randomized PARTNER 3 trial results. The data showed the effectiveness of the SAPIEN 3 transcatheter aortic valve over surgery.
The SAPIEN 3 valve has been approved by the FDA for treating intermediate and higher risk patients with severe, symptomatic aortic stenosis ("AS"). However, Edwards Lifesciences expects to gain the FDA approval for the low-risk indication in late-2019.
We believe the positive trial outcome will help the company rake in higher revenues from the Transcatheter Heart Valve Therapies ("THVT") business in the near term.
PARTNER 3 Trial in Detail
Independently assessed, the PARTNER 3 trial compared outcomes between transcatheter aortic valve replacement ("TAVR") and open-heart surgery in patients with severe symptomatic AS at a low risk of death from surgery. The trial randomized 1,000 patients at 71 centers between Mar 2016 and Oct 2017.
In the PARTNER 3 trial, TAVR with the SAPIEN 3 valve presented an impressively low death and disabling stroke rate of 1.0% at the end of a year in comparison with 2.9% in case of surgery.
Market Potential
Taking the huge potential of the transcatheter heart valve market into consideration, the recent development will help solidify Edwards Lifesciences' market position. Per a Persistence Market Research report, the global heart valve repair and replacement market is likely to reach a worth of $3,767.0 million in 2020, at a CAGR of 8.7%. Edwards Lifesciences also expects the global TAVR opportunity to exceed $7 billion by 2024.
However, Edwards Lifesciences faces competition from a few imminent players like Medtronic plc MDT , Boston Scientific Corporation BSX and Abbott Laboratories ABT in the niche space. Boston Scientific is gaining from the rising momentum of its ACURATE TAVR valve platform in Europe.
Meanwhile, Medtronic with its CoreValve Evolut TAVR platform comprising CoreValve, CoreValve Evolut R and the CoreValve Evolut PRO systems has maintained its position as a formidable player in the TAVR space.
Furthermore, post the acquisition of St. Jude Medical in 2017, Abbott integrated the popular CE Marked Portico TAVR of the former into its Structural Heart portfolio.
THVT in Focus
In the fourth quarter, Edwards Lifesciences' THVT sales totaled $592.4 million, up 14.1% from the prior-year quarter. Globally, TAVR procedures continued to deliver growth in the mid-teens. Further, Edwards Lifesciences aims at fortifying its position in Europe with the launch of CENTERA valve, which received CE Mark last February. Also, the company continues with the controlled rollout of SAPIEN 3 Ultra system in Europe and the United States. Edwards Lifesciences continues to see strong TAVR therapy adoption in Japan, driven by SAPIEN 3.
Considering these upbeat factors, Edwards Lifesciences continues to expect underlying TAVR sales growth of 11% to 15% for 2019.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, wouldn't you like to know about our 10 finest buy-and-holds for the year?
From more than 4,000 companies covered by the Zacks Rank, these 10 were picked by a process that consistently beats the market. Even during 2018 while the market dropped -5.2%, our Top 10s were up well into double-digits. And during bullish 2012 - 2017, they soared far above the market's +126.3%, reaching +181.9%.
This year, the portfolio features a player that thrives on volatility, an AI comer, and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs.
See Stocks Today >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Boston Scientific Corporation (BSX): Free Stock Analysis Report
Medtronic PLC (MDT): Free Stock Analysis Report
Edwards Lifesciences Corporation (EW): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | However, Edwards Lifesciences faces competition from a few imminent players like Medtronic plc MDT , Boston Scientific Corporation BSX and Abbott Laboratories ABT in the niche space. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report To read this article on Zacks.com click here. In the PARTNER 3 trial, TAVR with the SAPIEN 3 valve presented an impressively low death and disabling stroke rate of 1.0% at the end of a year in comparison with 2.9% in case of surgery. | However, Edwards Lifesciences faces competition from a few imminent players like Medtronic plc MDT , Boston Scientific Corporation BSX and Abbott Laboratories ABT in the niche space. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report To read this article on Zacks.com click here. PARTNER 3 Trial in Detail Independently assessed, the PARTNER 3 trial compared outcomes between transcatheter aortic valve replacement ("TAVR") and open-heart surgery in patients with severe symptomatic AS at a low risk of death from surgery. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report To read this article on Zacks.com click here. However, Edwards Lifesciences faces competition from a few imminent players like Medtronic plc MDT , Boston Scientific Corporation BSX and Abbott Laboratories ABT in the niche space. PARTNER 3 Trial in Detail Independently assessed, the PARTNER 3 trial compared outcomes between transcatheter aortic valve replacement ("TAVR") and open-heart surgery in patients with severe symptomatic AS at a low risk of death from surgery. | However, Edwards Lifesciences faces competition from a few imminent players like Medtronic plc MDT , Boston Scientific Corporation BSX and Abbott Laboratories ABT in the niche space. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report To read this article on Zacks.com click here. PARTNER 3 Trial in Detail Independently assessed, the PARTNER 3 trial compared outcomes between transcatheter aortic valve replacement ("TAVR") and open-heart surgery in patients with severe symptomatic AS at a low risk of death from surgery. |
33032.0 | 2019-03-20 00:00:00 UTC | Abbott (ABT) Gains Ground on Solid EPD and Diabetes Arms | ABT | https://www.nasdaq.com/articles/abbott-abt-gains-ground-on-solid-epd-and-diabetes-arms-2019-03-20 | nan | nan | On Mar 19, we issued an updated research report on Abbott LaboratoriesABT . The company has been consistently delivering solid organic growth in the Established Pharmaceuticals ("EPD") and Diabetes segments. The stock currently carries a Zacks Rank #2 (Buy).
This leading developer, manufacturer and seller of a diversified line of health care products has outperformed its industry over the past year. The stock has gained 27.7% in comparison with the industry's 6.6% rise.
The EPD business operates solely in emerging geographies, with leading positions in many of the largest and fastest growing pharmaceutical markets for branded generics in the world. These markets include India, Russia, China and Latin America.
The company recently noted that the Branded Generic operating model has positioned EPD for sustained above-market growth in many of these growing pharmaceutical markets. In the las t report ed quarter, sales were strong led by double-digit growth in both India and China.
We are also upbeat about Abbott's Diabetes arm which achieved mid-30s growth led by FreeStyle Libre's global sales of more than $1 billion in 2018, a 100% increase over the 2017 figure. As of 2018-end, there were approximately 1.3 million active users worldwide, of which approximately two-thirds were type 1 diabetics and one-third type 2.
Meanwhile, the United States has been seeing an accelerating trend of new users since Abbott ramped up its awareness efforts during the second half of 2018.
In Europe, the company initiated the launch of Libre 2.0, which offers optional alarms that set off when patients' glucose levels fall, in the fourth quarter.
Moreover, we are upbeat about the company's Diagnostics business delivering impressive performance over the past few quarters. Synergies from the Alere consolidation in the form of revenues from Rapid Diagnostics have been driving growth. Furthermore, Alinity, family of highly differentiated instruments, is achieving accelerated growth and competitive win rates in Europe.
Other Key Picks
Other top-ranked stocks in the broader medical space are Integer Holdings Corporation ITGR , Veeva Systems Inc. VEEV and Hologic, Inc. HOLX .
Integer Holdings projects an earnings growth rate of 31.2% for the first quarter. It currently carries a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Veeva Systems' long-term earnings growth rate is projected at 14.8%. The stock currently carries a Zacks Rank of 2.
Hologic's long-term earnings growth rate is projected at 8.9%. The stock presently has a Zacks Rank #2.
This Could Be the Fastest Way to Grow Wealth in 2019
Research indicates one sector is poised to deliver a crop of the best-performing stocks you'll find anywhere in the market. Breaking news in this space frequently creates quick double- and triple-digit profit opportunities.
These companies are changing the world - and owning their stocks could transform your portfolio in 2019 and beyond. Recent trades from this sector have generated +98% , +119% and +164% gains in as little as 1 month.
Click here to see these breakthrough stocks now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Veeva Systems Inc. (VEEV): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Integer Holdings Corporation (ITGR): Free Stock Analysis Report
Hologic, Inc. (HOLX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | On Mar 19, we issued an updated research report on Abbott LaboratoriesABT . Click to get this free report Veeva Systems Inc. (VEEV): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Integer Holdings Corporation (ITGR): Free Stock Analysis Report Hologic, Inc. (HOLX): Free Stock Analysis Report To read this article on Zacks.com click here. The EPD business operates solely in emerging geographies, with leading positions in many of the largest and fastest growing pharmaceutical markets for branded generics in the world. | Click to get this free report Veeva Systems Inc. (VEEV): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Integer Holdings Corporation (ITGR): Free Stock Analysis Report Hologic, Inc. (HOLX): Free Stock Analysis Report To read this article on Zacks.com click here. On Mar 19, we issued an updated research report on Abbott LaboratoriesABT . Other Key Picks Other top-ranked stocks in the broader medical space are Integer Holdings Corporation ITGR , Veeva Systems Inc. VEEV and Hologic, Inc. HOLX . | Click to get this free report Veeva Systems Inc. (VEEV): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Integer Holdings Corporation (ITGR): Free Stock Analysis Report Hologic, Inc. (HOLX): Free Stock Analysis Report To read this article on Zacks.com click here. On Mar 19, we issued an updated research report on Abbott LaboratoriesABT . The company recently noted that the Branded Generic operating model has positioned EPD for sustained above-market growth in many of these growing pharmaceutical markets. | On Mar 19, we issued an updated research report on Abbott LaboratoriesABT . Click to get this free report Veeva Systems Inc. (VEEV): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Integer Holdings Corporation (ITGR): Free Stock Analysis Report Hologic, Inc. (HOLX): Free Stock Analysis Report To read this article on Zacks.com click here. In the las t report ed quarter, sales were strong led by double-digit growth in both India and China. |
33033.0 | 2019-03-20 00:00:00 UTC | Medtronic (MDT) Releases Encouraging Evalut TAVR Result | ABT | https://www.nasdaq.com/articles/medtronic-mdt-releases-encouraging-evalut-tavr-result-2019-03-20 | nan | nan | Medtronic plcMDT recently presented the initial clinical outcome of its Evolut Low Risk Trial at the 68th Annual Scientific Session of the American College of Cardiology. This data was also published in the New England Journal of Medicine.
The clinical program was aimed at comparing the minimally invasive Evolut transcatheter aortic valve replacement (TAVR) system to the gold standard of open-heart surgery in younger, healthier aortic stenosis patients.
Per Medtronic, these low-risk aortic stenosis patients have special characteristics on account of their tendency to be younger and active as compared to their higher-risk counterparts. The study itself is significant and timely considering the fact that there are 165,000 low-risk patients suffering severe aortic stenosis per year in the United States, Western Europe and Japan. If left untreated, the ailment can cause heart failure within a span of two years.
Data at a Glance
In the second year, the findings of this randomized Evolut Low Risk study claim to meet its primary non-inferiority endpoint of all-cause mortality or disabling stroke as compared to surgery. More specifically, all-cause mortality or disabling stroke incident was 5.3% with the Evolut TAVR as compared to 6.7% incident with traditional surgery.
This apart, the pre-specified 30-day safety composite of all-cause mortality, disabling stroke, life-threatening bleeding, major vascular complications or acute kidney injury was significantly lower for TAVR in comparison to open heart surgery.
Peer Threat
Medtronic's success from this favorable study outcome has too some extent disappeared following its rival in this field - Edwards' Lifesciences EW - releasing a Phase 3 clinical trial outcome of its PARTNER 3 study on SAPIEN 3 mitral valve in patients with severe symptomatic aortic stenosis. Edwards' data showed a 1% incident for all-cause mortality or disabling stroke in these patients.
Other major peers of Medtronic in this field are Boston Scientific Corporation BSX and Abbott Laboratories ABT who are also presenting their study results at the latest session of the Americal College of Cardiology.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, wouldn't you like to know about our 10 finest buy-and-holds for the year?
From more than 4,000 companies covered by the Zacks Rank, these 10 were picked by a process that consistently beats the market. Even during 2018 while the market dropped -5.2%, our Top 10s were up well into double-digits. And during bullish 2012 - 2017, they soared far above the market's +126.3%, reaching +181.9%.
This year, the portfolio features a player that thrives on volatility, an AI comer, and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs.
See Stocks Today >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Boston Scientific Corporation (BSX): Free Stock Analysis Report
Edwards Lifesciences Corporation (EW): Free Stock Analysis Report
Medtronic PLC (MDT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Other major peers of Medtronic in this field are Boston Scientific Corporation BSX and Abbott Laboratories ABT who are also presenting their study results at the latest session of the Americal College of Cardiology. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. Data at a Glance In the second year, the findings of this randomized Evolut Low Risk study claim to meet its primary non-inferiority endpoint of all-cause mortality or disabling stroke as compared to surgery. | Other major peers of Medtronic in this field are Boston Scientific Corporation BSX and Abbott Laboratories ABT who are also presenting their study results at the latest session of the Americal College of Cardiology. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. Peer Threat Medtronic's success from this favorable study outcome has too some extent disappeared following its rival in this field - Edwards' Lifesciences EW - releasing a Phase 3 clinical trial outcome of its PARTNER 3 study on SAPIEN 3 mitral valve in patients with severe symptomatic aortic stenosis. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. Other major peers of Medtronic in this field are Boston Scientific Corporation BSX and Abbott Laboratories ABT who are also presenting their study results at the latest session of the Americal College of Cardiology. Data at a Glance In the second year, the findings of this randomized Evolut Low Risk study claim to meet its primary non-inferiority endpoint of all-cause mortality or disabling stroke as compared to surgery. | Other major peers of Medtronic in this field are Boston Scientific Corporation BSX and Abbott Laboratories ABT who are also presenting their study results at the latest session of the Americal College of Cardiology. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. Edwards' data showed a 1% incident for all-cause mortality or disabling stroke in these patients. |
33034.0 | 2019-03-20 00:00:00 UTC | Abbott's (ABT) MitraClip COAPT Trial Shows Favorable Results (Revised) | ABT | https://www.nasdaq.com/articles/abbotts-abt-mitraclip-coapt-trial-shows-favorable-results-revised-2019-03-20-0 | nan | nan | Abbott LaboratoriesABT recently announced favorable results from two distinctly-conducted analyses of the two-year long COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation) clinical trial.
The study sheds light on the additional benefits of the company's mitral valve repair device, the MitraClip. The positive data sets prove that the MitraClip ensures the sustenance of long-term quality of life for patients of secondary or functional mitral regurgitation (MR).
Results of COAPT Trial Study
Both sets of data were presented at the American College of Cardiology. Based on the results of the COAPT trial data, the FDA gave its approval for the expanded use of MitraClip in the treatment of secondary mitral regurgitation. In 2013, MitraClip was approved as a repair device for primary MR.
The study revealed that Abbott's MitraClip performs better than any traditional treatment for functional MR available in the market. A second round of sub-analysis compared the baseline characteristics of advanced heart failure patients, before and after their enrollment in the study. The results testified that all sub-groups of patients, who enrolled in the study, received long-term benefits from the application of MitraClip.
Results show that the device provides instant symptom relief and also ensures swift discharge of patients. In fact, the study noted that MitraClip alleviates the risk of hospitalization, prolongs life term and enhances the quality of life of patients affected with severe MR.
This two-year data by Abbott can be treated as a major development in the field of the complicated secondary mitral regurgitation. Per a Star Tribune report, in a recent study, two-thirds of the people, taking the maximum recommended doses of drugs for severe forms of secondary MR, were either hospitalized or dead within two years. The report, however, claims that at the late-breaking sessions of the American College of Cardiology, researchers noted that the rate of hospitalization and death dropped to 46% in patients implanted with a MitraClip device.
Market Prospects
Per Allied market research, the global market for transcatheter heart valve replacement and repair is projected to reach a worth of $8.13 billion, at a CAGR of 13.8% during the 2017-2025 period. Abbott expects MitraClip to reach a market worth of $4 billion in the United States, where about 6.5 million people suffer heart failure.
Other Researches by Abbott
New late-breaking Momentum 3 data has highlighted the efficiency of Abbott's recently-approved HeartMate 3 left ventricular assist device in treating advanced heart failure.
This February, the company announced real-world research findings that highlighted the global impact of its FreeStyle Libre flash glucose monitoring system on health outcomes for people affected with diabetes.
Earlier in January, Abbott presented study-based data which proved the benefits of the BURSTDR spinal cord stimulation for people suffering from chronic pain.
In September 2018, real-world research proved that Abbott's Portico transcatheter aortic valve was equipped to treat severe aortic stenosis. Later that November, Abbott started conducting studies to assess the efficacy of ablation in treating patients suffering from complex cardiac arrythmia.
Price Performance
Over the past year, Abbott's shares have outperformed the industry it belongs to. The stock has rallied 27.7% compared with the industry's rise of 6.6%.
Zacks Rank & Other Key Picks
Currently, Abbott has a Zacks Rank of #2 (Buy).
A few other top-ranked stocks in the broader medical space are Penumbra, Inc., PEN , Varian Medical Systems, Inc. VAR and Masimo, Inc. MASI . Each of these stocks currently carries a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Penumbra's long-term earnings growth rate is expected at 20.93%.
Varian's long-term earnings growth rate is projected at 8.00%.
Masimo's long-term earnings are projected to grow 15.60%.
(We are reissuing this article to correct a mistake. The original article, issued on March 19, 2019, should no longer be relied upon.)
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report
ABIOMED, Inc. (ABMD): Free Stock Analysis Report
Masimo Corporation (MASI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott LaboratoriesABT recently announced favorable results from two distinctly-conducted analyses of the two-year long COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation) clinical trial. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report To read this article on Zacks.com click here. Per a Star Tribune report, in a recent study, two-thirds of the people, taking the maximum recommended doses of drugs for severe forms of secondary MR, were either hospitalized or dead within two years. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT recently announced favorable results from two distinctly-conducted analyses of the two-year long COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation) clinical trial. The positive data sets prove that the MitraClip ensures the sustenance of long-term quality of life for patients of secondary or functional mitral regurgitation (MR). | Abbott LaboratoriesABT recently announced favorable results from two distinctly-conducted analyses of the two-year long COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation) clinical trial. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report To read this article on Zacks.com click here. Other Researches by Abbott New late-breaking Momentum 3 data has highlighted the efficiency of Abbott's recently-approved HeartMate 3 left ventricular assist device in treating advanced heart failure. | Abbott LaboratoriesABT recently announced favorable results from two distinctly-conducted analyses of the two-year long COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation) clinical trial. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report To read this article on Zacks.com click here. The positive data sets prove that the MitraClip ensures the sustenance of long-term quality of life for patients of secondary or functional mitral regurgitation (MR). |
33035.0 | 2019-03-20 00:00:00 UTC | Is Abbott Laboratories (ABT) Outperforming Other Medical Stocks This Year? | ABT | https://www.nasdaq.com/articles/is-abbott-laboratories-abt-outperforming-other-medical-stocks-this-year-2019-03-20 | nan | nan | Investors focused on the Medical space have likely heard of Abbott Laboratories (ABT), but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Abbott Laboratories is one of 833 individual stocks in the Medical sector. Collectively, these companies sit at #2 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. ABT is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ABT's full-year earnings has moved 0.28% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the most recent data, ABT has returned 10.55% so far this year. In comparison, Medical companies have returned an average of 10.46%. As we can see, Abbott Laboratories is performing better than its sector in the calendar year.
Looking more specifically, ABT belongs to the Medical - Products industry, which includes 77 individual stocks and currently sits at #74 in the Zacks Industry Rank. Stocks in this group have gained about 13.70% so far this year, so ABT is slightly underperforming its industry this group in terms of year-to-date returns.
Investors in the Medical sector will want to keep a close eye on ABT as it attempts to continue its solid performance.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Investors focused on the Medical space have likely heard of Abbott Laboratories (ABT), but is the stock performing well in comparison to the rest of its sector peers? Investors in the Medical sector will want to keep a close eye on ABT as it attempts to continue its solid performance. ABT is currently sporting a Zacks Rank of #2 (Buy). | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Investors focused on the Medical space have likely heard of Abbott Laboratories (ABT), but is the stock performing well in comparison to the rest of its sector peers? ABT is currently sporting a Zacks Rank of #2 (Buy). | Investors focused on the Medical space have likely heard of Abbott Laboratories (ABT), but is the stock performing well in comparison to the rest of its sector peers? Looking more specifically, ABT belongs to the Medical - Products industry, which includes 77 individual stocks and currently sits at #74 in the Zacks Industry Rank. ABT is currently sporting a Zacks Rank of #2 (Buy). | Investors focused on the Medical space have likely heard of Abbott Laboratories (ABT), but is the stock performing well in comparison to the rest of its sector peers? ABT is currently sporting a Zacks Rank of #2 (Buy). Within the past quarter, the Zacks Consensus Estimate for ABT's full-year earnings has moved 0.28% higher. |
33036.0 | 2019-03-19 00:00:00 UTC | What Makes Abbott (ABT) a New Buy Stock | ABT | https://www.nasdaq.com/articles/what-makes-abbott-abt-a-new-buy-stock-2019-03-19 | nan | nan | Abbott (ABT) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.
The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.
Since a changing earnings picture is a powerful factor influencing near-term stock price movements, the Zacks rating system is very useful for individual investors. They may find it difficult to make decisions based on rating upgrades by Wall Street analysts, as these are mostly driven by subjective factors that are hard to see and measure in real time.
Therefore, the Zacks rating upgrade for Abbott basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.
Most Powerful Force Impacting Stock Prices
The change in a company's future earnings potential, as reflected in earnings estimate revisions, and the near-term price movement of its stock are proven to be strongly correlated. That's partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their bulk investment action then leads to price movement for the stock.
Fundamentally speaking, rising earnings estimates and the consequent rating upgrade for Abbott imply an improvement in the company's underlying business. Investors should show their appreciation for this improving business trend by pushing the stock higher.
Harnessing the Power of Earnings Estimate Revisions
Empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, so it could be truly rewarding if such revisions are tracked for making an investment decision. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power o f earnings estimate revisions.
The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>> .
Earnings Estimate Revisions for Abbott
This maker of infant formula, medical devices and drugs is expected to earn $3.20 per share for the fiscal year ending December 2019, which represents a year-over-year change of 11.1%.
Analysts have been steadily raising their estimates for Abbott. Over the past three months, the Zacks Consensus Estimate for the company has increased 0.3%.
Bottom Line
Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of 'buy' and 'sell' ratings for its entire universe of more than 4000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a 'Strong Buy' rating and the next 15% get a 'Buy' rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.
You can learn more about the Zacks Rank here >>>
The upgrade of Abbott to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott (ABT) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. They may find it difficult to make decisions based on rating upgrades by Wall Street analysts, as these are mostly driven by subjective factors that are hard to see and measure in real time. | Abbott (ABT) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Since a changing earnings picture is a powerful factor influencing near-term stock price movements, the Zacks rating system is very useful for individual investors. | Abbott (ABT) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Most Powerful Force Impacting Stock Prices The change in a company's future earnings potential, as reflected in earnings estimate revisions, and the near-term price movement of its stock are proven to be strongly correlated. | Abbott (ABT) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Since a changing earnings picture is a powerful factor influencing near-term stock price movements, the Zacks rating system is very useful for individual investors. |
33037.0 | 2019-03-19 00:00:00 UTC | Abbott's (ABT) MitraClip COAPT Trial Shows Favorable Results | ABT | https://www.nasdaq.com/articles/abbotts-abt-mitraclip-coapt-trial-shows-favorable-results-2019-03-19 | nan | nan | Abbott LifesciencesABT recently announced favorable results from two distinctly-conducted analyses of the two-year long COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation) clinical trial.
The study sheds light on the additional benefits of the company's mitral valve repair device, the MitraClip. The positive data sets prove that the MitraClip ensures the sustenance of long-term quality of life for patients of secondary or functional mitral regurgitation (MR).
Results of COAPT Trial Study
Both sets of data were presented at the American College of Cardiology. Based on the results of the COAPT trial data, the U.S. FDA gave its approval for the expanded use of MitraClip in the treatment of secondary mitral regurgitation. In 2013, MitraClip was approved as a repair device for primary MR.
The study revealed that Abbott's MitraClip performs better than any traditional treatment for functional MR available in the market. A second round of sub-analysis compared the baseline characteristics of advanced heart failure patients, before and after their enrollment in the study. The results testified that all sub-groups of patients, who enrolled in the study, received long-term benefits from the application of MitraClip.
Results show that the device provides instant symptom relief and also ensures swift discharge of patients. In fact, the study noted that MitraClip alleviates the risk of hospitalization, prolongs life term and enhances the quality of life of patients affected with severe MR.
This two-year data by Abbott can be treated as a major development in the field of the complicated secondary mitral regurgitation. Per a Star Tribune report, in a recent study, two-thirds of the people, taking the maximum recommended doses of drugs for severe forms of secondary MR, were either hospitalized or dead within two years. The report, however, claims that at the late-breaking sessions of the American College of Cardiology, researchers noted that the rate of hospitalization and death dropped to 46% in patients implanted with a MitraClip device.
Market Prospects
Per Allied market research, the global market for transcatheter heart valve replacement and repair is projected to reach a worth of $8.13 billion, at a CAGR of 13.8% during the 2017-2025 period.Abbott expects MitraClip to reach a market worth $4 billion in the United States, where about 6.5 million people suffer from heart failures.
Other Researches by Abbott
New late-breaking Momentum 3 data has highlighted the efficiency of Abbott's recently-approved HeartMate 3 left ventricular assist device in treating advanced heart failure.
This February, the company announced real-world research findings that highlighted the global impact of its FreeStyle Libre flash glucose monitoring system on health outcomes for people affected with diabetes.
Earlier in January, Abbott presented study-based data which proved the benefits of the BURSTDR spinal cord stimulation for people suffering from chronic pain.
In September 2018, real-world research proved that Abbott's Portico transcatheter aortic valve was equipped to treat severe aortic stenosis.
Later that November, Abbott started conducting studies to assess the efficacy of ablation in treating patients suffering from complex cardiac arrythmia.
Price Performance
Over the past year, Abbott's shares have outperformed the industry it belongs to. The stock has rallied 25.9% compared to the industry's gain of 6.6%.
Zacks Rank & Other Key Picks
Currently, Abbott has a Zacks Rank of #2 (buy).
A few other top-ranked stocks in the broader medical space are ABIOMED, Inc., ABMD , Varian Medical Systems, Inc. VAR and Masimo, Inc. MASI . Each of these stocks currently carries a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
ABIOMED's long-term earnings growth rate is expected at 27.67%.
Varian's long-term earnings growth rate is projected at 8.00%.
Masimo's long-term earnings are projected to grow 15.60%.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year? Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.
See Latest Stocks Today >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Masimo Corporation (MASI): Free Stock Analysis Report
ABIOMED, Inc. (ABMD): Free Stock Analysis Report
Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott LifesciencesABT recently announced favorable results from two distinctly-conducted analyses of the two-year long COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation) clinical trial. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report To read this article on Zacks.com click here. Per a Star Tribune report, in a recent study, two-thirds of the people, taking the maximum recommended doses of drugs for severe forms of secondary MR, were either hospitalized or dead within two years. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LifesciencesABT recently announced favorable results from two distinctly-conducted analyses of the two-year long COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation) clinical trial. The positive data sets prove that the MitraClip ensures the sustenance of long-term quality of life for patients of secondary or functional mitral regurgitation (MR). | Abbott LifesciencesABT recently announced favorable results from two distinctly-conducted analyses of the two-year long COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation) clinical trial. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report To read this article on Zacks.com click here. Market Prospects Per Allied market research, the global market for transcatheter heart valve replacement and repair is projected to reach a worth of $8.13 billion, at a CAGR of 13.8% during the 2017-2025 period.Abbott expects MitraClip to reach a market worth $4 billion in the United States, where about 6.5 million people suffer from heart failures. | Abbott LifesciencesABT recently announced favorable results from two distinctly-conducted analyses of the two-year long COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation) clinical trial. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report To read this article on Zacks.com click here. The positive data sets prove that the MitraClip ensures the sustenance of long-term quality of life for patients of secondary or functional mitral regurgitation (MR). |
33038.0 | 2019-03-19 00:00:00 UTC | Why You Should Buy ABBV Stock for Income and Value | ABT | https://www.nasdaq.com/articles/why-you-should-buy-abbv-stock-income-and-value-2019-03-19 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Today, I'd like to discuss the outlook for AbbVie (NYSE: ABBV ), the $116-billion-market-cap biopharmaceutical stock, whose shares have been in a downtrend for almost a year and have especially been hammered following its earning report of Jan. 25.
Source: Shutterstock
Top 7 Service Sector Stocks That Will Pay You to Own Them
There could be further price volatility and weakness in the ABBV stock price in the coming weeks, pushing it toward the low-$70's or even mid-$60's level. However, it is a company with robust growth prospects and respectable dividends that may deserve a place in a diversified portfolio.
Therefore, if you already own AbbVie shares, you might want to hold your position. That said, within the parameters of your portfolio allocation and risk/return profile, you may consider placing a stop loss at about 5-7% below the current price point. Expect nearer-term trading to be choppy at best.
If you are an experienced investor in the options market, you may want to protect your portfolio with a covered call or possibly a put option spread with a 3-month time horizon. If you do not yet hold ABBV, you may want to wait several weeks to buy into the stock at the next dip.
With all of that in mind, here's a deeper look into at AbbVie stock.
A Hiccup in the Robust Fundamental Story
In 2013, Abbott Laboratories (NYSE: ABT ) spun off its research-based pharmaceuticals business, creating AbbVie, an independent biopharmaceutical company. Abbott decided to retain the branded generic pharmaceuticals, diagnostics, medical devices and nutrition.
Meanwhile, AbbVie took control of the development and commercialization of a range of brands , including Humira, its flagship drug used to treat autoimmune diseases, Imbruvica, which differentiates between cancer cells and regular cells, and Synthroid, a replacement for a hormone normally produced by the thyroid gland.
The company's financials and growth metrics over the past five years have been impressive and ABBV was in a strong financial position heading into 2019, with hopes of a higher share price during the first quarter.
However, in January, AbbVie's fourth-quarter earnings release weighed heavily on the stock. For starters, the company missed the consensus on revenue. Its earnings per share of $1.90 was below the expected number of $1.94. The next day, the stock fell by 6% and that decline has intensified over the past two months.
ABBV's quarterly report also showed that the international sales of Humira fell by almost 15% year over year, mostly as a result of 'biosimilar' competition in Europe , which makes up three-quarters of the overseas Humira business. In October 2018, its patent in the European Union (E.U) expired .
The U.S. Food and Drug Administration (FDA) refers to biosimilars as "highly similar to an FDA-approved biological product … [that has] no clinically meaningful differences in terms of safety and effectiveness." Although Wall Street had already known about this sales decline in Europe, when coupled with the other question marks in the earnings report, it was enough to increase the selling pressure on the stock.
It is also possible that investors got worried about the potential fall in Humira revenue when the drug comes off patent in 2023 in the U.S. It is important to emphasize that AbbVie's revenue from the drug will not decline to nothing when the biosimilars hit the market in 2023. What will most likely happen is that as the company's pricing power decreases, the revenue will also gradually decline.
Therefore, many analysts feel that ABBV shares offer value and that any bad news that is specific to Humira is already baked into the stock price.
Value Play
When markets penalize biopharma stocks, it can take some time for them to recover. However, for patient long-term investors, the returns can be significant - especially when the company boasts several other current drugs, as well promising ones in the pipeline.
At present, AbbVie's other major products include:
AndroGel, a testosterone replacement therapy.
Creon, a pancreatic enzyme therapy to treat exocrine pancreatic insufficiency.
Duopa and Duodopa, gels to treat Parkinson's disease.
Viekira Pak, which treats chronic hepatitis C.
Zinbryta, to treat multiple sclerosis.
Analysts are also expecting a slew of new products in 2020, such as next-generation immunology drugs. These drugs and others that are being developed and commercialized, highlight how impressive the potential growth story could be in the next few years.
ABBV trades at a trailing price-to-earnings (P/E) ratio of 21. This number is rather modest when compared with the P/E ratios of several competitors, including AstraZeneca (NYSE: AZN ) with a P/E of 49.9, Pfizer (NYSE: PFE ) with a P/E of 25.2, and Merck (NYSE: MRK ) with a P/E of 34.8.
Reinvesting the Sweet Dividend Yield of ABBV stock
Income investors know that they can compound their returns through reinvesting dividends from high-yielding shares. AbbVie also offers investors a healthy dividend yield of about 5.4%, another reason why I believe the stock belongs in a capital-growth portfolio.
Since its spin-off from Abbott Laboratories in 2013, ABBV has increased dividends every year - a trend that is likely to continue. The next dividend payment is scheduled for May 15, 2019, with an ex-dividend date of April 12.
It would not be wrong to call AbbVie a cashflow machine; as of Dec. 31, the company had a free cash flow of $3.27 billion. This strength not only gives shareholders conviction that the dividends are safe, but also provides the company with enough flexibility to, for example, make acquisitions to offset any further Humira revenue decline (especially in the U.S. when the drug comes off patent in 2023).
The Bottom Line on AbbVie Stock
Like most biopharma stocks, AbbVie is a high-momentum stock. In other words, when the broader markets go up or when the company's earnings beat expectations, both investors and momentum traders tend to hit the "buy" button fast, expecting superior gains within days or weeks.
However, if markets suffer a decline or if the company cannot keep up with the rising expectations, investors' risk appetite decreases fast and these stocks can fall much harder than less volatile stocks.
7 Financial Stocks to Invest In Today
The market has punished Abbvie stock since the start of the year. The stock may continue to struggle through much of 2019. However, patient ABBV bulls will probably be proven right to believe in the management's commitment to create shareholder value and to further grow the company both organically and through acquisitions. In the meantime, they can continue to collect high dividends.
As of this writing, Tezcan Gecgil did not hold a position in any of the aforementioned securities.
More From InvestorPlace
2 Toxic Pot Stocks You Should Avoid
7 Financial Stocks to Invest In Today
7 Single-Digit P/E Stocks With Massive Upside
5 Chip Stocks on the Rise
Compare Brokers
The post Why You Should Buy ABBV Stock for Income and Value appeared first on InvestorPlace .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A Hiccup in the Robust Fundamental Story In 2013, Abbott Laboratories (NYSE: ABT ) spun off its research-based pharmaceuticals business, creating AbbVie, an independent biopharmaceutical company. The U.S. Food and Drug Administration (FDA) refers to biosimilars as "highly similar to an FDA-approved biological product … [that has] no clinically meaningful differences in terms of safety and effectiveness." This strength not only gives shareholders conviction that the dividends are safe, but also provides the company with enough flexibility to, for example, make acquisitions to offset any further Humira revenue decline (especially in the U.S. when the drug comes off patent in 2023). | A Hiccup in the Robust Fundamental Story In 2013, Abbott Laboratories (NYSE: ABT ) spun off its research-based pharmaceuticals business, creating AbbVie, an independent biopharmaceutical company. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Today, I'd like to discuss the outlook for AbbVie (NYSE: ABBV ), the $116-billion-market-cap biopharmaceutical stock, whose shares have been in a downtrend for almost a year and have especially been hammered following its earning report of Jan. 25. Reinvesting the Sweet Dividend Yield of ABBV stock Income investors know that they can compound their returns through reinvesting dividends from high-yielding shares. | A Hiccup in the Robust Fundamental Story In 2013, Abbott Laboratories (NYSE: ABT ) spun off its research-based pharmaceuticals business, creating AbbVie, an independent biopharmaceutical company. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Today, I'd like to discuss the outlook for AbbVie (NYSE: ABBV ), the $116-billion-market-cap biopharmaceutical stock, whose shares have been in a downtrend for almost a year and have especially been hammered following its earning report of Jan. 25. The Bottom Line on AbbVie Stock Like most biopharma stocks, AbbVie is a high-momentum stock. | A Hiccup in the Robust Fundamental Story In 2013, Abbott Laboratories (NYSE: ABT ) spun off its research-based pharmaceuticals business, creating AbbVie, an independent biopharmaceutical company. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Today, I'd like to discuss the outlook for AbbVie (NYSE: ABBV ), the $116-billion-market-cap biopharmaceutical stock, whose shares have been in a downtrend for almost a year and have especially been hammered following its earning report of Jan. 25. It is also possible that investors got worried about the potential fall in Humira revenue when the drug comes off patent in 2023 in the U.S. |
33039.0 | 2019-03-19 00:00:00 UTC | 3 Blue Chip Stocks That Just Hit 52-Week Highs: Are They Buys? | ABT | https://www.nasdaq.com/articles/3-blue-chip-stocks-just-hit-52-week-highs-are-they-buys-2019-03-19 | nan | nan | Don't think for a second that all blue chip stocks are stuffy and deliver sluggish growth. Some of them are exactly the opposite of that description.
These three blue chip stocks recently hit 52-week highs, with two of the three reaching all-time-high marks. Here's why Abbott Labs (NYSE: ABT) , Novartis (NYSE: NVS) , and Stryker (NYSE: SYK) are performing so well -- and whether any of these stocks are buys right now.
1. Abbott Labs
Abbott Labs is the best performer of the three blue chip stocks on this list, with its shares up 24% over the last 12 months. You only have to look at Abbott's 2018 financial results to know why the big medical-device maker is doing so well. The company increased its earnings per share (EPS) by 15%, generated over $6 billion in cash flow, and boosted its dividend by 14%.
It would be a stretch to say that only one or two products led to Abbott's success. After all, the company markets a long list of products across multiple categories. And all four of its business segments generated year-over-year revenue growth in 2018. However, there are two products that warranted special attention from Abbott CEO Miles White in the company's Q4 conference call in January: FreeStyle Libre and Alinity.
FreeStyle Libre is Abbott's continuous glucose monitoring (CGM) system that doesn't require finger sticks. Sales for the system more than doubled last year to top $1 billion. Alinity is Abbott's suite of diagnostic products that have been launched in Europe and some international markets but not yet in the U.S. White stated in Abbott's Q4 call that Alinity's "rollout in Europe has been exceptional."
2. Novartis
Novartis' shares have gained 13% over the last 12 months and now trade at the highest level since January 2018. The big pharma company's momentum kicked into gear last July after Novartis reported solid second-quarter results.
While Novartis claims a whopping 15 blockbuster drugs on the market, its two fastest-rising stars right now are immunology drug Cosentyx and heart-failure drug Entresto. Last year, sales for Cosentyx soared by 37% to $2.8 billion, making the drug Novartis' No. 2 best seller overall. Entresto topped $1 billion in sales for the first time, with revenue more than doubling from the previous year.
Acquisitions have also fueled Novartis' rise. The company closed its purchase of French drugmaker Advanced Accelerator Applications in early 2018. It followed up in April with the acquisition of gene therapy biotech AveXis . Novartis also announced last October that it was buying cancer-focused biotech Endocyte .
3. Stryker
After finishing 2018 with a puny 1% gain, medical-device giant Stryker's shares have jumped 23% so far in 2019. The stock is now near its 52-week and all-time-high marks.
The primary catalyst for Stryker was the company's great Q4 update in January 2019. Stryker CEO Kevin Lobo stated on the company's conference call that the company "had an excellent finish to 2018 with the best organic sales growth in a decade, and strong adjusted earnings performance."
Two areas look especially strong for Stryker. The company's medical-surgical unit is firing on all cylinders, with endoscopy instruments experiencing notably strong sales growth. Stryker's acquisition of K2M also boosted the company's neurotechnology and spine growth.
Are they buys?
In my view, one of these three blue chip stocks is a solid pick and two are maybes to keep on your radar. Let's start with the ones to watch.
Novartis has a lot going for it with Cosentyx and Entresto, new products like migraine drug Aimovig, and a promising pipeline. However, it will likely take a few years for the drugmaker's pipeline to really begin contributing. In the meantime, Novartis faces headwinds for older products, including cancer drug Gleevec and multiple sclerosis drug Gilenya. My view is to hold off on Novartis for now, but it could be a stronger choice in the not-too-distant future.
I plan to closely watch Stryker as well. The company has some new products launching this year that should drive revenue higher. I think that Stryker is close to being a stock to buy, but I'm in wait-and-see mode for now.
My favorite of these three stocks is Abbott. I think that FreeStyle Libre should continue to perform really well, especially with a new version on the way. I also expect the U.S. launch for Alinity to be a great success for Abbott. With Abbott's increasing dividend, my take is that it could deliver market-beating total returns in the future.
10 stocks we like better than Abbott Laboratories
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 1, 2019
Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Here's why Abbott Labs (NYSE: ABT) , Novartis (NYSE: NVS) , and Stryker (NYSE: SYK) are performing so well -- and whether any of these stocks are buys right now. However, there are two products that warranted special attention from Abbott CEO Miles White in the company's Q4 conference call in January: FreeStyle Libre and Alinity. FreeStyle Libre is Abbott's continuous glucose monitoring (CGM) system that doesn't require finger sticks. | Here's why Abbott Labs (NYSE: ABT) , Novartis (NYSE: NVS) , and Stryker (NYSE: SYK) are performing so well -- and whether any of these stocks are buys right now. Abbott Labs Abbott Labs is the best performer of the three blue chip stocks on this list, with its shares up 24% over the last 12 months. However, there are two products that warranted special attention from Abbott CEO Miles White in the company's Q4 conference call in January: FreeStyle Libre and Alinity. | Here's why Abbott Labs (NYSE: ABT) , Novartis (NYSE: NVS) , and Stryker (NYSE: SYK) are performing so well -- and whether any of these stocks are buys right now. Abbott Labs Abbott Labs is the best performer of the three blue chip stocks on this list, with its shares up 24% over the last 12 months. Stryker CEO Kevin Lobo stated on the company's conference call that the company "had an excellent finish to 2018 with the best organic sales growth in a decade, and strong adjusted earnings performance." | Here's why Abbott Labs (NYSE: ABT) , Novartis (NYSE: NVS) , and Stryker (NYSE: SYK) are performing so well -- and whether any of these stocks are buys right now. Abbott Labs Abbott Labs is the best performer of the three blue chip stocks on this list, with its shares up 24% over the last 12 months. Stryker's acquisition of K2M also boosted the company's neurotechnology and spine growth. |
33040.0 | 2019-03-18 00:00:00 UTC | Abbott (ABT) Stock Sinks As Market Gains: What You Should Know | ABT | https://www.nasdaq.com/articles/abbott-abt-stock-sinks-as-market-gains%3A-what-you-should-know-2019-03-18 | nan | nan | Abbott (ABT) closed at $78.83 in the latest trading session, marking a -1.29% move from the prior day. This move lagged the S&P 500's daily gain of 0.37%. Meanwhile, the Dow gained 0.25%, and the Nasdaq, a tech-heavy index, added 0.34%.
Prior to today's trading, shares of the maker of infant formula, medical devices and drugs had gained 7.96% over the past month. This has outpaced the Medical sector's gain of 1.34% and the S&P 500's gain of 1.83% in that time.
Investors will be hoping for strength from ABT as it approaches its nex t earnings release. In tha t report , analysts expect ABT to post earnings of $0.61 per share. This would mark year-over-year growth of 3.39%. Our most recent consensus estimate is calling for quarterly revenue of $7.48 billion, up 1.17% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $3.20 per share and revenue of $31.80 billion, which would represent changes of +11.11% and +4.01%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for ABT. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. ABT is holding a Zacks Rank of #3 (Hold) right now.
Looking at its valuation, ABT is holding a Forward P/E ratio of 24.96. This represents a no noticeable deviation compared to its industry's average Forward P/E of 24.96.
Investors should also note that ABT has a PEG ratio of 2.13 right now. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Products was holding an average PEG ratio of 2.34 at yesterday's closing price.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 79, putting it in the top 31% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow ABT in the coming trading sessions, be sure to utilize Zacks.com.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott (ABT) closed at $78.83 in the latest trading session, marking a -1.29% move from the prior day. Investors will be hoping for strength from ABT as it approaches its nex t earnings release. In tha t report , analysts expect ABT to post earnings of $0.61 per share. | Abbott (ABT) closed at $78.83 in the latest trading session, marking a -1.29% move from the prior day. Investors will be hoping for strength from ABT as it approaches its nex t earnings release. In tha t report , analysts expect ABT to post earnings of $0.61 per share. | Abbott (ABT) closed at $78.83 in the latest trading session, marking a -1.29% move from the prior day. Investors will be hoping for strength from ABT as it approaches its nex t earnings release. In tha t report , analysts expect ABT to post earnings of $0.61 per share. | Abbott (ABT) closed at $78.83 in the latest trading session, marking a -1.29% move from the prior day. Investors might also notice recent changes to analyst estimates for ABT. Investors will be hoping for strength from ABT as it approaches its nex t earnings release. |
33041.0 | 2019-03-15 00:00:00 UTC | Abbott (ABT) Gets FDA Approval for Expanded Use of MitraClip | ABT | https://www.nasdaq.com/articles/abbott-abt-gets-fda-approval-for-expanded-use-of-mitraclip-2019-03-15 | nan | nan | Abbott LaboratoriesABT recently announced that its flagship platform - MitraClip transcatheter clip-based device - has received FDA approval for the treatment of secondary or functional mitral regurgitation ("MR").
The approval closely follows Abbott's favorable results from a two-year clinical trial called COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy). The study showed that Abbott's MitraClip performs better than any traditional treatment for functional MR available in the market.
This regulatory go-ahead is expected to strengthen the company's Structural Heart business.
MitraClip - a Strong Growth Driver
MitraClip is the world's first minimally-invasive mitral valve repair device. It provides instant symptom relief and ensures swift discharge of patients.
For investors' notice, MitraClip has been a significant top-line contributor. In fact, the platform registered year-over-year growth of about 30% in the fourth quarter of 2018.
In 2013, MitraClip was approved as a repair device for primary MR.
Structural Heart Unit Strengthens
Abbott's structural heart business is a leader in occlusion devices that treat or close openings in the heart caused by congenital defects.
Abbott Laboratories Price
Abbott Laboratories Price | Abbott Laboratories Quote
The company witnessed double-digit growth in the business in the fourth quarter of 2018. Growth was driven by several product areas, including AMPLATZERPFO Occluder and MitraClip.
Market Prospects
Per Allied market research, the global market for transcatheter heart valve replacement and repair is projected to reach a worth of $8.13 billion, at a CAGR of 13.8% in the 2017-2025 period.
About 6.5 million people suffer heart failure in the United States. Abbott expects MitraClip to reach a market worth of $4 billion in the Unites States.
Favorable Regulatory Tidings
In January 2019, Abbott received FDA approval for its TactiCath Contact Force Ablation Catheter, which has been designed for the treatment of atrial fibrillation. The FDA also approved Abbott's minimally-invasive transcatheter for the treatment of premature babies and newborns with an opening in their heart.
Last October, Abbott's HeartMate 3 heart pump was approved by the FDA for patients with advanced heart failure.
Just a month prior to that, real-world research proved that Abbott's Portico transcatheter aortic valve was equipped to treat severe aortic stenosis.
Meanwhile, the Zacks Consensus Estimate for the company's 2019 earnings per share is pegged at $3.20, reflecting a year-over-year increase of 11.1%. The same for revenues is pinned at $31.8 billion, indicating an increase of 4% year over year.
Zacks Rank & Key Picks
Abbott has a Zacks Rank of #3 (Hold). A few better-ranked stocks in the broader medical space are ABIOMED, Inc., ABMD , Varian Medical Systems, Inc. VAR and Masimo, Inc. MASI . Each of these stocks currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
ABIOMED's long-term earnings growth rate is expected at 27.67%.
Varian's long-term earnings growth rate is projected at 8.00%.
Masimo's long-term earnings are projected to grow 15.60%.
Is Your Investment Advisor Fumbling Your Financial Future?
See how you can more effectively safeguard your retirement with a new Special Report, "4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future."
Click to get it free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
ABIOMED, Inc. (ABMD): Free Stock Analysis Report
Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report
Masimo Corporation (MASI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott LaboratoriesABT recently announced that its flagship platform - MitraClip transcatheter clip-based device - has received FDA approval for the treatment of secondary or functional mitral regurgitation ("MR"). Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report To read this article on Zacks.com click here. The approval closely follows Abbott's favorable results from a two-year clinical trial called COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy). | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT recently announced that its flagship platform - MitraClip transcatheter clip-based device - has received FDA approval for the treatment of secondary or functional mitral regurgitation ("MR"). Structural Heart Unit Strengthens Abbott's structural heart business is a leader in occlusion devices that treat or close openings in the heart caused by congenital defects. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT recently announced that its flagship platform - MitraClip transcatheter clip-based device - has received FDA approval for the treatment of secondary or functional mitral regurgitation ("MR"). Structural Heart Unit Strengthens Abbott's structural heart business is a leader in occlusion devices that treat or close openings in the heart caused by congenital defects. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Masimo Corporation (MASI): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT recently announced that its flagship platform - MitraClip transcatheter clip-based device - has received FDA approval for the treatment of secondary or functional mitral regurgitation ("MR"). MitraClip - a Strong Growth Driver MitraClip is the world's first minimally-invasive mitral valve repair device. |
33042.0 | 2019-03-14 00:00:00 UTC | Health Care Sector Update for 03/14/2019: AXGT, JNJ, BDX, PFE, ABT, MRK, AMGN | ABT | https://www.nasdaq.com/articles/health-care-sector-update-03142019-axgt-jnj-bdx-pfe-abt-mrk-amgn-2019-03-14 | nan | nan | Top Health Care Stocks:
JNJ: -0.93%
PFE: -0.02%
ABT: Flat
MRK: -0.49%
AMGN: Flat
Leading health care stocks were mixed in pre-market trading Thursday.
Stocks moving on news include:
(-) Axovant Sciences ( AXGT ), which was down more than 18% after the company priced a public offering of 26.7 million shares at $1.50 per share, a 14.3% discount from the stock's previous close, for total expected gross proceeds of $40 million.
In other sector news:
(-) Johnson & Johnson ( JNJ ) was over 1% lower after media reports that the company was ordered by a California jury to pay $29.4 million to a woman who said that asbestos found in the company's talcum-powder-based products caused her cancer, marking another defeat for the health care company that is facing multiple talc-related trials this year.
(=) Becton, Dickinson and Co. ( BDX ) was flat after saying the US Food and Drug Administration (FDA) has granted premarket approval for its Venovo venous stent.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABT: Flat AMGN: Flat Leading health care stocks were mixed in pre-market trading Thursday. Stocks moving on news include: (-) Axovant Sciences ( AXGT ), which was down more than 18% after the company priced a public offering of 26.7 million shares at $1.50 per share, a 14.3% discount from the stock's previous close, for total expected gross proceeds of $40 million. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ABT: Flat In other sector news: (-) Johnson & Johnson ( JNJ ) was over 1% lower after media reports that the company was ordered by a California jury to pay $29.4 million to a woman who said that asbestos found in the company's talcum-powder-based products caused her cancer, marking another defeat for the health care company that is facing multiple talc-related trials this year. | ABT: Flat AMGN: Flat Leading health care stocks were mixed in pre-market trading Thursday. Stocks moving on news include: (-) Axovant Sciences ( AXGT ), which was down more than 18% after the company priced a public offering of 26.7 million shares at $1.50 per share, a 14.3% discount from the stock's previous close, for total expected gross proceeds of $40 million. | ABT: Flat Top Health Care Stocks: AMGN: Flat Leading health care stocks were mixed in pre-market trading Thursday. |
33043.0 | 2019-03-12 00:00:00 UTC | Abbott (ABT) Outpaces Stock Market Gains: What You Should Know | ABT | https://www.nasdaq.com/articles/abbott-abt-outpaces-stock-market-gains%3A-what-you-should-know-2019-03-12 | nan | nan | In the latest trading session, Abbott (ABT) closed at $78.24, marking a +0.55% move from the previous day. This move outpaced the S&P 500's daily gain of 0.3%. At the same time, the Dow lost 0.38%, and the tech-heavy Nasdaq gained 0.44%.
Coming into today, shares of the maker of infant formula, medical devices and drugs had gained 5.81% in the past month. In that same time, the Medical sector gained 2.07%, while the S&P 500 gained 2.91%.
Investors will be hoping for strength from ABT as it approaches its nex t earnings release. The company is expected to report EPS of $0.61, up 3.39% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $7.48 billion, up 1.17% from the prior-year quarter.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $3.20 per share and revenue of $31.80 billion. These totals would mark changes of +11.11% and +4.01%, respectively, from last year.
It is also important to note the recent changes to analyst estimates for ABT. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. ABT is currently sporting a Zacks Rank of #3 (Hold).
Investors should also note ABT's current valuation metrics, including its Forward P/E ratio of 24.32. This valuation marks a discount compared to its industry's average Forward P/E of 25.01.
Also, we should mention that ABT has a PEG ratio of 2.07. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Products was holding an average PEG ratio of 2.31 at yesterday's closing price.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 75, putting it in the top 30% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In the latest trading session, Abbott (ABT) closed at $78.24, marking a +0.55% move from the previous day. Investors will be hoping for strength from ABT as it approaches its nex t earnings release. It is also important to note the recent changes to analyst estimates for ABT. | In the latest trading session, Abbott (ABT) closed at $78.24, marking a +0.55% move from the previous day. Investors will be hoping for strength from ABT as it approaches its nex t earnings release. It is also important to note the recent changes to analyst estimates for ABT. | In the latest trading session, Abbott (ABT) closed at $78.24, marking a +0.55% move from the previous day. Investors will be hoping for strength from ABT as it approaches its nex t earnings release. It is also important to note the recent changes to analyst estimates for ABT. | In the latest trading session, Abbott (ABT) closed at $78.24, marking a +0.55% move from the previous day. Investors should also note ABT's current valuation metrics, including its Forward P/E ratio of 24.32. Investors will be hoping for strength from ABT as it approaches its nex t earnings release. |
33044.0 | 2019-03-10 00:00:00 UTC | Better Buy: Abbott Laboratories vs. Johnson & Johnson | ABT | https://www.nasdaq.com/articles/better-buy-abbott-laboratories-vs-johnson-johnson-2019-03-10 | nan | nan | You won't find many if any blue-chip healthcare stocks that are "bluer" than Abbott Laboratories (NYSE: ABT) and Johnson & Johnson (NYSE: JNJ) . Both companies have been around since the late 19th century. Both are Dividend Aristocrats with decades of consecutive dividend increases.
But Abbott Labs and Johnson & Johnson have different business dynamics at work. Which of these two healthcare stocks is the better pick for investors? Here's how Abbott Labs and J&J compare in three key areas.
Growth prospects
Abbott Labs has been the bigger winner by far when it comes to revenue and earnings growth in recent quarters. The company's momentum has been boosted by its super-successful Freestyle Libre continuous glucose monitoring (CGM) system and other new product launches. These new products should continue to drive Abbott's revenue and earnings higher in the future.
Sales for Freestyle Libre are picking up momentum. This growth is likely to accelerate once Abbott wins U.S. approval to market its second version of the system, which includes optional alarms to warn patients when glucose levels are out of range. Abbott is also poised to benefit as its continues to extend the functionality of its Alinity laboratory diagnostics products.
On the other hand, Johnson & Johnson's growth is slowing . The company's Q4 sales increased by only 1% year over year. J&J's top-selling drug, Remicade, faces competition from biosimilars. Its consumer healthcare business has struggled in international markets.
J&J does have products that should fuel future growth. Cancer drugs Imbruvica and Darzalex are high on that list. The company also is taking the robotic surgical systems opportunity seriously, recently announcing that it's buying Auris Health for $3.4 billion.
Wall Street analysts project that Abbott will grow earnings at a significantly faster rate than Johnson & Johnson will over the next five years. That's probably an accurate assessment. However, it's possible that strategic acquisitions by either company could impact growth prospects.
Dividends
There are two key things you need to look at when it comes to dividends -- yield and sustainability. Johnson & Johnson is the clear winner over Abbott Labs in the former category. The healthcare giant's dividend currently yields 2.6% compared to Abbott's yield of only 1.65%.
Both Abbott and J&J have great track records of paying and increasing their dividends. Abbott has boosted its dividend for 47 consecutive years. J&J has increased its quarterly dividend for 56 years in a row.
Abbott Labs' payout ratio of 85% is higher than J&J's payout ratio of 63%. However, neither company appears to be in any danger of ending its streak of dividend increases.
Valuation
By several metrics, Abbott Labs is significantly more expensive than Johnson & Johnson. Abbott stock trades at nearly 22 times expected earnings, while J&J's shares trade at only 15 times expected earnings. On one of the best valuation metrics, enterprise value-to-EBITDA , Johnson & Johnson is much more attractive than Abbott with multiples of 13 and 21, respectively.
However, when growth is factored in, the two healthcare stocks are basically tied. J&J's price-to-earnings-to-growth (PEG) ratio is 2.33 compared to Abbott's PEG ratio of 2.28.
Better buy
If you've been keeping score, Abbott clearly won in one category (growth prospects) while Johnson & Johnson clearly won in another (dividends) and appears to also have an advantage in valuation. So is J&J the better stock? It depends on what's most important to you.
Value investors probably won't be enamored of either stock. While neither Abbott Labs nor J&J are extremely expensive, they're not exactly cheap, either.
For investors primarily seeking income, Johnson & Johnson is the better pick. I don't think that Abbott will catch up with J&J on dividend yield anytime soon.
Growth investors will probably prefer Abbott Labs. The company's Freestyle Libre CGM system and other new products appear to give the company a clear advantage over J&J, especially as it continues to face falling sales for Remicade.
What about the overall best pick? I'd go with Abbott. Its growth prospects combined with a respectable dividend yield should enable the stock to deliver total returns in excess of Johnson & Johnson over the next few years. That being said, I think that conservative long-term investors would be in good shape going with either of these blue-chip healthcare stocks.
10 stocks we like better than Abbott Laboratories
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 1, 2019
Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | You won't find many if any blue-chip healthcare stocks that are "bluer" than Abbott Laboratories (NYSE: ABT) and Johnson & Johnson (NYSE: JNJ) . The company's momentum has been boosted by its super-successful Freestyle Libre continuous glucose monitoring (CGM) system and other new product launches. This growth is likely to accelerate once Abbott wins U.S. approval to market its second version of the system, which includes optional alarms to warn patients when glucose levels are out of range. | You won't find many if any blue-chip healthcare stocks that are "bluer" than Abbott Laboratories (NYSE: ABT) and Johnson & Johnson (NYSE: JNJ) . The company's momentum has been boosted by its super-successful Freestyle Libre continuous glucose monitoring (CGM) system and other new product launches. Better buy If you've been keeping score, Abbott clearly won in one category (growth prospects) while Johnson & Johnson clearly won in another (dividends) and appears to also have an advantage in valuation. | You won't find many if any blue-chip healthcare stocks that are "bluer" than Abbott Laboratories (NYSE: ABT) and Johnson & Johnson (NYSE: JNJ) . Better buy If you've been keeping score, Abbott clearly won in one category (growth prospects) while Johnson & Johnson clearly won in another (dividends) and appears to also have an advantage in valuation. Its growth prospects combined with a respectable dividend yield should enable the stock to deliver total returns in excess of Johnson & Johnson over the next few years. | You won't find many if any blue-chip healthcare stocks that are "bluer" than Abbott Laboratories (NYSE: ABT) and Johnson & Johnson (NYSE: JNJ) . Which of these two healthcare stocks is the better pick for investors? The company's Freestyle Libre CGM system and other new products appear to give the company a clear advantage over J&J, especially as it continues to face falling sales for Remicade. |
33045.0 | 2019-03-08 00:00:00 UTC | Is DexCom a Buy? | ABT | https://www.nasdaq.com/articles/dexcom-buy-2019-03-08 | nan | nan | DexCom (NASDAQ: DXCM) has been a home run stock for early investors. Its shares have thrashed the S&P 500 over the last one, three, and five years, showing no signs of slowing.
Can this winner keep thriving? Let's dig into the bull and bear cases for the California-based company to find out.
The business
DexCom, a medical device company focused on diabetes, sells a popular continuous glucose monitor (CGM) system called the DexCom G6. This device is worn on the body and constantly monitors a patient's blood glucose levels. That data is uploaded to a handheld controller, smartphone, or smartwatch that provides information needed to keep blood glucose levels in a healthy range.
DexCom operates on a razor-and-blade business model . The permanent "razor" is the company's handheld device that receives and displays the data, while the disposable "blades" are its sensors that are inserted directly into a patient's body. After 10 days of use, they need to be properly tossed and replaced, thus providing a dependable source of recurring revenue.
This business model has allowed DexCom's top line to grow at a breakneck pace as it brings on new patients over time.
DXCM revenue (TTM) . Data by YCharts .
Reasons for optimism
DexCom's revenue growth has been incredibly impressive, and it remains strong to this day. In 2018, its top line rose by 44%, sending it over the $1 billion mark.
Can the company keep its double-digit growth rate going? The odds look good for a number of reasons:
Dexcom has captured less than 20% of the 3.2 million patients in the U.S. who require intensive insulin therapy. The penetration rate looks even smaller when you factor in the international opportunity.
According to the company, several other groups of patients could benefit from CGM therapy. This includes people with gestational diabetes, those who require non-intensive insulin therapy, and intermittent CGM use in the hospital setting. Together, these opportunities add up to tens of millions of potential users in the U.S. alone.
Dexcom has struck up numerous partnerships with other diabetes companies like Tandem Diabetes Care , Insulet , Eli Lilly , and Novo Nordisk to help get the word out.
The company has teamed up with Alphabet 's healthcare division, Verily, to develop a next-generation sensor, which aims to be smaller, cheaper, and fully disposable.
Management forecasts that the company will pull in between $2 billion and $2.5 billion in total revenue by 2023 and improve profitability significantly. If those numbers prove to be anywhere close to accurate, shareholders should be nicely rewarded.
Reasons for caution
Dexcom would be a no-brainer investment if the company had the CGM market all to itself. Unfortunately, it faces a fair amount of competition.
Its primary competitor is medical device giant Medtronic (NYSE: MDT) , which has enjoyed a strong foothold in the diabetes market for decades, through its insulin pump division. It also launched a combination insulin pump/CGM system a few years ago, a device thath increased patient convenience and has proven quite popular with patients.
Another heavy hitter in the CGM space is Abbott Labs (NYSE: ABT) , which won FDA approval for a CGM device called the Freestyle Libre in 2017. The Libre was the first CGM system that did not require its users to perform daily finger sticks for calibration, and was also marketed at a much lower price point than DexCom's CGM. The Freestyle Libre has experienced a lot of market success .
Thus far, DexCom hasn't had any problems growing even with the competition from these well-funded giants, but it's possible that could change.
Another potential pitfall that could work against investors who buy today is Dexcom's generous valuation. The company is currently trading for more than 12 times sales and about 150 times next year's earnings estimates. Those figures suggest that Wall Street is pricing in a lot of growth. If it fails to deliver on its ambitious growth targets, shareholders could be in a for a world of hurt.
Is DexCom a buy?
While DexCom isn't an appropriate stock for risk-averse investors, I still think there is a lot like about the company. Its product is innovative, and the company has secured numerous partnership agreements, which should ensure it continues to win more than its fair share of the new business. What's more, the diabetes market is so huge that it could easily support multiple winners.
If you're a growth-focused investor who doesn't mind paying up for a high-growth business, DexCom could be a nice addition to your portfolio.
10 stocks we like better than DexCom
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of March 1, 2019
Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Brian Feroldi owns shares of Alphabet (A shares) and Alphabet (C shares). The Motley Fool owns shares of and recommends Alphabet (A shares) and Alphabet (C shares). The Motley Fool owns shares of Medtronic. The Motley Fool recommends Insulet and Novo Nordisk. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Another heavy hitter in the CGM space is Abbott Labs (NYSE: ABT) , which won FDA approval for a CGM device called the Freestyle Libre in 2017. The permanent "razor" is the company's handheld device that receives and displays the data, while the disposable "blades" are its sensors that are inserted directly into a patient's body. The company has teamed up with Alphabet 's healthcare division, Verily, to develop a next-generation sensor, which aims to be smaller, cheaper, and fully disposable. | Another heavy hitter in the CGM space is Abbott Labs (NYSE: ABT) , which won FDA approval for a CGM device called the Freestyle Libre in 2017. The business DexCom, a medical device company focused on diabetes, sells a popular continuous glucose monitor (CGM) system called the DexCom G6. The Motley Fool owns shares of and recommends Alphabet (A shares) and Alphabet (C shares). | Another heavy hitter in the CGM space is Abbott Labs (NYSE: ABT) , which won FDA approval for a CGM device called the Freestyle Libre in 2017. The business DexCom, a medical device company focused on diabetes, sells a popular continuous glucose monitor (CGM) system called the DexCom G6. While DexCom isn't an appropriate stock for risk-averse investors, I still think there is a lot like about the company. | Another heavy hitter in the CGM space is Abbott Labs (NYSE: ABT) , which won FDA approval for a CGM device called the Freestyle Libre in 2017. The business DexCom, a medical device company focused on diabetes, sells a popular continuous glucose monitor (CGM) system called the DexCom G6. While DexCom isn't an appropriate stock for risk-averse investors, I still think there is a lot like about the company. |
33046.0 | 2019-03-07 00:00:00 UTC | S&P 500 Analyst Moves: ABT | ABT | https://www.nasdaq.com/articles/sp-500-analyst-moves-abt-2019-03-07 | nan | nan | The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Abbott Laboratories ( ABT ) is now the #66 analyst pick, moving up by 1 spot.
This rank is formed by averaging the analyst opinions for each component from each broker, and then ranking the 500 components by those average opinion values.
Looking at the stock price movement year to date, Abbott Laboratories ( ABT ) is showing a gain of 6.9%.
VIDEO: S&P 500 Analyst Moves: ABT
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Abbott Laboratories ( ABT ) is now the #66 analyst pick, moving up by 1 spot. Looking at the stock price movement year to date, Abbott Laboratories ( ABT ) is showing a gain of 6.9%. VIDEO: S&P 500 Analyst Moves: ABT The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Looking at the stock price movement year to date, Abbott Laboratories ( ABT ) is showing a gain of 6.9%. VIDEO: S&P 500 Analyst Moves: ABT The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Abbott Laboratories ( ABT ) is now the #66 analyst pick, moving up by 1 spot. | The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Abbott Laboratories ( ABT ) is now the #66 analyst pick, moving up by 1 spot. VIDEO: S&P 500 Analyst Moves: ABT The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Looking at the stock price movement year to date, Abbott Laboratories ( ABT ) is showing a gain of 6.9%. | The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Abbott Laboratories ( ABT ) is now the #66 analyst pick, moving up by 1 spot. Looking at the stock price movement year to date, Abbott Laboratories ( ABT ) is showing a gain of 6.9%. VIDEO: S&P 500 Analyst Moves: ABT The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
33047.0 | 2019-03-06 00:00:00 UTC | The Zacks Analyst Blog Highlights: Boeing, Abbott, PayPal, Caterpillar and Anthem | ABT | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-boeing-abbott-paypal-caterpillar-and-anthem-2019-03-06 | nan | nan | For Immediate Release
Chicago, IL -March 6, 2019 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: BoeingBA , AbbottABT , PayPalPYPL , CaterpillarCAT and AnthemANTM .
Here are highlights from Tuesday's Analyst Blog:
Top Analyst Reports for Boeing, Abbott and PayPal
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Boeing, Abbott and PayPal. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all oftoday's research reports here >>>
Strong Buy-ranked Boeing 's shares have gained +34.2% year to date, outperforming the S&P 500, which increased +11.4% during the same time period. The company's 20-year market outlook forecasts commercial jetliner demand to increase by 4.1%, with single-aisle jets being the major driver behind this demand growth.
Boeing expects the commercial fleet to be fueled by sustained annual growth in commercial passenger traffic along with a big wave of retiring, old planes. The Zacks analyst thinks Boeing's strong balance sheet and cash flows provide financial flexibility in matters of incremental dividend, ongoing share repurchases and earnings accretive acquisitions.
Its revenue exposure is also spread across more than 90 countries around the globe. However, this aerospace giant may face competitive challenges once new manufacturers like China enters the commercial jet space.
(You can read the full research report on Boeing here >>> ).
Shares of Abbott have gained +9.9% over the past three months, outperforming the S&P 500, which has increased +3.6% over the same period. Abbott exited the fourth quarter on a mixed note with earnings in line with expectations and revenues missing the mark. Increasing currency headwinds to some extent dented the company's international performance.
Meanwhile, emerging market performance has been promising. The Zacks analyst is optimistic about the strong and consistent performance by the company's EPD and Medical Devices segments organically. The company has been hogging the limelight within Diabetic Care on growth with FreeStyle Libre. Within Structural Heart, worldwide strong uptake of MitraClip improves further following the FDA approval of its upgraded version.
This apart, synergies from Alere consolidation in the form of revenues from Rapid Diagnostics have been driving growth. On the flip side, sluggish Vascular arm in the United States continues to dent growth.
(You can read the full research report on Abbott here >>> ).
PayPal 's shares have outperformed the S&P 500 in the past year (+22.1% vs. +2.6%). The Zacks analyst thinks PayPal's rising transaction revenues, growth in active customer accounts and benefits from acquisitions of Hyperwallet and iZettle remain growth drivers. Further, Venmo's improving monetization efforts, partnerships and its increasing adoption rate across various platforms are aiding the company's user base.
Strong momentum of PayPal in international markets, especially in India and Japan remained a major positive. However, adverse foreign exchange translations, competition from Square and interest rate risks are concerns. Further, sale of the credit portfolio to Synchrony is expected to continue impacting negatively. Also, a challenging macroeconomic environment in China and the UK remain concerns.
(You can read the full research report on PayPal here >>> ).
Other noteworthy reports we are featuring today include Caterpillar and Anthem.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They're also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss . This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
PayPal Holdings, Inc. (PYPL): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
The Boeing Company (BA): Free Stock Analysis Report
Caterpillar Inc. (CAT): Free Stock Analysis Report
Anthem, Inc. (ANTM): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks recently featured in the blog include: BoeingBA , AbbottABT , PayPalPYPL , CaterpillarCAT and AnthemANTM . Click to get this free report PayPal Holdings, Inc. (PYPL): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report The Boeing Company (BA): Free Stock Analysis Report Caterpillar Inc. (CAT): Free Stock Analysis Report Anthem, Inc. (ANTM): Free Stock Analysis Report To read this article on Zacks.com click here. You can see all oftoday's research reports here >>> Strong Buy-ranked Boeing 's shares have gained +34.2% year to date, outperforming the S&P 500, which increased +11.4% during the same time period. | Click to get this free report PayPal Holdings, Inc. (PYPL): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report The Boeing Company (BA): Free Stock Analysis Report Caterpillar Inc. (CAT): Free Stock Analysis Report Anthem, Inc. (ANTM): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include: BoeingBA , AbbottABT , PayPalPYPL , CaterpillarCAT and AnthemANTM . Here are highlights from Tuesday's Analyst Blog: Top Analyst Reports for Boeing, Abbott and PayPal The Zacks Research Daily presents the best research output of our analyst team. | Click to get this free report PayPal Holdings, Inc. (PYPL): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report The Boeing Company (BA): Free Stock Analysis Report Caterpillar Inc. (CAT): Free Stock Analysis Report Anthem, Inc. (ANTM): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include: BoeingBA , AbbottABT , PayPalPYPL , CaterpillarCAT and AnthemANTM . Here are highlights from Tuesday's Analyst Blog: Top Analyst Reports for Boeing, Abbott and PayPal The Zacks Research Daily presents the best research output of our analyst team. | Stocks recently featured in the blog include: BoeingBA , AbbottABT , PayPalPYPL , CaterpillarCAT and AnthemANTM . Click to get this free report PayPal Holdings, Inc. (PYPL): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report The Boeing Company (BA): Free Stock Analysis Report Caterpillar Inc. (CAT): Free Stock Analysis Report Anthem, Inc. (ANTM): Free Stock Analysis Report To read this article on Zacks.com click here. Today's Research Daily features new research reports on 16 major stocks, including Boeing, Abbott and PayPal. |
33048.0 | 2019-03-04 00:00:00 UTC | Here's Why You Should Snap Up Abbott (ABT) Stock Right Now | ABT | https://www.nasdaq.com/articles/heres-why-you-should-snap-up-abbott-abt-stock-right-now-2019-03-04 | nan | nan | Abbott Laboratories ABT has been gaining investor confidence on continued positive results. The company's share price has outperformed the S&P 500 over the past year. The stock has gained 32.6% in comparison to the market's 3% rise in the said period.
This leading developer, manufacturer and seller of a diversified line of health care products has a market cap of $124.96 billion. The company has an expected earnings growth rate of 11.8% for the next three to five years.
With solid prospects, this Zacks Rank #2 (Buy) stock is an attractive pick for investors at the moment.
What's Working in Favor of the Stock?
Diagnostics Arm Grows on Alinity
Within Diagnostics, sales have been growing substantially over the past few quarters. Alinity, the family of highly differentiated instruments, is achieving accelerated growth and strong competitive win rates in Europe. The global rollout of Alinity positions this business for consistent above-market growth in the years to come.
Alere Integration Synergies Impressive
The integration of Alere has added Rapid Diagnostics to Abbott's existing leadership position in the $50-billion global diagnostics market. Alere's complementary portfolio of diagnostic products, comprising tests for infections such as HIV, tuberculosis, malaria and dengue will be added to Abbott's portfolio. Over the past few months, Abbott has made solid progress with the integration of this business and continues to see several levers for growth acceleration, including opportunities for geographic, platform and test menu expansion.
Progress With Diabetes Business
This business achieved growth of 35% in 2018 led by FreeStyle Libre which achieved global sales of more than $1 billion in 2018, an increase of 100% from the prior year. As of 2018-end, there are now approximately 1.3 million active users worldwide, of which approximately two-thirds are type 1 diabetics and one-third type 2.
In the United States, there has been an accelerating trend of new users as Abbott is ramping up its awareness efforts during the second half of the year.
Other Key Picks
Other top-ranked stocks in the broader medical space are Varian Medical Systems VAR , Illumina, Inc. ILMN and DexCom, Inc DXCM . Notably, each of these stocks currently carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Varian'slong-term earnings growth rate is expected at 8%.
Illumina'slong-term earnings growth rate is expected at 21.5%.
DexCom's second-quarter earnings per share are projected to grow 160%.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, wouldn't you like to know about our 10 finest buy-and-holds for the year?
From more than 4,000 companies covered by the Zacks Rank, these 10 were picked by a process that consistently beats the market. Even during 2018 while the market dropped -5.2%, our Top 10s were up well into double-digits. And during bullish 2012 - 2017, they soared far above the market's +126.3%, reaching +181.9%.
This year, the portfolio features a player that thrives on volatility, an AI comer, and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs.
See Stocks Today >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report
DexCom, Inc. (DXCM): Free Stock Analysis Report
Illumina, Inc. (ILMN): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ABT has been gaining investor confidence on continued positive results. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report To read this article on Zacks.com click here. Alinity, the family of highly differentiated instruments, is achieving accelerated growth and strong competitive win rates in Europe. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT has been gaining investor confidence on continued positive results. Other Key Picks Other top-ranked stocks in the broader medical space are Varian Medical Systems VAR , Illumina, Inc. ILMN and DexCom, Inc DXCM . | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT has been gaining investor confidence on continued positive results. Alere Integration Synergies Impressive The integration of Alere has added Rapid Diagnostics to Abbott's existing leadership position in the $50-billion global diagnostics market. | Abbott Laboratories ABT has been gaining investor confidence on continued positive results. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report To read this article on Zacks.com click here. The company has an expected earnings growth rate of 11.8% for the next three to five years. |
33049.0 | 2019-03-04 00:00:00 UTC | Abbott Laboratories Reaches Analyst Target Price | ABT | https://www.nasdaq.com/articles/abbott-laboratories-reaches-analyst-target-price-2019-03-04 | nan | nan | In recent trading, shares of Abbott Laboratories (Symbol: ABT) have crossed above the average analyst 12-month target price of $78.19, changing hands for $78.59/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business developments that may be responsible for driving the stock price higher - if things are looking up for the company, perhaps it is time for that target price to be raised.
There are 16 different analyst targets contributing to that average for Abbott Laboratories, but the average is just that - a mathematical average. There are analysts with lower targets than the average, including one looking for a price of $65.00. And then on the other side of the spectrum one analyst has a target as high as $86.00. The standard deviation is $5.901.
But the whole reason to look at the average ABT price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with ABT crossing above that average target price of $78.19/share, investors in ABT have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $78.19 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? Below is a table showing the current thinking of the analysts that cover Abbott Laboratories:
The average rating presented in the last row of the above table above is from 1 to 5 where 1 is Strong Buy and 5 is Strong Sell. This article used data provided by Zacks Investment Research via Quandl.com . Get the latest Zacks research report on ABT - FREE .
The Top 25 Broker Analyst Picks of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In recent trading, shares of Abbott Laboratories (Symbol: ABT) have crossed above the average analyst 12-month target price of $78.19, changing hands for $78.59/share. But the whole reason to look at the average ABT price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with ABT crossing above that average target price of $78.19/share, investors in ABT have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $78.19 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? | In recent trading, shares of Abbott Laboratories (Symbol: ABT) have crossed above the average analyst 12-month target price of $78.19, changing hands for $78.59/share. But the whole reason to look at the average ABT price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with ABT crossing above that average target price of $78.19/share, investors in ABT have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $78.19 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? | And so with ABT crossing above that average target price of $78.19/share, investors in ABT have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $78.19 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? In recent trading, shares of Abbott Laboratories (Symbol: ABT) have crossed above the average analyst 12-month target price of $78.19, changing hands for $78.59/share. But the whole reason to look at the average ABT price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. | In recent trading, shares of Abbott Laboratories (Symbol: ABT) have crossed above the average analyst 12-month target price of $78.19, changing hands for $78.59/share. But the whole reason to look at the average ABT price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with ABT crossing above that average target price of $78.19/share, investors in ABT have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $78.19 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? |
33050.0 | 2019-03-01 00:00:00 UTC | Here's Why You Should Buy Varian Medical (VAR) Stock Now | ABT | https://www.nasdaq.com/articles/heres-why-you-should-buy-varian-medical-var-stock-now-2019-03-01 | nan | nan | Varian Medical Systems, Inc.VAR is expected to benefit from solid fiscal first-quarter results and a slew of positive developments.
The stock currently has a Zacks Rank #2 (Buy).
Shares Up
Over the past year, shares of Varian Medical have rallied 11.5% compared with the S&P 500 index's 3.5% gain.
What's Favoring the Stock?
Fiscal Q1 Results
Varian Medical's first-quarter fiscal 2019 adjusted earnings of $1.06 per share were on par with the Zacks Consensus Estimate. Adjusted earnings were flat with the year-ago quarter.
Revenues totaled $741 million, which outpaced the consensus mark of $717.9 million. On a year-over-year basis, revenues rose 9.2% and 10% at constant currency.
The company has kept the guidance intact.
Notably, for fiscal 2019, year-over-year revenue growth is expected in the range of $3.06-$3.15 billion, up 5-8%. The Zacks Consensus Estimate is pegged at $4.70, much above the expected range.
Adjusted operating earnings, as a percentage of revenues, is projected in the band of 17-18%.
Adjusted ne t earnings per share are expected in the range of $4.60 to $4.75.
Cash flow from operations is expected in the band of $460-$510 million.
Developments
The California-based MedTech giant has seen a series of developments in recent times.
Last month, Varian Medical-equipped Danish Center for Particle Therapy officially opened at the Aarhus University Hospital in Aarhus, Denmark.
Moreover, Varian is equipping Nigeria's NSIA-LUTH Cancer Treatment Centre with one Halcyon treatment system and two VitalBeam radiotherapy systems. This fortifies the company's foothold in emerging economies.
In January, the company announced the installation of the gantry for the Varian ProBeam Compact single-room proton therapy system at the new oncology center at Biopolis, an international biomedical research hub in Singapore. (Read More: Varian Medical's ProBeam Compact Picked by Biopolis )
Which Way Are Estimates Headed?
For the fiscal second quarter, the Zacks Consensus Estimate for earnings is pegged at $1.16, reflecting a year-over-year increase of 0.9%. The same for revenues is pinned at $779.1 million, showing an increase of 6.7% year over year.
For fiscal 2019, the Zacks Consensus Estimate for revenues is at $3.12 billion, reflecting a rise of 7% year over year. The same for earnings shows growth of 6.3% year over year.
Varian Medical Systems, Inc. Price and Consensus
Varian Medical Systems, Inc. Price and Consensus | Varian Medical Systems, Inc. Quote
Other Key Picks
Other top-ranked stocks in the broader medical space are Abbott Laboratories ABT , Merit Medical Systems, Inc. MMSI and Surmodics, Inc. SRDX .
Abbott's long-term earnings growth rate is projected at 11.7%. The stock has a Zacks Rank #2.
Merit Medical's long-term earnings growth rate is projected at 13%. The stock has a Zacks Rank #2.
Surmodics' long-term earnings growth rate is expected to be 10%. The stock flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
This Could Be the Fastest Way to Grow Wealth in 2019
Research indicates one sector is poised to deliver a crop of the best-performing stocks you'll find anywhere in the market. Breaking news in this space frequently creates quick double- and triple-digit profit opportunities.
These companies are changing the world - and owning their stocks could transform your portfolio in 2019 and beyond. Recent trades from this sector have generated +98%, +119% and +164% gains in as little as 1 month.
Click here to see these breakthrough stocks now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report
Surmodics, Inc. (SRDX): Free Stock Analysis Report
Merit Medical Systems, Inc. (MMSI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Varian Medical Systems, Inc. Price and Consensus Varian Medical Systems, Inc. Price and Consensus | Varian Medical Systems, Inc. Quote Other Key Picks Other top-ranked stocks in the broader medical space are Abbott Laboratories ABT , Merit Medical Systems, Inc. MMSI and Surmodics, Inc. SRDX . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI): Free Stock Analysis Report To read this article on Zacks.com click here. Varian Medical Systems, Inc.VAR is expected to benefit from solid fiscal first-quarter results and a slew of positive developments. | Varian Medical Systems, Inc. Price and Consensus Varian Medical Systems, Inc. Price and Consensus | Varian Medical Systems, Inc. Quote Other Key Picks Other top-ranked stocks in the broader medical space are Abbott Laboratories ABT , Merit Medical Systems, Inc. MMSI and Surmodics, Inc. SRDX . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI): Free Stock Analysis Report To read this article on Zacks.com click here. Fiscal Q1 Results Varian Medical's first-quarter fiscal 2019 adjusted earnings of $1.06 per share were on par with the Zacks Consensus Estimate. | Varian Medical Systems, Inc. Price and Consensus Varian Medical Systems, Inc. Price and Consensus | Varian Medical Systems, Inc. Quote Other Key Picks Other top-ranked stocks in the broader medical space are Abbott Laboratories ABT , Merit Medical Systems, Inc. MMSI and Surmodics, Inc. SRDX . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI): Free Stock Analysis Report To read this article on Zacks.com click here. Fiscal Q1 Results Varian Medical's first-quarter fiscal 2019 adjusted earnings of $1.06 per share were on par with the Zacks Consensus Estimate. | Varian Medical Systems, Inc. Price and Consensus Varian Medical Systems, Inc. Price and Consensus | Varian Medical Systems, Inc. Quote Other Key Picks Other top-ranked stocks in the broader medical space are Abbott Laboratories ABT , Merit Medical Systems, Inc. MMSI and Surmodics, Inc. SRDX . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI): Free Stock Analysis Report To read this article on Zacks.com click here. Fiscal Q1 Results Varian Medical's first-quarter fiscal 2019 adjusted earnings of $1.06 per share were on par with the Zacks Consensus Estimate. |
33051.0 | 2019-02-28 00:00:00 UTC | IYH, ABT, MDT, ABBV: Large Outflows Detected at ETF | ABT | https://www.nasdaq.com/articles/iyh-abt-mdt-abbv-large-outflows-detected-etf-2019-02-28 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Healthcare ETF (Symbol: IYH) where we have detected an approximate $58.2 million dollar outflow -- that's a 2.4% decrease week over week (from 12,450,000 to 12,150,000). Among the largest underlying components of IYH, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.7%, Medtronic PLC (Symbol: MDT) is up about 0.2%, and AbbVie Inc (Symbol: ABBV) is lower by about 0.4%. For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year price performance of IYH, versus its 200 day moving average:
Looking at the chart above, IYH's low point in its 52 week range is $166.89 per share, with $204.83 as the 52 week high point - that compares with a last trade of $194.16. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IYH, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.7%, Medtronic PLC (Symbol: MDT) is up about 0.2%, and AbbVie Inc (Symbol: ABBV) is lower by about 0.4%. For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year price performance of IYH, versus its 200 day moving average: Looking at the chart above, IYH's low point in its 52 week range is $166.89 per share, with $204.83 as the 52 week high point - that compares with a last trade of $194.16. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IYH, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.7%, Medtronic PLC (Symbol: MDT) is up about 0.2%, and AbbVie Inc (Symbol: ABBV) is lower by about 0.4%. For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year price performance of IYH, versus its 200 day moving average: Looking at the chart above, IYH's low point in its 52 week range is $166.89 per share, with $204.83 as the 52 week high point - that compares with a last trade of $194.16. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of IYH, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.7%, Medtronic PLC (Symbol: MDT) is up about 0.2%, and AbbVie Inc (Symbol: ABBV) is lower by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Healthcare ETF (Symbol: IYH) where we have detected an approximate $58.2 million dollar outflow -- that's a 2.4% decrease week over week (from 12,450,000 to 12,150,000). For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year price performance of IYH, versus its 200 day moving average: Looking at the chart above, IYH's low point in its 52 week range is $166.89 per share, with $204.83 as the 52 week high point - that compares with a last trade of $194.16. | Among the largest underlying components of IYH, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.7%, Medtronic PLC (Symbol: MDT) is up about 0.2%, and AbbVie Inc (Symbol: ABBV) is lower by about 0.4%. For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year price performance of IYH, versus its 200 day moving average: Looking at the chart above, IYH's low point in its 52 week range is $166.89 per share, with $204.83 as the 52 week high point - that compares with a last trade of $194.16. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). |
33052.0 | 2019-02-28 00:00:00 UTC | Merit Medical (MMSI) Q4 Earnings & Revenues Surpass Estimates | ABT | https://www.nasdaq.com/articles/merit-medical-mmsi-q4-earnings-revenues-surpass-estimates-2019-02-28 | nan | nan | Merit Medical Systems, Inc.MMSI reported fourth-quarter 2018 adjusted earnings per share (EPS) of 48 cents, which exceeded the Zacks Consensus Estimate of 45 cents. The bottom line also improved 45.5% from the year-ago quarter's tally.
This Utah-based provider of peripheral and cardiac intervention products reported worldwide revenues of $233.2 million, up 22.2% from the year-ago quarter's tally. On a comparable, constant-currency basis, the metric increased 13.1% year over year. Revenues surpassed the Zacks Consensus Estimate of $230.1 million.
2018 at a Glance
Merit Medical reported 2018 worldwide revenues of $882.8 million, up 21.3% on a year-over-year basis.
Notably, the company generates revenues through two segments - the Cardiovascular unit and the Endoscopy devices segment.
The Cardiovascular segment recorded revenues of $849.5 million (96.2% of net revenues).
The Endoscopy devices segment's revenues amounted to $33.3 million (3.8% of net revenues).
Segmental Analysis
Cardiovascular
The Cardiovascular unit recorded fourth-quarter revenues of $225.1 million, up 22.7% year over year. The upside can be attributed to a 40.5% year-over-year increase in the segment's Stand-alone devices to $101.2 million. Also, revenues from Catheters increased 24.9% to $41.7 million. Inflation devices revenues grew 11% year over year to $22.8 million. The same at the CRM/EP unit rose 27.5% to $12.7 million.
On the flip side, revenues from Custom kits and procedure trays unit, under the Cardiovascular segment, declined 1.7%to $34.4 million. Also, embolization devices' revenues decreased 2.1% to $12.3 million.
Endoscopy Devices
Revenues from the Endoscopy devices totaled $8.2 million, up 9.9% year over year.
Margins
In the quarter under review, gross profit totaled $104.7 million, up 22.2% on a year-over-year basis. Gross margin came in at 44.9% of net revenues, almost flat year over year. Adjusted gross margins expanded 150 basis points (bps) on a year-over-year basis to 49.4% of net revenues.
Merit Medical registered selling, general and administrative expenses of $75.6 million, up 27.7% year over year.
Meanwhile, research and development expenses summed $15.4 million, up 20.8% year over year.
Adjusted operating income in the quarter totaled $13.7 million. Adjusted operating margin was 5.9% of net revenues, down 130 basis points (bps) year over year.
2019 Guidance
Merit Medical issued guidance for 2019.
This Zacks Rank #2 (Buy) company expects full-year revenues in the band of $1.01-$1.03 billion.The Zacks Consensus Estimate for the same is pegged at $1.01 billion, in line with the lower end of the guided range.
Adjusted EPS are expected between $1.97 and $2.08. The Zacks Consensus Estimate for the same is pinned at $1.97, in line with the lower end of the projected range.
The company expects adjusted gross margins within 50.6-51.3%.
Wrapping Up
Merit Medical exited the fourth quarter of 2018 on a solid note, with considerable expansion in adjusted gross margins. Furthermore, upbeat guidance for 2019 indicates at the company's bright prospects. A robust Cardiovascular segment is an added positive.
Management is optimistic about Merit Medical's Becton Dickinson deal, the acquisitions of Cianna Medical and Vascular Insights, and the execution of the global growth and profitability plan. New products like EmboCube Embolization Gelatin, the basixTAU Inflation Device, the Prelude Prestige Splittable Sheath Introducer, the Prelude Ideal Sheath Introducer, thePreludeSYNC Radial Hemostasis Device are likely to expand the company's customer base.
However, surging operating expenses is concerning. Headwinds like stiff competition and higher consolidation in the healthcare industry add to the woes. Sluggishness in the Custom kits and procedure trays and Embolization devices units is also worrisome.
Key Picks
Other top-ranked stocks in the MedTech space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII .
Surmodics has a long-term expected earnings growth rate of 10%. The stock sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Abbott's long-term earnings growth rate is projected at 11.7%. The stock carries a Zacks Rank #2.
Cardiovascular Systems exceeded the Zacks Consensus Estimate in each of the trailing four quarters, the average being 77.1%. The stock sports a Zacks Rank of 1.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?
Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.
See Latest Stocks Today >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report
Surmodics, Inc. (SRDX): Free Stock Analysis Report
Merit Medical Systems, Inc. (MMSI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Key Picks Other top-ranked stocks in the MedTech space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI): Free Stock Analysis Report To read this article on Zacks.com click here. This Utah-based provider of peripheral and cardiac intervention products reported worldwide revenues of $233.2 million, up 22.2% from the year-ago quarter's tally. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI): Free Stock Analysis Report To read this article on Zacks.com click here. Key Picks Other top-ranked stocks in the MedTech space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Merit Medical Systems, Inc.MMSI reported fourth-quarter 2018 adjusted earnings per share (EPS) of 48 cents, which exceeded the Zacks Consensus Estimate of 45 cents. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI): Free Stock Analysis Report To read this article on Zacks.com click here. Key Picks Other top-ranked stocks in the MedTech space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Segmental Analysis Cardiovascular The Cardiovascular unit recorded fourth-quarter revenues of $225.1 million, up 22.7% year over year. | Key Picks Other top-ranked stocks in the MedTech space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI): Free Stock Analysis Report To read this article on Zacks.com click here. Segmental Analysis Cardiovascular The Cardiovascular unit recorded fourth-quarter revenues of $225.1 million, up 22.7% year over year. |
33053.0 | 2019-02-28 00:00:00 UTC | Orthofix (OFIX) Earnings Beat Estimates in Q4, Margins Fall | ABT | https://www.nasdaq.com/articles/orthofix-ofix-earnings-beat-estimates-in-q4-margins-fall-2019-02-28 | nan | nan | OrthofixOFIX reported fourth-quarter 2018 adjusted earnings of $55 cents per share, up 5.8% year over year. The figure beat the Zacks Consensus Estimate by 17%. Adjusting for the operating loss incurred due to the acquisition of Spinal Kinetics, adjusted EPS in the quarter was 62 cents, reflecting 19.2% growth over the prior-year quarter.
Reported EPS in the quarter came in at 46 cents, showing a massive year-over-year surge of 475%.
For the full year, the company delivered an adjusted EPS of $1.79, marking an increase of 10.5% from a year ago. The bottom line beat the Zacks Consensus Estimate by 2.3%.
Revenues in the fourth quarter came in at $121.1 million, up 3.6% year over year. The figure, however, missed the Zacks Consensus Estimate by 0.6%. Excluding contributions from Spinal Kinetics, net sales increased 1.4% on a reported basis and 1.7% at constant exchange rate or CER.
For the full year, revenues totaled $453 million, up 4.4% from the year-ago period. The top line missed the Zacks Consensus Estimate by a meager 0.2%.
Segmental Analysis
The key operating segment of Orthofix is Orthofix Spine which comprises product lines like Bone Growth Therapies, Spinal Implants, Biologics, Orthofix Extremities. For the quarter under review, revenues from Bone Growth Therapies totaled $52.8 million, up 6.1 % year over year both on a reported basis and at CER.
Spinal implants posted revenues of $24.9 million, up 17.9% (18.5% at CER). This included $3.59 million from spinal kinetics. Biologics recorded revenues of $16 million, down 4.8%, both on a reported basis and at CER. Revenues from Orthofix Extremities grossed $27.2 million, down 6.4% on a reported basis and 3.6% at CER.
Margin details
In the fourth quarter of 2018, gross profit increased 2.3% year over year to $95.4 million. However, gross margin contracted 100 basis points (bps) to 78.8%. Adjusted operating profit declined 28% from the year-ago quarter to $12.8 million. The decline was led by a year-over-year increase in operating expenses. As a result, operating margin contracted 472 bps to 10.6%.
Operational update
Orthofix exited 2018 with a cash equivalent of $69.6 million compared with $81.2 million at the end of 2017. Net cash from operating activities at the end of 2018 was $49.9 million, reflecting an increase from $38.9 million in the year-ago period.
Guidance for 2019
Orthofix issued the 2019 financial guidance. Adjusted EPS at the end of 2019 is projected in the band of $1.75-$1.82 million. The Zacks Consensus Estimate of $1.86 is above the high end of the guidance. Revenues at the end of 2019 are projected in the range of $472-$477 million. The Zacks Consensus Estimate of $480.5 million is also above the high end of the guidance provided by the company.
Our take
Orthofix ended 2018 on a mixed note with earnings surpassing estimates but revenues missing the same by a narrow margin. Barring Extremities and Biologics, the other key operating segments saw year-over-year revenue growth. It is concerning to note that both gross and operating margin contracted in the fourth quarter. However, the recent FDA approval of the M6-C Artificial Cervical disc reflects the steady progress in the company's spine business.
Zacks Rank & Other Key Picks
Orthofix sports a Zacks Rank #1 (Strong Buy). A few other top-ranked medical stocks are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD .
Abbot t report ed fourth-quarter 2018 adjusted EPS of 81 cents, in line with the Zacks Consensus Estimate. Revenues of $7.77 billion were below the Zacks Consensus Estimate of $7.79 billion. The stock has a Zacks Rank #2 (Buy).
AngioDynamics' fiscal second-quarter adjusted EPS of 22 cents exceeded the Zacks Consensus Estimate by a penny. Revenues totaled $91.5 million, beating the consensus estimate by 2.9%. The stock carries a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here.
CONMED delivered fourth-quarter adjusted EPS of 73 cents, in line with the Zacks Consensus Estimate. Revenues of $242.4 million beat the Zacks Consensus Estimate of $229.2 million. The stock carries a Zacks Rank of 2.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year? Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.
See Latest Stocks Today >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
AngioDynamics, Inc. (ANGO): Free Stock Analysis Report
ORTHOFIX MEDICAL INC. (OFIX): Free Stock Analysis Report
CONMED Corporation (CNMD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A few other top-ranked medical stocks are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report ORTHOFIX MEDICAL INC. (OFIX): Free Stock Analysis Report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here. Excluding contributions from Spinal Kinetics, net sales increased 1.4% on a reported basis and 1.7% at constant exchange rate or CER. | A few other top-ranked medical stocks are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report ORTHOFIX MEDICAL INC. (OFIX): Free Stock Analysis Report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here. Segmental Analysis The key operating segment of Orthofix is Orthofix Spine which comprises product lines like Bone Growth Therapies, Spinal Implants, Biologics, Orthofix Extremities. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report ORTHOFIX MEDICAL INC. (OFIX): Free Stock Analysis Report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here. A few other top-ranked medical stocks are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . For the quarter under review, revenues from Bone Growth Therapies totaled $52.8 million, up 6.1 % year over year both on a reported basis and at CER. | A few other top-ranked medical stocks are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report ORTHOFIX MEDICAL INC. (OFIX): Free Stock Analysis Report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here. Revenues from Orthofix Extremities grossed $27.2 million, down 6.4% on a reported basis and 3.6% at CER. |
33054.0 | 2019-02-27 00:00:00 UTC | Veeva Systems (VEEV) Beats on Q4 Earnings and Revenues | ABT | https://www.nasdaq.com/articles/veeva-systems-veev-beats-on-q4-earnings-and-revenues-2019-02-27 | nan | nan | Veeva Systems Inc. VEEV reported fourth-quarter fiscal 2019 adjusted earnings of 45 cents per share, which surpassed the Zacks Consensus Estimate of 31 cents. The bottom line also increased a whopping 87.5% on a year-over-year basis.
Total revenues came in at $232.3 million, outpacing the Zacks Consensus Estimate of $228 million. On a year-over-year basis, the top line improved 25%.
The company has a Zacks Rank #3 (Hold).
Segmental Details
Subscription Service
Fiscal fourth-quarter subscription service revenues summed $190.7 million, up 25.5% year over year. Per management, solid momentum in bookings continued across all areas of Vault, which was 45% of subscription revenues compared with 39% a year ago.
Professional Service and Others
Professional Service revenues rose almost 22.4% to $41.7 million from the figure registered in the year-ago quarter.
According to Veeva Systems, this improvement in revenues can be attributed to continued strong demand within Veeva Vault R&D (research and development). Management also remains optimistic about the segment's impressive performance in the first quarter of fiscal 2020.
Margin Details
In the reported quarter, adjusted gross profit increased 31.2% to $171.9 million. Adjusted gross margin was 74%, which expanded 360 basis points (bps).
Adjusted operating income totaled $84.3 million, up 52.8% year over year. In the quarter under review, the adjusted operating margin was 36.3%, which expanded 660 bps. Per management, the upside was driven by impressive top-line performance.
However, adjusted operating expenses rose 15.7% year over year to $87.6 million.
Guidance
For first-quarter fiscal 2020, Veeva Systems expects total revenues to be between $238 million and $239 million. The Zacks Consensus Estimate for the same is pegged at $234.2 million, below the guided range.
Adjusted earnings are expected to be between 44 cents and 45 cents per share. The Zacks Consensus Estimate for the same stands at 40 cents, below the projected figure. Adjusted operating income is expected in the $85-$86 million band.
Veeva Systems issued guidance for fiscal 2020 as well.
Revenues are expected to be between $1.02 billion and $1.03 billion in fiscal 2020. The Zacks Consensus Estimate for the same stands at $1.02 billion, in line with the lower end of the guided range.
For the fiscal year, adjusted earnings are anticipated in the range of $1.91-$1.94 per share. The Zacks Consensus Estimate for earnings is pinned at $1.79, below the projected range.
Wrapping Up
Veeva Systems ended the fiscal fourth quarter on a strong note, wherein earnings and revenues outpaced the Zacks Consensus Estimate. Also, the Subscription business segment performed impressively in the quarter.
These apart, the company continues benefiting from its flagship Vault platform. In fact, Veeva Vault's customers have increased manifold in recent times. Markedly, Veeva Systems' unique solutions include Veeva Vault, Veeva CRM, Veeva Network and Veeva OpenData. Veeva's new CRM Sunrise UI and Nitro look promising as well. In Commercial Cloud, Veeva Systems secured a number of deals. The company is confident about growth in new markets with products like EDC, Safety, Nitro and Vault.
On the flip side, high expenses on the operational side are worrisome. Also, intense competition and a saturating life sciences market remain potent threats. Volatility in the foreign currency exchange rate is an added concern.
Key Picks
Some better-ranked stocks in the MedTech space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII .
Surmodics has a long-term expected earnings growth rate of 10%. The stock sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Abbott's long-term earnings growth rate is projected at 11.7%. The stock carries a Zacks Rank #2 (Buy).
Cardiovascular Systems exceeded the Zacks Consensus Estimate in each of the trailing four quarters, the average being 77.1%. The stock sports a Zacks Rank of 1.
Is Your Investment Advisor Fumbling Your Financial Future?
See how you can more effectively safeguard your retirement with a new Special Report, "4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future."
Click to get it free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Veeva Systems Inc. (VEEV): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Surmodics, Inc. (SRDX): Free Stock Analysis Report
Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Key Picks Some better-ranked stocks in the MedTech space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Click to get this free report Veeva Systems Inc. (VEEV): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report To read this article on Zacks.com click here. Wrapping Up Veeva Systems ended the fiscal fourth quarter on a strong note, wherein earnings and revenues outpaced the Zacks Consensus Estimate. | Click to get this free report Veeva Systems Inc. (VEEV): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report To read this article on Zacks.com click here. Key Picks Some better-ranked stocks in the MedTech space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Veeva Systems Inc. VEEV reported fourth-quarter fiscal 2019 adjusted earnings of 45 cents per share, which surpassed the Zacks Consensus Estimate of 31 cents. | Click to get this free report Veeva Systems Inc. (VEEV): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report To read this article on Zacks.com click here. Key Picks Some better-ranked stocks in the MedTech space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Veeva Systems Inc. VEEV reported fourth-quarter fiscal 2019 adjusted earnings of 45 cents per share, which surpassed the Zacks Consensus Estimate of 31 cents. | Key Picks Some better-ranked stocks in the MedTech space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Click to get this free report Veeva Systems Inc. (VEEV): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report To read this article on Zacks.com click here. According to Veeva Systems, this improvement in revenues can be attributed to continued strong demand within Veeva Vault R&D (research and development). |
33055.0 | 2019-02-27 00:00:00 UTC | Wright Medical (WMGI) Q4 Earnings & Revenues Beat Estimates | ABT | https://www.nasdaq.com/articles/wright-medical-wmgi-q4-earnings-revenues-beat-estimates-2019-02-27 | nan | nan | Wright Medical Group N.V. WMGI reported fourth-quarter 2018 adjusted earnings of 11 cents per share, which surpassed the Zacks Consensus Estimate of 6 cents. Notably, the company's adjusted earnings came in at 10 cents per share in the year-ago quarter.
Fourth-quarter revenues totaled $238.1 million, which outpaced the Zacks Consensus Estimate of $237.4 million. The top line also improved 9.4% year over year.
2018 at a Glance
For 2018, Wright Medical delivered revenues of $836.2 million, reflecting a year-over-year increase of 12.2%. The reported figure exceeded the Zacks Consensus Estimate of $834.7 million.
The Upper Extremities segment recorded sales of $395.8 million (47.3% of net revenues).
The Lower Extremities segment registered revenues of $311.5 million (37.3% of net revenues).
The Biologics segment's revenues totaled $108.8 million (13% of net revenues).
The Sports Med & Other segment recorded revenues of $20.1 million (2.1% of net revenues).
Segment Details
Lower Extremities
This segment posted worldwide revenues of $93.1 million, up 12.3% year over year.
Revenues in the United States increased 15% to $76.8 million on a year-over-year basis. International revenues totaled $16.2 million, up 0.9% year over year.
Upper Extremities
Revenues at this segment totaled $108.2 million, up 8.4% from the prior-year quarter's level.
In the United States, revenues increased 9% on a year-over-year basis to $78.2 million. Internationally, the segment raked in revenues worth $30 million, up 7% year over year.
Biologics
Biologics revenues amounted to $31.4 million in the quarter under review, up 9.8% on a year-over-year basis.
While international revenues at the segment rose 8.6% to $7.4 million, U.S. revenues summed $24 million, up 10.1% year over year.
Sports Med & Other
At this segment, net revenues came in at $5.5 million, down 13.3% on a year-over-year basis.
The segment's U.S. revenues decreased 15.3% to $2.6 million, while international revenues decreased 29.1% to $2.9 million.
Margin Analysis
In the quarter under review, gross profit totaled almost $189 million, up 11% year over year. Gross margin was 79.4% of net revenues, which expanded 110 basis points (bps) from the year-ago quarter's level.
Selling, general and administrative expenses were $160.6 million, up 20.7% year over year.
Research and development expenses amounted to $16.7 million, up 27.4% year over year.
Adjusted operating income in the fourth quarter of 2018 was $11.6 million, 4.9% of net revenues.
Guidance
For 2019, Wright Medical issued its revenue guidance in the band of $954-$966 million. The mid-point of $960 million is above the Zacks Consensus Estimate of $957.7 million. This also represents 15-17% net revenue growth on a constant-currency basis, 11-13% increase on a pro-forma constant-currency basis and 10-12% improvement on an organic constant-currency basis.
The company expects 2018 adjusted earnings per share of 17-25 cents. Notably, the mid-point of 21 cents is below the Zacks Consensus Estimate of 23 cents.
Conclusion
Wright Medical exited the fourth quarter on a promising note. The company's adjusted earnings and revenues outpaced Zacks Consensus Estimate. It expects to deliver double-digit, constant-currency net sales growth each year and maintain adjusted gross margin in the high 70% range every year.
Solid performance at the Upper and the Lower Extremities segments buoys optimism. Also, consistent growth in PERFORM Reversed glenoid and robust contributions from the SIMPLICITI shoulder system are impressive. Wright Medical is likely to gain from the upcoming launch of REVIVE revision shoulder system as well. Furthermore, management is confident about the recent acquisition of BLUEPRINT.
On the flip side, the Zacks Rank #2 (Buy) company's increasing operating expenses are worrisome. Additionally, the sports business performed disappointingly in the fourth quarter. Distribution issues in Europe and Asia as well as foreign currency volatility add to the woes. Increased costs related to product launch and re-building infrastructure is expected to keep the margins under pressure.
Other Key Picks
Some other top-ranked stocks in the MedTech space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII .
Surmodics has a long-term expected earnings growth rate of 10%. The stock sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Abbott's long-term earnings growth rate is projected at 11.7%. The stock carries a Zacks Rank #2.
Cardiovascular Systems exceeded the Zacks Consensus Estimate in each of the trailing four quarters, the average being 77.1%. The stock sports a Zacks Rank of 1.
Is Your Investment Advisor Fumbling Your Financial Future?
See how you can more effectively safeguard your retirement with a new Special Report, "4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future."
Click to get it free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Wright Medical Group N.V. (WMGI): Free Stock Analysis Report
Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report
Surmodics, Inc. (SRDX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Other Key Picks Some other top-ranked stocks in the MedTech space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Wright Medical Group N.V. (WMGI): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report To read this article on Zacks.com click here. Also, consistent growth in PERFORM Reversed glenoid and robust contributions from the SIMPLICITI shoulder system are impressive. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Wright Medical Group N.V. (WMGI): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report To read this article on Zacks.com click here. Other Key Picks Some other top-ranked stocks in the MedTech space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Wright Medical Group N.V. WMGI reported fourth-quarter 2018 adjusted earnings of 11 cents per share, which surpassed the Zacks Consensus Estimate of 6 cents. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Wright Medical Group N.V. (WMGI): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report To read this article on Zacks.com click here. Other Key Picks Some other top-ranked stocks in the MedTech space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . While international revenues at the segment rose 8.6% to $7.4 million, U.S. revenues summed $24 million, up 10.1% year over year. | Other Key Picks Some other top-ranked stocks in the MedTech space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Wright Medical Group N.V. (WMGI): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report To read this article on Zacks.com click here. Sports Med & Other At this segment, net revenues came in at $5.5 million, down 13.3% on a year-over-year basis. |
33056.0 | 2019-02-26 00:00:00 UTC | Teleflex (TFX) Q4 Earnings Miss Estimates, Margins Rise | ABT | https://www.nasdaq.com/articles/teleflex-tfx-q4-earnings-miss-estimates-margins-rise-2019-02-26 | nan | nan | Teleflex IncorporatedTFX announced earnings per share (EPS) from continuing operations of $2.77 for the fourth quarter of 2018, up 13.5% year over year. However, the bottom line missed the Zacks Consensus Estimate by a penny.
For the full year, adjusted earnings came in at $9.90 per share, a 17.9% increase on a year-over-year basis.
Net revenues in the fourth quarter rose 7.8% year over year to $641.6 million. Excluding the impact of currency fluctuations, fourth-quarter net revenues increased 9.4% year over year.
On a year-over-year basis, the company saw organic constant currency revenue growth of 9.1%. This includes the benefit of NeoTract becoming organic in the fourth quarter combined with strong growth from legacy product families.
The company registered revenues of $2.44 million in 2018, up 14.1% (up 12.95 at constant exchange rate or CER) from the year-ago period.
Revenues in Detail
In the fourth quarter, Teleflex's Vascular North America segment recognized net revenues of $85.7 million, up 6.3% year over year at CER. The company registered strong growth in PICC (Peripherally Inserted Central Catheters), visual navigation products and EZ-IO.
The Interventional North America business registered net revenues of $69.7 million, a 13.3% rise on a year-over-year basis at CER. This upside was fueled by higher sales of Vascular Solutions products as well as growth in OnControl.
Within Anesthesia North America, net revenues climbed 4.8% at CER to $53.2 million. Growth in sales volumes of existing products and stronger new product sales during the fourth quarter were partially offset by price declines.
Surgical North America realized net revenues of $50.8 million, a 2.1% rise at CER on increased sales of airway and EZ-IO products.
Meanwhile, EMEA recorded revenue growth of 8.2% at CER to $150.9 million, driven by distributor convergence as well as increased sales of vascular access products.
Asia, OEM and All Other logged net revenues of $79.8 million, $52.7 million and $109.6 million, respectively (corresponding top-line growth of 5.5%, 15.4% and 21.4% each at CER), in the quarter under review.
Margin
Gross margin of 57% in the quarter under discussion was up 144 basis points (bps) year over year on 10.6% improvement in gross profits to $365.8 million. Adjusted operating margin expanded 317 bps to 18.6% on 29.9% rise in operating profit to $119.5 million.
Liquidity Position
The company exited 2018 with cash and cash equivalents of $357.2 million compared with $333.6 million at the end of 2017. Full year, net cash provided by operating activities was $435.1 million compared with $426.3 million in the year-ago period.
Outlook
Teleflex has provided its 2019 guidance. Revenues are expected to increase in the band of 5% to 6% from the year-ago period.This reflects an 1% unfavorable impact of foreign exchange translation.
The company forecasts full-year adjusted earnings per share from continuing operations in the $10.90-$11.10 band, representing an increase of 10.1% to 12.1% over 2018 and reflecting a 2% negative impact from foreign exchange translation.
Our Take
Notably Teleflex continues to report a robust improvement in revenues, banking on balanced growth across all segments and geographies. The company's newly-acquired NeoTract has started to contribute to its top line quite handsomely. We are also upbeat about Urolift that maintained its sturdy momentum in the fourth quarter, delivering $49 million in revenues, an approximate 45% increase from the prior-year period.
Zacks Rank & Key Picks
Teleflex currently carries a Zacks Rank #3 (Hold). A few better-ranked medical stocks are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD .
Abbot t report ed fourth-quarter 2018 adjusted EPS of 81 cents, in line with the Zacks Consensus Estimate. Revenues of $7.77 billion were below the Zacks Consensus Estimate of $7.79 billion. The stock has a Zacks Rank #2 (Buy).
AngioDynamics' fiscal second-quarter adjusted EPS of 22 cents exceeded the Zacks Consensus Estimate by a penny. Revenues totaled $91.5 million, beating the consensus estimate by 2.9%. The stock sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
CONMED delivered fourth-quarter adjusted EPS of 73 cents, in line with the Zacks Consensus Estimate. Revenues of $242.4 million beat the Zacks Consensus Estimate of $229.2 million. The stock carries a Zacks Rank of 2.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They're also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98% , +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Teleflex Incorporated (TFX): Free Stock Analysis Report
AngioDynamics, Inc. (ANGO): Free Stock Analysis Report
CONMED Corporation (CNMD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A few better-ranked medical stocks are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Teleflex Incorporated (TFX): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here. Meanwhile, EMEA recorded revenue growth of 8.2% at CER to $150.9 million, driven by distributor convergence as well as increased sales of vascular access products. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Teleflex Incorporated (TFX): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked medical stocks are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . Revenues in Detail In the fourth quarter, Teleflex's Vascular North America segment recognized net revenues of $85.7 million, up 6.3% year over year at CER. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Teleflex Incorporated (TFX): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked medical stocks are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . Revenues in Detail In the fourth quarter, Teleflex's Vascular North America segment recognized net revenues of $85.7 million, up 6.3% year over year at CER. | A few better-ranked medical stocks are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Teleflex Incorporated (TFX): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here. Revenues in Detail In the fourth quarter, Teleflex's Vascular North America segment recognized net revenues of $85.7 million, up 6.3% year over year at CER. |
33057.0 | 2019-02-26 00:00:00 UTC | Bruker Rides on Robust NANO & CALID Groups, Recent Buyouts | ABT | https://www.nasdaq.com/articles/bruker-rides-on-robust-nano-calid-groups-recent-buyouts-2019-02-26 | nan | nan | On Feb 25, we issued an updated research report on Bruker CorporationBRKR . The stock carries a Zacks Rank #2 (Buy). The company's Scientific Instruments segment has been performing well, driven by strong results from NANO and CALID groups.
In 2018, the Bruker Nano Surfaces group, which includes Bruker's atomic force microscopy product, reported high single-digit revenue growth. Growth was driven by solid academic markets and strong industrial research demand for advanced X-ray and Nano Materials Analysis products.
This apart, acquisitions like Anasys and JPK (completed in April and July 2018, respectively) also contributed to the segment's top line. Nano Surfaces and Nano-analysis revenues increased in 2018 with organic growth supplemented by these two acquisitions.
The year 2019 is expected to be no exception in terms of revenue growth.
In mid-December 2018, NANO closed the acquisition of Alicona Imaging, a provider of optical metrology products for lab and production applications, which will start to contribute to the group's results from the beginning of 2019.
The CALID Group is also delivering well with impressive full-year revenues in high-single digits. Growth was driven by mass spectrometry and molecular spectroscopy businesses. The company eyes the benefits of its life science mass spec portfolio transformation and expects further growth in 2019 and beyond as recently launched products like timsTOF Pro and the new scimaX MRMS ramp up its product menu.
On the flip side, Bruker conducts 80% of its business in the international markets. As a result, adverse currency fluctuations may weigh on profits. Also, headwinds like unfavorable economic conditions and an intense competition pose threats to the stock.
Other Key Picks
Some other top-ranked stocks in the broader medical space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII .
Surmodics has a long-term expected earnings growth rate of 10%. The stock sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Abbott's long-term earnings growth rate is projected to be 11.7%. The stock carries a Zacks Rank #2.
Cardiovascular Systems exceeded the Zacks Consensus Estimate in each of the trailing four quarters, with the average beat being 77.1%. The stock sports a Zacks Rank of 1.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They're also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98% , +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Bruker Corporation (BRKR): Free Stock Analysis Report
Surmodics, Inc. (SRDX): Free Stock Analysis Report
Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Other Key Picks Some other top-ranked stocks in the broader medical space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Bruker Corporation (BRKR): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report To read this article on Zacks.com click here. The company's Scientific Instruments segment has been performing well, driven by strong results from NANO and CALID groups. | Other Key Picks Some other top-ranked stocks in the broader medical space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Bruker Corporation (BRKR): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Bruker Corporation (BRKR): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report To read this article on Zacks.com click here. Other Key Picks Some other top-ranked stocks in the broader medical space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . In 2018, the Bruker Nano Surfaces group, which includes Bruker's atomic force microscopy product, reported high single-digit revenue growth. | Other Key Picks Some other top-ranked stocks in the broader medical space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Bruker Corporation (BRKR): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report To read this article on Zacks.com click here. In 2018, the Bruker Nano Surfaces group, which includes Bruker's atomic force microscopy product, reported high single-digit revenue growth. |
33058.0 | 2019-02-26 00:00:00 UTC | Here's Why Investors Should Buy DexCom (DXCM) Stock Now | ABT | https://www.nasdaq.com/articles/heres-why-investors-should-buy-dexcom-dxcm-stock-now-2019-02-26 | nan | nan | DexCom, Inc.DXCM is one of the top players in the MedTech space. It is likely to gain from a solid fourth-quarter performance and robust growth at the Sensor, Transmitter and Receiver segments.
In the past three months, this Zacks Rank #2 (Buy) stock has rallied 13.4% compared with the S&P 500's 6.2% increase.
What's Favoring the Stock?
DexCom exited the fourth quarter on a strong note, wherein earnings and revenues outpaced the Zacks Consensus Estimate. Revenues at the Sensor segment (75% of total revenues) surged 57% on a year-over-year basis to $252.8 million. Transmitter revenues (17%) increased 39% year over year to $59 million. Receiver revenues (8%) rallied 46% year over year to $26.3 million.
For 2019, the company expects revenues in the range of $1.18-$1.23 billion. However, gross profit margin is projected to be 65% of net revenues. While adjusted operating margin is expected to be 5.5% of net revenues, adjusted EBITDA margin is expected to be 18%.
DexCom recently announced that it has received Health Canada approval for the next generation Dexcom G6 CGM System for people with diabetes aged two years and older.
Earlier, Dexcom G6 was introduced in the United States, the United Kingdom, Ireland and several other European countries, and has witnessed solid sales. In 2019, DexCom plans the G6 commercial launch in Canada as the company continues to build capacity for supporting global launch plans.
These apart, DexCom announced an amendment to its previously-announced collaboration with Verily. The revised terms are likely to expand DexCom's product development goals.
By the end of fourth-quarter 2018, management at DexCom announced that the company has been witnessing significant increases in adoption in both the Medicare and international markets.
Also, the company advanced its interoperability and decision support initiatives including the acquisition of TypeZero and solidified its product pipeline by amending the agreement with Verily.
Which Way Are Estimates Trending?
The Zacks Consensus Estimate for 2019 revenues is pegged at $1.23 billion, reflecting an 18.8% growth. The same for adjusted earnings is pinned at 28 cents, indicating a year-over-year decline of 6.7%.
Key Picks
Other top-ranked stocks in the MedTech space are Surmodics, Inc. SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII .
Surmodics has a long-term expected earnings growth rate of 10%. The stock sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Abbott's long-term earnings growth rate is projected at 11.7%. The stock carries a Zacks Rank #2.
Cardiovascular Systems exceeded the Zacks Consensus Estimate in each of the trailing four quarters, the average being 77.1%. The stock sports a Zacks Rank of 1.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They're also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
DexCom, Inc. (DXCM): Free Stock Analysis Report
Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report
Surmodics, Inc. (SRDX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Key Picks Other top-ranked stocks in the MedTech space are Surmodics, Inc. SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report To read this article on Zacks.com click here. By the end of fourth-quarter 2018, management at DexCom announced that the company has been witnessing significant increases in adoption in both the Medicare and international markets. | Key Picks Other top-ranked stocks in the MedTech space are Surmodics, Inc. SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report To read this article on Zacks.com click here. Key Picks Other top-ranked stocks in the MedTech space are Surmodics, Inc. SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . DexCom exited the fourth quarter on a strong note, wherein earnings and revenues outpaced the Zacks Consensus Estimate. | Key Picks Other top-ranked stocks in the MedTech space are Surmodics, Inc. SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report DexCom, Inc. (DXCM): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report To read this article on Zacks.com click here. In the past three months, this Zacks Rank #2 (Buy) stock has rallied 13.4% compared with the S&P 500's 6.2% increase. |
33059.0 | 2019-02-25 00:00:00 UTC | CVS Health Rides on Aetna Synergy, PBM Selling Season Modest | ABT | https://www.nasdaq.com/articles/cvs-health-rides-on-aetna-synergy-pbm-selling-season-modest-2019-02-25 | nan | nan | On Feb 22, we issued an updated research report on CVS HealthCVS . An increasing demand for Pharmacy Benefit Management (PBM) and specialty pharmacy was a major growth driver for the stock. The company currently carries a Zacks Rank #3 (Hold).
CVS Health ended fourth-quarter 2018 on a promising note with better-than-expected results. The year-over-year growth in the top line was driven by a strong Pharmacy Services segment, benefiting from the upside in specialty services.
In the las t report ed quarter, CVS Health completed the $70-billion consolidation of Aetna, marking the creation of a new healthcare powerhouse. The consolidated entity combines CVS Health's pharmacy business with Aetna's insurance base. Following this, CVS Health introduced Health Care Benefits segment, which holds immense potential.
With regard to its 2019 PBM selling season, CVS Health notes that the net benefits from this selling season are expected to be modest on Anthem-related headwinds. However, the retention rate is 98% currently, higher than the rates it has seen over the last few years.
We note that despite tough pricing competition, CVS Health is doing well on high levels of service and execution, competitive pricing along with unique integrated model that allows the company to provide differentiated products and services that generate savings, better health outcomes and convenience.
On the flip side, CVS Health expects to see fewer RFP (Requests for Proposals) opportunities in the market than what it has seen over the past few years. This might pose an obstacle to its PBM selling season performance in the coming quarters. Also, according to CVS Health, Omnicare business performance should continue to remain soft through 2019.
Key Picks
A few better-ranked stocks in the MedTech space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII .
Surmodics has a long-term expected earnings growth rate of 10%. The stock sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Abbott's long-term earnings growth rate is projected to be 11.7%. The stock carries a Zacks Rank #2 (Buy).
Cardiovascular Systems exceeded the Zacks Consensus Estimate in each of the trailing four quarters, with the average beat being 77.1%. The stock sports a Zacks Rank of 1.
This Could Be the Fastest Way to Grow Wealth in 2019
Research indicates one sector is poised to deliver a crop of the best-performing stocks you'll find anywhere in the market. Breaking news in this space frequently creates quick double- and triple-digit profit opportunities.
These companies are changing the world - and owning their stocks could transform your portfolio in 2019 and beyond. Recent trades from this sector have generated +98% , +119% and +164% gains in as little as 1 month.
Click here to see these breakthrough stocks now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Surmodics, Inc. (SRDX): Free Stock Analysis Report
Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report
CVS Health Corporation (CVS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Key Picks A few better-ranked stocks in the MedTech space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report CVS Health Corporation (CVS): Free Stock Analysis Report To read this article on Zacks.com click here. In the las t report ed quarter, CVS Health completed the $70-billion consolidation of Aetna, marking the creation of a new healthcare powerhouse. | Key Picks A few better-ranked stocks in the MedTech space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report CVS Health Corporation (CVS): Free Stock Analysis Report To read this article on Zacks.com click here. With regard to its 2019 PBM selling season, CVS Health notes that the net benefits from this selling season are expected to be modest on Anthem-related headwinds. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report CVS Health Corporation (CVS): Free Stock Analysis Report To read this article on Zacks.com click here. Key Picks A few better-ranked stocks in the MedTech space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . With regard to its 2019 PBM selling season, CVS Health notes that the net benefits from this selling season are expected to be modest on Anthem-related headwinds. | Key Picks A few better-ranked stocks in the MedTech space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report CVS Health Corporation (CVS): Free Stock Analysis Report To read this article on Zacks.com click here. The company currently carries a Zacks Rank #3 (Hold). |
33060.0 | 2019-02-25 00:00:00 UTC | Chemed (CHE) Q4 Earnings Beat Estimates, Gross Margin Falls | ABT | https://www.nasdaq.com/articles/chemed-che-q4-earnings-beat-estimates-gross-margin-falls-2019-02-25 | nan | nan | Chemed CorporationCHE delivered fourth-quarter 2018 adjusted earnings per share (EPS) of $3.35, up 44.3% year over year. The adjusted number also surpassed the Zacks Consensus Estimate of $3.27 by 2.4%.
Reported EPS came in at $3.26, up 0.3% year over year.
For the full year, adjusted EPS was $11.93, reflecting an increase of 41.5% from the year-ago period.
Revenues in the reported quarter increased 6.8% year over year to $457.5 million. For the full year, the company reported revenues of $1.78 billion, up 6.6% from the year-ago period.
Segmental details
Chemed operates through two wholly-owned subsidiaries, namely, VITAS (a major provider of end-of-life care) and Roto-Rooter (a leading commercial and residential plumbing plus drain cleaning service provider).
Chemed Corporation Price, Consensus and EPS Surprise
Chemed Corporation Price, Consensus and EPS Surprise | Chemed Corporation Quote
In the fourth quarter, net revenues at VITAS totaled $306.9 million, reflecting an increase of 4.9% year over year. The top line was driven by 1.1% growth in geographically weighted average Medicare reimbursement rate and a 7.3% rise in average daily census. A Medicare Cap liability partially offset this revenue improvement by 0.4%. The revenue strength was partially offset by acuity mix shift, which negatively impacted revenues by 1.0%.
Roto-Rooter reported sales of $150.5 million in the fourth quarter rose 10.6% year over year. According to the company, revenues from water restoration increased 9.7% year over year to $24.3 million. The upside was driven by 12% year-over-year growth in commercial revenues and 11.4% rise in residential revenues.
Margin details
Gross profit increased 5.5% year over year to $144.4 million in the fourth quarter of 2018. However, gross margin contracted 37 basis points (bps) year over year to 31.5%. Adjusted operating profit saw growth of 20.7% from the year-ago period to $78.7 million. This was on account of declining operating costs. Accordingly, the operating margin expanded 197 bps to 17.2%.
Operational update
Chemed exited 2018 with total cash and cash equivalents of $4.83 million, showing a significant decline from $11.1 million at the end of 2017. The company had total debt of $89.2 million at the end of 2018, which again reflected a decline from $101.2 million at the end of 2017. During the fourth quarter, the company repurchased shares worth $36.9 million.
At the end of 2018, net cash provided by operating activities was $287.1 million, compared with $162.5 million at 2017-end.
Guidance for 2019
Chemed has provided guidance for 2019.The company projects VITAS Healthcare revenue growth (prior to Medicare Cap) within 5.5-6%. In 2019, admissions within this segment are anticipated to improve 3-4% and Average Daily Census is predicted to rise 4-5%. Medicare Cap billing limitations are expected to cap around $10 million.
The Roto-Rooter business is likely to register revenue growth of 13-14% in the year. The view was backed by a 2% increase in job pricing, consistent growth in core plumbing plus drain cleaning services as well as revenue generation from water restoration services.
The Zacks Consensus Estimate of 2019 revenues is pegged at $1.87 billion.
Adjusted EPS for 2019 has been projected in the range of $12.65-$12.85. The Zacks Consensus Estimate of $12.64 is below the low end of the guidance provided by the company.
Our Take
Chemed exited 2018 on a promising note. The company registered strong year-over-year growth in earnings and revenues. It is optimistic to note that the company witnessed solid revenue growth across its key subsidiaries. The expansion in adjusted operating margin buoys optimism. However, uncertainties are likely to arise from factors like possible changes in regulations governing the hospice care or plumbing and drain cleaning industries, periodic changes in reimbursement levels and procedures under Medicare and Medicaid program.
Zacks Rank & Key Picks
Chemed carries a Zacks Rank #3 (Hold). A few better-ranked medical stocks are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD .
Abbot t report ed fourth-quarter 2018 adjusted EPS of 81 cents, in line with the Zacks Consensus Estimate. Revenues of $7.77 billion were below the Zacks Consensus Estimate of $7.79 billion. The stock has a Zacks Rank #2 (Buy).
AngioDynamics' fiscal second-quarter adjusted EPS of 22 cents exceeded the Zacks Consensus Estimate by a penny. Revenues totaled $91.5 million, beating the consensus estimate by 2.9%. The stock sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
CONMED delivered fourth-quarter adjusted EPS of 73 cents, in line with the Zacks Consensus Estimate. Revenues of $242.4 million beat the Zacks Consensus Estimate of $229.2 million. The stock carries a Zacks Rank of 2.
This Could Be the Fastest Way to Grow Wealth in 2019
Research indicates one sector is poised to deliver a crop of the best-performing stocks you'll find anywhere in the market. Breaking news in this space frequently creates quick double- and triple-digit profit opportunities. These companies are changing the world - and owning their stocks could transform your portfolio in 2019 and beyond. Recent trades from this sector have generated +98%, +119% and +164% gains in as little as 1 month.
Click here to see these breakthrough stocks now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
AngioDynamics, Inc. (ANGO): Free Stock Analysis Report
Chemed Corporation (CHE): Free Stock Analysis Report
CONMED Corporation (CNMD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A few better-ranked medical stocks are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report Chemed Corporation (CHE): Free Stock Analysis Report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here. Abbot t report ed fourth-quarter 2018 adjusted EPS of 81 cents, in line with the Zacks Consensus Estimate. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report Chemed Corporation (CHE): Free Stock Analysis Report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked medical stocks are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . Segmental details Chemed operates through two wholly-owned subsidiaries, namely, VITAS (a major provider of end-of-life care) and Roto-Rooter (a leading commercial and residential plumbing plus drain cleaning service provider). | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report Chemed Corporation (CHE): Free Stock Analysis Report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked medical stocks are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . Chemed Corporation Price, Consensus and EPS Surprise Chemed Corporation Price, Consensus and EPS Surprise | Chemed Corporation Quote In the fourth quarter, net revenues at VITAS totaled $306.9 million, reflecting an increase of 4.9% year over year. | A few better-ranked medical stocks are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report Chemed Corporation (CHE): Free Stock Analysis Report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here. Chemed Corporation Price, Consensus and EPS Surprise Chemed Corporation Price, Consensus and EPS Surprise | Chemed Corporation Quote In the fourth quarter, net revenues at VITAS totaled $306.9 million, reflecting an increase of 4.9% year over year. |
33061.0 | 2019-02-22 00:00:00 UTC | Quest Diagnostics Grows on Innovation Amid Reimbursement Woe | ABT | https://www.nasdaq.com/articles/quest-diagnostics-grows-on-innovation-amid-reimbursement-woe-2019-02-22 | nan | nan | On Feb 20, we issued an updated research report on Quest Diagnostics, Inc.DGX . The stock carries a Zacks Rank #3 (Hold).
Quest Diagnostics exited the fourth quarter on a sluggish note. A decline in Diagnostic information services revenues was also disappointing. Moreover, we are concerned about factors like unfavorable changes in prescription drug monitoring, vitamin D and hepatitis C testing marketplace that can dent growth going forward.
Additionally, a rise in patient concession along with certain reserve adjustments affected the top line, inducing lower revenue per requisition.
On a brighter note, Quest Diagnostics is refocusing on diagnostic information services wing and a disciplined capital deployment. The company's acquisitions and collaborations with hospitals and integrated delivery networks consistently act as major growth drivers.
We are upbeat about the company's strategic partnership with UnitedHealthcare, a business of UnitedHealth Group, to operate as a preferred national laboratory for all the company's members starting Jan 1, 2019.
Quest Diagnostics Incorporated Price
Quest Diagnostics Incorporated Price | Quest Diagnostics Incorporated Quote
This expanded agreement will provide in-network access to Quest Diagnostics' complete portfolio of laboratory services to more than 48 million eligible members. Under the expanded tie-up, the companies are going to join forces on a variety of value-based programs.
Of late, major new developments included the company's progress in prescription drug monitoring, QuantiFERON and non-invasive prenatal screening. In advanced diagnostics, Quest Diagnostics witnessed a strong uptick with its new center of excellence in precision medicine oncology in Texas. This apart, with the buyout of Med Fusion, the company has seen accelerated growth of its tumor panels.
However, on fourth-quarter earnings call , Quest Diagnostics announced that its guidance for 2019 reflects a massive reimbursement pressure, which may be partially offset by the company's steady execution of Invigorate program. More specifically, in 2019, the company expects about a 10% reduction in Medicare reimbursement rates. The impact of these cutbacks will be more significant on smaller independent hospital outreach laboratories, which the company believes, could eliminate the majority of profit and provide a catalyst for market consolidation.
Shares of Quest Diagnostics have outperformed its industry in the past six months. The stock has declined 20.7%, narrower than the 26.2% fall of the industry.
Stocks to Consider
Some better-ranked stocks in the broader medical space are Penumbra, Inc. PEN , Amedisys, Inc. AMED and Abbott Laboratories ABT .
Penumbra's long-term earnings growth rate is expected at 20%. The stock carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Amedisys' long-term earnings growth rate is projected at 18.8%. The stock sports a Zacks Rank #1.
Abbott's long-term earnings growth rate is estimated at 11.7%. The stock has a Zacks Rank of 2.
Wall Street's Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Penumbra, Inc. (PEN): Free Stock Analysis Report
Amedisys, Inc. (AMED): Free Stock Analysis Report
Quest Diagnostics Incorporated (DGX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | PEN , Amedisys, Inc. AMED and Abbott Laboratories ABT . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Penumbra, Inc. (PEN): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report Quest Diagnostics Incorporated (DGX): Free Stock Analysis Report To read this article on Zacks.com click here. However, on fourth-quarter earnings call , Quest Diagnostics announced that its guidance for 2019 reflects a massive reimbursement pressure, which may be partially offset by the company's steady execution of Invigorate program. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Penumbra, Inc. (PEN): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report Quest Diagnostics Incorporated (DGX): Free Stock Analysis Report To read this article on Zacks.com click here. PEN , Amedisys, Inc. AMED and Abbott Laboratories ABT . Quest Diagnostics Incorporated Price Quest Diagnostics Incorporated Price | Quest Diagnostics Incorporated Quote This expanded agreement will provide in-network access to Quest Diagnostics' complete portfolio of laboratory services to more than 48 million eligible members. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Penumbra, Inc. (PEN): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report Quest Diagnostics Incorporated (DGX): Free Stock Analysis Report To read this article on Zacks.com click here. PEN , Amedisys, Inc. AMED and Abbott Laboratories ABT . Quest Diagnostics Incorporated Price Quest Diagnostics Incorporated Price | Quest Diagnostics Incorporated Quote This expanded agreement will provide in-network access to Quest Diagnostics' complete portfolio of laboratory services to more than 48 million eligible members. | PEN , Amedisys, Inc. AMED and Abbott Laboratories ABT . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Penumbra, Inc. (PEN): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report Quest Diagnostics Incorporated (DGX): Free Stock Analysis Report To read this article on Zacks.com click here. Quest Diagnostics Incorporated Price Quest Diagnostics Incorporated Price | Quest Diagnostics Incorporated Quote This expanded agreement will provide in-network access to Quest Diagnostics' complete portfolio of laboratory services to more than 48 million eligible members. |
33062.0 | 2019-02-22 00:00:00 UTC | Daily Dividend Report: PLD, SRE, DLR, ABT, CCI | ABT | https://www.nasdaq.com/articles/daily-dividend-report-pld-sre-dlr-abt-cci-2019-02-22 | nan | nan | Prologis ( PLD ) approved a plan to raise the company's annualized dividend level by ten percent to $2.12 per share of common stock. The board declared a regular cash dividend of $0.53 per share of the company's common stock, which will be payable on March 29, 2019, to common stockholders of record at the close of business on March 15, 2019.
Sempra Energy ( SRE ) approved an 8.1-percent increase in the dividend on shares of the company's common stock to $3.87 per share, on an annualized basis, from $3.58 per share. The first quarterly installment of the new common stock dividend, $0.9675 per share, is payable April 15, 2019, to common stock shareholders of record as of March 22, 2019.
Digital Realty authorized a cash dividend of $1.08 per share to common stockholders of record as of the close of business on March 15, 2019. The common stock cash dividend will be paid on March 29, 2019.
Abbott ( ABT ) declared a quarterly common dividend of 32 cents per share. The cash dividend is payable May 15, 2019, to shareholders of record at the close of business on April 15, 2019.
Crown Castle International ( CCI ) has declared a quarterly cash dividend of $1.125 per common share. The quarterly dividend will be payable on March 29, 2019 to common stockholders of record at the close of business on March 15, 2019.
VIDEO: Daily Dividend Report: PLD, SRE, DLR, ABT, CCI
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott ( ABT ) declared a quarterly common dividend of 32 cents per share. VIDEO: Daily Dividend Report: PLD, SRE, DLR, ABT, CCI The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Prologis ( PLD ) approved a plan to raise the company's annualized dividend level by ten percent to $2.12 per share of common stock. | VIDEO: Daily Dividend Report: PLD, SRE, DLR, ABT, CCI The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Abbott ( ABT ) declared a quarterly common dividend of 32 cents per share. The board declared a regular cash dividend of $0.53 per share of the company's common stock, which will be payable on March 29, 2019, to common stockholders of record at the close of business on March 15, 2019. | Abbott ( ABT ) declared a quarterly common dividend of 32 cents per share. VIDEO: Daily Dividend Report: PLD, SRE, DLR, ABT, CCI The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The board declared a regular cash dividend of $0.53 per share of the company's common stock, which will be payable on March 29, 2019, to common stockholders of record at the close of business on March 15, 2019. | Abbott ( ABT ) declared a quarterly common dividend of 32 cents per share. VIDEO: Daily Dividend Report: PLD, SRE, DLR, ABT, CCI The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The board declared a regular cash dividend of $0.53 per share of the company's common stock, which will be payable on March 29, 2019, to common stockholders of record at the close of business on March 15, 2019. |
33063.0 | 2019-02-22 00:00:00 UTC | NuVasive (NUVA) Q4 Earnings Beat Estimates, Margins Fall | ABT | https://www.nasdaq.com/articles/nuvasive-nuva-q4-earnings-beat-estimates-margins-fall-2019-02-22 | nan | nan | NuVasive, Inc . NUVA reported fourth-quarter 2018 adjusted earnings per share (EPS) of 69 cents, reflecting a 23.2% rise from the year-ago quarter. The figure also surpassed the Zacks Consensus Estimate by 9.5%. On a reported basis, fourth-quarter 2018 EPS came in at 23 cents, a plunge of 48.9% from the year-ago period.
For the full year of 2018, adjusted EPS came in at $2.23, an increase of 17.9% from the year-ago period.
Revenues in the fourth quarter came in at $288.3 million, up 6.3% on a reported basis (up 6.9% at constant exchange rate or CER) year over year. The top line also beat the Zacks Consensus Estimate, by a margin of 0.01%. For the full year, total revenues came in at $1.10 billion, up 7.3% on a reported basis, and at 7.1% at CER.
Geographical & Segmental Details
In the quarter under review, revenues at the U.S. Spinal Hardware business increased 4.5% year over year to $156.6 million. This revenue upside was contributed by product launches like expandable, titanium and Porous PEEK implants, TLIF and XLIF Modulus, COHERE and COALESCE, TLX 20 Degree expandable cage, and RELINE Small Stature.
Revenues in the U.S. Surgical Support business were $75.3 million in the fourth quarter, up 8.9% year over year. This upside was driven by 12.9% year-over-year growth of organic revenues in the NCS, excluding the $5-million contribution from the SafePassage acquisition.
NuVasive, Inc. Price, Consensus and EPS Surprise
NuVasive, Inc. Price, Consensus and EPS Surprise | NuVasive, Inc. Quote
Within the Biologics segment, there was a sequential revenue increment of 4% over the third quarter, even though the business line faced a 6.5% year-over-year decline. The Biologics segment has made strong strides on account of the increased sales of its products in majority of spine and orthopedic cases.
In the fourth quarter, the company registered international revenues amounting to $56.4 million, reflecting 11% year-over-year growth at CER. The EMEA region witnessed growth of 11.1% year over year at CER. This upswing stemmed from recurring investments in Germany and ongoing synergies with a Swiss acquisition. Solid revenue growth in the Southern Europe region came primarily from Italy and Spain.
The revenues from the Asia-Pacific region grew 9.5% at CER, fueled primarily by new surgeon conversion in Japan, Australia and New Zealand. Revenues from Latin America climbed 18% at CER, banking on an increase in procedural volumes and continued recovery in Puerto Rico.
Margin Details
In the reported quarter, gross profit improved 3.2% year over year to $202.2 million. However, gross profit margin contracted 210 basis points (bps) to 70.1%. Adjusted operating profit declined 11.9% from the year-ago period to $42.9 million owing to year-over-year rise in operating expenses. Accordingly, adjusted operating margin shrunk 306 bps to 14.9% in the quarter under review.
Operational Update
The company exited 2018 with cash and cash equivalents of $117.8 million, up from $72.8 million at the end of 2017. Net cash provided by operating activities at the end of 2018 was $219.2 million as compared to $176.9 million.
Guidance for 2019
NuVasive has provided its guidance for 2019. The revenues have been estimated to be in the range of $1.14-$1.16 billion. The Zacks Consensus Estimate for 2019 revenues is $1.17 billion, which lies above the higher-end of the guided range provided by the company. The company expects the adjusted EPS for 2019 to be in the $2.20-$2.30 range. The Zacks Consensus Estimate for this metric is $2.45, which falls above the higher-end of the guided range.
Our Take
NuVasive exited 2018 on an overall promising note with better-than-expected numbers. The company witnessed balanced revenue growth across all its key operating segments. Robust sales figures in international markets buoy optimism. We are upbeat about the company having witnessed strong demand across several of its recently-launched products in the U.S. Spinal Hardware business.
On the flip side, the contraction in the margins is disappointing.
Zacks Rank & Key Picks
NuVasive carries a Zacks Rank #3 (Hold). A few top-ranked medical stocks that have reported quarterly results in the recently are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD .
Abbot t report ed fourth-quarter 2018 adjusted EPS of 81 cents, in line with the Zacks Consensus Estimate. Revenues of $7.77 billion missed the Zacks Consensus Estimate of $7.79 billion. The stock has a Zacks Rank #2 (Buy).
AngioDynamics' fiscal second-quarter adjusted EPS of 22 cents exceeded the Zacks Consensus Estimate by a penny. Revenues totaled $91.5 million, beating the consensus estimate by 2.9%. The stock sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
CONMED delivered fourth-quarter adjusted EPS of 73 cents, in line with the Zacks Consensus Estimate. Revenues of $242.4 million beat the Zacks Consensus Estimate of $229.2 million. The stock carries a Zacks Rank of #2.
Wall Street's Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
AngioDynamics, Inc. (ANGO): Free Stock Analysis Report
NuVasive, Inc. (NUVA): Free Stock Analysis Report
CONMED Corporation (CNMD): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A few top-ranked medical stocks that have reported quarterly results in the recently are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report NuVasive, Inc. (NUVA): Free Stock Analysis Report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here. The Biologics segment has made strong strides on account of the increased sales of its products in majority of spine and orthopedic cases. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report NuVasive, Inc. (NUVA): Free Stock Analysis Report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here. A few top-ranked medical stocks that have reported quarterly results in the recently are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . Geographical & Segmental Details In the quarter under review, revenues at the U.S. Spinal Hardware business increased 4.5% year over year to $156.6 million. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report NuVasive, Inc. (NUVA): Free Stock Analysis Report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here. A few top-ranked medical stocks that have reported quarterly results in the recently are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . NuVasive, Inc. Price, Consensus and EPS Surprise NuVasive, Inc. Price, Consensus and EPS Surprise | NuVasive, Inc. Quote Within the Biologics segment, there was a sequential revenue increment of 4% over the third quarter, even though the business line faced a 6.5% year-over-year decline. | A few top-ranked medical stocks that have reported quarterly results in the recently are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report NuVasive, Inc. (NUVA): Free Stock Analysis Report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here. Geographical & Segmental Details In the quarter under review, revenues at the U.S. Spinal Hardware business increased 4.5% year over year to $156.6 million. |
33064.0 | 2019-02-22 00:00:00 UTC | Why Is Abbott (ABT) Up 6% Since Last Earnings Report? | ABT | https://www.nasdaq.com/articles/why-is-abbott-abt-up-6-since-last-earnings-report-2019-02-22 | nan | nan | It has been about a month since the las t earnings report for Abbott (ABT). Shares have added about 6% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Abbott due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recen t earnings report in order to get a better handle on the important catalysts.
Abbott Posts In Line Q4 Earnings, Provides '19 View
Abbot t report ed fourth-quarter 2018 adjusted earnings from continuing operations of 81 cents per share, in line with the Zacks Consensus Estimate. The bottom line improved 9.5% year over year and fell within the company's guided range of 80-82 cents. Reported earnings from continuing operation in the quarter came in at 37 cents against the year-ago loss of 48 cents per share.
Full-year adjusted EPS was $2.88, a 15.2% improvement from the year-ago period. However, it missed the Zacks Consensus Estimate by a penny.
Fourth-quarter worldwide sales came in at $7.77 billion, up 2.3% year over year on a reported basis. The top line remained slightly below the Zacks Consensus Estimate of $7.79 billion.
On an organic basis (adjusting for the impact of foreign exchange as well as certain acquisitions and divestments), sales increased 6.4% year over year in the reported quarter.
For 2018, sales were $30.6 billion, up 11.6% on a reported basis and up 7.3% on an organic basis from 2017. The top line remained in line with the Zacks Consensus Estimate.
Quarter in Detail
Abbott operates through four segments, namely Established Pharmaceuticals Division (EPD), Medical Devices, Nutrition and Diagnostics.
In the fourth quarter, EPD sales dropped 4.8% on a reported basis (improved 3.6% on an organic basis) to $1.09 billion. This included an 8.4% adverse impact from currency fluctuations. Sales in the key emerging markets declined 6.2% year over year on a 10.5% adverse impact of foreign exchange. Organically, sales improved 4.3% in this market.
The Medical Devices business sales increased 6.7% on a reported basis to $2.92 billion. On an organic basis, sales grew 9%.
Cardiovascular and Neuromodulation sales reportedly (up 4.8% on an organic basis) rose 6.7% on double-digit growth in Electrophysiology and Structural Heart.In Electrophysiology, growth was led by strong performance in cardiac mapping and ablation catheters. Within Structural Heart, growth was driven by several product areas across Abbott's broad portfolio, including AMPLATZERPFO Occluder and MitraClip.
Diabetes Care sales improved 28.3% (up 32.4% organically), buoyed consistent consumer uptake of FreeStyle Libre, the revolutionary continuous glucose monitoring system of Abbott.
Nutrition sales were down 0.4% year over year on a reported basis (up 3.6% on an organic basis) to $1.78 billion. Pediatric Nutrition sales increased 3.7% on an organic basis. Adult Nutrition sales were up 3.5% organically.
Diagnostics sales were up 2.9% year over year on a reported basis (up 7.4% on a comparable operational basis) to $1.96 billion. Core Laboratory Diagnostics sales grew 9.4% while Point of Care Diagnostics slipped 5.1%, on an organic basis. Molecular Diagnostics sales were up 3.8% banking on strong growth in the infectious disease testing business. Rapid Diagnostics recorded sales of $548 million, driven by solid contributions from cardiometabolic testing.
2019 Guidance
Abbott has initiated its 2019 guidance.
Adjusting for certain net specified items for the full year, adjusted earnings from continuing operations are expected in the band of $3.15-$3.25. The Zacks Consensus Estimate of $3.19 remains within this projected range. Organic sales growth is expected in the range of 6.5% -7.5%. The Zacks Consensensus Estimate for the top line is pegged at $32.03 billion.
The company has also provided first-quarter 2019 adjusted earnings per share outlook. It expects to report adjusted earnings from continuing operations in the range of 60-62 cents. The consensus mark of 66 cents falls outside the predicted range.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in fresh estimates. The consensus estimate has shifted -5.72% due to these changes.
VGM Scores
Currently, Abbott has a nice Growth Score of B, a grade with the same score on the momentum front. Charting a somewhat similar path, the stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Abbott has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | It has been about a month since the las t earnings report for Abbott (ABT). Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recen t earnings report in order to get a better handle on the important catalysts. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. It has been about a month since the las t earnings report for Abbott (ABT). Abbott Posts In Line Q4 Earnings, Provides '19 View Abbot t report ed fourth-quarter 2018 adjusted earnings from continuing operations of 81 cents per share, in line with the Zacks Consensus Estimate. | It has been about a month since the las t earnings report for Abbott (ABT). Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Posts In Line Q4 Earnings, Provides '19 View Abbot t report ed fourth-quarter 2018 adjusted earnings from continuing operations of 81 cents per share, in line with the Zacks Consensus Estimate. | It has been about a month since the las t earnings report for Abbott (ABT). Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Posts In Line Q4 Earnings, Provides '19 View Abbot t report ed fourth-quarter 2018 adjusted earnings from continuing operations of 81 cents per share, in line with the Zacks Consensus Estimate. |
33065.0 | 2019-02-21 00:00:00 UTC | Medidata's (MDSO) Margins Under Pressure, Competition Rife | ABT | https://www.nasdaq.com/articles/medidatas-mdso-margins-under-pressure-competition-rife-2019-02-21 | nan | nan | On Feb 19, we issued an updated research report on MedidataSolutions, Inc.MDSO . In the fourth quarter of 2018, the company's growth margins remained under pressure mainly due to the SHYFT buyout and associated purchase accounting implications. Additionally, its earnings per share declined in the same time frame. Adjusted earnings came in at 45 cents per share, which dropped by a penny from the year-ago quarter number.
Notably, expensive valuation, a complex cloud-based platform and stiff competition in the MedTech space are the major deterrents.
The stock currently carries a Zacks Rank #4 (Sell).
Factors Hurting Medidata's Performance
The market for clinical trial solutions is impacted by stiff competition, and changing technology and customer needs. Also, changes in laws and regulations, and frequent introductions of new products and services are concerning.
Further, Medidata has strong contenders like BioClinica, Inc., IQVIA (formerly QuintilesIMS), Oracle, Parexel Informatics, Veeva Systems, Inc. and other large-scale technology providers. It also competes with a number of vendors offering applications and systems namely ERT, CRF Health, Bracket, DataTrak International, Inc., Medrio, Inc., Merge Healthcare (an IBM Company), and OmniComm Systems, Inc.
In fact, Medidata stock looks a bit expensive at the moment. A comparative analysis of the company's forward P/E (TTM basis) ratio paints a drab picture, which might be a cause of concern for investors. The ratio is currently pegged at 78.95, significantly stretched when compared with the markets at large. The P/E (TTM) ratio of S&P 500 is 17.52 and the median level 19.50 over the past year.
Medidata also looks overvalued when compared with the broader industry's ratio of 48.32.
Price Performance
Shares of Medidata have gained 11.1% compared with the industry 's growth of 2.3% in a year's time. The current level is also higher than the S&P 500 index's increase of 3% over the same time frame.
Notably, a solid focus on cloud-based services and lucrative acquisitions are aiding Medidata's performance. In this regard, it is imperative to mention that the company expanded the use of Medidata Clinical Cloud in 2018 to automate operations, increase efficiencies, and gain better data visibility for accelerating their 2125 oncology development program. The Medidata Implementation Team ("MIT") will deploy the solution to seamlessly enhance and maximize value throughout the company.
Moreover, it had earlier added regulated content and document management capabilities to the Medidata Clinical Cloud, which is noteworthy.
Stocks to Consider
A few better-ranked stocks in the broader medical space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII .
Surmodics has a long-term expected earnings growth rate of 10%. The stock sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Abbott's long-term earnings growth rate is projected at 11.7%. The stock carries a Zacks Rank #2 (Buy).
Cardiovascular Systems exceeded the Zacks Consensus Estimate in each of the trailing four quarters, the average being 77.1%. The stock sports a Zacks Rank of 1.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 - 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Medidata Solutions, Inc. (MDSO): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report
Surmodics, Inc. (SRDX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks to Consider A few better-ranked stocks in the broader medical space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Click to get this free report Medidata Solutions, Inc. (MDSO): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report To read this article on Zacks.com click here. Factors Hurting Medidata's Performance The market for clinical trial solutions is impacted by stiff competition, and changing technology and customer needs. | Stocks to Consider A few better-ranked stocks in the broader medical space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Click to get this free report Medidata Solutions, Inc. (MDSO): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks to Consider A few better-ranked stocks in the broader medical space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Click to get this free report Medidata Solutions, Inc. (MDSO): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report To read this article on Zacks.com click here. Price Performance Shares of Medidata have gained 11.1% compared with the industry 's growth of 2.3% in a year's time. | Stocks to Consider A few better-ranked stocks in the broader medical space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Click to get this free report Medidata Solutions, Inc. (MDSO): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report To read this article on Zacks.com click here. Additionally, its earnings per share declined in the same time frame. |
33066.0 | 2019-02-21 00:00:00 UTC | Abbott (ABT) Dips More Than Broader Markets: What You Should Know | ABT | https://www.nasdaq.com/articles/abbott-abt-dips-more-than-broader-markets%3A-what-you-should-know-2019-02-21 | nan | nan | Abbott (ABT) closed the most recent trading day at $75.14, moving -0.53% from the previous trading session. This change lagged the S&P 500's daily loss of 0.35%. At the same time, the Dow lost 0.4%, and the tech-heavy Nasdaq lost 0.39%.
Prior to today's trading, shares of the maker of infant formula, medical devices and drugs had gained 8.05% over the past month. This has outpaced the Medical sector's gain of 3.02% and the S&P 500's gain of 4.48% in that time.
Wall Street will be looking for positivity from ABT as it approaches its nex t earnings report date. On that day, ABT is projected to report earnings of $0.61 per share, which would represent year-over-year growth of 3.39%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $7.48 billion, up 1.17% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $3.20 per share and revenue of $31.80 billion, which would represent changes of +11.11% and +4.01%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for ABT. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.42% higher within the past month. ABT currently has a Zacks Rank of #2 (Buy).
Investors should also note ABT's current valuation metrics, including its Forward P/E ratio of 23.61. This valuation marks a discount compared to its industry's average Forward P/E of 23.87.
Investors should also note that ABT has a PEG ratio of 2.01 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. Medical - Products stocks are, on average, holding a PEG ratio of 2.35 based on yesterday's closing prices.
The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 88, which puts it in the top 35% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow ABT in the coming trading sessions, be sure to utilize Zacks.com.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott (ABT) closed the most recent trading day at $75.14, moving -0.53% from the previous trading session. Wall Street will be looking for positivity from ABT as it approaches its nex t earnings report date. On that day, ABT is projected to report earnings of $0.61 per share, which would represent year-over-year growth of 3.39%. | Abbott (ABT) closed the most recent trading day at $75.14, moving -0.53% from the previous trading session. Wall Street will be looking for positivity from ABT as it approaches its nex t earnings report date. On that day, ABT is projected to report earnings of $0.61 per share, which would represent year-over-year growth of 3.39%. | Abbott (ABT) closed the most recent trading day at $75.14, moving -0.53% from the previous trading session. Wall Street will be looking for positivity from ABT as it approaches its nex t earnings report date. On that day, ABT is projected to report earnings of $0.61 per share, which would represent year-over-year growth of 3.39%. | Abbott (ABT) closed the most recent trading day at $75.14, moving -0.53% from the previous trading session. On that day, ABT is projected to report earnings of $0.61 per share, which would represent year-over-year growth of 3.39%. Wall Street will be looking for positivity from ABT as it approaches its nex t earnings report date. |
33067.0 | 2019-02-20 00:00:00 UTC | CVS Health's (CVS) Q4 Earnings Top Estimates, Margins Up | ABT | https://www.nasdaq.com/articles/cvs-healths-cvs-q4-earnings-top-estimates-margins-up-2019-02-20 | nan | nan | CVS Health Corporation 's CVS fourth-quarter 2018 adjusted earnings per share (EPS) of $2.14 surged 11.5% year over year and exceeded the Zacks Consensus Estimate by 3.4%. The quarter's adjusted EPS considered certain transaction and integration costs related to the recently-closed acquisition of Aetna and the purchase of Omnicare. It also adjusted certain goodwill impairment related to the LTC reporting unit.
On a reported basis, the company registered loss of 37 cents per share as compared to the year-ago EPS of $3.22.
Full-year adjusted EPS was $7.08, a 20% rise from the year-ago period. This also exceeded the Zacks Consensus Estimate of $6.98.
Net revenues in the fourth quarter increased 12.5% year over year to $54.42 billion. This surpassed the Zacks Consensus Estimate by 1.3%.
The company registered revenues of $194.58 billion in 2018, a 5.3% improvement from the year-ago period. This exceeds the Zacks Consensus Estimate of $193.13 billion.
Quarter in Details
Pharmacy Services revenues increased 2.2% to $34.09 billion in the reported quarter, driven by growth in total pharmacy claims volume. This was, however, partially offset by continued client price compression.
Total pharmacy claims processed increased 5.6% on a 30-day equivalent basis driven by net new business and the continued adoption of Maintenance Choice offerings.
CVS Health Corporation Price, Consensus and EPS Surprise
CVS Health Corporation Price, Consensus and EPS Surprise | CVS Health Corporation Quote
Revenues from CVS Health's Retail/LTC were up by 5.4% year over year to $22.03 billion. According to the company, the result was based on increased prescription volume and branded drug price inflation, partially offset by continued reimbursement pressure and the impact of recent generic introductions. Front store revenues increased in the reported quarter primarily banking on improvement in health product sales.
Total prescription volume grew 8.6% driven by the continued adoption of patient care programs and collaborations with PBMs as well as preferred status in a number of Medicare Part D networks during 2018.
LTC business in the quarter however, was facing industry wide challenges like lower occupancy rates in skilled nursing facilities, significant deterioration in the financial health of numerous skilled nursing facility customers which resulted in a number of customer bankruptcies in 2018. These have adversely affected the company's ability to grow the business at the rate that was originally estimated when the company acquired Omnicare.
Following the closing of CVS Health's acquisition of Aetna, the company has integrated Aetna's Health Care segment to its business and renamed it as Health Care Benefits segment. In the reported quarter, the company registered revenues of $5.55 billion within this segment.
Gross profit improved 67.1% to $13.9 billion. Accordingly, gross margin expanded 833 bps to 25.5%. Adjusted operating margin in the quarter expanded 597 bps to 13.3%.
Outlook
CVS Health has provided its 2019 guidance.
Adjusted EPS is expected in the band of $6.68 to $6.88. The Zacks Consensus Estimate for earnings is pegged at $7.38 per share, outside the company's guided range. This apart, its 2019 adjusted operating profit guidance remains in the range $14.8 billion to $15.2 billion.
Further, the company expects cash flow from operations in the band of $9.8 billion to $10.3 billion.
Our Take
CVS Health ended the year 2018 on promising note with fourth-quarter earnings and revenues both ahead of the respective Zacks Consensus Estimate. The year-over-year growth in the top line was driven by a strong Pharmacy Services segment, benefiting from the upside in the specialty services. The company's recently introduced Health Care Benefits segment following the Aetna acquisition holds immense promise.
Also, strong year-over-year Retail/LTC comparisons were encouraging. However, the LTC business is facing industry-wide challenges. The EPS projection for the full-year 2019 currently looks lackluster.
Zacks Rank & Key Picks
CVS Health currently carries a Zacks Rank #3 (Hold).
A few better-ranked medical stocks are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Abbot t report ed fourth-quarter 2018 adjusted EPS of 81 cents, in line with the Zacks Consensus Estimate. Revenues of $7.77 billion were below the Zacks Consensus Estimate of $7.79 billion. The stock has a Zacks Rank #2 (Buy).
AngioDynamics' fiscal second-quarter adjusted EPS of 22 cents exceeded the Zacks Consensus Estimate by a penny. Revenues totaled $91.5 million, beating the consensus estimate by 2.9%. The stock sports a Zacks Rank #1.
CONMED delivered fourth-quarter adjusted EPS of 73 cents, in line with the Zacks Consensus Estimate. Revenues of $242.4 million beat the Zacks Consensus Estimate of $229.2 million. The stock carries a Zacks Rank of 2.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?
Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.
See Latest Stocks Today >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
AngioDynamics, Inc. (ANGO): Free Stock Analysis Report
CONMED Corporation (CNMD): Free Stock Analysis Report
CVS Health Corporation (CVS): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A few better-ranked medical stocks are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report CONMED Corporation (CNMD): Free Stock Analysis Report CVS Health Corporation (CVS): Free Stock Analysis Report To read this article on Zacks.com click here. Total pharmacy claims processed increased 5.6% on a 30-day equivalent basis driven by net new business and the continued adoption of Maintenance Choice offerings. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report CONMED Corporation (CNMD): Free Stock Analysis Report CVS Health Corporation (CVS): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked medical stocks are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . CVS Health Corporation 's CVS fourth-quarter 2018 adjusted earnings per share (EPS) of $2.14 surged 11.5% year over year and exceeded the Zacks Consensus Estimate by 3.4%. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report CONMED Corporation (CNMD): Free Stock Analysis Report CVS Health Corporation (CVS): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked medical stocks are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . CVS Health Corporation 's CVS fourth-quarter 2018 adjusted earnings per share (EPS) of $2.14 surged 11.5% year over year and exceeded the Zacks Consensus Estimate by 3.4%. | A few better-ranked medical stocks are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report CONMED Corporation (CNMD): Free Stock Analysis Report CVS Health Corporation (CVS): Free Stock Analysis Report To read this article on Zacks.com click here. CVS Health Corporation 's CVS fourth-quarter 2018 adjusted earnings per share (EPS) of $2.14 surged 11.5% year over year and exceeded the Zacks Consensus Estimate by 3.4%. |
33068.0 | 2019-02-20 00:00:00 UTC | Notable ETF Outflow Detected - IYH, ABT, MDT, ABBV | ABT | https://www.nasdaq.com/articles/notable-etf-outflow-detected-iyh-abt-mdt-abbv-2019-02-20 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Healthcare ETF (Symbol: IYH) where we have detected an approximate $68.2 million dollar outflow -- that's a 2.7% decrease week over week (from 12,800,000 to 12,450,000). Among the largest underlying components of IYH, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.4%, Medtronic PLC (Symbol: MDT) is up about 0.1%, and AbbVie Inc (Symbol: ABBV) is lower by about 1.4%. For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year price performance of IYH, versus its 200 day moving average:
Looking at the chart above, IYH's low point in its 52 week range is $166.89 per share, with $204.83 as the 52 week high point - that compares with a last trade of $194.19. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IYH, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.4%, Medtronic PLC (Symbol: MDT) is up about 0.1%, and AbbVie Inc (Symbol: ABBV) is lower by about 1.4%. For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year price performance of IYH, versus its 200 day moving average: Looking at the chart above, IYH's low point in its 52 week range is $166.89 per share, with $204.83 as the 52 week high point - that compares with a last trade of $194.19. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IYH, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.4%, Medtronic PLC (Symbol: MDT) is up about 0.1%, and AbbVie Inc (Symbol: ABBV) is lower by about 1.4%. For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year price performance of IYH, versus its 200 day moving average: Looking at the chart above, IYH's low point in its 52 week range is $166.89 per share, with $204.83 as the 52 week high point - that compares with a last trade of $194.19. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of IYH, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.4%, Medtronic PLC (Symbol: MDT) is up about 0.1%, and AbbVie Inc (Symbol: ABBV) is lower by about 1.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Healthcare ETF (Symbol: IYH) where we have detected an approximate $68.2 million dollar outflow -- that's a 2.7% decrease week over week (from 12,800,000 to 12,450,000). For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year price performance of IYH, versus its 200 day moving average: Looking at the chart above, IYH's low point in its 52 week range is $166.89 per share, with $204.83 as the 52 week high point - that compares with a last trade of $194.19. | Among the largest underlying components of IYH, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.4%, Medtronic PLC (Symbol: MDT) is up about 0.1%, and AbbVie Inc (Symbol: ABBV) is lower by about 1.4%. For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year price performance of IYH, versus its 200 day moving average: Looking at the chart above, IYH's low point in its 52 week range is $166.89 per share, with $204.83 as the 52 week high point - that compares with a last trade of $194.19. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). |
33069.0 | 2019-02-20 00:00:00 UTC | Intuitive Surgical Gets FDA Nod for Ion Endoluminal System | ABT | https://www.nasdaq.com/articles/intuitive-surgical-gets-fda-nod-for-ion-endoluminal-system-2019-02-20 | nan | nan | Intuitive Surgical, Inc. ISRG announced that the U.S. FDA has granted 501(k) clearance for the Ion endoluminal system to enable minimally invasive biopsy in the peripheral lung. The company plans a limited rollout of the platform in the United States, with customer shipments to commence during the second quarter of 2019.
About Ion
Ion is a new robotic endoluminal platform in development for peripheral lung biopsy. The system features an ultra-thin, ultra-maneuverable catheter that allows navigation far into the peripheral lung. Moreover, its unprecedented stability enables the precision needed for biopsy.
Apart from lung nodule biopsy, Ion integrates existing imaging technology including fluoroscopy, radial-endobronchial ultrasound, and cone-beam CT.
Market Prospects
The Ion platform represents Intuitive Surgical's solid focus on minimally invasive care. Per Mordor Intelligence, the global minimally invasive devices market is expected to multiply at a CAGR of nearly 8% during the 2018-2023 time frame. Apart from Intuitive Surgical, Abbot Laboratories ABT and Medtronic MDT are the other key players in this space.
The latest development also provides Intuitive Surgical a favorable exposure in the peripheral lung biopsy markets. Per GlobeNewswire, Lung Cancer Diagnostics market size is projected to reach a worth of $3.64 billion by 2024. Notably, the market is consolidated in nature. In 2018, Qiagen N.V. QGEN - a global player in the niche space - received the FDA approval to expand the usage of EGFR test in lung cancer.
A Plethora of Regulatory Approvals
Favorable tidings on the regulatory front have always favored Intuitive Surgical. Of the latest ones, the company submitted 510(k) for the second indication of TransOral Robotic Surgery. It is also working through supply chain optimization as Intuitive Surgical begins to ramp up production for SP.
Further, a suite of regulatory approvals for the Vessel Sealer Extend - the da Vinci SP Surgical System - and the Sure Form 60 buoys optimism.
Intuitive Surgical gained significantly on the CE Mark approval for da Vinci X in Europe. The stock has got a further boost from the recent FDA approval of the same.
Price Performance
Intuitive Surgical outperformed its industry in a year's time. The Zacks Rank #3 (Hold) company has gained 40%, comparing favorably with the industry's 9.9% growth. The current level is also higher than the S&P 500's decline of 6.1% over the same time frame. You can see the complete list of today's Zacks #1 (Strong Buy) Rank stocks here .
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?
Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.
See Latest Stocks Today >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
Medtronic PLC (MDT): Free Stock Analysis Report
QIAGEN N.V. (QGEN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Apart from Intuitive Surgical, Abbot Laboratories ABT and Medtronic MDT are the other key players in this space. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report QIAGEN N.V. (QGEN): Free Stock Analysis Report To read this article on Zacks.com click here. Intuitive Surgical, Inc. ISRG announced that the U.S. FDA has granted 501(k) clearance for the Ion endoluminal system to enable minimally invasive biopsy in the peripheral lung. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report QIAGEN N.V. (QGEN): Free Stock Analysis Report To read this article on Zacks.com click here. Apart from Intuitive Surgical, Abbot Laboratories ABT and Medtronic MDT are the other key players in this space. Intuitive Surgical, Inc. ISRG announced that the U.S. FDA has granted 501(k) clearance for the Ion endoluminal system to enable minimally invasive biopsy in the peripheral lung. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report QIAGEN N.V. (QGEN): Free Stock Analysis Report To read this article on Zacks.com click here. Apart from Intuitive Surgical, Abbot Laboratories ABT and Medtronic MDT are the other key players in this space. Apart from lung nodule biopsy, Ion integrates existing imaging technology including fluoroscopy, radial-endobronchial ultrasound, and cone-beam CT. Market Prospects The Ion platform represents Intuitive Surgical's solid focus on minimally invasive care. | Apart from Intuitive Surgical, Abbot Laboratories ABT and Medtronic MDT are the other key players in this space. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report QIAGEN N.V. (QGEN): Free Stock Analysis Report To read this article on Zacks.com click here. Intuitive Surgical, Inc. ISRG announced that the U.S. FDA has granted 501(k) clearance for the Ion endoluminal system to enable minimally invasive biopsy in the peripheral lung. |
33070.0 | 2019-02-19 00:00:00 UTC | Medtronic (MDT) Beats on Q3 Earnings, Gross Margin Down | ABT | https://www.nasdaq.com/articles/medtronic-mdt-beats-on-q3-earnings-gross-margin-down-2019-02-19 | nan | nan | Medtronic plc MDT reported third-quarter fiscal 2019 adjusted earnings per share (EPS) of $1.29, beating the Zacks Consensus Estimate by 4%. Adjusted earnings rose 10.3% year over year.
Adjustments in the quarter primarily included the impact of restructuring charges, intangible asset amortization and impairment of in-process research and development (IPR&D) assets among others. After adjusting for foreign exchange tailwind of 2 cent, adjusted EPS increased 8.5% year over year.
Without the adjustments, ne t earnings were 94 cents per share, compared with loss of $1.03 in the year-ago quarter.
Total Revenues
Worldwide revenues in the reported quarter grossed $7.55 billion, up 4.4% on an organic basis (up 2.4% on a reported basis). The top line missed the Zacks Consensus Estimate by 0.13%. Organic revenues in the quarter include adjustments for a $149-million negative impact from foreign currency.
Medtronic PLC Price, Consensus and EPS Surprise
Medtronic PLC Price, Consensus and EPS Surprise | Medtronic PLC Quote
In the quarter under review, U.S. sales (53% of total revenues) increased 2.3% year over year on a reported basis to $4 billion. Non-U.S. developed market revenues totaled $2.37 billion (31% of total revenues), reflecting a 0.6% increase reportedly (up 3.6% on a constant currency basis). Emerging market revenues (16% of total revenues) amounted to $1.18 billion, up 6.8% reportedly (up 13.9% on a constant currency basis).
Segment Details
The company currently generates revenues from four major groups, viz. Cardiac and Vascular Group (CVG), Minimally Invasive Therapies Group (MITG), Restorative Therapies Group (RTG) and Diabetes Group.
CVG comprises Cardiac Rhythm & Heart Failure (CRHF), Coronary & Structural Heart (CSH) and Aortic & Peripheral Vascular divisions (APV). MITG includes the Surgical Innovations (SI) and the Respiratory, Gastrointestinal & Renal (RGR) divisions. RTG comprises the Spine, Brain Therapies, Specialty Therapies and Pain Therapies segments, while the Diabetes Group incorporates the Intensive Insulin Management (IIM), Non-Intensive Diabetes Therapies (NDT), and Diabetes Service & Solutions (DSS) divisions.
CVG revenues improved 1.6% at constant exchange rate or CER (down 0.5% as reported) to $2.79 billion, driven by mid-single digit growth in CSH and APV offset by low-single digit drop in CRHF, all at CER.
CRHF sales totaled $1.39 billion, down 2.3% year over year at CER (down 4.1% as reported). The mid-single digits growth in Arrhythmia Managementwas offset by mid-teens declines in Heart Failure, including mid-forties declines in sales of left ventricular assist devices.
CSH revenues were up 5.9% at CER (up 3% as reported) to $913 million driven by mid-teens constant currency growth in transcatheter aortic valves as a result of strong global uptake of the CoreValve Evolut PRO platform. The company reported flat year-over-year coronary sales in the reported quarter as the mid-teens growth in guide catheters and low-double digit growth in coronary balloons were offset by mid-single digit declines in drug-eluting stents.
APV revenues registered 6.1% growth at CER (up 4.2% as reported) to $476 million, driven by mid-teens growth in Venous, mid-teens growth of in drug-coated balloon (DCB) and high-single digit growth in thoracic stent graft systems, all at comparable CER basis.
In MITG, worldwide sales totaled $2.12 billion, marking a 6.6% year-over-year increase at CER (up 4.1% on a reported basis) on high-single-digit growth in RGRand mid-single digit growth in SI.
In RTG, worldwide revenues of $2.03 billion were up 5.5% year over year at CER (up 4.2% as reported) on low-double-digit growth in Brain Therapies, mid-single-digit growth in pain therapies, low-single-digit growth in Specialty Therapies and flat performance in the Spine business.
Moreover, revenues at the Diabetes group increased 6.5% at CER (up 4.5% as reported) to $610 million.
Margins
Gross margin in the reported quarter contracted 24 basis points (bps) to 69.9% on a 3.2% rise in cost of revenues to $2.27 billion. Adjusted operating margin improved 73 bps year over year to 27.4% despite a 0.4% rise in research and development expenses (to $561 million) and a 2.9% uptick in selling, general and administrative expenses (to $2.59 billion). Other expenses in the reported quarter totaled $57 million as compared with $128 million a year ago.
Guidance Revised
The company has updated its fiscal 2019 revenue guidance.
For the full year, organic revenue growth expectations have been narrowed to the range of 5.25-5.5% from the previous range of 5.0-5.5%. Currency fluctuation is now expected to negatively impact the top line by $425-$475 million (previous guidance range was $420-$520 million). The current Zacks Consensus Estimate for revenues is pegged at $30.53 billion.
Fiscal 2019 adjusted EPS view is raised at the range of $5.14-$5.16 from the earlier-announced range of $5.10-$5.15. Currency fluctuation is expected to havea modestly positive impact on the full-year adjusted EPS. The Zacks Consensus Estimate of $5.12 falls below the guided range.
Our Take
Medtronic exited third-quarter fiscal 2019 on a mixed note. While i t report ed a better-than-expected earnings performance, revenues missed the mark. The company has demonstrated improved performances at CER banking on growth in most of the business segments and all geographies. This highlighted sustainability across groups and regions, in addition to displaying successful integration and achievement of synergy targets. Apart from product innovation, the company is focusing on geographical diversification of its businesses.
However, we are concerned about the company's sluggish CRHF performance. This apart, costs continue to escalate putting pressure on margins.
Zacks Rank & Peer Performances
Medtronic has a Zacks Rank #3 (Hold).
A few better-ranked medical stocks are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Abbott reported fourth-quarter 2018 adjusted EPS of 81 cents, in line with the Zacks Consensus Estimate. Revenues of $7.77 billion were below the Zacks Consensus Estimate of $7.79 billion. The stock has a Zacks Rank #2 (Buy).
AngioDynamics' fiscal second-quarter adjusted EPS of 22 cents exceeded the Zacks Consensus Estimate by a penny. Revenues totaled $91.5 million, beating the consensus estimate by 2.9%. The stock sports a Zacks Rank #1.
CONMED delivered fourth-quarter adjusted EPS of 73 cents, in line with the Zacks Consensus Estimate. Revenues of $242.4 million beat the Zacks Consensus Estimate of $229.2 million. The stock carries a Zacks Rank of 2.
Is Your Investment Advisor Fumbling Your Financial Future?
See how you can more effectively safeguard your retirement with a new Special Report, "4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future."
Click to get it free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
AngioDynamics, Inc. (ANGO): Free Stock Analysis Report
Medtronic PLC (MDT): Free Stock Analysis Report
CONMED Corporation (CNMD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A few better-ranked medical stocks are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here. Medtronic plc MDT reported third-quarter fiscal 2019 adjusted earnings per share (EPS) of $1.29, beating the Zacks Consensus Estimate by 4%. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked medical stocks are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . Medtronic PLC Price, Consensus and EPS Surprise Medtronic PLC Price, Consensus and EPS Surprise | Medtronic PLC Quote In the quarter under review, U.S. sales (53% of total revenues) increased 2.3% year over year on a reported basis to $4 billion. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked medical stocks are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . Medtronic PLC Price, Consensus and EPS Surprise Medtronic PLC Price, Consensus and EPS Surprise | Medtronic PLC Quote In the quarter under review, U.S. sales (53% of total revenues) increased 2.3% year over year on a reported basis to $4 billion. | A few better-ranked medical stocks are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here. Medtronic plc MDT reported third-quarter fiscal 2019 adjusted earnings per share (EPS) of $1.29, beating the Zacks Consensus Estimate by 4%. |
33071.0 | 2019-02-19 00:00:00 UTC | Here's Why Investors Should Buy Surmodics (SRDX) Stock Now | ABT | https://www.nasdaq.com/articles/heres-why-investors-should-buy-surmodics-srdx-stock-now-2019-02-19 | nan | nan | Surmodics, Inc.SRDX is one of the top players in the MedTech space. The company's impressive performance in first-quarter fiscal 2019 and consistent focus on Research and Development (R&D) are working in favor of the stock.
In a year's time, this Zacks Rank #1 (Strong Buy) stock has skyrocketed 106.9% compared with the industry's 5.9% growth. The current level is also significantly higher than the S&P 500's 1.6% increase.
What's Favoring Surmodics?
Surmodics' solid efforts to improve its research and development stature have been a key growth driver. Also, the company's whole product solutions pipeline and sirolimus-based below-the-knee DCB program deserve a mention here.
Meanwhile, Surmodics has been making progress using its internally developed .014 balloon platform. The company has also been working through the preclinical studies for the data package that will be used to determine the readiness for first-in-human clinical trial. It is expected to make continued progress throughout the remainder of fiscal 2019.
Furthermore, the company has made dramatic progress in developing its AV fistula drug-coated balloon. In the non-drug delivery R&D pipeline, Surmodics also got the FDA clearance for its Telemark support microcatheter.
In first-quarter fiscal 2019, R&D expenses shot up 46.7% year over year. Considering the company's strength in the R&D prospects, Surmodics has long-term goals of generating double-digit top-line growth by the end of calendar 2019.
Markedly, Surmodics' performance continues to be driven by its In Vitro Diagnostics (IVD) unit. For over 35 years, the segment has been a leader in developing an ELISA/EIA, immunoblot/western blot, line assay or microarray. In the first quarter of fiscal 2019, sales at IVD increased 17.6%, reflecting strong sales growth of clinical components used in diagnostic tests and microarray slides slide. Operating income at the segment registered a robust growth of 47% from the year-ago quarter's level.
Which Way Are Estimates Treading?
The Zacks Consensus Estimate for fiscal 2019 revenues is pegged at $96.7 million, reflecting an 18.9% growth. The same for adjusted earnings is pinned at 15 cents, indicating a year-over-year decline of 69.4%.
Other Key Picks
Some other top-ranked stocks in the broader medical space are Wright Medical Group N.V. WMGI , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII .
Wright Medical has a long-term expected earnings growth rate of 11%. The stock sports a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Abbott's long-term earnings growth rate is projected at 11.7%. The stock carries a Zacks Rank #2.
Cardiovascular Systems exceeded the Zacks Consensus Estimate in each of the trailing four quarters, the average being 77.1%. The stock sports a Zacks Rank of 1.
Is Your Investment Advisor Fumbling Your Financial Future?
See how you can more effectively safeguard your retirement with a new Special Report, "4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future."
Click to get it free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Surmodics, Inc. (SRDX): Free Stock Analysis Report
Wright Medical Group N.V. (WMGI): Free Stock Analysis Report
Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Other Key Picks Some other top-ranked stocks in the broader medical space are Wright Medical Group N.V. WMGI , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report Wright Medical Group N.V. (WMGI): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report To read this article on Zacks.com click here. The company's impressive performance in first-quarter fiscal 2019 and consistent focus on Research and Development (R&D) are working in favor of the stock. | Other Key Picks Some other top-ranked stocks in the broader medical space are Wright Medical Group N.V. WMGI , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report Wright Medical Group N.V. (WMGI): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report To read this article on Zacks.com click here. In the first quarter of fiscal 2019, sales at IVD increased 17.6%, reflecting strong sales growth of clinical components used in diagnostic tests and microarray slides slide. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report Wright Medical Group N.V. (WMGI): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report To read this article on Zacks.com click here. Other Key Picks Some other top-ranked stocks in the broader medical space are Wright Medical Group N.V. WMGI , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . The company's impressive performance in first-quarter fiscal 2019 and consistent focus on Research and Development (R&D) are working in favor of the stock. | Other Key Picks Some other top-ranked stocks in the broader medical space are Wright Medical Group N.V. WMGI , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report Wright Medical Group N.V. (WMGI): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report To read this article on Zacks.com click here. The company's impressive performance in first-quarter fiscal 2019 and consistent focus on Research and Development (R&D) are working in favor of the stock. |
33072.0 | 2019-02-19 00:00:00 UTC | Align Technology Unveils iTero Element 5D Imaging System | ABT | https://www.nasdaq.com/articles/align-technology-unveils-itero-element-5d-imaging-system-2019-02-19 | nan | nan | Expanding the iTero suite, Align Technology, Inc.ALGN recently announced the launch of its first intraoral scanner with near-infrared imaging (NIRI) technology - iTero Element 5D Imaging System. The company is planning to display the complete range of iTero products, including the iTero Element 5D Imaging System, at the 38th International Dental Show in Cologne Germany.
Per management, the iTero Element 5D Imaging System featuring integrated 3D, intra-oral color and NIRI technology helps in discovering and monitoring interproximal caries lesions above the gingiva without applying harmful radiation and provides doctors with solid visualization capacities.
The system has been made commercially available in Canada, European Union countries acknowledging CE mark (excluding Greece), Switzerland, Norway, Australia, New Zealand, Hong Kong and Thailand. However, the iTero Element 5D Imaging System is currently not available in the United States or Latin America.
Market Potential
Per a Research And Markets report, the global 3D dental scanner market is expected to see a CAGR of 10.2% in the 2017-2021 period. The latest developments will help Align Technology cash in on the opportunities.
iTero Portfolio in Focus
Align Technology has been focusing on expanding work flow options of its leading iTero scanners. The company has begun manufacturing the iTero Element intraoral scanner in China post-receipt of Certificate of Medical Device Registration and Certificate of Production from the China Food and Drug Administration. Align Technology is sees rising Scanner and Services business sales globally, including Italy, Japan and China.
The company is also gaining from the adoption of the iTero platform by dental service organizations or DSO partners.
We are also upbeat about the company's expansion of the iTero Element portfolio with the launch of iTero Element 2 and iTero Element Flex scanners in the United States and majority of European countries, including France, Germany, Italy, Spain, and the United Kingdom.
Align Technology received encouraging response for its new Invisalign Go product with an improved user-interface in iTero digital chairside experience and increased flexibility for treating a variety of mild to moderate cases.
Share Price Movement
Over the past three months, Align Technology's share price has outperformed its industry . The stock has gained 24.7% compared with the industry's 5.8% rise.
Zacks Rank & Key Picks
Align Technology currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space include Penumbra, Inc. PEN , Amedisys, Inc. AMED and Abbott Laboratories ABT .
Penumbra's long-term earnings growth rate is expected at 20%. The stock carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Amedisys' long-term earnings growth rate is projected at 18.8%. The stock carries a Zacks Rank #1.
Abbott's long-term earnings growth rate is expected at 11.7%. The stock carries a Zacks Rank of 2.
Is Your Investment Advisor Fumbling Your Financial Future?
See how you can more effectively safeguard your retirement with a new Special Report, "4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future."
Click to get it free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Penumbra, Inc. (PEN): Free Stock Analysis Report
Amedisys, Inc. (AMED): Free Stock Analysis Report
Align Technology, Inc. (ALGN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | PEN , Amedisys, Inc. AMED and Abbott Laboratories ABT . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Penumbra, Inc. (PEN): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. Per management, the iTero Element 5D Imaging System featuring integrated 3D, intra-oral color and NIRI technology helps in discovering and monitoring interproximal caries lesions above the gingiva without applying harmful radiation and provides doctors with solid visualization capacities. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Penumbra, Inc. (PEN): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. PEN , Amedisys, Inc. AMED and Abbott Laboratories ABT . Expanding the iTero suite, Align Technology, Inc.ALGN recently announced the launch of its first intraoral scanner with near-infrared imaging (NIRI) technology - iTero Element 5D Imaging System. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Penumbra, Inc. (PEN): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. PEN , Amedisys, Inc. AMED and Abbott Laboratories ABT . Expanding the iTero suite, Align Technology, Inc.ALGN recently announced the launch of its first intraoral scanner with near-infrared imaging (NIRI) technology - iTero Element 5D Imaging System. | PEN , Amedisys, Inc. AMED and Abbott Laboratories ABT . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Penumbra, Inc. (PEN): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report Align Technology, Inc. (ALGN): Free Stock Analysis Report To read this article on Zacks.com click here. Expanding the iTero suite, Align Technology, Inc.ALGN recently announced the launch of its first intraoral scanner with near-infrared imaging (NIRI) technology - iTero Element 5D Imaging System. |
33073.0 | 2019-02-18 00:00:00 UTC | Cryolife (CRY) Earnings Miss, Revenues Top Estimates in Q4 | ABT | https://www.nasdaq.com/articles/cryolife-cry-earnings-miss-revenues-top-estimates-in-q4-2019-02-18 | nan | nan | CryoLife, Inc . CRY reported fourth-quarter 2018 adjusted earnings per share (EPS) of 5 cents, down 64.3% year over year. This figure missed the Zacks Consensus Estimate by 58.33%.
On a reported basis, the company saw loss of 5 cents a share, narrower than the year-ago loss of 9 cents.
For the full year, adjusted EPS came in at 26 cents, down 45.8% from a year ago. This figure missed the Zacks Consensus Estimate by 21.2%.
CryoLife raked in total revenues of $67.8 million in the quarter under review, up 28.4% from the year-ago period. This figure also beat the Zacks Consensus Estimate by 1.2%. The upside was driven by significant increase in sales of some key products like JOTEC, On-X and tissue processing.
For the full year, total revenues came in at $262.8 million, marking an increase of 38.5% from the year-ago period. This figure surpassed the Zacks Consensus Estimate by 0.7%.
Geographic and Segmental Details
The company reported revenues from domestic and international markets. From the domestic market, i.e. the United States, the company earned total revenues of $36.5 million, showing an increase of 5.5% from the year-ago quarter. From international markets, the company earned $31.3 million, a remarkable rise of 71.9% year over year.
CryoLife, Inc. Price, Consensus and EPS Surprise
CryoLife, Inc. Price, Consensus and EPS Surprise | CryoLife, Inc. Quote
Cryolife's operations are divided into two major categories, products and preservation services. Within the product category, Bioglue and Biofoam revenues totaled $17.9 million, up a meager 0.6% from the year-ago quarter. JOTEC revenues grossed $16.7 million, a stupendous rise of 307.3% year over year. On-X raked in $11.3 million, up 14.1%. Cardio-Genesis Cardiac Laser Therapy earned $1.7 million, down 1.7%. PerClot revenues were $0.95 million, reflecting an increase of 6.7% from the year-ago quarter. PhotoFix earned $0.69 million, up 35.2%.
In the preservation services category, cardiac tissue revenues totaled $9 million, marking an increase of 4.7% from the year-ago quarter. Revenues for the vascular tissue segment came in at $9.4 million, up 3.3%.
Margin details
In the quarter under review, gross profit grew 24.3% year over year to $45.2 million. However, gross margin contracted 218 basis points to 66.7%.
General, administrative, and marketing expenses rose 17.9% year over year to $35.6 million. Research and development expenses increased 6.6% from the year-ago quarter to $6.8 million. In the fourth quarter of 2018, Cryolife reported an operating profit of $2.8 million against operating loss of $0.20 million in the year-ago quarter.
Guidance for 2019
Cryolife has provided a financial guidance for 2019. Total revenues at the end of 2019 were projected in the range of $280-$284 million. The Zacks Consensus Estimate for full-year revenues is pegged at $282.8 million, within the guidance. Adjusted EPS for 2019 is estimated by Cryolife in the band of 28-32 cents. The Zacks Consensus Estimate for the same is 48 cents, much above the high end of the guided range.
Our take
Cryolife exited 2019 on a mixed note. Fourth-quarter EPS figure declined year over year due to increasing expenses from the product pipeline and investment in global expansion. On a positive note, both fourth quarter and year-end revenues surged significantly from the year-ago figures. Revenues from both domestic and international markets rose as well. The company witnessed year-over-year growth in revenues across majority of its operating segments. The company expects to deliver high revenue growth over the next five years banking on its JOTEC and On-X products. Cryolife plans to continue investing in research and development in order to expand its product portfolio.
Zacks Rank & Key Picks
Cryolife has a Zacks Rank #3 (Hold). A few better-ranked medical stocks are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Abbot t report ed fourth-quarter 2018 adjusted EPS of 81 cents, in line with the Zacks Consensus Estimate. Revenues of $7.77 billion were below the Zacks Consensus Estimate of $7.79 billion. The stock has a Zacks Rank #2 (Buy).
AngioDynamics' fiscal second-quarter adjusted EPS of 22 cents exceeded the Zacks Consensus Estimate by a penny. Revenues totaled $91.5 million, beating the consensus estimate by 2.9%. The stock sports a Zacks Rank #1.
CONMED delivered fourth-quarter adjusted EPS of 73 cents, in line with the Zacks Consensus Estimate. Revenues of $242.4 million beat the Zacks Consensus Estimate of $229.2 million. The stock carries a Zacks Rank of 2.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
AngioDynamics, Inc. (ANGO): Free Stock Analysis Report
CryoLife, Inc. (CRY): Free Stock Analysis Report
CONMED Corporation (CNMD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A few better-ranked medical stocks are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report CryoLife, Inc. (CRY): Free Stock Analysis Report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here. From the domestic market, i.e. the United States, the company earned total revenues of $36.5 million, showing an increase of 5.5% from the year-ago quarter. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report CryoLife, Inc. (CRY): Free Stock Analysis Report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked medical stocks are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . CryoLife, Inc. Price, Consensus and EPS Surprise CryoLife, Inc. Price, Consensus and EPS Surprise | CryoLife, Inc. Quote Cryolife's operations are divided into two major categories, products and preservation services. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report CryoLife, Inc. (CRY): Free Stock Analysis Report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked medical stocks are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . CryoLife, Inc. Price, Consensus and EPS Surprise CryoLife, Inc. Price, Consensus and EPS Surprise | CryoLife, Inc. Quote Cryolife's operations are divided into two major categories, products and preservation services. | A few better-ranked medical stocks are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report CryoLife, Inc. (CRY): Free Stock Analysis Report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here. From the domestic market, i.e. the United States, the company earned total revenues of $36.5 million, showing an increase of 5.5% from the year-ago quarter. |
33074.0 | 2019-02-15 00:00:00 UTC | Here's Why You Must Buy Cardiovascular Systems' (CSII) Stock | ABT | https://www.nasdaq.com/articles/heres-why-you-must-buy-cardiovascular-systems-csii-stock-2019-02-15 | nan | nan | Cardiovascular Systems, Inc.CSII has been gaining investor confidence on continued positive results. The company's share price has outperformed its industry over the past year. The stock has gained 46.9% in comparison to the industry's 4.2% rise and the S&P 500's 0.9% increase in the said period.
This leading medical device manufacturer, which develops and commercializes innovative solutions to treat patients suffering from peripheral and coronary arterial diseases, including those with arterial calcium, has a market cap of $1.18 billion.
With solid prospects, this Zacks Rank #2 (Buy) stock is an attractive pick for investors at the moment.
What's Working in Favor of the Stock?
Focus on International Business
Cardiovascular Systems has been firing on all cylinders of late to expand its geographical presence. The company is progressing well with its objective to introduce Orbital Atherectomy System (OAS) globally. In this regard, management is upbeat about entering into an extended partnership agreement with OrbusNeich under which OrbusNeich will distribute Cardiovascular Systems' coronary and peripheralOASs in multiple countries in Europe and Southeast Asia, outside the United States and Japan.
Moreover, the fiscal second-quarter global peripheral revenues included around $800,000 from the international distribution agreement with OrbusNeich as the company continued the launch in Asia, the Middle East and Europe. Notably, Cardiovascular Systems has earned $1.6 million in revenues in the quarter, led by strength in Japan.
Impressive Portfolio Expansion
Cardiovascular Systems has long been expanding its product portfolio to enhance market reach and versatility. Currently, the company is pursuing product improvement and evaluating technologies to strengthen and broaden its portfolio of powerful micro invasive tools. Cardiovascular Systems plans to launch more than 20 products in the next five years.
The company expects product launches to contribute to at least 10% of its core business growth in the second half of the year. These launches include the Teleport microcatheter, the coronary ViperWire Advance FlexTip, consistent expansion of the peripheral radial device along with the new ViperCath Radial Exchange Catheter and ViperWire FlexTip launches in the fiscal third quarter. The company is also planning the launch of peripheral exchangeable with GlideAssist later in fiscal 2019.
Market Dynamics
Currently, Cardiovascular Systems firmly stands to gain from several favorable trends existing in the peripheral artery disease (PAD) as well coronary artery disease (CAD) market spaces. According to estimates delivered by the American Heart Association (AHA), as many as eight to 12 million Americans suffer from PAD). Moreover, an aging population, coupled with increasing incidence of diabetes and obesity, is likely to propel the prevalence of PAD. Meanwhile, according to AHA estimates, 15.4 million people in the United States suffer from CAD.
Other Key Picks
Other top-ranked stocks in the broader medical space include Penumbra, Inc. PEN , Amedisys, Inc. AMED and Abbott Laboratories ABT .
Penumbra's long-term earnings growth rate is expected at 20%. The stock carries a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Amedisys' long-term earnings growth rate is projected at 18.8%. The stock carries a Zacks Rank #1.
Abbott's long-term earnings growth rate is expected at 11.7%. The stock carries a Zacks Rank of 2.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, wouldn't you like to know about our 10 finest buy-and-holds for the year?
From more than 4,000 companies covered by the Zacks Rank, these 10 were picked by a process that consistently beats the market. Even during 2018 while the market dropped -5.2%, our Top 10s were up well into double-digits. And during bullish 2012 - 2017, they soared far above the market's +126.3%, reaching +181.9%.
This year, the portfolio features a player that thrives on volatility, an AI comer, and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs.
See Stocks Today >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Penumbra, Inc. (PEN): Free Stock Analysis Report
Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report
Amedisys, Inc. (AMED): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | PEN , Amedisys, Inc. AMED and Abbott Laboratories ABT . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Penumbra, Inc. (PEN): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. Moreover, the fiscal second-quarter global peripheral revenues included around $800,000 from the international distribution agreement with OrbusNeich as the company continued the launch in Asia, the Middle East and Europe. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Penumbra, Inc. (PEN): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. PEN , Amedisys, Inc. AMED and Abbott Laboratories ABT . Moreover, the fiscal second-quarter global peripheral revenues included around $800,000 from the international distribution agreement with OrbusNeich as the company continued the launch in Asia, the Middle East and Europe. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Penumbra, Inc. (PEN): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. PEN , Amedisys, Inc. AMED and Abbott Laboratories ABT . Market Dynamics Currently, Cardiovascular Systems firmly stands to gain from several favorable trends existing in the peripheral artery disease (PAD) as well coronary artery disease (CAD) market spaces. | PEN , Amedisys, Inc. AMED and Abbott Laboratories ABT . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Penumbra, Inc. (PEN): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. Impressive Portfolio Expansion Cardiovascular Systems has long been expanding its product portfolio to enhance market reach and versatility. |
33075.0 | 2019-02-14 00:00:00 UTC | Baxter's Acute Therapies Profile Strong, Competition Rife | ABT | https://www.nasdaq.com/articles/baxters-acute-therapies-profile-strong-competition-rife-2019-02-14 | nan | nan | On Feb 13, we issued an updated research report on Baxter International Inc.BAX . While solid Acute Therapies profile is a positive, generic competition for Cyclophosphamide and lackluster sales in a few sub-segments are key concerns.
The stock currently carries a Zacks Rank #3 (Hold).
Solid Acute Therapies Profile
Baxter's performance in Acute Therapies has been consistently driven by improving utilization for CRRT globally and increased demand for multi-organ support products. In Acute Therapies, Baxter launched the first 3-in-1 oXIRIS set for continuous renal replacement therapy and sepsis management protocols. This adds to Baxter's multi-organ therapy offering, utilizing the Prismaflex system.
For the Acute Therapies business, Baxter expects approximately 7-8% growth on a year-over-year basis in 2019.
In fourth-quarter 2018, net revenues at the Acute Therapies business totaled $137 million, representing 12% growth on a constant-currency basis. Increased global demand for Baxter's continuous renal replacement therapieshelped the business to perform exceedingly well.
This apart, management at Baxter expects an upward trend across most of its segments in 2019. Also, it expects acquisitions to be accretive. Renal Care is expected to witness 2-3% growth. In Medication Delivery, management at Baxter expects sales to increase approximately 6%.
Moving to Clinical Nutrition, Baxter expects sales growth of approximately 3%. In the Advanced Surgery business, the company anticipates sales to increase 3-4% on a constant-currency basis.
Generic Competition for Cyclophosphamide
Cyclophosphamide is a part of Baxter's Hospital Products segment. Over the last five years, cyclophosphamide has been displaying disappointing performance for the most part. Lower cyclophosphamide sales pose threats to the Integrated Pharmacy Solutions franchise business.
Despite a promising portfolio, the company has failed to grab market share and substantially boost its top line due to generic competition for cyclophosphamide.
For 2019, Baxter expects U.S cyclophosphamide sales of approximately $95 million compared with $166 million registered in 2018.
Price Performance
In a year's time, shares of Baxter have gained 10.1% comparing favorably with the industry 's 6.5% growth. The current level also compares favorably with the S&P 500 index's decline of 6.9% over the same time frame.
Key Picks
A few better-ranked stocks in the broader medical space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII .
Surmodics has a long-term expected earnings growth rate of 10%. The stock sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Abbott's long-term earnings growth rate is projected at 11.7%. The stock carries a Zacks Rank #2 (Buy).
Cardiovascular Systems exceeded the Zacks Consensus Estimate in the trailing four quarters, the average being 77.1%. The stock sports a Zacks Rank of 1.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Baxter International Inc. (BAX): Free Stock Analysis Report
Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report
Surmodics, Inc. (SRDX): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Key Picks A few better-ranked stocks in the broader medical space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Baxter International Inc. (BAX): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report To read this article on Zacks.com click here. Despite a promising portfolio, the company has failed to grab market share and substantially boost its top line due to generic competition for cyclophosphamide. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Baxter International Inc. (BAX): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report To read this article on Zacks.com click here. Key Picks A few better-ranked stocks in the broader medical space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Solid Acute Therapies Profile Baxter's performance in Acute Therapies has been consistently driven by improving utilization for CRRT globally and increased demand for multi-organ support products. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Baxter International Inc. (BAX): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report To read this article on Zacks.com click here. Key Picks A few better-ranked stocks in the broader medical space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Solid Acute Therapies Profile Baxter's performance in Acute Therapies has been consistently driven by improving utilization for CRRT globally and increased demand for multi-organ support products. | Key Picks A few better-ranked stocks in the broader medical space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Baxter International Inc. (BAX): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report To read this article on Zacks.com click here. In Acute Therapies, Baxter launched the first 3-in-1 oXIRIS set for continuous renal replacement therapy and sepsis management protocols. |
33076.0 | 2019-02-14 00:00:00 UTC | Bio-Techne (TECH) Q2 Earnings Beat, Gross Margin Declines | ABT | https://www.nasdaq.com/articles/bio-techne-tech-q2-earnings-beat-gross-margin-declines-2019-02-14 | nan | nan | Bio-Techne CorporationTECH reported second-quarter fiscal 2019 adjusted earnings per share (EPS) of $1.06, up 3.9% from the year-ago quarter. This figure surpassed the Zacks Consensus Estimate by 6%.
Reported EPS in the quarter under review was 45 cents, down 65.1% year over year.
Net sales in the quarter rose 13.2% (up 11% organically) year over year to $174.5 million. This figure beat the Zacks Consensus Estimate by 2.6%.
Revenues saw a 3% contribution from acquisitions. However, foreign currency translation had a 1% adverse impact.
Revenues by Geography
United States reported revenues in the low teens during the reported quarter. Growth within Europe was in the high single digits (organically). China registered robust performance with growth of more than 30% from the year-ago quarter. For the rest of Asia, organic growth was in the mid-teens led by solid contributions from South Korea and India.
Segment Details
The company has two key operating divisions, viz. Protein Sciences & Diagnostics and Genomics.
Bio-Techne Corp Price, Consensus and EPS Surprise
Bio-Techne Corp Price, Consensus and EPS Surprise | Bio-Techne Corp Quote
In the reported quarter, Protein Sciences saw 15.7% growth from the prior-year quarter (up 14% organically) to $135.5 million. The upside was primarily driven by double-digit growth in most consumable and instrument product categories.
The Diagnostics and Genomics segment's net sales came in at $39.3 million, up 5.9% (up 2% organically) from the year-ago quarter.
By end market, biopharma growth was 10% and academic sales growth was in the mid-single digits.
Margin Details
Gross profit in the second quarter increased 10.9% year over year to $113.1 million. However, gross profit margin contracted 130 basis points (bps) from the year-ago quarter to 64.8% on a 17.5% rise in cost of sales.
Selling, general and administrative expenses (SG&A) dropped a slight 0.3 % year over year to $63.6 million. Research & development (R&D) expenses totaled $15.8 million, up 13.7% from the year-ago quarter. Operating profit witnessed year-over-year growth of 39.2% to $33.6 million. Operating margin expanded 359 bps from the year-ago period to 19.3%.
According to the company, volume leverage and operational productivity contributed to the Protein Sciences segment's operating margin in the quarter. Meanwhile, within Diagnostics and Genomics, operating margin was impacted by the recent acquisition of ExosomeDx.
Balance Sheet
Bio-Techne exited the second quarter of fiscal 2019 with cash and cash equivalents and short-term investment of $156.5 million, down from $163.7 million at the end of first quarter of fiscal 2019. The company had total long-term debt of $545.4 million at the end of second quarter of fiscal 2019, compared with $561.4 million at the end of the first quarter of fiscal 2019.
Our Take
Bio-Techne exited the second quarter of fiscal 2019 on a promising note. The company reported robust top-line growth in its operating segments and geographic locations.
On a positive note, consumer demand for the reagent and instrument products has been consistently rising in emerging markets. The brands of Bio-Techne continue to garner high demand in both the end markets. We are optimistic about the company's ability to continue on its growth trajectory.
Zacks Rank & Key Picks
Bio-Techne currently has a Zacks Rank #3 (Hold). A few better-ranked medical stocks are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD .
Abbot t report ed fourth-quarter 2018 adjusted EPS of 81 cents, in line with the Zacks Consensus Estimate. Revenues of $7.77 billion were below the Zacks Consensus Estimate of $7.79 billion. The stock has a Zacks Rank #2 (Buy).
AngioDynamics' fiscal second-quarter adjusted EPS of 22 cents exceeded the Zacks Consensus Estimate by a penny. Revenues totaled $91.5 million, beating the consensus estimate by 2.9%. The stock sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
CONMED delivered fourth-quarter adjusted EPS of 73 cents, in line with the Zacks Consensus Estimate. Revenues of $242.4 million beat the Zacks Consensus Estimate of $229.2 million. The stock carries a Zacks Rank of 2.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
AngioDynamics, Inc. (ANGO): Free Stock Analysis Report
Bio-Techne Corp (TECH): Free Stock Analysis Report
CONMED Corporation (CNMD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A few better-ranked medical stocks are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report Bio-Techne Corp (TECH): Free Stock Analysis Report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here. Bio-Techne CorporationTECH reported second-quarter fiscal 2019 adjusted earnings per share (EPS) of $1.06, up 3.9% from the year-ago quarter. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report Bio-Techne Corp (TECH): Free Stock Analysis Report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked medical stocks are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . Bio-Techne Corp Price, Consensus and EPS Surprise Bio-Techne Corp Price, Consensus and EPS Surprise | Bio-Techne Corp Quote In the reported quarter, Protein Sciences saw 15.7% growth from the prior-year quarter (up 14% organically) to $135.5 million. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report Bio-Techne Corp (TECH): Free Stock Analysis Report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked medical stocks are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . Bio-Techne Corp Price, Consensus and EPS Surprise Bio-Techne Corp Price, Consensus and EPS Surprise | Bio-Techne Corp Quote In the reported quarter, Protein Sciences saw 15.7% growth from the prior-year quarter (up 14% organically) to $135.5 million. | A few better-ranked medical stocks are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report Bio-Techne Corp (TECH): Free Stock Analysis Report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here. Bio-Techne CorporationTECH reported second-quarter fiscal 2019 adjusted earnings per share (EPS) of $1.06, up 3.9% from the year-ago quarter. |
33077.0 | 2019-02-14 00:00:00 UTC | Johnson & Johnson (JNJ) to Acquire Auris Health for $3.4B | ABT | https://www.nasdaq.com/articles/johnson-johnson-jnj-to-acquire-auris-health-for-%243.4b-2019-02-14 | nan | nan | Johnson & Johnson 's JNJ robotic surgery and medical device division, Ethicon entered into a definitive agreement to acquire Auris Health, Inc., a developer of robotic technologies focused on lung cancer, for approximately $3.4 billion in cash. If certain milestones are achieved, Auris could also receive as much as $2.35 billion more from the deal. The transaction is expected to close by the end of the second quarter of 2019, subject to customary closing conditions.
J&J's stock has gained 6.5% in the past year compared with growth of 9.9% recorded by the industry.
With this acquisition, J&J will gain access to robotics along with potential for growth and expansion into other interventional applications. According to J&J, Auris's technology will help the former develop a digital solution addressing different parts of patients' lung-cancer treatment. Auris developed the Monarch Platform, a medical device that can help physicians access nodules in patients' lungs to diagnose and target treatments.
Upon completion of the deal, Frederic Moll, M.D., CEO and Founder of Auris Health, and a visionary in the field of surgical robotics, will be joining J&J.
J&J will continue to make investments to make the surgical experience better by connecting digital solutions. In this endeavor, Auris's technology will support J&J's vision of becoming a world leader across the continuum of surgical approaches, including open, laparoscopic, robotic and endoluminal.
J&J previously forayed into surgical robotics by forming Verb Surgical, a joint venture with Alphabet's Verily unit, in 2015. Last year, J&J acquired Orthotaxy, a privately held developer of robotic-assisted surgery software.
J&J struck several deals, which should boost the top line. In June 2017, J&J acquired Swiss biotech Actelion for $30 billion, which diversified its revenues in the pulmonary arterial hypertension (PAH) category and will bolster long-term growth. In February 2017, J&J acquired Abbott's ABT vision care business, Abbott Medical Optics for $4.325 billion, which has strengthened the former's Medical Device segment.
Johnson & Johnson Price
Johnson & Johnson Price | Johnson & Johnson Quote
Zacks Rank and Stocks to Consider
J&J currently has a Zacks Rank #3 (Hold).
Some better-ranked stocks from the same space are GlaxoSmithKline GSK and Bristol-Myers Squibb BMY . While GlaxoSmithKline sports a Zacks Rank #1 (Strong Buy), Bristol-Myers carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
GlaxoSmithKline's earnings per share estimates have increased from $2.86 to $2.95 for 2019 and from $2.94 to $3.01 for 2020 in the past 60 days. The company delivered a positive earnings surprise in two of the trailing four quarters, with average of 3.74%.
Bristol-Myers'earnings per share estimates have increased from $4.07 to $4.16 for 2019 in the past 60 days. The company delivered a positive earnings surprise in all the trailing four quarters, with average of 14.26%.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research. It's not the one you think.
See This Ticker Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report
GlaxoSmithKline plc (GSK): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In February 2017, J&J acquired Abbott's ABT vision care business, Abbott Medical Optics for $4.325 billion, which has strengthened the former's Medical Device segment. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Auris developed the Monarch Platform, a medical device that can help physicians access nodules in patients' lungs to diagnose and target treatments. | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. In February 2017, J&J acquired Abbott's ABT vision care business, Abbott Medical Optics for $4.325 billion, which has strengthened the former's Medical Device segment. Johnson & Johnson 's JNJ robotic surgery and medical device division, Ethicon entered into a definitive agreement to acquire Auris Health, Inc., a developer of robotic technologies focused on lung cancer, for approximately $3.4 billion in cash. | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. In February 2017, J&J acquired Abbott's ABT vision care business, Abbott Medical Optics for $4.325 billion, which has strengthened the former's Medical Device segment. Johnson & Johnson 's JNJ robotic surgery and medical device division, Ethicon entered into a definitive agreement to acquire Auris Health, Inc., a developer of robotic technologies focused on lung cancer, for approximately $3.4 billion in cash. | In February 2017, J&J acquired Abbott's ABT vision care business, Abbott Medical Optics for $4.325 billion, which has strengthened the former's Medical Device segment. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Johnson & Johnson 's JNJ robotic surgery and medical device division, Ethicon entered into a definitive agreement to acquire Auris Health, Inc., a developer of robotic technologies focused on lung cancer, for approximately $3.4 billion in cash. |
33078.0 | 2019-02-13 00:00:00 UTC | Boston Scientific Benefits From New Buyouts & Product Launch | ABT | https://www.nasdaq.com/articles/boston-scientific-benefits-from-new-buyouts-product-launch-2019-02-13 | nan | nan | On Feb 12, we issued an updated research report on Boston Scientific CorporationBSX . The company's recent acquisitions have added various products (though many are under development) with immense potential to its portfolio. The stock carries a Zacks Rank #3 (Hold).
Over the past three months, shares of Boston Scientific have outperformed the industry it belongs to. The stock has gained 6.1% compared with with the 1% rise of its industry.
Boston Scientific delivered a solid fourth quarter with both earnings and revenues surpassing the respective Zacks Consensus Estimate. Growth across all business lines and geographies was promising. The company is leaving no stone unturned to strengthen its core businesses and invest in new technologies and global market s. We are also optimistic about the receipt of an FDA approval for its SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System with 4.50 mm and 5 mm diameter. The company also got an FDA nod for its Vercise Primary Cell and Vercise Gevia Deep Brain Stimulation (DBS) Systems. It is currently preparing for the upcoming U.S. launch of VICI VENOUS STENT, which will be the first on label VENOUS STENT in the said market.
Boston Scientific Corporation Price
Boston Scientific Corporation Price | Boston Scientific Corporation Quote
As major developments, the company closed the acquisition of Millipede and entered into an agreement to buy BTG plc. With the completion of BTG buyout, the company expects to gain an enhanced category leadership position in interventional oncology, arterial and venous therapies. Meanwhile, Millipede is likely to leverage its position in the growing field of mitral regurgitation (MR) falling under the structural heart business.
We are also looking forward to the company's recently-concluded acquisitions, which are NxThera, Claret Medical, VENITI and Augmenix. These are projected to strongly enhance the company's inorganic growth profile going forward.
Moreover, the company's significant progress related to its LOTUS valve relaunch encourages us. Also, post the suspension of Lotus valve in Europe, ACURATE TAVR valve platform continues to build momentum. The company announced that it will begin a limited release of LOTUS Edge TAVR platform during March in Europe. The company hopes to initiate a controlled launch of the same in early second-quarter 2019 across the United States following the FDA approval. The company also noted that it began enrolling patients in the LOTUS REPRISE IV study in intermediate risk.
On the flip side, an unfavorable currency movement and product recall were major dampeners during the reported quarter. Strong competitors in the large medical device market also pose a tough challenge to Boston Scientific.
Key Picks
Some better-ranked stocks in the broader medical space are Penumbra, Inc. PEN , Amedisys, Inc. AMED and Abbott Laboratories ABT .
Penumbra's long-term earnings growth rate is expected at 20%. The stock carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Amedisys' long-term earnings growth rate is projected at 18.8%. The stock has a Zacks Rank of 2.
Abbott's long-term earnings growth rate is estimated at 11.7%. The company is a Zacks #2 Ranked player.
3 Medical Stocks to Buy Now
The greatest discovery in this century of biology is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating revenue, and cures for a variety of deadly diseases are in the pipeline.
So are big potential profits for early investors. Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it.
See them today for free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Penumbra, Inc. (PEN): Get Free Report
Boston Scientific Corporation (BSX): Free Stock Analysis Report
Amedisys, Inc. (AMED): Get Free Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | PEN , Amedisys, Inc. AMED and Abbott Laboratories ABT . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Penumbra, Inc. (PEN): Get Free Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Amedisys, Inc. (AMED): Get Free Report To read this article on Zacks.com click here. Boston Scientific delivered a solid fourth quarter with both earnings and revenues surpassing the respective Zacks Consensus Estimate. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Penumbra, Inc. (PEN): Get Free Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Amedisys, Inc. (AMED): Get Free Report To read this article on Zacks.com click here. PEN , Amedisys, Inc. AMED and Abbott Laboratories ABT . Boston Scientific Corporation Price Boston Scientific Corporation Price | Boston Scientific Corporation Quote As major developments, the company closed the acquisition of Millipede and entered into an agreement to buy BTG plc. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Penumbra, Inc. (PEN): Get Free Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Amedisys, Inc. (AMED): Get Free Report To read this article on Zacks.com click here. PEN , Amedisys, Inc. AMED and Abbott Laboratories ABT . The company is leaving no stone unturned to strengthen its core businesses and invest in new technologies and global market s. We are also optimistic about the receipt of an FDA approval for its SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System with 4.50 mm and 5 mm diameter. | PEN , Amedisys, Inc. AMED and Abbott Laboratories ABT . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Penumbra, Inc. (PEN): Get Free Report Boston Scientific Corporation (BSX): Free Stock Analysis Report Amedisys, Inc. (AMED): Get Free Report To read this article on Zacks.com click here. On Feb 12, we issued an updated research report on Boston Scientific CorporationBSX . |
33079.0 | 2019-02-13 00:00:00 UTC | Here's Why Investors Should Retain AmerisourceBergen Stock | ABT | https://www.nasdaq.com/articles/heres-why-investors-should-retain-amerisourcebergen-stock-2019-02-13 | nan | nan | AmerisourceBergen CorporationABC is expected to benefit from its first-quarter fiscal 2019 results and a strong Pharmaceutical Distribution unit. However, sluggishness in the MWI unit might hurt prospects.
Price Performance
In a year's time, shares of this Zacks Rank #3 (Hold) company have lost 11% compared with the industry 's 4.4% decline. The current level also compares unfavorably with the S&P 500 index's 0.6% decrease. Sluggishness in the MWI unit and an intensely competitive industry negatively impacted the company's prospects.
Let's take a quick look at AmerisourceBergen's major headwinds and discuss the factors that ensure near-term recovery.
Why Should You Retain the Stock?
AmerisourceBergen's Pharmaceutical Distribution segment serves healthcare providers in the pharmaceutical supply channel. At this unit, the company has been witnessing solid revenue growth for the last couple of quarters. Markedly, Pharmaceutical Distribution rides on increasing volume and an expanding customer base. Strong organic growth rates in the U.S. pharmaceutical market, improving patient access to medical care, improved economic conditions and population demographics should benefit the segment in the quarters to come.
In the first quarter of fiscal 2019, revenues at this segment totaled $43.74 billion, which increased 12.3% on a year-over-year basis. However, segmental operating income of $373.2 million declined 3.9% year over year. Meanwhile, the company's Specialty Distribution franchise of oncology and physician administered products continues to perform exceptionally well.
We are also optimistic about the deals signed by AmerisourceBergen, which should boost its top line. By the end of first-quarter fiscal 2019, management at AmerisourceBergen announced that it currently partners with Good Neighbor Pharmacy Network, Walgreens and others on safe drug disposal programs.
MWI Slows Down
MWI unit's revenues remained flat in the first quarter of fiscal 2019. Per management, the metric was negatively impacted by certain issues. From an operating income standpoint, MWI's operating income of $99 million decreased about 1% year over year. MWI experienced pressure relating to rebates as well. Moving ahead, the company's operating income growth rate is expected to improve with consistently strong customer relationships and commercial partnerships.
These apart, AmerisourceBergen's Memphis facility (PharMEDium) is not likely reopen in this fiscal year.
For fiscal 2019, adjusted earnings per share are expected in the range of $6.65-$6.85, lower than the previous guidance of $6.65-$6.95. Also, adjusted operating income growth is expected in the low-single-digit percent range. Pharmaceutical Distribution segment's operating income growth is too projected to be the low-single-digit percent range.
Which Way are Estimates Trending?
The Zacks Consensus Estimate for second-quarter earnings is pegged at $1.98, up 2.1% year over year. The same for revenues stands at $43.7 billion, mirroring a 6.4% improvement year over year.
For fiscal 2019, the Zacks Consensus Estimate for earnings is pinned at $6.75, up 4% year over year. The same for revenues is pegged at $180.2 billion, reflecting a 7.3% improvement year over year.
AmerisourceBergen Corporation Price and Consensus
AmerisourceBergen Corporation Price and Consensus | AmerisourceBergen Corporation Quote
Key Picks
A few better-ranked stocks in the broader medical space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII .
Surmodics has a long-term expected earnings growth rate of 10%. The stock sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Abbott's long-term earnings growth rate is projected at 11.7%. The stock carries a Zacks Rank #2 (Buy).
Cardiovascular Systems exceeded the Zacks Consensus Estimate in the trailing four quarters, the average being 77.1%. The stock sports a Zacks Rank of 1.
3 Medical Stocks to Buy Now
The greatest discovery in this century of biology is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating revenue, and cures for a variety of deadly diseases are in the pipeline.
So are big potential profits for early investors. Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it.
See them today for free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report
Surmodics, Inc. (SRDX): Free Stock Analysis Report
AmerisourceBergen Corporation (ABC): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AmerisourceBergen Corporation Price and Consensus AmerisourceBergen Corporation Price and Consensus | AmerisourceBergen Corporation Quote Key Picks A few better-ranked stocks in the broader medical space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report AmerisourceBergen Corporation (ABC): Free Stock Analysis Report To read this article on Zacks.com click here. Price Performance In a year's time, shares of this Zacks Rank #3 (Hold) company have lost 11% compared with the industry 's 4.4% decline. | AmerisourceBergen Corporation Price and Consensus AmerisourceBergen Corporation Price and Consensus | AmerisourceBergen Corporation Quote Key Picks A few better-ranked stocks in the broader medical space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report AmerisourceBergen Corporation (ABC): Free Stock Analysis Report To read this article on Zacks.com click here. Pharmaceutical Distribution segment's operating income growth is too projected to be the low-single-digit percent range. | AmerisourceBergen Corporation Price and Consensus AmerisourceBergen Corporation Price and Consensus | AmerisourceBergen Corporation Quote Key Picks A few better-ranked stocks in the broader medical space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report AmerisourceBergen Corporation (ABC): Free Stock Analysis Report To read this article on Zacks.com click here. From an operating income standpoint, MWI's operating income of $99 million decreased about 1% year over year. | AmerisourceBergen Corporation Price and Consensus AmerisourceBergen Corporation Price and Consensus | AmerisourceBergen Corporation Quote Key Picks A few better-ranked stocks in the broader medical space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report AmerisourceBergen Corporation (ABC): Free Stock Analysis Report To read this article on Zacks.com click here. AmerisourceBergen CorporationABC is expected to benefit from its first-quarter fiscal 2019 results and a strong Pharmaceutical Distribution unit. |
33080.0 | 2019-02-13 00:00:00 UTC | Edwards Lifesciences to Buy CASMED to Boost Critical Care Arm | ABT | https://www.nasdaq.com/articles/edwards-lifesciences-to-buy-casmed-to-boost-critical-care-arm-2019-02-13 | nan | nan | Edwards Lifesciences CorporationEW entered an agreement to purchase CAS Medical Systems, Inc. ("CASMED") for an equity value of around $100 million in an all-cash transaction. Notably, CASMED is a leading medical technology company involved in non-invasive monitoring of tissue oxygenation in the brain. Subject to customary closing conditions, the transaction is expected to be completed in the second quarter of 2019.
Per Edwards Lifesciences, integration of CASMED's FORE-SIGHT technology with its hemodynamic monitoring platform, along with the company's predictive analytic capability, will strengthen Edwards Lifesciences' position in smart monitoring technologies. We believe that the buyout is likely to boost top-line contributions from the Critical Care arm.
However, Edwards Lifesciences is awaiting a 510(k) clearance in the United States for a smart cable and software module that allows for compatibility between CASMED's FORE-SIGHT sensor and the HemoSphere hemodynamic monitoring platform. Notably, this technology was already granted a CE mark in Europe.
Market Potential
Per a report by Market Research Hub, North America holds a large share in the global brain tissue oxygen monitoring systems market, and is backed by rising demands for neurosurgery, advanced healthcare facilities and dominance of major players. The brain tissue oxygen monitoring systems market is also expected to witness improved performances in the Asia Pacific, and the Middle East and Africa regions. Given bountiful opportunities in the niche market, the buyout decision seems to be fit.
A Glimpse of the Critical Care Arm
Critical Care portfolio includes pulmonary artery catheters, disposable pressure transducers and advanced monitoring systems. The portfolio also includes a line of balloon catheter-based products, surgical clips and inserts.
Critical Care sales totaled $178.1 million in the fourth quarter of 2018, up 8.4% year over year. The upside can be attributed to solid growth across all product categories, primarily led by HemoSphere advanced monitoring platform and consistent strength in Enhanced Recovery. Moreover, the company continued to deliver impressive performance in the United States.
Furthermore, in the last December, Edwards Lifesciences announced that the HemoSphere advanced hemodynamic monitoring platform received FDA approval for the Acumen suite of intelligent decision-support solutions.
Share Price Movement
Edwards Lifesciences has been gaining investor confidence on consistently positive results. Over a year, the company's share price has outperformed its industry . The stock soared 36.4% compared with the industry's 9.9% rally.
Zacks Rank & Stocks to Consider
Edwards Lifesciences currently carries a Zacks Rank #3 (Hold). A few better-ranked stocks in the broader medical space are Penumbra, Inc. PEN , Amedisys, Inc. AMED and Abbott Laboratories ABT .
Penumbra's long-term earnings growth rate is expected at 20%. The stock presently carries a Zacks Rank #2 (Buy).
Amedisys' long-term earnings growth rate is projected at 18.8%. The stock currently carries a Zacks Rank #1 (Strong Buy).You can see the complete list of today's Zacks #1 Rank stocks here .
Abbott's long-term earnings growth rate is expected at 11.7%. The stock presently carries a Zacks Rank of 2.
3 Medical Stocks to Buy Now
The greatest discovery in this century of biology is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating revenue, and cures for a variety of deadly diseases are in the pipeline.
So are big potential profits for early investors. Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it.
See them today for free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Penumbra, Inc. (PEN): Get Free Report
Edwards Lifesciences Corporation (EW): Free Stock Analysis Report
Amedisys, Inc. (AMED): Get Free Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | PEN , Amedisys, Inc. AMED and Abbott Laboratories ABT . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Penumbra, Inc. (PEN): Get Free Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Amedisys, Inc. (AMED): Get Free Report To read this article on Zacks.com click here. However, Edwards Lifesciences is awaiting a 510(k) clearance in the United States for a smart cable and software module that allows for compatibility between CASMED's FORE-SIGHT sensor and the HemoSphere hemodynamic monitoring platform. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Penumbra, Inc. (PEN): Get Free Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Amedisys, Inc. (AMED): Get Free Report To read this article on Zacks.com click here. PEN , Amedisys, Inc. AMED and Abbott Laboratories ABT . Market Potential Per a report by Market Research Hub, North America holds a large share in the global brain tissue oxygen monitoring systems market, and is backed by rising demands for neurosurgery, advanced healthcare facilities and dominance of major players. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Penumbra, Inc. (PEN): Get Free Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Amedisys, Inc. (AMED): Get Free Report To read this article on Zacks.com click here. PEN , Amedisys, Inc. AMED and Abbott Laboratories ABT . Per Edwards Lifesciences, integration of CASMED's FORE-SIGHT technology with its hemodynamic monitoring platform, along with the company's predictive analytic capability, will strengthen Edwards Lifesciences' position in smart monitoring technologies. | PEN , Amedisys, Inc. AMED and Abbott Laboratories ABT . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Penumbra, Inc. (PEN): Get Free Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report Amedisys, Inc. (AMED): Get Free Report To read this article on Zacks.com click here. Per Edwards Lifesciences, integration of CASMED's FORE-SIGHT technology with its hemodynamic monitoring platform, along with the company's predictive analytic capability, will strengthen Edwards Lifesciences' position in smart monitoring technologies. |
33081.0 | 2019-02-12 00:00:00 UTC | Here's Why You Should Buy IDEXX Laboratories (IDXX) Stock | ABT | https://www.nasdaq.com/articles/heres-why-you-should-buy-idexx-laboratories-idxx-stock-2019-02-12 | nan | nan | IDEXX Laboratories, Inc.IDXX has been gaining investor confidence on continued positive results. Over the past year, the company's share price has outperformed its industry . The stock has gained 18% in comparison with the industry's 11% rise and the S&P 500's 2.1% increase.
This leading developer, manufacturer and distributer of products and services, primarily for the companion animal veterinary, livestock and poultry, water testing and dairy markets, has a market cap of $17.91 billion. The company has an expected earnings growth rate of 18.8% for the next three to five years.
With solid prospects, this Zacks Rank #2 (Buy) stock is an attractive pick for investors at the moment.
What's Working in Favor of the Stock?
Solid Quarterly Performance
IDEXX exited the fourth quarter on a promising note. Solid year-over year growth in organic revenues and a raised earnings guidance for 2019 are encouraging. The top line in the quarter was driven by strong sales at the CAG business. The company witnessed strong gains in CAG Diagnostics recurring revenue and global premium instrument installed base in the quarter.
Strong International Performance
IDEXX continues to demonstrate solid growth globally with strong international expansion. International revenues in the fourth quarter of 2018 were up 7.7% organically, driven by 12.5% organic gains in CAG Diagnostics recurring revenues. This reflected continued consumable revenue gains supported by reference lab growth. This apart, international Catalyst placements at newer competitive accounts increased 29% year over year in the quarter, accounting for 48% of total international Catalyst placements. Further, there was solid double-digit worldwide gain in economic value index.
CAG Continues to Perform Well
IDEXX derives the lion's share of its revenues from its Companion Animal Group segment. In the fourth quarter, CAG revenues rose 13% organically year over year, supported by strong CAG Diagnostics recurring organic revenue growth, high premium CAG instrument placements and continued solid growth in software, services and diagnostic imaging system businesses.
The U.S. CAG Diagnostic recurring revenues increased 13.3% organically, driven by mid-teen growth in consumables and reference lab sales and solid growth in rapid assay revenues. The international CAG Diagnostic recurring revenues increased 12.5% organically in the fourth quarter driven by 20%-plus organic growth in international consumable revenues.
Other Key Picks
Other top-ranked stocks in the broader medical space include Penumbra, Inc. PEN , Amedisys, Inc. AMED and Abbott Laboratories ABT .
Penumbra's long-term earnings growth rate is expected at 20%. The stock carries a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Amedisys' long-term earnings growth rate is projected at 18.8%. The stock carries a Zacks Rank #2.
Abbott's long-term earnings growth rate is expected at 11.7%. The stock carries a Zacks Rank of 2.
Zacks' Best Stock-Picking Strategy
It's hard to believe, even for us at Zacks. But from 2000-2018, while the market gained +4.8% per year, our top stock-picking strategy averaged +54.3% per year.
How has that screen done lately? From 2017-2018, it sextupled the market's +15.8% gain with a soaring +98.3% return.
Free - See the Stocks It Turned Up for Today >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Penumbra, Inc. (PEN): Get Free Report
IDEXX Laboratories, Inc. (IDXX): Get Free Report
Amedisys, Inc. (AMED): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | PEN , Amedisys, Inc. AMED and Abbott Laboratories ABT . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Penumbra, Inc. (PEN): Get Free Report IDEXX Laboratories, Inc. (IDXX): Get Free Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. Solid year-over year growth in organic revenues and a raised earnings guidance for 2019 are encouraging. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Penumbra, Inc. (PEN): Get Free Report IDEXX Laboratories, Inc. (IDXX): Get Free Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. PEN , Amedisys, Inc. AMED and Abbott Laboratories ABT . In the fourth quarter, CAG revenues rose 13% organically year over year, supported by strong CAG Diagnostics recurring organic revenue growth, high premium CAG instrument placements and continued solid growth in software, services and diagnostic imaging system businesses. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Penumbra, Inc. (PEN): Get Free Report IDEXX Laboratories, Inc. (IDXX): Get Free Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. PEN , Amedisys, Inc. AMED and Abbott Laboratories ABT . In the fourth quarter, CAG revenues rose 13% organically year over year, supported by strong CAG Diagnostics recurring organic revenue growth, high premium CAG instrument placements and continued solid growth in software, services and diagnostic imaging system businesses. | PEN , Amedisys, Inc. AMED and Abbott Laboratories ABT . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Penumbra, Inc. (PEN): Get Free Report IDEXX Laboratories, Inc. (IDXX): Get Free Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. In the fourth quarter, CAG revenues rose 13% organically year over year, supported by strong CAG Diagnostics recurring organic revenue growth, high premium CAG instrument placements and continued solid growth in software, services and diagnostic imaging system businesses. |
33082.0 | 2019-02-12 00:00:00 UTC | STERIS (STE) Q3 Earnings In Line, Revenues Beat Estimates | ABT | https://www.nasdaq.com/articles/steris-ste-q3-earnings-in-line-revenues-beat-estimates-2019-02-12 | nan | nan | STERIS plc STE reported third-quarter fiscal 2019 adjusted earnings per share (EPS) of $1.26, up 12.5% year over year. The metric is in line with the Zacks Consensus Estimate. Reported EPS came in at 56 cents, down from the year-ago $1.11.
Revenues of $696.2 million in the fiscal third quarter rose 5.2% year over year. Revenues also topped the Zacks Consensus Estimate by 1.2%.
Quarter in Detail
Organic revenue growth at constant currency was 7% year over year in the fiscal third quarter, mainly driven by growth across all segments.
The company operates through four segments: Healthcare Products, Healthcare Specialty Services, Applied Sterilization Technologies and Life Sciences.
STERIS plc Price, Consensus and EPS Surprise
STERIS plc Price, Consensus and EPS Surprise | STERIS plc Quote
Revenues at Healthcare Products increased 4% year over year to $338.3 million (up 7% on a constant currency organic basis). In the quarter under review, service revenues grew 4% and capital equipment revenues rose 7%. Meanwhile, consumable revenues grew 1% on divestitures limiting growth.
Revenues at the Healthcare Specialty Services segment were up 9% to $127.8 million (up 10% on a constant currency organic basis).
Revenues at Applied Sterilization Technologies rose 6% to $136.8 million (up 8%) backed by increased demand from core medical device customers.
Revenues at Life Sciences segment rose 3% to $93.5 million (up 4%) on 9% growth in consumable revenues along with a 5% rise in service revenues. However, capital equipment revenues declined 8% year over year.
Margins
Adjusted gross margin (after excluding cost of revenues for restructuring) expanded 50 basis points (bps) year over year to 42.5% in the reported quarter.
STERIS witnessed a 10.3% year-over-year rise in selling, general and administrative expenses to $176.1 million. Research and development expenses declined 0.2% to $15.2 million. However, adjusted operating margin contracted 190 bps on a year-over-year basis to 13.7% in the reported quarter.
Financial Details
STERIS exited third-quarter fiscal 2019 with cash and cash equivalents of $224.9 million compared with $209.9 million at the end of second-quarter fiscal 2019. The company had long-term debt of $1.25 billion at the end of the third quarter compared with $1.27 billion at the end of second quarter fiscal 2019.
For the first nine months of fiscal 2019, the company generated $360.6 million in cash flow from operations, up from $327.9 million in the year-ago period. Further, free cash flow in the same period was $252.9 million compared with $216.4 million a year ago.
2019 Guidance
Based on the results for the first nine months of fiscal 2019, STERIS updated its full-year projections for constant currency organic revenue growth to around 6% from 5-6%. The Zacks Consensus Estimate for fiscal 2019 revenues is pegged at $2.75 billion.
The company continues to expect the adjusted EPS guidance for fiscal 2019 in the range of $4.74-$4.84. The consensus estimate for fiscal 2019 adjusted EPS lies at $4.78.
Our Take
STERIS exited third-quarter fiscal 2019 on a mixed note. We are encouraged by the favorable underlying market trends along with new product and service offerings. Further, growth in free cash flow reserve is indicative of the company's strong cash balance. The company raising its constant currency organic revenue growth expectations for fiscal 2019 is indicative of brighter prospects. During the reported quarter, STERIS announced a restructuring plan that involved shutting down of two manufacturing units along with product rationalization. STERIS has also made certain divestments and organizational changes, which are expected to better align with its operations.
Zacks Rank & Other Key Picks
STERIS has a Zacks Rank #2 (Buy).
Other top-ranked medical stocks that have recently reported quarterly results are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD .
Abbot t report ed fourth-quarter 2018 adjusted EPS of 81 cents, in line with the Zacks Consensus Estimate. Revenues of $7.77 billion were below the Zacks Consensus Estimate of $7.79 billion. The stock has a Zacks Rank #2.
AngioDynamics' fiscal second-quarter adjusted EPS of 22 cents exceeded the Zacks Consensus Estimate by a penny. Revenues totaled $91.5 million, beating the consensus estimate by 2.9%. The stock sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
CONMED delivered fourth-quarter adjusted EPS of 73 cents, in line with the Zacks Consensus Estimate. Revenues of $242.4 million beat the Zacks Consensus Estimate of $229.2 million. The stock carries a Zacks Rank of 2.
Zacks' Best Stock-Picking Strategy
It's hard to believe, even for us at Zacks. But from 2000-2018, while the market gained +4.8% per year, our top stock-picking strategy averaged +54.3% per year.
How has that screen done lately? From 2017-2018, it sextupled the market's +15.8% gain with a soaring +98.3% return.
Free - See the Stocks It Turned Up for Today >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
AngioDynamics, Inc. (ANGO): Free Stock Analysis Report
STERIS plc (STE): Get Free Report
CONMED Corporation (CNMD): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Other top-ranked medical stocks that have recently reported quarterly results are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report STERIS plc (STE): Get Free Report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here. Revenues at Applied Sterilization Technologies rose 6% to $136.8 million (up 8%) backed by increased demand from core medical device customers. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report STERIS plc (STE): Get Free Report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here. Other top-ranked medical stocks that have recently reported quarterly results are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . The company operates through four segments: Healthcare Products, Healthcare Specialty Services, Applied Sterilization Technologies and Life Sciences. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report STERIS plc (STE): Get Free Report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here. Other top-ranked medical stocks that have recently reported quarterly results are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . Quarter in Detail Organic revenue growth at constant currency was 7% year over year in the fiscal third quarter, mainly driven by growth across all segments. | Other top-ranked medical stocks that have recently reported quarterly results are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report STERIS plc (STE): Get Free Report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here. STERIS plc STE reported third-quarter fiscal 2019 adjusted earnings per share (EPS) of $1.26, up 12.5% year over year. |
33083.0 | 2019-02-12 00:00:00 UTC | Here's Why Investors Should Retain Accuray (ARAY) Stock Now | ABT | https://www.nasdaq.com/articles/heres-why-investors-should-retain-accuray-aray-stock-now-2019-02-12 | nan | nan | Accuray Incorporated ARAY is gaining prominence in the MedTech space, courtesy of solid demand for Radixact & CyberKnife platforms. Moreover, the company has been fortifying its foothold worldwide.
In 2018, the company received regulatory approval from India to sell its flagship Radixact X9 system. Management is optimistic about this development as it will expand Accuray's precision treatment solutions in emerging markets. These apart, the company has a strong presence in India's leading hospitals.
However, Accuray faces cutthroat competition in the radiation-oncology space. In a year's time, this Zacks Rank #3 (Hold) stock has gained 3.1% compared with the industry 's 11.1% growth.
So here we take a quick look at Accuray's major headwinds and discuss the factors that ensure near-term recovery.
Cutthroat Competition in the Niche Markets
Accuray is exposed to significant competition in the radiation oncology market, which is characterized by rapid technological changes.
The company competes head-to-head with Varian Medical, Elekta, ViewRay and BrainLAB AG in this market. While, the CyberKnife System faces challenges from Varian's Trilogy system, TomoTherapy systems are challenged by Varian's RapidArc technology and the TrueBeam systems.
Software Upgrades
A series of software upgrades has been acting as a key catalyst for Accuray. These upgrades were primarily focused on improvised imaging, faster planning capabilities as well as system connectivity.
Further, software enhancements involved improvisation of CyberKnife treatment planning efficiency. In this regard, it is imperative to mention that Accuray had introduced CTrue iterative reconstruction - an enhanced CT imaging capability for Radixact.
In fiscal 2018, Accuray launched an imaging software for Radixact. Per management, this software offers significant improvement in soft tissue resolution with up to 50% lesser image noise than the previous version. Another important development program for Radixact System is the launch of intra-fraction motion tracking and correction capability.
It is encouraging to note that in second-quarter fiscal 2019, Accuray received the FDA approval for its 510(k)-application motion synchronization on the Radixact treatment system. Notably, motion synchronization has been a unique functional feature of the CyberKnife platform. Meanwhile, the kVCT imaging on Radixact is under development.
Which Way Are Estimates Trending?
The Zacks Consensus Estimate for third-quarter fiscal 2019 is pegged at a loss of 4 cents. The same for revenues stands at $104 million, mirroring a 4.2% improvement year over year.
For fiscal 2019, the Zacks Consensus Estimate is pinned at a loss of 16 cents. The same for revenues is pegged at $420.4 million, reflecting a 3.8% improvement year over year.
Accuray Incorporated Price and Consensus
Accuray Incorporated Price and Consensus | Accuray Incorporated Quote
Key Picks
A few better-ranked stocks in the broader medical space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII .
Surmodics has a long-term expected earnings growth rate of 10%. The stock sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Abbott's long-term earnings growth rate is projected at 11.7%. The stock carries a Zacks Rank #2 (Buy).
Cardiovascular Systems exceeded the Zacks Consensus Estimate in the trailing four quarters, the average being 77.1%. The stock sports a Zacks Rank of 2.
Zacks' Best Stock-Picking Strategy
It's hard to believe, even for us at Zacks. But from 2000-2018, while the market gained +4.8% per year, our top stock-picking strategy averaged +54.3% per year.
How has that screen done lately? From 2017-2018, it sextupled the market's +15.8% gain with a soaring +98.3% return.
Free - See the Stocks It Turned Up for Today >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Accuray Incorporated (ARAY): Free Stock Analysis Report
Cardiovascular Systems, Inc. (CSII): Get Free Report
Surmodics, Inc. (SRDX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Accuray Incorporated Price and Consensus Accuray Incorporated Price and Consensus | Accuray Incorporated Quote Key Picks A few better-ranked stocks in the broader medical space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Accuray Incorporated (ARAY): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Get Free Report Surmodics, Inc. (SRDX): Free Stock Analysis Report To read this article on Zacks.com click here. Accuray Incorporated ARAY is gaining prominence in the MedTech space, courtesy of solid demand for Radixact & CyberKnife platforms. | Accuray Incorporated Price and Consensus Accuray Incorporated Price and Consensus | Accuray Incorporated Quote Key Picks A few better-ranked stocks in the broader medical space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Accuray Incorporated (ARAY): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Get Free Report Surmodics, Inc. (SRDX): Free Stock Analysis Report To read this article on Zacks.com click here. While, the CyberKnife System faces challenges from Varian's Trilogy system, TomoTherapy systems are challenged by Varian's RapidArc technology and the TrueBeam systems. | Accuray Incorporated Price and Consensus Accuray Incorporated Price and Consensus | Accuray Incorporated Quote Key Picks A few better-ranked stocks in the broader medical space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Accuray Incorporated (ARAY): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Get Free Report Surmodics, Inc. (SRDX): Free Stock Analysis Report To read this article on Zacks.com click here. While, the CyberKnife System faces challenges from Varian's Trilogy system, TomoTherapy systems are challenged by Varian's RapidArc technology and the TrueBeam systems. | Accuray Incorporated Price and Consensus Accuray Incorporated Price and Consensus | Accuray Incorporated Quote Key Picks A few better-ranked stocks in the broader medical space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Accuray Incorporated (ARAY): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Get Free Report Surmodics, Inc. (SRDX): Free Stock Analysis Report To read this article on Zacks.com click here. In a year's time, this Zacks Rank #3 (Hold) stock has gained 3.1% compared with the industry 's 11.1% growth. |
33084.0 | 2019-02-12 00:00:00 UTC | Bruker (BRKR) Q4 Earnings In Line, Margin Growth Strong | ABT | https://www.nasdaq.com/articles/bruker-brkr-q4-earnings-in-line-margin-growth-strong-2019-02-12 | nan | nan | Bruker CorporationBRKR delivered adjusted earnings per share (EPS) of 54 cents in the fourth quarter of 2018, up 5.9% from the year-ago figure. Meanwhile, the metric came in line with the Zacks Consensus Estimate.
On a reported basis, earnings were 50 cents a share against the year-earlier loss of 2 cents. The number also matched the Zacks Consensus Estimate
Full-year adjusted EPS totaled $1.40, reflecting an increase of 15.7% from the prior-year period.
Revenues in Detail
Bruker registered revenues of $553.6 million in the fourth quarter, up 4.4% year over year. The top line also surpassed the Zacks Consensus Estimate of $544.5 million.
Excluding a positive effect of 3.2% from acquisitions and a 2.2% negative impact from changes in foreign currency rates, Bruker generated higher organic revenues of 3.4% year over year.
Bruker Corporation Price, Consensus and EPS Surprise
Bruker Corporation Price, Consensus and EPS Surprise | Bruker Corporation Quote
The company's organic revenue growth was driven by the strength in Bruker Scientific Instruments (BSI) and BEST segments.
Geographically, the United States registered 19% growth in the reported quarter. Meanwhile, European revenues dipped 1.6% year over year. Asia Pacific revenues also slipped 0.2%. In Other category, the revenue uptick was 11.9%.
Bruker's BioSpin Group revenues were 0.7% above the year-ago quarter's level. Revenues in the NANO group rose 5.2%, fueled by a strong uptrend in academic research and industrial research markets. CALID revenues were up 4.5% year over year.
Margin Trend
Gross margin in the quarter under review expanded 98 basis points (bps) to 49.3%. While selling, general & administrative expenses climbed 4.8% to $117.3 million. Research and development expenses ascended 3.9% year over year to $44.8 million. Overall, adjusted operating margin grew 92 bps to 19.9%.
Financial Position
Bruker exited 2018 with cash and cash equivalents plus short-term investments of $322.4 million, down from $439.2 million at the end of 2017. Full-year operating cashflow was $239.7 million in comparison to $154.4 million in the year-ago period.
2019 Guidance
Bruker has provided a preliminary 2019 guidance. For the full year, the company projects approximately 6-7% revenue growth including nearly 4-5% of organic revenue rise and an estimated 2% headwind from adverse foreign currency translation. The company envisions a year-over-year expansion of 70-100 bps in adjusted operating margin.
For 2019, Bruker expects its adjusted EPS view in the range of $1.54-$1.58, up 10-13% from the previous year's figure. The Zacks Consensus Estimate of $1.56 remains within this guided range.
Our Take
Bruker ended the fourth quarter on a mixed note with earnings on par with the Zacks Consensus Estimate while revenues, staying ahead of the mark. A strong year-over-year rise in organic revenues was encouraging. Additionally, the improvement in gross and operating margins buoys optimism. The company's strategic acquisition activity has also been impressive. Further, we are upbeat about the company's current focus on product development through higher R&D investment.
On the flip side, a competitive landscape and macroeconomic woes pose persistent challenges to the company.
Zacks Rank & Key Picks
Bruker carries a Zacks Rank #3 (Hold). A few better-ranked medical stocks that have reported quarterly results are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD .
Abbot t report ed fourth-quarter 2018 adjusted EPS of 81 cents, in line with the Zacks Consensus Estimate. Revenues of $7.77 billion were below the Zacks Consensus Estimate of $7.79 billion. The stock has a Zacks Rank #2 (Buy).
AngioDynamics' second-quarter fiscal 2019 adjusted EPS of 22 cents exceeded the Zacks Consensus Estimate by a penny. Revenues totaled $91.5 million, beating the consensus estimate by 2.9%. The stock sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
CONMED's fourth-quarter adjusted EPS of 73 cents met the Zacks Consensus Estimate. Revenues of $242.4 million topped the Zacks Consensus Estimate of $229.2 million. The stock carries a Zacks Rank of 2.
Zacks' Best Stock-Picking Strategy
It's hard to believe, even for us at Zacks. But from 2000-2018, while the market gained +4.8% per year, our top stock-picking strategy averaged +54.3% per year.
How has that screen done lately? From 2017-2018, it sextupled the market's +15.8% gain with a soaring +98.3% return.
Free - See the Stocks It Turned Up for Today >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Bruker Corporation (BRKR): Free Stock Analysis Report
AngioDynamics, Inc. (ANGO): Free Stock Analysis Report
CONMED Corporation (CNMD): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A few better-ranked medical stocks that have reported quarterly results are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Bruker Corporation (BRKR): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here. The number also matched the Zacks Consensus Estimate Full-year adjusted EPS totaled $1.40, reflecting an increase of 15.7% from the prior-year period. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Bruker Corporation (BRKR): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked medical stocks that have reported quarterly results are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . The number also matched the Zacks Consensus Estimate Full-year adjusted EPS totaled $1.40, reflecting an increase of 15.7% from the prior-year period. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Bruker Corporation (BRKR): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked medical stocks that have reported quarterly results are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . Revenues in Detail Bruker registered revenues of $553.6 million in the fourth quarter, up 4.4% year over year. | A few better-ranked medical stocks that have reported quarterly results are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Bruker Corporation (BRKR): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here. Revenues in Detail Bruker registered revenues of $553.6 million in the fourth quarter, up 4.4% year over year. |
33085.0 | 2019-02-11 00:00:00 UTC | Here's Why Momentum Investors Will Love Abbott (ABT) | ABT | https://www.nasdaq.com/articles/heres-why-momentum-investors-will-love-abbott-abt-2019-02-11 | nan | nan | Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.
Even though momentum is a popular stock characteristic, it can be tough to define. Debate surrounding which are the best and worst metrics to focus on is lengthy, but the Zacks Momentum Style Score, part of the Zacks Style Scores , helps address this issue for us.
Below, we take a look at Abbott (ABT) , a company that currently holds a Momentum Style Score of B. We also talk about price change and earnings estimate revisions, two of the main aspects of the Momentum Style Score.
It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Abbott currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of A or B outperform the market over the following one-month period.
You can see the current list of Zacks #1 Rank Stocks here >>>
Set to Beat the Market?
In order to see if ABT is a promising momentum pick, let's examine some Momentum Style elements to see if this maker of infant formula, medical devices and drugs holds up.
A good momentum benchmark for a stock is to look at its short-term price activity, as this can reflect both current interest and if buyers or sellers currently have the upper hand. It's also helpful to compare a security to its industry; this can show investors the best companies in a particular area.
For ABT, shares are up 1.7% over the past week while the Zacks Medical - Products industry is up 0.91% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 6.15% compares favorably with the industry's 4.66% performance as well.
Considering longer term price metrics, like performance over the last three months or year, can be advantageous as well. Over the past quarter, shares of Abbott have risen 3.68%, and are up 30.32% in the last year. In comparison, the S&P 500 has only moved -3.05% and 6.96%, respectively.
Investors should also pay attention to ABT's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. ABT is currently averaging 6,200,330 shares for the last 20 days.
Earnings Outlook
The Zacks Momentum Style Score also takes into account trends in estimate revisions, in addition to price changes. Please note that estimate revision trends remain at the core of Zacks Rank as well. A nice path here can help show promise, and we have recently been seeing that with ABT.
Over the past two months, 7 earnings estimates moved higher compared to 1 lower for the full year. These revisions helped boost ABT's consensus estimate, increasing from $3.19 to $3.20 in the past 60 days. Looking at the next fiscal year, 4 estimates have moved upwards while there have been 1 downward revision in the same time period.
Bottom Line
Taking into account all of these elements, it should come as no surprise that ABT is a #2 (Buy) stock with a Momentum Score of B. If you've been searching for a fresh pick that's set to rise in the near-term, make sure to keep Abbott on your short list.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Bottom Line Taking into account all of these elements, it should come as no surprise that ABT is a #2 (Buy) stock with a Momentum Score of B. Below, we take a look at Abbott (ABT) , a company that currently holds a Momentum Style Score of B. In order to see if ABT is a promising momentum pick, let's examine some Momentum Style elements to see if this maker of infant formula, medical devices and drugs holds up. | Below, we take a look at Abbott (ABT) , a company that currently holds a Momentum Style Score of B. In order to see if ABT is a promising momentum pick, let's examine some Momentum Style elements to see if this maker of infant formula, medical devices and drugs holds up. For ABT, shares are up 1.7% over the past week while the Zacks Medical - Products industry is up 0.91% over the same time period. | Below, we take a look at Abbott (ABT) , a company that currently holds a Momentum Style Score of B. In order to see if ABT is a promising momentum pick, let's examine some Momentum Style elements to see if this maker of infant formula, medical devices and drugs holds up. For ABT, shares are up 1.7% over the past week while the Zacks Medical - Products industry is up 0.91% over the same time period. | ABT is currently averaging 6,200,330 shares for the last 20 days. Below, we take a look at Abbott (ABT) , a company that currently holds a Momentum Style Score of B. In order to see if ABT is a promising momentum pick, let's examine some Momentum Style elements to see if this maker of infant formula, medical devices and drugs holds up. |
33086.0 | 2019-02-11 00:00:00 UTC | IRADIMED (IRMD) Q4 Earnings Surpass Estimates, Margins Up | ABT | https://www.nasdaq.com/articles/iradimed-irmd-q4-earnings-surpass-estimates-margins-up-2019-02-11 | nan | nan | IRADIMED CORPORATION. IRMD reported fourth-quarter 2018 adjusted earnings per share (EPS) of 16 cents, up 60% year over year. This figure surpassed the Zacks Consensus Estimate by 23.1%. The reported EPS was 14 cents, as compared with the year-ago figure of 2 cents.
For the full year, adjusted EPS came in at 54 cents, marking a remarkable rise from 22 cents a year ago.
Revenue details
In the fourth quarter of 2018, revenues totaled $8.3 million, up 24.5% year over year. This figure, however, missed the Zacks Consensus Estimate by 10.7%. For the full year, the company registered revenues of $30.4 million, up 31.6% from the year-ago period.
Geographical and segmental details
IRADIMED registered international revenues of $1.6 million for the fourth quarter, up 14.3% year over year. Domestic revenues came in at $6.7 million, reflecting a rise of 26.4%.
iRadimed Corporation Price, Consensus and EPS Surprise
iRadimed Corporation Price, Consensus and EPS Surprise | iRadimed Corporation Quote
The company reports revenues through two operating segments viz. devices and disposables and services. Fourth-quarter revenues from the sale of devices came in at $5.9 million, up 25.5% year over year. The upside was driven by strong revenues from MRI-compatible patient vital monitors, which registered a count of $2.1 million, showing a huge 133.3% rise from the year-ago period. Revenues from the disposables and services segment in the fourth quarter were $2 million, up 17.6% year over year.
Margins
In the fourth quarter, gross profit came in at $6.4 million, reflecting an increase of 25.5% from the year-ago period. Gross margin expanded 69 basis points (bps) to 76.2%. In the quarter under review, operating profit increased 79.3% year over year to reach $1.8 million. Operating margin expanded 659 bps to 21.5%.
In the fourth quarter, sales and marketing expenses came in at $2.1 million, up 31.1% year over year. General and administrative expenses grossed $2.15 million, showing a meager drop of 0.3% year over year. Research and development expenses came in at $0.37 million, a rise of 5.2% from the year-ago period.
Cash Position
IRADIMED exited 2018 with cash and cash equivalent of $28 million, a significant rise of 55.6% from the end of 2017. For the year, net cash provided by operating activities was $7.4 million, compared with $3.4 million a year ago.
Guidance for 2019
The company has provided a financial guidance for 2019. Revenues for the full year are estimated in the range of $38.5-$39.5 million. Adjusted EPS for the full year is projected in the range of 69-73 cents.
The company has also provided the guidance for first-quarter 2019. Revenues are expected within $8.3-$8.5 million, whereas adjusted EPS is estimated in the range of 12-13 cents.
Our take
IRADIMED exited the fourth quarter of 2018 on a positive note. The company reported growth across all operating segments and geographic locations. The company is making solid progress with regard to product development. In 2018, it had significantly enhanced its next generation IV pump. It expects to release this device in early 2021. It has also made progress with regard to its magnetic detection device, the FMD, and is on track for a late 2019 launch.
On account of these factors, we are optimistic about IRADIMED's growth potential.
Key Picks
A few top-ranked medical stocks that have reported quarterly results in the recently are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD .
Abbot t report ed fourth-quarter 2018 adjusted EPS of 81 cents, in line with the Zacks Consensus Estimate. Revenues of $7.77 billion were below the Zacks Consensus Estimate of $7.79 billion. The stock has a Zacks Rank #2 (Buy).
AngioDynamics' fiscal second-quarter adjusted EPS of 22 cents exceeded the Zacks Consensus Estimate by a penny. Revenues totaled $91.5 million, beating the consensus estimate by 2.9%. The stock sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
CONMED delivered fourth-quarter adjusted EPS of 73 cents, in line with the Zacks Consensus Estimate. Revenues of $242.4 million beat the Zacks Consensus Estimate of $229.2 million. The stock carries a Zacks Rank of 2.
Is Your Investment Advisor Fumbling Your Financial Future?
See how you can more effectively safeguard your retirement with a new Special Report, "4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future."
Click to get it free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
iRadimed Corporation (IRMD): Get Free Report
AngioDynamics, Inc. (ANGO): Free Stock Analysis Report
CONMED Corporation (CNMD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Key Picks A few top-ranked medical stocks that have reported quarterly results in the recently are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report iRadimed Corporation (IRMD): Get Free Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here. The upside was driven by strong revenues from MRI-compatible patient vital monitors, which registered a count of $2.1 million, showing a huge 133.3% rise from the year-ago period. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report iRadimed Corporation (IRMD): Get Free Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here. Key Picks A few top-ranked medical stocks that have reported quarterly results in the recently are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . Geographical and segmental details IRADIMED registered international revenues of $1.6 million for the fourth quarter, up 14.3% year over year. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report iRadimed Corporation (IRMD): Get Free Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here. Key Picks A few top-ranked medical stocks that have reported quarterly results in the recently are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . Revenue details In the fourth quarter of 2018, revenues totaled $8.3 million, up 24.5% year over year. | Key Picks A few top-ranked medical stocks that have reported quarterly results in the recently are Abbott Laboratories ABT , AngioDynamics Inc. ANGO and CONMED, Corp. CNMD . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report iRadimed Corporation (IRMD): Get Free Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here. For the full year, the company registered revenues of $30.4 million, up 31.6% from the year-ago period. |
33087.0 | 2019-02-11 00:00:00 UTC | Here's Why You Should Buy Wright Medical (WMGI) Stock Now | ABT | https://www.nasdaq.com/articles/heres-why-you-should-buy-wright-medical-wmgi-stock-now-2019-02-11 | nan | nan | Wright Medical Group N.V. WMGI has been enjoying a favorable place in the investors' book, courtesy of its continued developments. In a year's time, the stock has outperformed its industry. Shares of the company have surged 51.5% compared with the industry and S&P 500's growth of 11.1% and 2.1%, respectively.
Notably, a growing orthopedic market, launch of new products like PERFORM Reversed glenoid, ORTHOLOC 3Di and the SIMPLICITI shoulder system are likely to drive the company's top line in the quarters ahead.
With solid prospects, this Zacks Rank #2 (Buy) stock is an attractive pick for investors at the moment.
International Expansion
Wright Medical's international net sales are expected to grow in the high single-digits on a constant-currency basis driven by continued strong performance in biologics. Further, solid improvement at upper extremities growth unit instils optimism. Meanwhile, the company's shoulder portfolio is gaining momentum in international markets, particularly with the launch of PERFORM Reversed.
In 2019, it intends to put more PERFORM Reversed into international market. Earlier in 2018, management confirmed that the launch of AUGMENT Injectable in Australia and Canada has considerably driven growth.
In the third quarter of 2018, international sales grew 13% on a year-over-year basis.
Strong Foothold in the Foot & Ankle Market
Wright Medical's solid foot and ankle products portfolio, and extensive training provided to extremities-dedicated surgeons have enabled it to emerge as a leading player in the foot and ankle market.
Furthermore, ORTHOLOC ankle and small bone fracture product launches has been impressive. Management is also upbeat about the third-quarter launch of the Minimally Invasive Surgery System and AUGMENT Injectable, which is likely to provide further momentum to the U.S. lower extremity business.
In the third quarter of 2018, Wright Medical's Lower Extremities business posted worldwide revenues of $71.1 million, up 8.8% year over year. While revenues in the United States increased 12% to $57.6 million on a year-over-year basis, international sales totaled $13.5 million, down 3.3% year over year.
Which Way Are Estimates Trending?
The Zacks Consensus Estimate for fourth-quarter earnings is pegged at 6 cents, reflecting year-over-year decline of 40%. The same for revenues stands at $237.4 million, mirroring a 9.1% improvement year over year.
For 2018, the Zacks Consensus Estimate is pinned at a loss of 7 cents. The same for revenues is pegged at $836 million.
Wright Medical Group N.V. Price and Consensus
Wright Medical Group N.V. Price and Consensus | Wright Medical Group N.V. Quote
Key Picks
A few top-ranked stocks in the broader medical space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII .
Surmodics has a long-term expected earnings growth rate of 10%. The stock sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Abbott's long-term earnings growth rate is projected at 11.7%. The stock carries a Zacks Rank #2.
Cardiovascular Systems exceeded the Zacks Consensus Estimate in the trailing four quarters, the average beat being 77.1%. The stock sports a Zacks Rank of 1.
Is Your Investment Advisor Fumbling Your Financial Future?
See how you can more effectively safeguard your retirement with a new Special Report, "4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future."
Click to get it free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report
Surmodics, Inc. (SRDX): Free Stock Analysis Report
Wright Medical Group N.V. (WMGI): Get Free Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Wright Medical Group N.V. Price and Consensus Wright Medical Group N.V. Price and Consensus | Wright Medical Group N.V. Quote Key Picks A few top-ranked stocks in the broader medical space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report Wright Medical Group N.V. (WMGI): Get Free Report To read this article on Zacks.com click here. Wright Medical Group N.V. WMGI has been enjoying a favorable place in the investors' book, courtesy of its continued developments. | Wright Medical Group N.V. Price and Consensus Wright Medical Group N.V. Price and Consensus | Wright Medical Group N.V. Quote Key Picks A few top-ranked stocks in the broader medical space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report Wright Medical Group N.V. (WMGI): Get Free Report To read this article on Zacks.com click here. Strong Foothold in the Foot & Ankle Market Wright Medical's solid foot and ankle products portfolio, and extensive training provided to extremities-dedicated surgeons have enabled it to emerge as a leading player in the foot and ankle market. | Wright Medical Group N.V. Price and Consensus Wright Medical Group N.V. Price and Consensus | Wright Medical Group N.V. Quote Key Picks A few top-ranked stocks in the broader medical space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report Wright Medical Group N.V. (WMGI): Get Free Report To read this article on Zacks.com click here. Strong Foothold in the Foot & Ankle Market Wright Medical's solid foot and ankle products portfolio, and extensive training provided to extremities-dedicated surgeons have enabled it to emerge as a leading player in the foot and ankle market. | Wright Medical Group N.V. Price and Consensus Wright Medical Group N.V. Price and Consensus | Wright Medical Group N.V. Quote Key Picks A few top-ranked stocks in the broader medical space are Surmodics, Inc SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report Wright Medical Group N.V. (WMGI): Get Free Report To read this article on Zacks.com click here. International Expansion Wright Medical's international net sales are expected to grow in the high single-digits on a constant-currency basis driven by continued strong performance in biologics. |
33088.0 | 2019-02-11 00:00:00 UTC | Top Ranked Momentum Stocks to Buy for February 11th | ABT | https://www.nasdaq.com/articles/top-ranked-momentum-stocks-to-buy-for-february-11th-2019-02-11 | nan | nan | Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, February 11th:
Apartment Investment and Management Company (AIV): This real estate investment trust has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.4% over the last 60 days.
Apartment Investment and Management Company Price and Consensus
Apartment Investment and Management Company price-consensus-chart | Apartment Investment and Management Company Quote
Apartment Investment's shares gained 8.9% over the last one month more than S&P 500's gain of 4.9%. The company possesses a Momentum Score of B.
Apartment Investment and Management Company Price
Apartment Investment and Management Company price | Apartment Investment and Management Company Quote
ABIOMED, Inc. (ABMD): This developer and seller of medical devices has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.2% over the last 60 days.
ABIOMED, Inc. Price and Consensus
ABIOMED, Inc. price-consensus-chart | ABIOMED, Inc. Quote
ABIOMED's shares gained 8.2% over the last one month. The company possesses a Momentum Score of A.
ABIOMED, Inc. Price
ABIOMED, Inc. price | ABIOMED, Inc. Quote
Abbott Laboratories (ABT): This developer and manufacturer of health care products has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.3% over the last 60 days.
Abbott Laboratories Price and Consensus
Abbott Laboratories price-consensus-chart | Abbott Laboratories Quote
Abbott Laboratories' shares gained 7.4% over the last one month. The company possesses a Momentum Score of B.
Abbott Laboratories Price
Abbott Laboratories price | Abbott Laboratories Quote
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here .
Is Your Investment Advisor Fumbling Your Financial Future?
See how you can more effectively safeguard your retirement with a new Special Report, "4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future."
Click to get it free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Apartment Investment and Management Company (AIV): Get Free Report
Abbott Laboratories (ABT): Free Stock Analysis Report
ABIOMED, Inc. (ABMD): Get Free Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The company possesses a Momentum Score of A. ABIOMED, Inc. Price ABIOMED, Inc. price | ABIOMED, Inc. Quote Abbott Laboratories (ABT): This developer and manufacturer of health care products has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.3% over the last 60 days. Click to get this free report Apartment Investment and Management Company (AIV): Get Free Report Abbott Laboratories (ABT): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Get Free Report To read this article on Zacks.com click here. Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, February 11th: Apartment Investment and Management Company (AIV): This real estate investment trust has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.4% over the last 60 days. | Click to get this free report Apartment Investment and Management Company (AIV): Get Free Report Abbott Laboratories (ABT): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Get Free Report To read this article on Zacks.com click here. The company possesses a Momentum Score of A. ABIOMED, Inc. Price ABIOMED, Inc. price | ABIOMED, Inc. Quote Abbott Laboratories (ABT): This developer and manufacturer of health care products has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.3% over the last 60 days. Apartment Investment and Management Company Price and Consensus Apartment Investment and Management Company price-consensus-chart | Apartment Investment and Management Company Quote Apartment Investment's shares gained 8.9% over the last one month more than S&P 500's gain of 4.9%. | The company possesses a Momentum Score of A. ABIOMED, Inc. Price ABIOMED, Inc. price | ABIOMED, Inc. Quote Abbott Laboratories (ABT): This developer and manufacturer of health care products has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.3% over the last 60 days. Click to get this free report Apartment Investment and Management Company (AIV): Get Free Report Abbott Laboratories (ABT): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Get Free Report To read this article on Zacks.com click here. Apartment Investment and Management Company Price and Consensus Apartment Investment and Management Company price-consensus-chart | Apartment Investment and Management Company Quote Apartment Investment's shares gained 8.9% over the last one month more than S&P 500's gain of 4.9%. | The company possesses a Momentum Score of A. ABIOMED, Inc. Price ABIOMED, Inc. price | ABIOMED, Inc. Quote Abbott Laboratories (ABT): This developer and manufacturer of health care products has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.3% over the last 60 days. Click to get this free report Apartment Investment and Management Company (AIV): Get Free Report Abbott Laboratories (ABT): Free Stock Analysis Report ABIOMED, Inc. (ABMD): Get Free Report To read this article on Zacks.com click here. Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, February 11th: Apartment Investment and Management Company (AIV): This real estate investment trust has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 0.4% over the last 60 days. |
33089.0 | 2019-02-08 00:00:00 UTC | Omnicell (OMCL) Q4 Earnings Beat Estimates, Revenues Miss | ABT | https://www.nasdaq.com/articles/omnicell-omcl-q4-earnings-beat-estimates-revenues-miss-2019-02-08 | nan | nan | Omnicell, Inc.OMCL delivered adjusted earnings per share (EPS) of 70 cents in fourth-quarter 2018, beating the Zacks Consensus Estimate of 67 cents.
Adjusted earnings improved 27.3% from the year-ago figure and also surpassed the company's guided range of 64-69 cents.
Full-year adjusted earnings came in at $2.09 per share, reflecting a 48.2% surge from the year-ago period. Moreover, the figure exceeded the Zacks Consensus Estimate of $2.04
Revenues in Detail
Adjusted revenues in the fourth quarter increased 7.7% year over year to $211.8 million. However, the top line missed the Zacks Consensus Estimate by 1.3%.
Omnicell, Inc. Price, Consensus and EPS Surprise
Omnicell, Inc. Price, Consensus and EPS Surprise | Omnicell, Inc. Quote
The company reported 2018 revenues of $787.3 million, up 10.3% from the year-earlier period. But the number lagged the Zacks Consensus Estimate of $790.2 million.
Quarterly Details
On a segmental basis, Automation and Analytics revenues increased 9.9% year over year in the reported quarter to $177.6 million.
Moreover, revenues at the Medication Adherence segment inched up 1.9% year over year to $34.1 million.
Operational Update
Omnicell's gross profit in the reported quarter rose 9.3% to $102.1 million. Gross margin expanded 65 basis points (bps) to 48.3%.
SG&A expenses in the fourth quarter escalated 7.9% year over year to $66.3 million. Research and development expenses were up 6.9% year over year to $16.9 million. Operating expenses were $83.3 million in the fourth quarter, up 7.7% year over year.
Operating profit in the quarter under review totaled $18.9 million, up 16.8% from the prior-year quarter. Operating margin in the fourth quarter rose 69 bps to 8.9%.
Financial Update
Omnicell exited 2018 with cash and cash equivalents of $67.2 million compared with $32.4 million at the end of 2017.
2019 Guidance
For the first quarter of 2019, Omnicell expects adjusted revenues in the band of $196-$202 million. The company expects first-quarter adjusted earnings per share within 38-43 cents. The Zacks Consensus Estimate for first-quarter revenues is pegged at $204.2 million, ahead of the guided range. The consensus estimate for EPS of 37 cents lies below the projected range.
For 2019, Omnicell raised product bookings to $745-$780 million.
The company's full year expects adjusted revenues in the band of $880-$900 million. The Zacks Consensus Estimate for full-year revenues stands at $878.1 million, falling short of the company's forecast.
Omnicell expects adjusted EPS in the range of $2.40-$2.60. The Zacks Consensus Estimate for full-year earnings is pegged at $2.40, in line with the lower end of the company's expectation.
Our Take
Omnicell's fourth-quarter 2018 performance was mixed. While earnings exceeded the Zacks Consensus Estimate, revenues fell shy of the same. The company continued to see a solid uptake of Omnicell XT. It also inked various deals for both the XR2 and the IVX Workflow products. A rise in bookings and product backlogs was also observed in the reported quarter. We are encouraged to note that the company is working on product innovation through R&D. Also, Omnicell is expected to gain traction from launches, strategic partnerships and digital transformation.
However, a tough competitive landscape acts as a dampener.
Zacks Rank & Key Picks
Omnicell has a Zacks Rank #3 (Hold). Some better-ranked MedTech stocks that delivered solid results in the respective quarters are Abbott Laboraories ABT , AngioDynamics ANGO and CONMED Corp. CNMD .
Abbot t report ed fourth-quarter 2018 adjusted EPS of 81 cents, in line with the Zacks Consensus Estimate. Revenues of $7.77 billion remained slightly below the Zacks Consensus Estimate of $7.79 billion. The stock has a Zacks Rank #2 (Buy).
AngioDynamics' second-quarter fiscal 2019 adjusted EPS of 22 cents trumped the Zacks Consensus Estimate by a penny. Revenues totaled $91.5 million, surpassing the consensus estimate by 2.9%. The stock sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
CONMED delivered fourth-quarter adjusted EPS of 73 cents, matching the Zacks Consensus Estimate. Revenues of $242.4 million beat the Zacks Consensus Estimate of $229.2 million. The stock carries a Zacks Rank of 2.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Omnicell, Inc. (OMCL): Get Free Report
Abbott Laboratories (ABT): Free Stock Analysis Report
AngioDynamics, Inc. (ANGO): Free Stock Analysis Report
CONMED Corporation (CNMD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked MedTech stocks that delivered solid results in the respective quarters are Abbott Laboraories ABT , AngioDynamics ANGO and CONMED Corp. CNMD . Click to get this free report Omnicell, Inc. (OMCL): Get Free Report Abbott Laboratories (ABT): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here. Abbot t report ed fourth-quarter 2018 adjusted EPS of 81 cents, in line with the Zacks Consensus Estimate. | Click to get this free report Omnicell, Inc. (OMCL): Get Free Report Abbott Laboratories (ABT): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked MedTech stocks that delivered solid results in the respective quarters are Abbott Laboraories ABT , AngioDynamics ANGO and CONMED Corp. CNMD . Moreover, the figure exceeded the Zacks Consensus Estimate of $2.04 Revenues in Detail Adjusted revenues in the fourth quarter increased 7.7% year over year to $211.8 million. | Some better-ranked MedTech stocks that delivered solid results in the respective quarters are Abbott Laboraories ABT , AngioDynamics ANGO and CONMED Corp. CNMD . Click to get this free report Omnicell, Inc. (OMCL): Get Free Report Abbott Laboratories (ABT): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here. Moreover, the figure exceeded the Zacks Consensus Estimate of $2.04 Revenues in Detail Adjusted revenues in the fourth quarter increased 7.7% year over year to $211.8 million. | Some better-ranked MedTech stocks that delivered solid results in the respective quarters are Abbott Laboraories ABT , AngioDynamics ANGO and CONMED Corp. CNMD . Click to get this free report Omnicell, Inc. (OMCL): Get Free Report Abbott Laboratories (ABT): Free Stock Analysis Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report CONMED Corporation (CNMD): Free Stock Analysis Report To read this article on Zacks.com click here. Moreover, the figure exceeded the Zacks Consensus Estimate of $2.04 Revenues in Detail Adjusted revenues in the fourth quarter increased 7.7% year over year to $211.8 million. |
33090.0 | 2019-02-08 00:00:00 UTC | Here's Why You Should Invest in Stryker (SYK) Stock Right Now | ABT | https://www.nasdaq.com/articles/heres-why-you-should-invest-in-stryker-syk-stock-right-now-2019-02-08 | nan | nan | Stryker CorporationSYK has been gaining investor confidence on continued positive results. Over the past year, the company's stock has outperformed its industry . The stock has rallied 22.1% compared with the industry's 8.9% gain. Also, the company has outperformed the S&P 500's 6.2% rally.
Notably, a solid 2018 fourth-quarter show by the company and solid international presence currently boost the stock.
With solid prospects, this Zacks Rank #2 (Buy) stock is an attractive pick for investors at the moment.
What's Working in Favor of the Stock?
Solid Q4 Show
In the recently-reported fourth quarter of 2018, adjusted earnings per share (EPS) of $2.18 beat the Zacks Consensus Estimate by 1.4%. Earnings improved 11.2% year over year and were at the high end of the company's guidance.
The Michigan-based medical device company reported revenues of $3.80 billion, which were well ahead of the Zacks Consensus Estimate of $3.73 billion. Revenues increased 9.4% on a year-over-year basis and 11.3% at constant currency (cc).
For the first quarter of 2019, the company expects adjusted EPS within $1.80 and $1.85. The midpoint of the latest guidance of $1.83 million is in line with the Zacks Consensus Estimate.
Solid Global Presence
Stryker has had consistent focus on international growth.
In the fourth quarter of 2018, the company's international sales rose 7.3%, year over year to $1.03 billion. Organically, international sales grew double digits powered by performances in emerging markets and Europe. In fact, management stated that full-year growth in South Pacific, Japan and Canada was higher than U.S. growth.
Stryker's core Orthopaedic segment also put up a solid show in Europe, emerging markets and Canada. Additionally, MedSurg performed strongly in Europe, Australia and emerging markets. Neurotechnology & Spine also saw strong demand in Europe, China and Japan in recent times.
Stryker Corporation Price and Consensus
Stryker Corporation Price and Consensus | Stryker Corporation Quote
Which Way Are Estimates Treading?
The Zacks Consensus Estimate for first-quarter EPS reflects a year-over-year increase of 8.9%. The same for revenues stands at $3.51 billion, indicating an 8.4% rise year over year.
For the full year, the Zacks Consensus Estimate is pegged a t earnings of $8.11, reflecting a rise of 10.9%. The same for revenues stands at $14.80 billion, indicating an 8.8% rise year over year.
Want More From the Industry?
Other top-ranked stocks from the Medical Product space are Abbott Laboratories ABT , Surmodics, Inc. SRDX and BioLife Solutions, Inc. BLFS .
Abbott's long-term earnings growth rate is projected at 11.7%. The stock carries a Zacks Rank #2.
Surmodics' long-term earnings growth rate is projected at 10%. The stock sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
BioLife has an expected earnings growth rate of 180% for the current quarter. The stock has a Zacks Rank #2.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
BioLife Solutions, Inc. (BLFS): Get Free Report
Surmodics, Inc. (SRDX): Free Stock Analysis Report
Stryker Corporation (SYK): Get Free Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Other top-ranked stocks from the Medical Product space are Abbott Laboratories ABT , Surmodics, Inc. SRDX and BioLife Solutions, Inc. BLFS . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report BioLife Solutions, Inc. (BLFS): Get Free Report Surmodics, Inc. (SRDX): Free Stock Analysis Report Stryker Corporation (SYK): Get Free Report To read this article on Zacks.com click here. Solid Q4 Show In the recently-reported fourth quarter of 2018, adjusted earnings per share (EPS) of $2.18 beat the Zacks Consensus Estimate by 1.4%. | Other top-ranked stocks from the Medical Product space are Abbott Laboratories ABT , Surmodics, Inc. SRDX and BioLife Solutions, Inc. BLFS . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report BioLife Solutions, Inc. (BLFS): Get Free Report Surmodics, Inc. (SRDX): Free Stock Analysis Report Stryker Corporation (SYK): Get Free Report To read this article on Zacks.com click here. Stryker Corporation Price and Consensus Stryker Corporation Price and Consensus | Stryker Corporation Quote Which Way Are Estimates Treading? | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report BioLife Solutions, Inc. (BLFS): Get Free Report Surmodics, Inc. (SRDX): Free Stock Analysis Report Stryker Corporation (SYK): Get Free Report To read this article on Zacks.com click here. Other top-ranked stocks from the Medical Product space are Abbott Laboratories ABT , Surmodics, Inc. SRDX and BioLife Solutions, Inc. BLFS . The Michigan-based medical device company reported revenues of $3.80 billion, which were well ahead of the Zacks Consensus Estimate of $3.73 billion. | Other top-ranked stocks from the Medical Product space are Abbott Laboratories ABT , Surmodics, Inc. SRDX and BioLife Solutions, Inc. BLFS . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report BioLife Solutions, Inc. (BLFS): Get Free Report Surmodics, Inc. (SRDX): Free Stock Analysis Report Stryker Corporation (SYK): Get Free Report To read this article on Zacks.com click here. The Michigan-based medical device company reported revenues of $3.80 billion, which were well ahead of the Zacks Consensus Estimate of $3.73 billion. |
33091.0 | 2019-02-08 00:00:00 UTC | Smith & Nephew in talks to buy NuVasive for over $3 bln - FT | ABT | https://www.nasdaq.com/articles/smith-nephew-talks-buy-nuvasive-over-3-bln-ft-2019-02-08 | nan | nan | Feb 8 (Reuters) - Britain'sSmith & Nephew Plc has held talks to buy U.S. medical equipment maker NuVasive in a deal that would be worth more than $3 billion, the Financial Times reported on Friday, citing people familiar with the talks.
When contacted by Reuters, Smith & Nephew and NuVasive said they do not comment on market speculation.
The exact terms of any talks could not be learned, and the discussions may still fall apart, the FT reported.
Nawana was appointed to the job last April in part for his deal-making expertise and his knowledge of the U.S. market, where the London-based company makes about half its revenue.
He was most recently chief executive of medical diagnostics company Alere, where he oversaw its $5.3 billion acquisition by Abbott Laboratories in 2017.
Smith & Nephew has been under pressure to improve its margins and find new sources of growth to tighten its competition with bigger rivals such as Stryker Corp, Zimmer Biomet Holdings and Johnson & Johnson.
The British maker of hip and knee replacement products last month closed the acquisition of a small California-based maker of surgical tools used in knee replacement, Ceterix Orthopaedics.
NuVasive, which designs and develops medical devices for spine disorders, has a market value of about $2.55 billion.
Smith & Nephew is valued at 13.28 billion GBP ($17.19 billion).
($1 = 0.7727 pounds)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Nawana was appointed to the job last April in part for his deal-making expertise and his knowledge of the U.S. market, where the London-based company makes about half its revenue. He was most recently chief executive of medical diagnostics company Alere, where he oversaw its $5.3 billion acquisition by Abbott Laboratories in 2017. NuVasive, which designs and develops medical devices for spine disorders, has a market value of about $2.55 billion. | Feb 8 (Reuters) - Britain'sSmith & Nephew Plc has held talks to buy U.S. medical equipment maker NuVasive in a deal that would be worth more than $3 billion, the Financial Times reported on Friday, citing people familiar with the talks. When contacted by Reuters, Smith & Nephew and NuVasive said they do not comment on market speculation. He was most recently chief executive of medical diagnostics company Alere, where he oversaw its $5.3 billion acquisition by Abbott Laboratories in 2017. | Feb 8 (Reuters) - Britain'sSmith & Nephew Plc has held talks to buy U.S. medical equipment maker NuVasive in a deal that would be worth more than $3 billion, the Financial Times reported on Friday, citing people familiar with the talks. Smith & Nephew has been under pressure to improve its margins and find new sources of growth to tighten its competition with bigger rivals such as Stryker Corp, Zimmer Biomet Holdings and Johnson & Johnson. Smith & Nephew is valued at 13.28 billion GBP ($17.19 billion). | Feb 8 (Reuters) - Britain'sSmith & Nephew Plc has held talks to buy U.S. medical equipment maker NuVasive in a deal that would be worth more than $3 billion, the Financial Times reported on Friday, citing people familiar with the talks. When contacted by Reuters, Smith & Nephew and NuVasive said they do not comment on market speculation. Nawana was appointed to the job last April in part for his deal-making expertise and his knowledge of the U.S. market, where the London-based company makes about half its revenue. |
33092.0 | 2019-02-06 00:00:00 UTC | Here's Why You Should Invest in McKesson (MCK) Stock Now | ABT | https://www.nasdaq.com/articles/heres-why-you-should-invest-in-mckesson-mck-stock-now-2019-02-06 | nan | nan | McKesson Corporation'sMCK third-quarter fiscal 2019 performance was commendable. The U.S. Pharmaceutical and Specialty Solutions unit also performed encouragingly. Management is optimistic about the 10-year partnership signed with Rite Aid.
With solid prospects, this Zacks Rank #2 (Buy) stock is an attractive pick for investors at the moment. In a month's time, McKesson has gained 14.2% compared with the industry's 13% growth.
Strong Player in Distribution Market
McKesson is a key player in the pharmaceutical and medical supplies distribution market.
In fiscal 2018, the company's Distribution Solutions segment continued to deliver solid performance despite weak pricing trends and customer consolidation. Notably, this segment caters to a wide range of customers and businesses, and stands to benefit from increased generic utilization and an aging population.
It is encouraging to note that, Rite Aid renewed its distribution and sourcing relationship with McKesson for another 10 years in the fiscal third quarter. Additionally, McKesson launched its Opioid Foundation that will focus on helping advance solutions to the U.S. opioid crisis in the same period.
McKesson Canada Picks Up Pace
McKesson Canada plays a pivotal role in providing solutions to manufacturers, pharmacies and hospitals that serve the needs of patients in Canada every day.
Markedly, the segment rebounded in the fiscal third quarter. Evidently, McKesson Canada, a sub unit of the Other business segment of the company, saw a year-over-year upside in the quarter driven by high organic growth.
Which Way Are Estimates Trending?
The Zacks Consensus Estimate for fourth-quarter fiscal 2019 earnings is pegged at $3.68, mirroring 5.4% growth on a year-over-year basis. The same for revenues stands at $53.43 billion, reflecting a 3.5% improvement year over year.
For fiscal 2019, the Zacks Consensus Estimate for revenues is pinned at $215.02 billion, indicating 3.2% growth. The same for adjusted earnings is pegged at $13.51, showcasing a 7.1% rise year over year.
Want More from the MedTech Space?
A few other top-ranked stocks in the MedTech space are Surmodics, Inc. SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII .
Surmodics has a long-term expected earnings growth rate of 10%. The stock sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Abbott's long-term earnings growth rate is projected at 11.7%. The stock carries a Zacks Rank #2.
Cardiovascular Systems exceeded the Zacks Consensus Estimate in each of the trailing four quarters, the average being 77.1%. The stock has a Zacks Rank of 1.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report
Surmodics, Inc. (SRDX): Free Stock Analysis Report
McKesson Corporation (MCK): Get Free Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A few other top-ranked stocks in the MedTech space are Surmodics, Inc. SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report McKesson Corporation (MCK): Get Free Report To read this article on Zacks.com click here. In fiscal 2018, the company's Distribution Solutions segment continued to deliver solid performance despite weak pricing trends and customer consolidation. | A few other top-ranked stocks in the MedTech space are Surmodics, Inc. SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report McKesson Corporation (MCK): Get Free Report To read this article on Zacks.com click here. In fiscal 2018, the company's Distribution Solutions segment continued to deliver solid performance despite weak pricing trends and customer consolidation. | Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report McKesson Corporation (MCK): Get Free Report To read this article on Zacks.com click here. A few other top-ranked stocks in the MedTech space are Surmodics, Inc. SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . It is encouraging to note that, Rite Aid renewed its distribution and sourcing relationship with McKesson for another 10 years in the fiscal third quarter. | A few other top-ranked stocks in the MedTech space are Surmodics, Inc. SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report McKesson Corporation (MCK): Get Free Report To read this article on Zacks.com click here. In fiscal 2018, the company's Distribution Solutions segment continued to deliver solid performance despite weak pricing trends and customer consolidation. |
33093.0 | 2019-02-04 00:00:00 UTC | Here's Why You Should Hold Intuitive Surgical (ISRG) Stock | ABT | https://www.nasdaq.com/articles/heres-why-you-should-hold-intuitive-surgical-isrg-stock-2019-02-04 | nan | nan | Intuitive Surgical Inc. ISRG has been gaining from the adoption of da Vinci system, increasing procedure volumes, continuous innovations and a solid recurring revenue base. Currently, it has a market capitalization of approximately $59.92 billion.
In a year's time, this Zacks Rank #3 (Hold) stock has rallied 31.5% compared with the industry's 9.1% growth.
Why Should You Retain?
Intuitive Surgical's da Vinci surgical system enables minimally-invasive surgery, which reduces the trauma associated with open surgery. Powered by robotic technology, this surgical system has provided the company with a solid exposure to medical mechatronics, robotics and Artificial Intelligence for healthcare. The platform bolstered Intuitive Surgical's foothold in the Cardiac Surgery, Colorectal Surgery, General Surgery, Gynecologic Surgery, Head & Neck Surgery, Thoracic Surgery and Urologic Surgerymarkets.
The company also launched an upgrade to its flagship Vinci Xi technology - da Vinci X. Notably, the Xi suite is designed to seamlessly integrate future innovationssuch as advanced instrumentation, surgical skills simulation, software upgrades, and other advancements into one dynamic platform.
Meanwhile, the da Vinci Surgical System has been observed to cure patients diagnosed with inguinal hernia.
In the fourth quarter of 2018, da Vinci procedures grew approximately 19% over the fourth quarter of last year. Mature procedure growth in the United States, including prostatectomy and hysterectomy, has been robust. In Japan, procedures grew above 40% in the second half of 2018. European procedure performance has been in line, with solid growth in the United Kingdom and France.
For 2018, the company has strong prospects in the U.S. general surgery market, particularly driven by procedures for hernia repair and colorectal surgery. Internationally, the company has significant opportunities in Japan, South Korea and China.
What's Deterring the Stock?
Intuitive Surgical used to enjoy a monopoly stature in the market for robots used in abdominal surgery since the launch of its flagship device called da Vinci back in 2000. However, competition for the company intensified following the regulatory approval of Transenterix's surgical robot for abdominal surgery in 2017.
Which Way Are Estimates Trending?
The Zacks Consensus Estimate for first-quarter 2019 earnings is pegged at $2.67, mirroring 9.4% growthon a year-over-year basis. The same for revenues stands at $971.9 million, reflecting growth of 14.7% year over year.
For 2019, the Zacks Consensus Estimate for revenues is pinned at $4.30billion, indicating 15.4% growth. The same for adjusted earnings for 2019 is pegged at $12.01, showcasing a 9.3% rise year over year.
Intuitive Surgical, Inc. Price and Consensus
Intuitive Surgical, Inc. Price and Consensus | Intuitive Surgical, Inc. Quote
Key Picks
A few better-ranked stocks in the broader medical space are Surmodics, Inc. SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII .
Surmodics has a long-term expected earnings growth rate of 10%. The stock sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Abbott's long-term earnings growth rate is projected at 11.7%. The stock carries a Zacks Rank #2 (Buy).
Cardiovascular Systems topped the Zacks Consensus Estimate in each of the trailing four quarters, the average beat being77.1%. The stock has a Zacks Rank of 1.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1% and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 - 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report
Surmodics, Inc. (SRDX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Intuitive Surgical, Inc. Price and Consensus Intuitive Surgical, Inc. Price and Consensus | Intuitive Surgical, Inc. Quote Key Picks A few better-ranked stocks in the broader medical space are Surmodics, Inc. SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report To read this article on Zacks.com click here. Intuitive Surgical Inc. ISRG has been gaining from the adoption of da Vinci system, increasing procedure volumes, continuous innovations and a solid recurring revenue base. | Intuitive Surgical, Inc. Price and Consensus Intuitive Surgical, Inc. Price and Consensus | Intuitive Surgical, Inc. Quote Key Picks A few better-ranked stocks in the broader medical space are Surmodics, Inc. SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report To read this article on Zacks.com click here. In the fourth quarter of 2018, da Vinci procedures grew approximately 19% over the fourth quarter of last year. | Intuitive Surgical, Inc. Price and Consensus Intuitive Surgical, Inc. Price and Consensus | Intuitive Surgical, Inc. Quote Key Picks A few better-ranked stocks in the broader medical space are Surmodics, Inc. SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report To read this article on Zacks.com click here. The platform bolstered Intuitive Surgical's foothold in the Cardiac Surgery, Colorectal Surgery, General Surgery, Gynecologic Surgery, Head & Neck Surgery, Thoracic Surgery and Urologic Surgerymarkets. | Intuitive Surgical, Inc. Price and Consensus Intuitive Surgical, Inc. Price and Consensus | Intuitive Surgical, Inc. Quote Key Picks A few better-ranked stocks in the broader medical space are Surmodics, Inc. SRDX , Abbott Laboratories ABT and Cardiovascular Systems, Inc. CSII . Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report Cardiovascular Systems, Inc. (CSII): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report To read this article on Zacks.com click here. Intuitive Surgical Inc. ISRG has been gaining from the adoption of da Vinci system, increasing procedure volumes, continuous innovations and a solid recurring revenue base. |
33094.0 | 2019-02-03 00:00:00 UTC | Better Buy: Abbott Laboratories vs. DexCom | ABT | https://www.nasdaq.com/articles/better-buy-abbott-laboratories-vs-dexcom-2019-02-03 | nan | nan | Two companies are making life a lot easier for people with diabetes. Abbott Laboratories (NYSE: ABT) and DexCom (NASDAQ: DXCM) market devices that allow for convenient monitoring of blood sugar levels without the need for daily finger sticks.
The success of these companies' glucose monitors for diabetic patients has helped make Abbott Labs' and DexCom's shareholders winners, too. Last year, while many stocks languished, Abbott Labs' share price jumped nearly 27% and DexCom's share price more than doubled.
But which of these stocks is the better pick for investors now? Here's how Abbott Labs and DexCom stack up against each other.
The case for Abbott Laboratories
Abbott Labs' FreeStyle Libre continuous glucose monitoring (CGM) system has been one of the most successful products ever for diabetes patients. Abbott CEO Miles White said in the company's Q4 conference call that global sales for FreeStyle Libre doubled in 2018 from the previous year to more than $1 billion.
Momentum for FreeStyle Libre is picking up rather than slowing. In the fourth quarter alone, Abbott added 300,000 new users for the product -- almost as many devices as the entire user base of the No. 2 competitor in the market. The company also already launched a second version of the product in Europe that includes optional alarms for patients to warn them when glucose levels are out of range. White said that this new version "should come to the U.S. shortly."
But Abbott's success isn't driven just by its diabetes products. The company's Alinity line of lab diagnostics systems also continues to be a huge winner, even though its launch has been limited for the most part to Europe so far. As Abbott fully rolls out the Alinity products in the U.S. and Asia and extends the functionality to additional areas including molecular diagnostics, sales will likely skyrocket. The company's structural heart portfolio of products is also performing very well and should continue to do so.
Abbott also makes around 39% of its total revenue from established pharmaceuticals and nutritional products. Both units generated solid sales growth last year and contribute significantly to the company's strong cash flow.
Fast-growing new products and a broad array of other products and services have enabled Abbott Labs to deliver great value to shareholders. The company recently boosted its dividend payout by 14.3% -- its 47th consecutive year of dividend increases. With Abbott's dividend now yielding 1.8% and analysts projecting average annual earnings growth of nearly 12% over the next five years, the stock should remain a winner.
The case for DexCom
Don't worry that DexCom has existed for only a fraction of the time that Abbott Labs has been around. The company's annual revenue and share price have soared thanks in large part to its G6 CGM system.
Like Abbott's FreeStyle Libre, DexCom's G6 doesn't require daily finger sticks for calibration. But the G6 goes even further. The only time it requires finger sticks is when readings don't match symptoms or expectations. Other CGM systems, including FreeStyle Libre, can require finger sticks in other events, such as during the first few hours of readings and when symptoms of high or low blood sugar are present.
In addition, the G6 system is integrated with insulin patch pumps, smart insulin pens, and insulin pumps from key manufacturers. Probably the most important integration is with Tandem Diabetes Care 's insulin pump. The combination of DexCom's G6 and Tandem's X2 provides a closed-loop system that continually monitors glucose levels and automatically administers insulin when needed.
The G6 isn't DexCom's first CGM, though, and it won't be its last. DexCom is already working with Verily, a subsidiary of Alphabet , on developing the G7 CGM. This device could offer a fully disposable, real-time glucose monitoring system at relatively low costs.
DexCom's opportunity in diabetes is huge. Of the estimated 415 million people with diabetes, only 50% are diagnosed. And only 6% of the total number of individuals with diabetes achieve their desired outcomes.
Wall Street appears to be sold on the company's potential. Analysts project that DexCom will increase its earnings by a whopping 140% annually on average over the next five years.
Better buy
Both Abbott Labs and DexCom have great products and track records. So which is the better stock to buy right now? I think it depends on your investing style.
More conservative investors will prefer Abbott. The company is a Dividend Aristocrat that offers an attractive dividend with solid growth prospects as well. Abbott's broad scope of operations also gives the company diversification into multiple areas.
Aggressive investors, on the other hand, might like DexCom better. DexCom is a pure-play bet on the growing diabetes market with arguably the best CGM product.
Both Abbott and DexCom are top-tier diabetes stocks , with Abbott offering more than just a focus on diabetes. I don't think long-term investors will go wrong buying either stock.
10 stocks we like better than Abbott Laboratories
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of November 14, 2018
Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Keith Speights owns shares of Alphabet (A shares). The Motley Fool owns shares of and recommends Alphabet (A shares) and Alphabet (C shares). The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories (NYSE: ABT) and DexCom (NASDAQ: DXCM) market devices that allow for convenient monitoring of blood sugar levels without the need for daily finger sticks. Abbott CEO Miles White said in the company's Q4 conference call that global sales for FreeStyle Libre doubled in 2018 from the previous year to more than $1 billion. Other CGM systems, including FreeStyle Libre, can require finger sticks in other events, such as during the first few hours of readings and when symptoms of high or low blood sugar are present. | Abbott Laboratories (NYSE: ABT) and DexCom (NASDAQ: DXCM) market devices that allow for convenient monitoring of blood sugar levels without the need for daily finger sticks. The success of these companies' glucose monitors for diabetic patients has helped make Abbott Labs' and DexCom's shareholders winners, too. The case for Abbott Laboratories Abbott Labs' FreeStyle Libre continuous glucose monitoring (CGM) system has been one of the most successful products ever for diabetes patients. | Abbott Laboratories (NYSE: ABT) and DexCom (NASDAQ: DXCM) market devices that allow for convenient monitoring of blood sugar levels without the need for daily finger sticks. Last year, while many stocks languished, Abbott Labs' share price jumped nearly 27% and DexCom's share price more than doubled. The case for Abbott Laboratories Abbott Labs' FreeStyle Libre continuous glucose monitoring (CGM) system has been one of the most successful products ever for diabetes patients. | Abbott Laboratories (NYSE: ABT) and DexCom (NASDAQ: DXCM) market devices that allow for convenient monitoring of blood sugar levels without the need for daily finger sticks. The success of these companies' glucose monitors for diabetic patients has helped make Abbott Labs' and DexCom's shareholders winners, too. The case for Abbott Laboratories Abbott Labs' FreeStyle Libre continuous glucose monitoring (CGM) system has been one of the most successful products ever for diabetes patients. |
33095.0 | 2019-01-31 00:00:00 UTC | Surmodics (SRDX) Q1 Earnings & Revenues Beat, Guidance Solid | ABT | https://www.nasdaq.com/articles/surmodics-srdx-q1-earnings-revenues-beat-guidance-solid-2019-01-31 | nan | nan | Surmodics, Inc.SRDX reported adjusted earnings per share (EPS) of 12 cents in first-quarter fiscal 2019, comparing favorably with the Zacks Consensus Estimate of a loss of a penny. Earnings rose 20% from the year-ago quarter's figure.
Revenues in the quarter increased 30.7% to $22.2 million, which outpaced the Zacks Consensus Estimate by 17.7%.
Meanwhile, over the past year, shares of the Zacks Rank #2 (Buy) company have rallied 77.5% against the industry 's 6.3% and the S&P 500 index's 6.5% declines.
Q1 Highlights
In the quarter under review, Product sales were $9.8 million, up 20.6% year over year. Royalty and license fee revenues totaled $10.1 million, up 42.7% from the year-ago quarter. Research, development and other revenues were $2.4 million, up 29.5% year over year.
In the reported quarter, first patient was treated for the first study of the Avess arteriovenous (AV) access drug coated balloon (DCB). Additionally, the enrollment under Surmodics' TRANSCEND clinical trial continued in the quarter.
Surmodics, Inc. Price, Consensus and EPS Surprise
Surmodics, Inc. Price, Consensus and EPS Surprise | Surmodics, Inc. Quote
Segmental Analysis
Medical Device
In the reported quarter, sales at the segment rose 35.1% to $17.3 million, which includes $2.4 million from the SurVeil agreement with Abbott ABT . Per management, the uptick can be attributed to an increase in balloon catheter unit volume as a result of recent product launches.
The Medical Device business unit also reported $0.4 million of operating income in the first quarter against an operating loss of $0.4 million a year ago.
IVD
In the quarter under review, sales increased 17.6% to $5 million, reflecting strong growth in sales of the company's clinical components used in diagnostic tests and microarray slides slide.
Operating income at the segment was $2.5 million in the reported quarter, up 47% from the year-ago quarter's level.
Operating Details
Surmodics registered Product costs of $3.5 million in the quarter, up 21.9% year over year.
The company had research and development costs of $11.5 million, up 46.7% year over year.
Selling, general and administrative expenditures were almost $5.9 million, up 14.7% from the prior-year quarter.
Total operating costs and expenses in the quarter were $21.5 million, up 22% year over year.
Guidance
Surmodics raised the low end of its fiscal 2019 revenue expectation to $94 million from $92 million, while the high end is maintained at $97 million. The Zacks Consensus Estimate is pegged at $93.3 million, below the guided range.
Adjusted EPS is projected between 2 cents and 22 cents, compared with the previous projection of a loss of 7 cents to EPS of 23 cents. The Zacks Consensus Estimate is pinned at EPS of 8 cents, within the guided range.
Conclusion
Surmodics exited the fiscal first quarter on a strong note, with EPS and revenues outpacing estimates. The company continues to gain from its core Medical Devices unit which saw significant contribution from the SurVeil agreement with Abbott in the quarter. In fact, management expects the segment to see double-digit revenues growth in fiscal 2019. Strong sales of the company's clinical components drove the IVD segment. Management is also optimistic about the ongoing TRANSCEND enrollment. Additionally, the company expects a CE mark for SurVeil in Europe in the near future. A strong guidance for fiscal 2019 buoys optimism.
On the flip side, surging operating expenses is a concern. Additionally, unfavorable foreign currency movement impacted the company's bottom line in the fiscal first quarter. Surmodics' drug-coated balloons face stiff competition in the niche space.
Earnings of Other MedTech Majors at a Glance
Other top-ranked MedTech stocks which posted solid results this earnings season are Varian Medical Systems VAR and AngioDynamics ANGO .
Varian's fiscal first-quarter adjusted EPS of $1.06 was in line with the Zacks Consensus Estimate. Revenues of $741 million outpaced the consensus mark of $717.9 million. The stock has a Zacks Rank #2.
AngioDynamics' fiscal second-quarter adjusted EPS of 22 cents beat the Zacks Consensus Estimate by a penny. Revenues totaled $91.5 million, surpassing the consensus estimate by 2.9%. The stock flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Get Free Report
AngioDynamics, Inc. (ANGO): Free Stock Analysis Report
Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report
Surmodics, Inc. (SRDX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Surmodics, Inc. Price, Consensus and EPS Surprise Surmodics, Inc. Price, Consensus and EPS Surprise | Surmodics, Inc. Quote Segmental Analysis Medical Device In the reported quarter, sales at the segment rose 35.1% to $17.3 million, which includes $2.4 million from the SurVeil agreement with Abbott ABT . Click to get this free report Abbott Laboratories (ABT): Get Free Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report To read this article on Zacks.com click here. Surmodics, Inc.SRDX reported adjusted earnings per share (EPS) of 12 cents in first-quarter fiscal 2019, comparing favorably with the Zacks Consensus Estimate of a loss of a penny. | Surmodics, Inc. Price, Consensus and EPS Surprise Surmodics, Inc. Price, Consensus and EPS Surprise | Surmodics, Inc. Quote Segmental Analysis Medical Device In the reported quarter, sales at the segment rose 35.1% to $17.3 million, which includes $2.4 million from the SurVeil agreement with Abbott ABT . Click to get this free report Abbott Laboratories (ABT): Get Free Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report To read this article on Zacks.com click here. Surmodics, Inc.SRDX reported adjusted earnings per share (EPS) of 12 cents in first-quarter fiscal 2019, comparing favorably with the Zacks Consensus Estimate of a loss of a penny. | Surmodics, Inc. Price, Consensus and EPS Surprise Surmodics, Inc. Price, Consensus and EPS Surprise | Surmodics, Inc. Quote Segmental Analysis Medical Device In the reported quarter, sales at the segment rose 35.1% to $17.3 million, which includes $2.4 million from the SurVeil agreement with Abbott ABT . Click to get this free report Abbott Laboratories (ABT): Get Free Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report To read this article on Zacks.com click here. The Medical Device business unit also reported $0.4 million of operating income in the first quarter against an operating loss of $0.4 million a year ago. | Surmodics, Inc. Price, Consensus and EPS Surprise Surmodics, Inc. Price, Consensus and EPS Surprise | Surmodics, Inc. Quote Segmental Analysis Medical Device In the reported quarter, sales at the segment rose 35.1% to $17.3 million, which includes $2.4 million from the SurVeil agreement with Abbott ABT . Click to get this free report Abbott Laboratories (ABT): Get Free Report AngioDynamics, Inc. (ANGO): Free Stock Analysis Report Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report Surmodics, Inc. (SRDX): Free Stock Analysis Report To read this article on Zacks.com click here. Surmodics, Inc.SRDX reported adjusted earnings per share (EPS) of 12 cents in first-quarter fiscal 2019, comparing favorably with the Zacks Consensus Estimate of a loss of a penny. |
33096.0 | 2019-01-31 00:00:00 UTC | iShares S&P 100 ETF Experiences Big Outflow | ABT | https://www.nasdaq.com/articles/ishares-sp-100-etf-experiences-big-outflow-2019-01-31 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares S&P 100 ETF (Symbol: OEF) where we have detected an approximate $112.4 million dollar outflow -- that's a 2.5% decrease week over week (from 38,750,000 to 37,800,000). Among the largest underlying components of OEF, in trading today PepsiCo Inc (Symbol: PEP) is up about 0.3%, Abbott Laboratories (Symbol: ABT) is up about 0.6%, and International Business Machines Corp (Symbol: IBM) is lower by about 0.1%. For a complete list of holdings, visit the OEF Holdings page » The chart below shows the one year price performance of OEF, versus its 200 day moving average:
Looking at the chart above, OEF's low point in its 52 week range is $104.23 per share, with $131.30 as the 52 week high point - that compares with a last trade of $119.16. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of OEF, in trading today PepsiCo Inc (Symbol: PEP) is up about 0.3%, Abbott Laboratories (Symbol: ABT) is up about 0.6%, and International Business Machines Corp (Symbol: IBM) is lower by about 0.1%. For a complete list of holdings, visit the OEF Holdings page » The chart below shows the one year price performance of OEF, versus its 200 day moving average: Looking at the chart above, OEF's low point in its 52 week range is $104.23 per share, with $131.30 as the 52 week high point - that compares with a last trade of $119.16. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of OEF, in trading today PepsiCo Inc (Symbol: PEP) is up about 0.3%, Abbott Laboratories (Symbol: ABT) is up about 0.6%, and International Business Machines Corp (Symbol: IBM) is lower by about 0.1%. For a complete list of holdings, visit the OEF Holdings page » The chart below shows the one year price performance of OEF, versus its 200 day moving average: Looking at the chart above, OEF's low point in its 52 week range is $104.23 per share, with $131.30 as the 52 week high point - that compares with a last trade of $119.16. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of OEF, in trading today PepsiCo Inc (Symbol: PEP) is up about 0.3%, Abbott Laboratories (Symbol: ABT) is up about 0.6%, and International Business Machines Corp (Symbol: IBM) is lower by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares S&P 100 ETF (Symbol: OEF) where we have detected an approximate $112.4 million dollar outflow -- that's a 2.5% decrease week over week (from 38,750,000 to 37,800,000). For a complete list of holdings, visit the OEF Holdings page » The chart below shows the one year price performance of OEF, versus its 200 day moving average: Looking at the chart above, OEF's low point in its 52 week range is $104.23 per share, with $131.30 as the 52 week high point - that compares with a last trade of $119.16. | Among the largest underlying components of OEF, in trading today PepsiCo Inc (Symbol: PEP) is up about 0.3%, Abbott Laboratories (Symbol: ABT) is up about 0.6%, and International Business Machines Corp (Symbol: IBM) is lower by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares S&P 100 ETF (Symbol: OEF) where we have detected an approximate $112.4 million dollar outflow -- that's a 2.5% decrease week over week (from 38,750,000 to 37,800,000). For a complete list of holdings, visit the OEF Holdings page » The chart below shows the one year price performance of OEF, versus its 200 day moving average: Looking at the chart above, OEF's low point in its 52 week range is $104.23 per share, with $131.30 as the 52 week high point - that compares with a last trade of $119.16. |
33097.0 | 2019-01-29 00:00:00 UTC | Here's Why You Should Snap Up Abbott (ABT) Stock Right Now | ABT | https://www.nasdaq.com/articles/heres-why-you-should-snap-up-abbott-abt-stock-right-now-2019-01-29 | nan | nan | Abbott LaboratoriesABT has been gaining investor confidence on continued positive results. The company's share price has outperformed its industry over the past year. The stock has gained 9.1% against its industry's 6.3% decline and the S&P 500's 6.5% fall in the said period.
This leading developer, manufacturer and seller of a diversified line of health care products has a market cap of $124.96 billion. The company has an expected earnings growth rate of 11.8% over the next three-five years.
With solid prospects, this Zacks Rank #2 (Buy) stock is an attractive pick for investors at the moment.
What's Working in Favor of the Stock?
Strong EPD Business
Abbott's EPD business operates solely in emerging geographies, with leading positions in many of the largest and fastest growing pharmaceutical markets for branded generics in the world. These markets include India, Russia, China and Latin America.
The company recently noted that banking on successful execution of the Branded Generic operating model, EPD is well positioned for sustained above-market growth in many of these growing pharmaceutical markets. Sales were strong in the las t report ed quarter, led by double-digit growth in both India and China.
Progress With Diabetes Business
This business achieved 35% growth in 2018, led by FreeStyle Libre, which achieved global sales of more than $1 billion during the year, reflecting a 100% increase from a year ago. At the end of 2018, there were approximately 1.3 million active users worldwide, of which nearly two-thirds constituted type 1 diabetics and one-third accounted for type 2.
In the United States, there has been an accelerating trend of new users as Abbott is ramping up its awareness efforts during the second half of the year. The pharmacy insurance coverage has continued to increase, including an emerging trend of seeing Libre granted preferred copay status versus competitive systems, due to its compelling overall value proposition. In Europe, during the fourth quarter, the company initiated the launch of Libre 2.0, which includes optional alarms that work when patients' glucose levels fall below the normal range.
These developments are expected to enable the company to gain further traction in the Diabetes Care segment, which saw significant sales growth in the last reported quarter on continued consumer acceptance of FreeStyle Libre internationally.
Diagnostics Arm Gets a Boost From Alinity
Abbott is well placed on a healthy sales growth trajectory within Diagnostics over the past few quarters. Alinity, a family of highly differentiated instruments, is achieving accelerated growth and strong competitive win rates in Europe, where more than 50% of Alinity instrument placements are coming from share capture. The global rollout of Alinity positions this business for a consistent above market growth for years to come.
Other Key Picks
Other top-ranked stocks in the broader medical space include Omnicell, Inc. OMCL , Amedisys, Inc. AMED and Illumina, Inc. ILMN .
Omnicell's long-term earnings growth rate is estimated at 11.8%. The stock flaunts a Zacks Rank of 2. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Amedisys' long-term earnings growth rate is projected at 18.8%. The stock carries a Zacks Rank #2.
Illumina's long-term earnings growth rate is expected at 20.9%. The stock carries a Zacks Rank of 2.
Wall Street's Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Omnicell, Inc. (OMCL): Free Stock Analysis Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Illumina, Inc. (ILMN): Free Stock Analysis Report
Amedisys, Inc. (AMED): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott LaboratoriesABT has been gaining investor confidence on continued positive results. Click to get this free report Omnicell, Inc. (OMCL): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. The company recently noted that banking on successful execution of the Branded Generic operating model, EPD is well positioned for sustained above-market growth in many of these growing pharmaceutical markets. | Click to get this free report Omnicell, Inc. (OMCL): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT has been gaining investor confidence on continued positive results. Strong EPD Business Abbott's EPD business operates solely in emerging geographies, with leading positions in many of the largest and fastest growing pharmaceutical markets for branded generics in the world. | Click to get this free report Omnicell, Inc. (OMCL): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT has been gaining investor confidence on continued positive results. Progress With Diabetes Business This business achieved 35% growth in 2018, led by FreeStyle Libre, which achieved global sales of more than $1 billion during the year, reflecting a 100% increase from a year ago. | Abbott LaboratoriesABT has been gaining investor confidence on continued positive results. Click to get this free report Omnicell, Inc. (OMCL): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report Amedisys, Inc. (AMED): Free Stock Analysis Report To read this article on Zacks.com click here. Sales were strong in the las t report ed quarter, led by double-digit growth in both India and China. |
33098.0 | 2019-01-29 00:00:00 UTC | Abbott (ABT) Gains As Market Dips: What You Should Know | ABT | https://www.nasdaq.com/articles/abbott-abt-gains-as-market-dips%3A-what-you-should-know-2019-01-29 | nan | nan | Abbott (ABT) closed at $69.69 in the latest trading session, marking a +0.93% move from the prior day. This change outpaced the S&P 500's 0.15% loss on the day. Meanwhile, the Dow gained 0.21%, and the Nasdaq, a tech-heavy index, lost 0.81%.
Coming into today, shares of the maker of infant formula, medical devices and drugs had lost 4.53% in the past month. In that same time, the Medical sector gained 2.7%, while the S&P 500 gained 6.55%.
Investors will be hoping for strength from ABT as it approaches its nex t earnings release, which is expected to be April 17, 2019. The company is expected to report EPS of $0.62, up 5.08% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $7.48 billion, up 1.17% from the year-ago period.
ABT's full-year Zacks Consensus Estimates are calling for earnings of $3.20 per share and revenue of $31.81 billion. These results would represent year-over-year changes of +11.11% and +4.04%, respectively.
It is also important to note the recent changes to analyst estimates for ABT. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 0.28% higher. ABT is currently a Zacks Rank #2 (Buy).
Digging into valuation, ABT currently has a Forward P/E ratio of 21.58. This valuation marks a discount compared to its industry's average Forward P/E of 21.61.
Also, we should mention that ABT has a PEG ratio of 1.84. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. Medical - Products stocks are, on average, holding a PEG ratio of 2.09 based on yesterday's closing prices.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 102, putting it in the top 40% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott (ABT) closed at $69.69 in the latest trading session, marking a +0.93% move from the prior day. Investors will be hoping for strength from ABT as it approaches its nex t earnings release, which is expected to be April 17, 2019. ABT's full-year Zacks Consensus Estimates are calling for earnings of $3.20 per share and revenue of $31.81 billion. | Abbott (ABT) closed at $69.69 in the latest trading session, marking a +0.93% move from the prior day. Investors will be hoping for strength from ABT as it approaches its nex t earnings release, which is expected to be April 17, 2019. ABT's full-year Zacks Consensus Estimates are calling for earnings of $3.20 per share and revenue of $31.81 billion. | ABT's full-year Zacks Consensus Estimates are calling for earnings of $3.20 per share and revenue of $31.81 billion. Abbott (ABT) closed at $69.69 in the latest trading session, marking a +0.93% move from the prior day. Investors will be hoping for strength from ABT as it approaches its nex t earnings release, which is expected to be April 17, 2019. | Abbott (ABT) closed at $69.69 in the latest trading session, marking a +0.93% move from the prior day. ABT is currently a Zacks Rank #2 (Buy). Investors will be hoping for strength from ABT as it approaches its nex t earnings release, which is expected to be April 17, 2019. |
33099.0 | 2019-01-24 00:00:00 UTC | Company News For Jan 24, 2019 | ABT | https://www.nasdaq.com/articles/company-news-for-jan-24-2019-2019-01-24 | nan | nan | Kimberly-Clark Corp. KMB shares declined 2.7% after reporting fourth-quarter 2018 adjusted earnings per share of $1.60, missing the Zacks Consensus Estimate of $1.68
Shares of Abbott Laboratories ABT fell 2.2% after posting fourth quarter 2018 revenues of $7.77 billion, lagging the Zacks Consensus Estimate of $7.79 billion
Synchrony Financial SYF shares jumped 10.7% after the company extended its partnership with Walmart Inc.'s WMT Sam's club
Shares of Restaurant Brands International Inc. QSR surged 9.8% after the company promoted Jose Cil, president of Burger King division, as it CEO
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Kimberly-Clark Corporation (KMB): Get Free Report
Abbott Laboratories (ABT): Free Stock Analysis Report
Synchrony Financial (SYF): Free Stock Analysis Report
Walmart Inc. (WMT): Get Free Report
Restaurant Brands International Inc. (QSR): Get Free Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Kimberly-Clark Corp. KMB shares declined 2.7% after reporting fourth-quarter 2018 adjusted earnings per share of $1.60, missing the Zacks Consensus Estimate of $1.68 Shares of Abbott Laboratories ABT fell 2.2% after posting fourth quarter 2018 revenues of $7.77 billion, lagging the Zacks Consensus Estimate of $7.79 billion Synchrony Financial SYF shares jumped 10.7% after the company extended its partnership with Walmart Inc.'s WMT Sam's club Shares of Restaurant Brands International Inc. QSR surged 9.8% after the company promoted Jose Cil, president of Burger King division, as it CEO Want the latest recommendations from Zacks Investment Research? Click to get this free report Kimberly-Clark Corporation (KMB): Get Free Report Abbott Laboratories (ABT): Free Stock Analysis Report Synchrony Financial (SYF): Free Stock Analysis Report Walmart Inc. (WMT): Get Free Report Restaurant Brands International Inc. (QSR): Get Free Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Kimberly-Clark Corp. KMB shares declined 2.7% after reporting fourth-quarter 2018 adjusted earnings per share of $1.60, missing the Zacks Consensus Estimate of $1.68 Shares of Abbott Laboratories ABT fell 2.2% after posting fourth quarter 2018 revenues of $7.77 billion, lagging the Zacks Consensus Estimate of $7.79 billion Synchrony Financial SYF shares jumped 10.7% after the company extended its partnership with Walmart Inc.'s WMT Sam's club Shares of Restaurant Brands International Inc. QSR surged 9.8% after the company promoted Jose Cil, president of Burger King division, as it CEO Want the latest recommendations from Zacks Investment Research? Click to get this free report Kimberly-Clark Corporation (KMB): Get Free Report Abbott Laboratories (ABT): Free Stock Analysis Report Synchrony Financial (SYF): Free Stock Analysis Report Walmart Inc. (WMT): Get Free Report Restaurant Brands International Inc. (QSR): Get Free Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Kimberly-Clark Corp. KMB shares declined 2.7% after reporting fourth-quarter 2018 adjusted earnings per share of $1.60, missing the Zacks Consensus Estimate of $1.68 Shares of Abbott Laboratories ABT fell 2.2% after posting fourth quarter 2018 revenues of $7.77 billion, lagging the Zacks Consensus Estimate of $7.79 billion Synchrony Financial SYF shares jumped 10.7% after the company extended its partnership with Walmart Inc.'s WMT Sam's club Shares of Restaurant Brands International Inc. QSR surged 9.8% after the company promoted Jose Cil, president of Burger King division, as it CEO Want the latest recommendations from Zacks Investment Research? Click to get this free report Kimberly-Clark Corporation (KMB): Get Free Report Abbott Laboratories (ABT): Free Stock Analysis Report Synchrony Financial (SYF): Free Stock Analysis Report Walmart Inc. (WMT): Get Free Report Restaurant Brands International Inc. (QSR): Get Free Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Kimberly-Clark Corp. KMB shares declined 2.7% after reporting fourth-quarter 2018 adjusted earnings per share of $1.60, missing the Zacks Consensus Estimate of $1.68 Shares of Abbott Laboratories ABT fell 2.2% after posting fourth quarter 2018 revenues of $7.77 billion, lagging the Zacks Consensus Estimate of $7.79 billion Synchrony Financial SYF shares jumped 10.7% after the company extended its partnership with Walmart Inc.'s WMT Sam's club Shares of Restaurant Brands International Inc. QSR surged 9.8% after the company promoted Jose Cil, president of Burger King division, as it CEO Want the latest recommendations from Zacks Investment Research? Click to get this free report Kimberly-Clark Corporation (KMB): Get Free Report Abbott Laboratories (ABT): Free Stock Analysis Report Synchrony Financial (SYF): Free Stock Analysis Report Walmart Inc. (WMT): Get Free Report Restaurant Brands International Inc. (QSR): Get Free Report To read this article on Zacks.com click here. Today, you can download 7 Best Stocks for the Next 30 Days. |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.